"TrialID","Last Refreshed on","Public title","Scientific title","Acronym","Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design","Phase","Countries","Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria","Condition","Intervention","Primary outcome","results date posted","results date completed","results url link","Retrospective flag","Bridging flag truefalse","Bridged type","results yes no"
"ChiCTR2000029953","2020-02-17","Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                             ","","Zhongnan Hospital of Wuhan University","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49217","Not Recruiting","No","","","Both","2020-02-01","survival group:200;died:200;","Observational study","Factorial","N/A","China","Yan Zhao","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","doctoryanzhao@whu.edu.cn","+86 13995577963","Emergency Department of Zhongnan Hospital of Wuhan University","Inclusion criteria: 2019-nCoV-infected pneumonia diagnosed patients, the diagnostic criteria refer to ""guideline of the diagnose and treatment of 2019-nCoV (trial)"" published by National Health Committees of Peoples' Republic Country ""","Exclusion criteria: Patients diagnosed with pneumonia of age <15 years diagnosed according to""guideline of the diagnose and treatment of 2019-nCoV (tested)"" published by National Health Committees of Peoples' Republic Country;  Suspected patient with vira","2019-nCoV Pneumonia","survival group:none;died:none;","duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;","","","","No","0","          ",""
"ChiCTR2000029935","2020-02-17","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                                          ","","HwaMei Hospital, University of Chinese Academy of Sciences","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49607","Recruiting","No","","","Both","2020-02-06","Case series:100;","Interventional study","Single arm","N/A","China","Ting Cai","","41 Xibei Street, Ningbo, Zhejiang, China","caiting@ucas.ac.cn","+86 13738498188","HwaMei Hospital, University of Chinese Academy of Sciences","Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.<br>Criteria for diagnosis (meet all the following crite","Exclusion criteria: 1. Female patients during pregnancy; <br>2. Patients with known allergy to chloroquine; <br>3. Patients with haematological diseases; <br>4. Patients with chronic liver or kidney diseases at the end stage; <br>5. Patients with arrh","Novel Coronavirus Pneumonia (COVID-19)","Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","Length of hospital stay;","","","","No","0","          ",""
"ChiCTR2000029850","2020-02-17","Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study                                                                                                                ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49533","Recruiting","No","16.0","99.0","Male","2020-02-15","experimental group:10;control group:10;","Interventional study","Non randomized control","0.0","China","Xiaowei Xu","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","xxw69@126.com","+86 13605708066","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR;<br>2. Aged > 18 years;<br>3. Written informed consent given by the patient or next-of-kin;<br>4. Clinical deterioration despite conventional treatment that required i","Exclusion criteria: 1. Hypersensitive to immunoglobulin;<br>2. Have immunoglobulin A deficiency.","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","Fatality rate;","","","","Yes","0","          ",""
"ChiCTR2000029814","2020-02-17","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                            ","","Children's Hospital of Fudan University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49387","Recruiting","No","0.0","18.0","Both","2020-02-14","control group:15;experimental group:15;","Interventional study","Non randomized control","0.0","China","Zhai Xiaowen","","399 Wanyuan Road, Minhang District, Shanghai","zhaixiaowendy@163.com","+86 64931902","Children's Hospital of Fudan University","Inclusion criteria: Children diagnosed with novel coronavirus pneumonia through epidemiological history, clinical symptoms, and nucleic acid test results.","Exclusion criteria: No exclusion criteria","Novel Coronavirus Pneumonia  (COVID-19)","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;","","","","Yes","0","          ",""
"NCT04245631","2020-02-17","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV","","Beijing Ditan Hospital","2020-01-26","2020-01-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04245631","Recruiting","No","1 Year","90 Years","All","2020-01-01","50.0","Observational","","N/A","China"," ; ; ","Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor","",";xieyao00120184@sina.com;xieyao00120184@sina.com",";8610-84322200;8610-84322200","Department of Hepatology, Division 2, Beijing Ditan Hospital;","<br>        Inclusion Criteria:<br><br>          -  1. Suspected cases (formerly observed cases)<br><br>        Meet the following 2 at the same time:<br><br>        Epidemiological history There was a history of travel or residence in Wuhan within","","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Detection sensitivity is greater than 95%;Detection specificity is greater than 95%","","","","Yes","0","          ",""
"NCT04252885","2020-02-17","The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","ELACOI","Guangzhou 8th People's Hospital","2020-01-30","2020-01-30","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04252885","Recruiting","No","18 Years","80 Years","All","2020-01-28","125.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","China"," ; ","Yueping Li, MD, Master;Linghua Li, MD, PhD","","lipipi007@163.com;","020- 36052117;","","<br>        Inclusion Criteria:<br><br>          -  In sputum, throat swab, lower respiratory tract secretion, blood and other samples,<br>             the nucleic acid of the novel coronavirus was positive, or the sequencing of the virus<br>        ","","Coronavirus Infections","Drug: Lopinavir and Ritonavir Tablets;Drug: Arbidol","The rate of virus inhibition","","","","Yes","0","          ",""
"NCT04255940","2020-02-17","2019-nCoV Outbreak and Cardiovascular Diseases","Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China","","Qilu Hospital of Shandong University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04255940","Recruiting","No","N/A","N/A","All","2020-01-20","12000.0","Observational","","Phase 4","China"," ","Panpan Hao, MD","","panda.how@sdu.edu.cn","86-18560086593","","<br>        Inclusion Criteria:<br><br>          -  Patients visiting emergency department.<br><br>        Exclusion Criteria:<br><br>        -<br>      ","","Cardiovascular Death; Major Adverse Cardiovascular Events","","Cardiovascular Death","","","","Yes","0","          ",""
"NCT04260308","2020-02-17","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia in Wuhan, China","","Huazhong University of Science and Technology","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04260308","Recruiting","No","N/A","N/A","All","2020-02-03","30000.0","Observational","","N/A","China"," ; ","Yuhong Dai;Yuhong Dai","","eier_dai@163.com;eier_dai@163.com","+86 13476229575;+86 13476229575","","<br>        Inclusion Criteria:<br><br>          -  can use mobil phone or computer<br><br>          -  volunteer to take part in the investigation<br><br>        Exclusion Criteria:<br><br>          -  can not use phone or computer<br><br>    ","","Virus; Pneumonia","","GHQ-12(general health questionnaire-12)","","","","Yes","0","          ",""
"ChiCTR2000029805","2020-02-17","Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                       ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49188","Recruiting","No","","","Both","2020-02-12","case series:100;","Observational study","Sequential","N/A","China","Wu Wenjuan","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","88071718@qq.com","+86 13397192695","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) ","Inclusion criteria: (1) Patients diagnosed with 2019-nCoV pneumonia;<br>(2) Patients admitted to the ICU during the study period.","Exclusion criteria: N/A","Novel Coronavirus Pneumonia (COVID-19)","case series:N/A;","28-day mortality and 90-day mortality.;","","","","No","0","          ",""
"ChiCTR2000029789","2020-02-17","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)                                                                                        ","","The First Affiliated Hospital of He'nan University of Chinese Medicine","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49348","Recruiting","No","18.0","90.0","Both","2020-02-15","Experimental group:50;Control group:50;","Interventional study","Parallel","0.0","China","Li Jiansheng","","156 Jinshui Road East, Zhengzhou, He'nan, China","li_js8@163.com","+86 371-65676568","He'nan University of Chinese Medicine","Inclusion criteria: 1. General/severe/critical patients who meet the diagnostic criteria of new coronavirus pneumonia;<br>2. Patients whose viral nucleic acid has turned negative after treatment;<br>3. Patients who are characterized by respiratory sympt","Exclusion criteria: 1. Patients with cognitive disorder or known mental illness;<br>2. Pregnant or lactating women;<br>3. Patients with active tuberculosis, pulmonary abscess or chronic respiratory failure;<br>4. Patients with tumor;<br>5. Patients wi","Novel Coronavirus Pneumonia  (COVID-19)","Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","St. George's Respiratory Questionnaire;","","","","Yes","0","          ",""
"NCT04246242","2020-02-03","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","","Xiangya Hospital of Central South University","2020-01-27","2020-01-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04246242","Not recruiting","No","N/A","N/A","All","2020-01-25","500.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 4",""," ","Pinhua Pan, Medical PhD","","pinhuapan668@126.com","+86 13574810968","","<br>        Inclusion Criteria:<br><br>        Patients diagnosed with RT-PCR for 2019 Novel Coronavirus (2019-nCoV)<br><br>        Exclusion Criteria:<br><br>        Patients infected with other viruses<br>      ","","2019 Novel Coronavirus","Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid","mortality","","","","Yes","0","          ",""
"ChiCTR2000029949","2020-02-17","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                      ","","Emergency Department of Zhongnan hospital of Wuhan University","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49181","Not Recruiting","No","18.0","","Both","2020-02-16","Case series:40;","Observational study","Sequential","Retrospective study","China","Yan, Zhao","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","doctoryanzhao@whu.edu.cn","+86 13995577963","Emergency Department of Zhongnan hospital of Wuhan University","Inclusion criteria: 1. Aged >=18 years; <br>2. Diagnosed of 2019-nCoV infection with ""guideline of the diagnose and treatment of 2019-nCoV (tested the fourth edition)"" published by National Health Committees of Peoples' Republic Country.<br>3. Failed by","Exclusion criteria: Absolutely forbidden criteria for ECMO application","Novel Coronavirus Pneumonia (COVID-19)","Case series:Extracorporeal Membrane Oxygenation;","inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;","","","","Yes","0","          ",""
"ChiCTR2000029883","2020-02-17","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR                                                                                                                           ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49549","Not Recruiting","No","18.0","75.0","Both","2020-02-17","Target condition:200;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Xu Shuyun","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","sxu@hust.edu.cn","+86 13517248539","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.<br>1. Aged <= 75 years;<br>2. Patients with newly diagnosed and suspected coronavirus pneumonia;<br>3","Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;<br>2. Those with severe nasal diseases affecting the sampling;<br>3. Inability to understand or follow research protocols for severe mental illness;<br>4. Invasive ve","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: <br>1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; <br>2. Gene sequencing of respiratory or blood samples is highly ","detection of SARS-CoV-2 nucleic acid;SEN;","","","","Yes","0","          ",""
"ChiCTR2000029869","2020-02-17","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy                        ","","Huangshi Hospital of Traditional Chinese Medicine","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49486","Not Recruiting","No","18.0","80.0","Both","2020-02-10","experimental group:150;control group:150;","Interventional study","Parallel","4.0","China","Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang ","","6 Guangchang Road, Huangshi, Hubei, China","fangbji@163.com","+86 0714-6224162","Huangshi Hospital of Traditional Chinese Medicine","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;<br>2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;<br>3. Aged 18 to 80 years;<br>4. Signed informed cons","Exclusion criteria: 1. Pregancy or lactating women;<br>2. People with allergies or allergies to traditional Chinese medicine  <br>3. Severe Primary disease such as uncontrolled and metastasis malignancy, hematopathy, HIV;<br>4. Obstructive pneumonia ca","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","","","","No","0","          ",""
"ChiCTR2000029947","2020-02-17","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                   ","","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49599","Not Recruiting","No","18.0","75.0","Both","2020-03-01","experimental group :100;control group :100;","Interventional study","Parallel","N/A","China","LU Zhenhui","","725 Wanping Road South, Xuhui District, Shanghai, China","tcmdoctorlu@163.com","+86 13817729859","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ","Inclusion criteria: 1. Meet the diagnostic criteria forconfirmed cases  in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);<br>2. The acute stage is complicated by sepsis, respiratory failure, ARDS and so on. The p","Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;<br>2. Pregnant, preparing or lac","Novel Coronavirus Pneumonia (COVID-19)","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","Lung function;","","","","Yes","0","          ",""
"ChiCTR2000029896","2020-02-17","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                          ","","Affiliated Hospital of Changchun University of traditional Chinese Medicine","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49432","Recruiting","No","","","Both","2020-01-31","Case series:100;","Observational study","Sequential","N/A","China","Wang Tan","","1478 Gongnong Road, Changchun, Jilin, China","Wangtan215@sina.com","+86 13756858523","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);<br>2. The expert team of consultation in our hospital will par","Exclusion criteria: 1. Unable to receive traditional Chinese medicine treatment.<br>2. Cases where complete diagnosis and treatment information is not available.","novel coronavirus pneumonia","Case series:Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Conversion rate of mild and common type patients to severe type;Mortality Rate;","","","","No","0","          ",""
"ChiCTR2000029782","2020-02-17","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)                                      ","","Zhejiang Provincial People's Hospital","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49445","Not Recruiting","No","18.0","80.0","Both","2020-01-30","Case series:27;","Observational study","Sequential","N/A","China","Yongshi Jia","","158 Shangtang Road, Xiacheng District, Hangzhou, China","jiayongshi@medmail.com.cn","+86 13605813177","Zhejiang Provincial People's Hospital","Inclusion criteria: Medical staff who are currently working during the epidemic of new coronavirus (Covid-19)","Exclusion criteria: 1. Rest or unattended staff;<br>2. Staff with respiratory symptoms;<br>3. Staff who need the necessary isolation.","novel coronavirus pneumonia (COVID-19); mental health status","Case series:Not applicable.;","PSQI;","","","","No","0","          ",""
"ChiCTR2000029764","2020-02-17","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study                                                                                                                                                                 ","","West China Hospital, Sichuan University","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49388","Not Recruiting","No","","","Both","2020-02-16","case series:100;","Observational study","Sequential","0.0","China","Bin Song","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","songlab_radiology@163.com","86 28 85423680","West China Hospital, Sichuan University","Inclusion criteria: 1. Patients diagnosed with COVID-19;<br>2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;<br>3. Able to complete the study.","Exclusion criteria: 1. CT image quality does not meet the analysis criteria;<br>2. Pregnant and lactating women.","Novel Coronavirus Pneumonia (COVID-19)","case series:N/A;","imaging feature;","","","","Yes","0","          ",""
"ChiCTR2000029867","2020-02-17","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                               ","","Beijing You'an Hospital, Capital Medical University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49514","Recruiting","No","18.0","75.0","Both","2020-02-15","Experimental group:260;Control group:260;","Interventional study","Parallel","4.0","China","Ronghua Jin","","8 Xitoutou, You'anmen, Fengtai District, Beijing","dinghuiguo@medmail.com.cn","+86 13811611118","Beijing You'an Hospital, Capital Medical University","Inclusion criteria: 1. Subjects have signed informed consent; agree not to participate in other clinical studies within 30 days from the first administration of the research drug to the last administration.<br>2. Aged >= 18 and <= 75 years.<br>3. Met th","Exclusion criteria: 1. Patients who have received immunotherapy (such as PD-1 / L1, CTLA4, etc.) and inflammatory factor modulators (such as Ulinastatin) within one month.<br>2. Patients who have used antibacterial drugs such as macrolides within one wee","Novel Coronavirus Pneumonia  (COVID-19)","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;","","","","Yes","0","          ",""
"ChiCTR2000029849","2020-02-17","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                   ","","The First Affiliated Hospital of Zhengzhou University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49530","Recruiting","No","18.0","75.0","Both","2020-02-01","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","China","Huaqi Wang","","1 Jianshe Road East, Zhengzhou, He'nan, China","wanghuaqi2004@126.com","+86 15890689220","The First Affiliated Hospital of Zhengzhou University","Inclusion criteria: Participants with 18 to 75 years of age who have been diagnosed with NCP by nucleic acid testing and meet the clinical classification of severe NCP referring to the clinical classification standard in the General Office of the National","Exclusion criteria: Participants who have used fluoroquinolone antibiotics within 1 week","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","Length of admission;mortality rate;","","","","No","0","          ",""
"ChiCTR2000029811","2020-02-17","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                             ","","Guangzhou reborn health management consultation co., LTD","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49355","Not Recruiting","No","18.0","","Both","2020-02-20","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","","Chao Xu","","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","164972769@qq.com","+86 15018720816","","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Voluntarily sign written informed consent. ","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","novel coronavirus pneumonia (COVID-19)","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Time to disease recovery;","","","","Yes","0","          ",""
"ChiCTR2000029810","2020-02-17","Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein","Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein                                                                                                             ","","Shenzhen Second People's Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49407","Recruiting","No","1.0","100.0","Both","2020-02-16","Target condition:10000;Difficult condition:300","Diagnostic test","Factorial","0.0","China","Weiren Huang","","3002 Sungang Road West, Futian District, Shenzhen","pony8980@163.com","+86 13923781386","Shenzhen Second People's Hospital","Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2have either of the following epidemiological histories consistent with the following two clinical manifestations:<br>A comprehensive analysis was conducted based on the following epidemiologica","Exclusion criteria: Suspected patients with inability to collect deep sputum, throat swabs, or nose swabs from alveolar lavage.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&#32;product&#32;of&#32;SARS-CoV-2.;","SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000029695","2020-02-17","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath                                                                                        ","","Shenzhen Third People's Hospital","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49219","Not Recruiting","No","1.0","100.0","Both","2020-03-01","Target condition:300;Difficult condition:300","Diagnostic test","Sequential","0.0","China","Deng Guofang","","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","jxxk1035@yeah.net","+86 13530027001","Pulmonary Diseases Department, Shenzhen Third People's Hospital","Inclusion criteria: Suspected cases of pneumonitis with the novel coronavirus infection. Suspected case criteria: Any one of the following epidemiological histories meets any two of the clinical manifestations:<br>Comprehensive analysis based on the foll","Exclusion criteria: Severe novel coronavirus pneumonia patients who cannot provide exhaled breath samples.","novel coronavirus pneumonia (COVID-19)","Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled&#32;breath&#32;detection&#32;by&#32;mass&#32;spectrometry;","Sensitivity of detection of NCP;Specificity of detection of NCP;","","","","Yes","0","          ",""
"ChiCTR2000029656","2020-02-17","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                            ","","Wuhan Pulmonary Hosptial","2020-02-09","2020-02-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49086","Not Recruiting","No","18.0","","Both","2020-02-14","control group:50;experimental group:50;","Interventional study","Parallel","0.0","China","Ronghui Du","","28 Baofeng Road, Qiaokou District, Wuhan, Hubei, China","bluesearh006@sina.com","+86 15337110926","Wuhan Pulmonary Hospital","Inclusion criteria: 1. Adults (defined as age >= 18 years); <br>2. Patients with new type of coronavirus infection confirmed by PCR / serum antibodies; <br>3. The time interval between symptom onset and random enrollment is within 10 days.The onset of s","Exclusion criteria: 1. Known to receive hormone therapy orally or intravenously; <br>2. Hormone therapy is needed due to concomitant disease upon admission; <br>3. Patients with diabetes are receiving oral medication or insulin therapy; <br>4. Known co","novel coronavirus pneumonia (COVID-19)","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","ECG;Chest imaging;Complications;vital signs;NEWS2 score;","","","","Yes","0","          ",""
"ChiCTR2000029822","2020-02-17","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection                                                                                                                               ","","Nanjing Second Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49502","Recruiting","No","0.0","100.0","Both","2020-02-07","Experimental group:70;Control group:40;","Interventional study","Parallel","0.0","","Yongxiang Yi","","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China","ian0126@126.com","+86 13338628626","Nanjing Second Hospital","Inclusion criteria: 1. Age is not limited;<br>2. Clinical diagnosis is in accordance with the ""Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)"" on the diagnosis of a new type of coronavirus infection;","Exclusion criteria: (1) Those who cannot take Chinese traditional medicine decoction;<br>(2) mentally ill subjects who are not easy to control;<br>(3) those who are pregnant or breast-feeding;<br>(4) those who use other Chinese medicines;<br>(5) those","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:honeysuckle decoction;Control group:placebo;","rate of cure;","","","","No","0","          ",""
"ChiCTR2000029815","2020-02-17","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","","Guangdong Provincial Hospital of Chinese Medicine","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49346","Recruiting","No","18.0","75.0","Both","2020-02-01","Case series:800;","Observational study","Sequential","N/A","China","Zhan Jie","","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","zhanjie34@126.com","+86 15818136908","Guangdong Provincial Hospital of Chinese Medicine","Inclusion criteria: 1. Aged> 18 years old;<br>2. Working time in the front line of novel coronavirus pneumonia prevention and control =1 week;<br>3. The working department is the hot spot for the sample hospital, the ward for the suspected cases, and th","Exclusion criteria: 1. Staff and pharmacists in the administrative, logistics and medical technology departments;<br>2. Regulatory students, interns, re-employment, external employment and labor dispatch personnel;<br>3. Those who refused to participate","Emotional  disorder","Case series:Nil;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;","","","","No","0","          ",""
"ChiCTR2000029779","2020-02-17","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging                                                                                                                                 ","","Wuxi People's Hospital","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49378","Recruiting","No","","","Both","2020-02-14","Target condition:0;Difficult condition:0","Diagnostic test","Factorial","0.0","China","Xiangming Fang","","299 Qingyang Road, Liangxi District, Wuxi, Jiangsu","xiangming_fang@njmu.edu.cn","+86 13861779030","Wuxi People's Hospital","Inclusion criteria: Patients diagnosed by nucleic acid and/or genetic test in Wuxi (later expanded to southern Jiangsu and Jiangsu Province) with novel coronavirus pneumonia, and other types of viral pneumonia confirmed by nucleic acid and/or genetic test","Exclusion criteria: N/A","Novel Coronavirus Pneumonia  (COVID-19)","Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis&#32;model&#32;based&#32;on&#32;Artificial&#32;Intelligence&#32;(Epidemiological&#32;history,&#32;clinical&#32;information,&#32;laboratory&#32;examination,&#32;ho","Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000029778","2020-02-17","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                          ","","Shanghai University of TCM","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49422","Recruiting","No","15.0","85.0","Both","2020-02-14","TCM Group:150;QFPD decoction group:150;SFJD capsuale group:150;control group:150;","Interventional study","Non randomized control","0.0","China","Wei Zhang","","Pulmonary Department, 5A Ward, 528 Zhanghen Road, Pudong New Area District, Shanghai, China","zhangw1190@sina.com","+86 13601733045","Shuguang Hospital Affiliated to Shanghai University of TCM.","Inclusion criteria: Meet the diagnostic criteria of Novel Coronavirus Pneumonia (COVID-19).","Exclusion criteria: 1. Pregnant or lactating women, allergic to the research drug; <br>2. Combined with cardiovascular, liver, kidney and hematopoietic systems and other serious primary diseases, mental illness;<br>3. Those with observational factors af","Novel Coronavirus Pneumonia (COVID-19)","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","Length of hospital stay;fever clearance time;","","","","Yes","0","          ",""
"NCT04251871","2020-02-17","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection","Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","","Beijing 302 Hospital","2020-01-28","2020-01-28","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04251871","Recruiting","No","14 Years","80 Years","All","2020-01-22","150.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ; ; ","Xiao-he Xiao, PD.;Rui-lin Wang, Dr.;Rui-lin Wang, Dr.","",";wrl7905@163.com;wrl7905@163.com",";+86 10 66933436;+86 66933323","302 Military Hospital;","<br>        Inclusion Criteria:<br><br>          -  Confirmed 2019-nCoV infection case in term of laboratory evidence;<br><br>          -  80 years = age = 14years;<br><br>          -  Within 72 hours after the onset of abnormalities shown by Chest","","Pneumonia Caused by Human Coronavirus (Disorder)","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules;Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopi","Time to complete remission of 2019-nCoV infection-associated symptoms","","","","Yes","0","          ",""
"NCT04260594","2020-02-17","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","","Jieming QU","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04260594","Not recruiting","No","18 Years","75 Years","All","2020-02-07","380.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","","","","","","","","<br>        Inclusion Criteria:<br><br>          1. Sign the informed consent form;<br><br>          2. Age =18 years, regardless of gender;<br><br>          3. Subjects with pneumonia diagnosed as 2019-nCoV infection; A) Detection of 2019-nCoV<br","","2019-nCoV","Other: basic treatment;Drug: Arbidol","Virus negative conversion rate in the first week","","","","Yes","0","          ",""
"NCT04261426","2020-02-17","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","","Peking Union Medical College Hospital","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04261426","Not recruiting","No","18 Years","N/A","All","2020-02-10","80.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3",""," ","Taisheng Li","","litsh@263.net","010-69155086","","<br>        Inclusion Criteria:<br><br>          -  Adult aged >=18years old;<br><br>          -  Laboratory (RT-PCR) confirmed 2019-nCoV infection in throat swab and/or sputum and/or<br>             lower respiratory tract samples;<br><br>       ","","2019-nCoV","Other: Standard care;Drug: Intravenous Immunoglobulin","Lower Murray lung injury score;Lower Murray lung injury score;Clinical improvement based on the 7-point scale","","","","Yes","0","          ",""
"NCT04261907","2020-02-17","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","","First Affiliated Hospital of Zhejiang University","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04261907","Not recruiting","No","18 Years","75 Years","All","2020-02-07","160.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A",""," ; ","Yunqing Qiu, Master;Xiaowei Xu, Master","",";xxw69@126.com",";+86 13605708066","First Affiliated Hospital of Zhejiang University;","<br>        Inclusion Criteria:<br><br>          -  1. Aged between 18 and 75 years, extremes included, male or female<br><br>          -  2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia,<br>             according ","","2019-nCoV","Drug: lopinavir/ritonavir group;Drug: ASC09/ritonavir group","The incidence of composite adverse outcome","","","","Yes","0","          ",""
"ChiCTR2000029813","2020-02-17","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                               ","","Shanghai Public Health Clinical Center","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49425","Recruiting","No","18.0","75.0","Both","2020-02-14","Experimental group:36;Control Group:36;","Interventional study","Parallel","0.0","China","Hongzhou Lu, Xiaorong Chen","","2901 Caolang Road, Jinshan District, Shanghai","luhongzhou@fudan.edu.cn","+86 18930810088","Shanghai Public Health Clinical Center","Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;<br>(2) Those who have been diagnosed with TCM as epidemic-closed lungs;<br>(3) Inpatients aged 18 to 75 years, regardle","Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;<br>(2) Preparing pregnant, pregnant and lactating women;<br>(3) Patients with allergies (referring to allergie","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional Treatment & Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","Time of viral nucleic acid turns negative;Antipyretic time;","","","","Yes","0","          ",""
"ChiCTR2000029806","2020-02-17","Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                       ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49161","Recruiting","No","18.0","","Both","2020-02-12","Thymosin treatment group:40;PD-1 treatment group:40;Conventional treatment group:40;","Interventional study","Parallel","N/A","China","Xia Jiaan","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","3131862959@qq.com","+86 13871120171","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) ","Inclusion criteria: 1. 2019 adult patients with new-type coronavirus pneumonia diagnosed with 2019-nCoV infection by PCR according to the ""Pneumonitis Diagnosis and Treatment Protocol for New-type Coronavirus Infection (Trial Version 5)""<br>2. The absolu","Exclusion criteria: 1. Aged <18 years;<br>2. Pregnant or lactating women;<br>3. Allergic to the test drug;<br>4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors);<br>5. CO","Novel Coronavirus Pneumonia (COVID-19)","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;","","","","No","0","          ",""
"ChiCTR2000029626","2020-02-17","Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)","Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients                                                                                                                     ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49170","Not Recruiting","No","18.0","90.0","Both","2020-02-17","Normal group:10;Severe group:10;","Basic Science","Factorial","0.0","China","Fang Xueling","","79 Qingchun Road, Hangzhou, China","13588867114@163.com","+86 13588867114","The First Affiliated Hospital of Zhejiang University School of Medicine ","Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"";<br>","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)","novel coronavirus pneumonia (COVID-19)","Normal group:No;Severe group:No;","TCR sequencing;BCR sequencing;HLA sequencing;","","","","Yes","0","          ",""
"ChiCTR2000029624","2020-02-17","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia ((COVID-19)                                                                                                                                                ","","Shanghai Public Health Clinical Center","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49132","Not Recruiting","No","","","Both","2020-02-08","Case series:500;","Observational study","Sequential","N/A","China","Lu Hongzhou","","2901 Caolang Road, Jinshan District, Shanghai, China","Luhongzhou@shphc.org.cn","+86 18930810088","Shanghai Public Health Clinical Center","Inclusion criteria: 1. Suspected case:<br>Patients in observation period of traditional Chinese medicine who are in line with the diagnostic criteria for suspected cases of pneumonia caused by 2019 novel coronavirus infection in the ""diagnosis and treatm","Exclusion criteria: Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other condit","novel coronavirus pneumonia (COVID-19)","Case series:Traditional Chinese Medicine;","Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;","","","","Yes","0","          ",""
"ChiCTR2000029777","2020-02-17","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy                                                                   ","","Huangshi Hospital of Traditional Chinese Medicine","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49380","Recruiting","No","18.0","80.0","Both","2020-02-05","experimental group:80;control group:80;","Interventional study","Parallel","0.0","China","Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang","","6 Guangchang Road, Huangshi, Hubei ","fangbji@163.com","+86 0714-6224162","Huangshi Hospital of Traditional Chinese Medicine","Inclusion criteria: 1. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection<br>2. Meet any one of the criteria for severe type:<br>1) Respiratory distress: RP >= 30/min;<br>2) At rest, the oxygen saturation <= 93%;<","Exclusion criteria: 1. Pregancy or lactating women;<br>2. People with allergies or allergies to components of Truncated Torsion formula; <br>3. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage)","severe novel coronavirus pneumonia (COVID-19)","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","","","","No","0","          ",""
"ChiCTR2000029776","2020-02-17","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","","The First Affiliated of Wenzhou Medical University","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49342","Recruiting","No","","","Both","2020-02-11","experimental group:20;control group:20;","Interventional study","Parallel","4.0","China","Xiaoyin Huang","","Nanbaixiang, Ouhai District, Wenzhou, Zhejiang","zjwzhxy@126.com","+86 13819711719","The First Affiliated of Wenzhou Medical University","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Above 18 years old (inclusive);<br>3. Voluntarily sign written informed consent.  ","Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;<br>2. Estimated Time of Death is less than 48 hours;<br>3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic dis","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;","Time to Clinical recovery;","","","","No","0","          ",""
"ChiCTR2000029790","2020-02-17","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","","Shanghai Pulmonary Hospital","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49453","Recruiting","No","18.0","80.0","Both","2020-02-17","Control group:60;Experimental group:60;","Interventional study","Parallel","N/A","China","Lixin Wang","","507 Zhengmin Road, Yangpu District, Shanghai, China ","wlx1126@hotmail.com","+86 18917962300","Shanghai Pulmonary Hospital ","Inclusion criteria: (1) Comply with the standards of diagnosis and classification of western medicine, and the standards of syndromes of traditional Chinese medicine.<br>(2) Aged 18-80 years.<br>(3) Those who voluntarily participated in this research an","Exclusion criteria: (1) Impaired consciousness or mental illness cannot cooperate with treating the observer.<br>(2) Those with severe organ dysfunction.<br>(3) Pregnant women.","Novel Coronavirus Pneumonia (COVID-19)","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","TCM symptoms efficacy;","","","","Yes","0","          ",""
"ChiCTR2000029788","2020-02-17","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                                                                                       ","","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49452","Not Recruiting","No","18.0","80.0","Both","2020-03-01","Control group :30;Intervention group :30;","Interventional study","Parallel","N/A","China"," Yaosheng Zhang, Jianwei Shang","","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China","zysjsgzs@163.com","+86 18134048843","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","Inclusion criteria: 1. Meet the diagnostic criteria of the ""New Coronavirus Pneumonia Diagnosis and Treatment Scheme"", patients with pneumonia confirmed by new coronavirus infection; <br>2. Pneumonia Severity Index (PSI) grade is I ~ II; <br>3. Aged 18-","Exclusion criteria: 1. People with allergies and allergies to experimental drugs; <br>2. Combined with other malignant tumors; <br>3. Patients with hematological diseases, coagulopathy and autoimmune diseases; <br>4. Combined with severe cardiovascular","Novel Coronavirus Pneumonia (COVID-19)","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;","","","","Yes","0","          ",""
"ChiCTR2000029601","2020-02-17","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population                                                                                                              ","","Hubei Provincial Hospital of TCM","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48988","Recruiting","No","18.0","65.0","Both","2020-02-01","Control group:200;Experimental group:200;","Interventional study","Parallel","0.0","China","Tong Xiaolin","","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","252417083@qq.com","+86 18908628577","Hubei Provincial Hospital of TCM","Inclusion criteria: 1. Suspected and confirmed cases of pneumonia in accordance with the above new signs of coronavirus infection and the standard of clinical common diagnosis;<br>2. Aged 18-65 years old;<br>3. Signing the general informed consent form.","Exclusion criteria: 1. Clear evidences?of bacterial infection;<br>2. Serious primary diseases judged by researchers,such as heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract,?may affect the patients' participation in the trial ","novel coronavirus pneumonia (COVID-19)","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;","","","","No","0","          ",""
"ChiCTR2000029569","2020-02-17","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                               ","","Xiangyang 1st People's Hospital","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49062","Not Recruiting","No","18.0","","Both","2020-02-05","control group :15;Experimental group :15;","Interventional study","Parallel","0.0","China","Pei Bin","","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China ","xyxzyxzh@163.com","+86 18995678520","Xiangyang 1st People's Hospital ","Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial","Exclusion criteria: (1) diseases need to be differentiated from 2019-ncov, such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pulmonary virus, SARS coronavirus and other known viral pneumonia, ","novel coronavirus pneumonia (COVID-19)","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","PSI;","","","","Yes","0","          ",""
"ChiCTR2000029941","2020-02-17","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                     ","","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49596","Not Recruiting","No","18.0","75.0","Both","2020-03-01","experimental group :100;control group:100;","Interventional study","Parallel","N/A","China","LU Zhenhui","","725 Wanping Road South, Xuhui District, Shanghai, China","tcmdoctorlu@163.com","+86 13817729859","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ","Inclusion criteria: 1. Meet the diagnostic criteria for suspected and confirmed cases (including mild, general, and severe) in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);<br>2. Meet the TCM diagnostic criteria","Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;<br>2. Pregnant, preparing or lac","Novel Coronavirus Pneumonia (COVID-19)","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;"," Number of worsening events;","","","","Yes","0","          ",""
"ChiCTR2000029939","2020-02-17","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                ","","HwaMei Hospital, University of Chinese Academy of Sciences","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49612","Recruiting","No","","","Both","2020-02-10","Conventional treatment group:50;Experimental group:50;","Interventional study","Parallel","N/A","China","Ting Cai","","41 Xibei Street, Ningbo, Zhejiang, China","caiting@ucas.ac.cn","+86 13738498188","HwaMei Hospital, University of Chinese Academy of Sciences","Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.<br>Criteria for diagnosis (meet all the following crite","Exclusion criteria: 1. Female patients during pregnancy; <br>2. Patients with known allergy to chloroquine; <br>3. Patients with haematological diseases; <br>4. Patients with chronic liver or kidney diseases at the end stage; <br>5. Patients with arrh","Novel Coronavirus Pneumonia (COVID-19)","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined","Length of hospital stay;","","","","No","0","          ",""
"ChiCTR2000029742","2020-02-17","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)                                                                                                       ","","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49297","Recruiting","No","18.0","70.0","Both","2020-02-10","General patients treated with normal treatment:30;General patients experimental group:30;Severe patients control group 1:10;Severe patients control group 2:10;Severe patients experimental group:10;","Interventional study","Parallel","4.0","China","Qin Ning, Meifang Han","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","31531955@qq.com","+86 27 83662688","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged >=18 to 70 years;<br>2. Diagnosed 2019-nCoV infected patients by viral nucleic acid,or although the test was negative and even not be detected, the reseachers judged it to be a novel coronavirus pneumonia;<br>3. Understand an","Exclusion criteria: 1. Pregnant or lactating women, or pregnant;<br>2. Those who are allergic to the drug ingredients of this program;<br>3. Severe cardiovascular diseases, such as severe center of gravity dysfunction, second or third degree atrioventri","Novel Coronavirus Pneumonia (COVID-19)","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:N","Chest imaging (CT);","","","","No","0","          ",""
"ChiCTR2000029741","2020-02-17","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study                                                                          ","","The Fifth Affiliated Hospital Sun Yat-Sen University","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49263","Recruiting","No","","","Both","2020-02-12","experimental group:56;control group:56;","Interventional study","Parallel","4.0","China","Xia Jinyu","","52 Meihua Road East, Xiangzhou District, Zhuhai, China","xiajinyu@mail.sysu.edu.cn","+86 13823078064","The Fifth Affiliated Hospital Sun Yat-Sen University","Inclusion criteria: (All the following criteria are met before being selected):<br>1. Aged >= 18 years;<br>2. Meet all the following criteria (refer to confirmed cases in the 5th edition of the diagnosis and treatment plan):<br>(1) Epidemiological hist","Exclusion criteria: (Subjects cannot enter the study if they meet any of the following conditions):<br>1. Patients with a history of allergy to chloroquine phosphate, lopinavir, and ritonavir;<br>2. Patients with hematological diseases;<br>3. Patients ","2019 Novel Coronavirus Infection (CoVID-19)","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL","","","","Yes","0","          ",""
"ChiCTR2000029765","2020-02-17","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)                                                                                                                 ","","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49409","Recruiting","No","18.0","85.0","Both","2020-02-10","control group:94;Experience group:94;","Interventional study","Parallel","4.0","China","Xiaoling Xu","","17 Lujiang Road, Luyang District, Hefei, Anhui, China","xxlahh08@163.com","+86 18963789002","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including   severe risk factors) and severe cases of new coronavirus pneumonia;<br>2. Aged 18 to 85 years;<br>3. IL-6 elevated (using Elisa method, using the same compan","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;<br>2. Pregnant or lactating women;<br>3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50;<br>4. Definite diagnosis of rheumatic immune-related diseases;<br","new coronavirus pneumonia","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","cure rate;","","","","No","0","          ",""
"ChiCTR2000029763","2020-02-17","The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                  ","","China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49408","Recruiting","No","18.0","75.0","Both","2020-02-13","experimental group:204;control group:204;","Interventional study","Parallel","N/A","China","Huang Luqi; Li Zhiqiang","","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","huangluqi01@126.com","+86 010-64089801","China Academy of Chinese Medical Sciences","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the ""Diagnosis and Treatment Program for COVID-19""(trial version 5th).<br>(2) Agree to participate in the study and the patient or legal guardian signs the informed ","Exclusion criteria: (1) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route.<br>(2) Patients who have been more than 7 days since definite diagnosis.<b","novel coronavirus pneumonia (COVID-19)","experimental group:TCM and general treatment;control group:general treatment;","Rate of conversion to severe or critical illness;","","","","Yes","0","          ",""
"ChiCTR2000029907","2020-02-17","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients                                                                                                                            ","","West China Hospital, Sichuan University","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49587","Not Recruiting","No","0.0","100.0","Both","2020-02-16","Case series:1000;","Observational study","Sequential","0.0","China","Yao, Rong","","37 Guoxue Lane, Chengdu, Sichuan, China","1037070596@qq.com","+86 18980601415","West China Hospital, Sichuan University","Inclusion criteria: Patients who meet the suspected or confirmed diagnostic criteria of COVID-19.","Exclusion criteria: N/A","COVID-19","Case series:Nil;","clinical features and risk factors;validity and reliability of the model;","","","","Yes","0","          ",""
"ChiCTR2000029905","2020-02-17","A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection","Co-infection of novel coronavirus pneumonia (COVID-19) and influenza virus: a single-center, two-phase, observational study                                                                                                                                    ","","Zhongnan Hospital of Wuhan University","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49595","Recruiting","No","","","Both","2020-02-10","Case series:271;","Observational study","Factorial","N/A","China","Zhao Yan","","169 Donghu Road, Wuhan, Hubei, China","doctoryanzhao@whu.edu.cn","+86 13995577963","Zhongnan Hospital of Wuhan University","Inclusion criteria: 1. Influenza patients diagnosed in our center from December 1 to February 28 in the past 5 years (positive throat swab antigens of influenza A, B and H7 subtypes);<br>2. From December 1, 2019 to February 13, 2020, patients with positi","Exclusion criteria: 1. Patients who refuse to sign informed consent;<br>2. Clinical data is seriously missing or unable to ensure the authenticity of data.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Incidence of co-infection;","","","","No","0","          ",""
"ChiCTR2000029542","2020-02-17","Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                     ","","Sun Yat sen Memorial Hospital of Sun Yat sen University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48968","Recruiting","No","18.0","80.0","Both","2020-02-03","Experimental group:10;control group:10;","Interventional study","Non randomized control","4.0","China","Jiang Shanping","","102 Yanjiang Road West, Guangzhou, Guangdong, China","shanpingjiang@126.com","+86 13922738892","Sun Yat sen Memorial Hospital of Sun Yat sen University","Inclusion criteria: 1. Aged >=18 years old; <br>2. Patients has been diagnosed with 2019-nCoV pneumonia according to WHO interim guidance*.<br>* WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is su","Exclusion criteria: 1. pregnant woman patients;<br>2. Documented allergic history to chloroquine; <br>3. Documented history of hematological system diseases;<br>4. Documented history of chronic liver and kidney diseases; <br>5. Documented history of c","novel coronavirus pneumonia (COVID-19)","Experimental group:chloroquine;control group:conventional management;","viral negative-transforming time;30-day cause-specific mortality;","","","","Yes","0","          ",""
"ChiCTR2000029539","2020-02-17","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)                                                                                                         ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48991","Recruiting","No","18.0","","Both","2020-02-04","experimental group:164;control group:164;","Interventional study","Parallel","0.0","China","Jianping Zhao","","1095 Jiefang Avenue, Wuhan, Hubei","zhaojp@tjh.tjmu.edu.cn","+86 13507138234","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Adult aged >= 18 years old;<br>2. Patients with unexplained viral pneumonia that have been clinically diagnosed or patients with novel coronavirus serum antibody (IgM or IgG) positive or patients with novel coronavirus infection co","Exclusion criteria: 1) Any situation that makes the programme cannot proceed safely; <br>2) patients who have used Kaletra or remdesivir; <br>3) no clinical or chest imaging manifestations; <br>4) In the state of no oxygen at rest, the patient's SPO2 <","novel coronavirus pneumonia (COVID-19)","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;","","","","Yes","0","          ",""
"ChiCTR2000029637","2020-02-17","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                      ","","Guangdong Provincial Hospital of Chinese Medicine","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49127","Not Recruiting","No","","","Both","2020-02-07","Experimental group:50;Control group:50;","Observational study","Sequential","0.0","China","Zhang Zhongde","","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","doctorzzd99@163.com","+86 13903076359","Guangdong Provincial Hospital of Chinese Medicine","Inclusion criteria: Patients who meet the diagnostic criteria of Hubei Province pneumonia infected by novel coronavirus(2019-nCoV), and clinical classification of mild, moderate and severe were included.","Exclusion criteria: ?Allergic constitution, ie, allergic history to 2 or more kinds of medicine or food, or to the medicines of our study.<br>?Patients who do not agree with taking traditional Chinese medicine.","novel coronavirus pneumonia (COVID-19)","Experimental group:Xinguan-1 formula+Standard treatment;Control group:Standard treatment;","Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, an","","","","No","0","          ",""
"ChiCTR2000029636","2020-02-17","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial                                                                                                                      ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49215","Recruiting","No","18.0","","Both","2020-02-09","Case series:40;","Interventional study","Single arm","0.0","China","Hu bo, Li wei","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","hubo@mail.hust.edu.cn","+86 13707114863","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1) Aged >=18 years, gender unlimited, inpatient;<br>2) Patients with new coronavirus infection were confirmed: respiratory or blood samples were positive for 2019 ncov nucleic acid by real-time fluorescent RT-PCR, or respiratory or bl","Exclusion criteria: 1) Known or suspected to be allergic to the components of vMIP.<br>2) Confirmed hepatitis B, C, AIDS and other viral infections.<br>3) Acute respiratory distress syndrome (ARDS) was found.<br>4) According to the judgment of the rese","novel coronavirus pneumonia (COVID-19)","Case series:Conventional standardized treatment and vMIP atomized inhalation;","2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;","","","","Yes","0","          ",""
"ChiCTR2000029758","2020-02-17","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients                                                                                                                                                                                   ","","Department of Critical Care Medicine, West China Hospital of Sichuan University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49295","Recruiting","No","","","Both","2020-02-03","Case series:100;","Observational study","Sequential","0.0","China","Kang Yan","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","Kangyan@scu.edu.cn","+86 18980601566","Department of Critical Care Medicine, West China Hospital of Sichuan University","Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus.","Exclusion criteria: N/A","novel coronavirus pneumonia  (COVID-19)","Case series:Nil;","length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;","","","","No","0","          ",""
"ChiCTR2000029756","2020-02-17","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                     ","","Renmin Hospital of Wuhan University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49222","Recruiting","No","18.0","60.0","Both","2020-02-15","experimental group:119;control group:119;","Interventional study","Parallel","0.0","China","Zhan Zhang","","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","doctorzhang2003@163.com","+86 18062567610","Renmin Hospital of Wuhan University","Inclusion criteria: 1. 18 years old <= age <= 60 years old at the time of screening;<br>2. Pharyngeal swabs, alveolar lavage fluid, or sputum specimens during screening showed that 2019-nCoV virus nucleic acid test results were positive for at least two ","Exclusion criteria: 1. Chronic lung diseases requiring long-term oxygen therapy;<br>2. Long-term application of glucocorticoids due to underlying diseases;<br>3. Based on the researcher's judgment, previous or current diseases may affect patients' parti","novel coronavirus pneumonia (COVID-19)","experimental group:Xiyanping injection;control group:alpha-interferon;","vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;","","","","Yes","0","          ",""
"ChiCTR2000029870","2020-02-17","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                        ","","Jiangsu Institute of Parasitic Diseases","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49563","Recruiting","No","","","Both","2020-02-15","Target condition:500;Difficult condition:100","Diagnostic test","Sequential","0.0","China","Cao Jun","","117 Meiyuan Yangxiang, Wuxi, Jiangsu, China","caojuncn@hotmail.com","+86 0510-68781007","Jiangsu Institute of Parasitic Diseases","Inclusion criteria: Confirmed and suspected cases of novel Coronavirus pneumonia ","Exclusion criteria: None","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;","Positive/Negtive;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000029855","2020-02-17","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                   ","","The First Affiliated Hospital of Medical College of Zhejiang University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49543","Recruiting","No","18.0","75.0","Both","2020-02-15","Chinese traditional medicine group 1:60;Chinese traditional medicine group 2:60;Control group:60;","Interventional study","Parallel","N/A","China","Wu Guolin","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","wuguolin28@163.com","+86 13136150848","The First Affiliated Hospital of Medical College of Zhejiang University","Inclusion criteria: 1) common type pneumonia patients with confirmed new coronavirus infection;<br>2) aged 18 to 75 years old;<br>3) voluntary signing of written informed consent.","Exclusion criteria: 1) pneumonia patients with severe or critical new coronavirus infection;<br>2) daily treatment of asthma, any other chronic respiratory disease;<br>3) patients with confirmed history of diabetes and HbA1C >=8.0%;<br>4) those allergi","Novel Coronavirus Pneumonia (COVID-19)","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional","TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;","","","","Yes","0","          ",""
"ChiCTR2000029747","2020-02-17","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                            ","","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49287","Recruiting","No","12.0","80.0","Both","2020-02-11","Experimental group:100;control group:100;","Interventional study","Parallel","0.0","China","Nianzhi Zhang","","117 Meishan Road, Hefei, Anhui, China","13505615645@163.com","+86 13505615645","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","Inclusion criteria: Conforming to the diagnostic standard of COVID-19; Participants in the first and second trials need to meet the diagnostic criteria of traditional Chinese medicine for epidemic diseases; Participants in the third trial need to meet the","Exclusion criteria: Patients over 80 years of age or less than 12 years of age (trial 3 and less than 18 years old); patients with contraindications to study drugs; cancer patients, life expectancy <6 months; participants in other clinical trials in the p","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","Chest CT;Routine blood test;liver and renal function;TCM syndrome;","","","","Yes","0","          ",""
"ChiCTR2000029739","2020-02-17","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)                                                                                     ","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49283","Recruiting","No","18.0","85.0","Both","2020-02-12","Experimental group:220;Control group:220;","Interventional study","Parallel","N/A","China","Nanshan Zhong, Zeguang Zheng","","151 Yanjing Road, Yuexiu District, Guangzhou, China","zheng862080@139.com","+86 18928868242","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: Subjects participating in this clinical study must meet all of the following criteria:<br>1. General- severe hospitalized patients who meet the diagnostic criteria of the ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Pla","Exclusion criteria: 1. Patients with a significant disease or condition other than the new coronavirus pneumonia, that is, a disease that, according to the investigator's judgment, may cause the subject to be at risk due to participation in the study, or ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;","","","","Yes","0","          ",""
"ChiCTR2000029589","2020-02-17","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19)","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                  ","","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49104","Recruiting","No","","","Both","2020-02-06","control group:30;experimental group:30;","Interventional study","Non randomized control","0.0","China","LIU QINGQUAN","","23 Art Gallery Back Street, Dongcheng District, Beijing, China ","Liuqingquan2003@126.com","+86 010-52176520","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital ","Inclusion criteria: (1) Comply with the diagnostic criteria of ""Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 5)"";<br>(2) The classification was judged as common type;<br>(3) Body temperature > 37.3 degree C;<b","Exclusion criteria: (1) Patients whose estimated survival time does not exceed 48 hours from the start of screening;<br>(2) Tracheal intubation and mechanical ventilation have been performed during screening;<br>(3) Other problems that doctor's judgment","novel coronavirus pneumonia (COVID-19)","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","Antipyretic time;","","","","Yes","0","          ",""
"ChiCTR2000029578","2020-02-17","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","","Zhejiang Chinese Medical University","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49080","Recruiting","No","","","Both","2020-02-06","Treatment group:1000;","Interventional study","Single arm","0.0","China","Chengping Wen","","548 Binwen Road, Hangzhou, Zhejiang, China","wengcp@163.com","+86 571 86613587","Zhejiang Chinese Medical University","Inclusion criteria: 1. Patients who meet the diagnostic criteria of the fifth edition of pneumonia diagnosis and treatment plan for new coronavirus infection issued by the national health and health commission (annex 1) for the confirmed cases of light (m","Exclusion criteria: Patients with other serious organ diseases or mental illness.","novel coronavirus pneumonia (COVID-19)","Treatment group:Integrated Traditional Chinese and Western Medicine;","Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;","","","","Yes","0","          ",""
"ChiCTR2000029853","2020-02-17","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                    ","","People's Hospital of Guangshan County","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49532","Recruiting","No","18.0","","Both","2020-02-16","Experimental group:10;Control group:10;","Interventional study","Parallel","0.0","China","Pei Guangzhong","","222 Zhengda Street, Guangshan County, He'nan, China","503818505@qq.com","+86 13839708181","People's Hospital of Guangshan County","Inclusion criteria: (1) aged >=18 years old;<br>(2) real-time fluorescence rt-pcr of respiratory or blood samples presents the positive nucleic acid of COVID-19, or the viral gene sequencing of respiratory or blood samples was highly homologous with the ","Exclusion criteria: (1) known or suspected allergy to the components of Azivudine tablets;<br>(2) patients with malabsorption syndrome or any other condition that affects gastrointestinal absorption and requires intravenous nutrition or unable to take or","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the ""Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)"" issued by National Health Commission of People's Repu","time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pu","","","","Yes","0","          ",""
"ChiCTR2000029839","2020-02-17","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)                                                                                                                                        ","","Ningbo First Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49439","Recruiting","No","18.0","","Both","2020-02-10","Case series:100;","Observational study","Sequential","4.0","China","Chao Cao","","59 Liuting Road, Ningbo, Zhejiang, China","caocdoctor@163.com","+86 574-87089878","Ningbo First Hospital","Inclusion criteria: 1. Aged >= 18 years; <br>2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV;<br>3. Pneumonia confirmed with chest CT;<br>4. <= 8 days since illness onset and hospitalization with feverat, cough, or dyspnea; <br>5. Willing to","Exclusion criteria: 1. Pregnant and nursing women;<br>2. Patients with severe liver disease and severe renal dysfunction.","Novel Coronavirus Pneumonia (COVID-19)","Case series:variety treatments;","Time to clinical recovery;","","","","No","0","          ",""
"ChiCTR2000029462","2020-02-17","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)                                                                                                                                                  ","","The First Affiliated Hospital of He'nan University of Chinese Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48922","Not Recruiting","No","18.0","90.0","Both","2020-02-01","Case series:200;","Observational study","Sequential","N/A","China","Li Jiansheng","","156 Jinshui East Road, Zhengzhou, He'nan, China","li_js8@163.com","+86 371 65676568","The First Affiliated Hospital of He'nan University of Chinese Medicine","Inclusion criteria: 1. Patients with pneumonia infected by new coronavirus; <br>2. To sign informed consent.","Exclusion criteria: Serious cognitive or mental disorder.","novel coronavirus pneumonia (COVID-19)","Case series:NA;","Clinical characteristics;TCM syndrome;","","","","No","0","          ",""
"ChiCTR2000029438","2020-02-17","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                         ","","Beijing hospital of Traditional Chinese medicine; Hubei integrated traditional Chinese and Western Medicine Hospital","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48911","Not Recruiting","No","","","Both","2020-02-04","control group:50;Experimental group:50;","Interventional study","Parallel","4.0","China","LIU QINGQUAN, MIAO QING, ZHANG BOLI","","23 Back Street of Art Gallery, Dongcheng District, Beijing, China","ZJHTCM@FOXMAIL.COM","+86 13902020873","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","Inclusion criteria: 1) Pneumonia patients diagnosed as new coronavirus infection;<br>2) The type of pneumonia was judged as severe and critical;<br>3) Informed consent.","Exclusion criteria: 1) patients were judged not suitable to participate in the study; <br>2) patients were not suitable to use Chinese patent medicine.","novel coronavirus pneumonia (COVID-19)","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;","","","","Yes","0","          ",""
"ChiCTR2000029732","2020-02-17","Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)","Impact of vitamin D deficiency on prognosis of patients novel coronavirus pneumonia (COVID-19)                                                                                                                                                                 ","","West China Hospital, Sichuan University","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49302","Not Recruiting","No","","","Both","2020-02-10","Vitamin D deficiency group:104;Vitamin D normal group:52;","Observational study","Factorial","0.0","China","Jun Guo","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China  ","guojun@wchscu.cn","+86 15388178461","West China Hospital, Sichuan University ","Inclusion criteria: 1. Aged >= 18 years.<br>2. Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection. ","Exclusion criteria: 1. Patients without any clinical and chest imaging findings;<br>2. Supplementation with vitamin D or calcium within one week before admission<br>3. Patients with severe failure with chronic organ dysfunction;<br>4. Malignant tumors;","novel coronavirus pneumonia (COVID-19)","Vitamin D deficiency group:N/A;Vitamin D normal group:N/A;","ROX index;","","","","Yes","0","          ",""
"ChiCTR2000029639","2020-02-17","Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study                                                            ","","The Fifth Affiliated Hospital Sun Yat-Sen University","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49187","Recruiting","No","14.0","??","Both","2020-02-10","doctors group:48;nurses group:48;suspected cases group:48;cases group:48;","Interventional study","Factorial","0.0","China","Wen Shenglin, Xia Jinyu","","52 Meihua Road East, Zhuhai, Guangdong, China","wenshl@mail.sysu.edu.cn","+86 13312883618","Department of Psychology, the Fifth Affiliated Hospital Sun Yat-Sen University","Inclusion criteria: 1) Medical staff involved in the diagnosis and treatment of new coronavirus pneumonia;<br>2) 2019-nCoV infection suspected or confirmed cases;<br>3) Voluntarily participate in this research project and sign informed consent;<br>4) A","Exclusion criteria: no exclusion criteria.","novel coronavirus pneumonia (NCP)","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;","","","","Yes","0","          ",""
"ChiCTR2000029518","2020-02-17","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                      ","","Zhejiang Chinese Medical University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48860","Recruiting","No","14.0","80.0","Both","2020-02-04","(ordinary) Western medicine group:40;(ordinary) Chinese and Western Medicine Group:40;(severe) Western medicine group:30;(severe) Chinese and Western Medicine Group:30;","Interventional study","Parallel","0.0","China","Wen Chengping","","548 Binwen Road, Binjiang District, Hangzhou, Zhejiang","wengcp@163.com","+86 13906514781","Zhejiang Chinese Medical University","Inclusion criteria: (1) Patients who meet the diagnostic criteria of the common type of confirmed cases (the initial stage of clinical treatment of traditional Chinese medicine) or the severe cases of confirmed cases (the middle stage of clinical treatmen","Exclusion criteria: (1) The critically ill patients in the diagnosis and treatment program of pneumonia with new coronavirus infection issued by the National Health Commission;<br>(2) It is not suitable for patients who take traditional Chinese medicine ","novel coronavirus pneumonia (COVID-19)","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in ""the diagnosis and treatment plan of new coronavirus infection pneumonia"" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Weste","Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;","","","","Yes","0","          ",""
"ChiCTR2000029517","2020-02-17","Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","","Zhejiang Chinese Medical University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48861","Recruiting","No","14.0","80.0","Both","2020-02-04","treament group:50;placebo group:50;","Interventional study","Parallel","0.0","China","Chengping Wen","","548 Binwen Road, Hangzhou, Zhejiang, China","wengcp@163.com","+86 13601331063","Zhejiang Chinese Medical University","Inclusion criteria: (1) Conforming to the diagnostic criteria of suspected cases (Chiese medicine observation period) in the fourth edition of pneumonia diagnosis and treatment program for new coronavirus infection issued by the national health and health","Exclusion criteria: (1) Patients are not suitable to take Chinese medicine decoction.<br>(2) Patients have other serious organ disease or mental illness;<br>(3) Patients allergy or have contraindications to the drugs involved in the research program.","novel coronavirus pneumonia (COVID-19)","treament group:Chinese medicine decoction;placebo group:placebo;","Relief of clinical symptoms and duration;","","","","Yes","0","          ",""
"ChiCTR2000029821","2020-02-17","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation                              ","","Deyang Integrated Traditional Chinese and Western Medicine Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49306","Not Recruiting","No","3.0","85.0","Both","2020-02-14","Observation  group:300;Health  education unit:100;","Prevention","Non randomized control","N/A","China","Qiu Jun","","159 Tianshan Road South, Jingyang District, Deyang, Sichuan, China","973007530@qq.com","+86 13881070630","Deyang integrative medicine hospital ","Inclusion criteria: 1. Non suspected cases and non confirmed cases;<br>2. Participate in novel coronavirus front-line prevention and control of medical staff, street community office staff;<br>3. Novel coronavirus pneumonia is recommended by people who ","Exclusion criteria: 1. Suspected cases and confirmed cases;<br>2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;<br>3. People who could not complete the study for other reaso","Novel Coronavirus Pneumonia (COVID-19)","Observation  group:TCM prevention;Health  education unit:Health  education;","CD4+;CD3+;HAMA;HAMD;STAI;","","","","Yes","0","          ",""
"ChiCTR2000029819","2020-02-17","Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network                                                                                   ","","Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49490","Recruiting","No","18.0","90.0","Both","2020-02-11","Experimental group:40;Control group:40;","Interventional study","Non randomized control","4.0","China","Ying Kejing","","3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China","yingsrrsh@163.com","+86 13588706900","Sir Run Run Show Hospital, School of Medicine, Zhejiang University","Inclusion criteria: 1. Aged >=18 years, unlimited for men and women;<br>2. A novel coronavirus infection confirmed by pathogenic detection;<br>3. According to novel coronavirus infection pneumonia treatment plan (trial version fifth), severe patients sh","Exclusion criteria: 1. Pregnant or lactating women;<br>2. The patients had mental disorder, drug abuse or dependence history, allergy to research drugs, and participated in other clinical studies within 3 months;<br>3. Potential violation of test compli","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;","","","","No","0","          ",""
"ChiCTR2000029436","2020-02-17","A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                               ","","The First Hospital of He'nan University of Chinese Medicine","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48884","Not Recruiting","No","","","Both","2020-02-01","Group 1:50;Group 2:50;","Interventional study","Non randomized control","0.0","China","Li Jiansheng, Li Suyun","","19 Renmin Road, Zhengzhou, He'nan, China ","lisuyun2000@126.com","+86 371 66248624","The First Hospital of He'nan University of Chinese Medicine","Inclusion criteria: 1. patients with 2019-nCoV pneumonia;<br>2. Sign informed consent.","Exclusion criteria: 1. Patients complicated with active tuberculosis, malignant arrhythmia, acute myocardial infarction and stroke;<br>2. pregnant and lactating women;<br>3. Patients complicated with severe cognitive and mental disorders;<br>4. Clinica","novel coronavirus pneumonia (COVID-19)","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","Duration of PCR normalization;Clinical symptom score;","","","","Yes","0","          ",""
"ChiCTR2000029418","2020-02-17","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial                                                                                                                                                       ","","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","2020-01-30","2020-01-30","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48886","Recruiting","No","18.0","","Both","2020-02-03","Experimental Group:28;Control Group:14;","Interventional study","Parallel","0.0","China","Tengxiao Liang, Tong Wang, Xuezeng Hao, Jingfeng Zhang, Yaosheng  Zhang","","5 Haiyuncang Lane, Dongcheng District, Beijing","shanghongcai@126.com","+86 010 84012510","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","Inclusion criteria: 1) Aged  >= 18 years;<br>2) Meet the diagnostic criteria of severe pneumonia patients with new coronavirus;<br>3) The informed consent form.","Exclusion criteria: 1) Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;<br>2) Obstruct","novel coronavirus pneumonia (COVID-19)","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","Critically ill patients (%);","","","","Yes","0","          ",""
"ChiCTR2000029628","2020-02-17","A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","","Guangdong Provincial Hospital of Chinese Medicine","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49155","Not Recruiting","No","","","Both","2020-02-07","Experimental group:50;Control group:50;","Observational study","Non randomized control","0.0","China","Zhang Zhongde","","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","doctorzzd99@163.com","+86 13903076359","Guangdong Provincial Hospital of Chinese Medicine","Inclusion criteria: Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.","Exclusion criteria: An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in Xin-Guan-2 formula.","novel coronavirus pneumonia (COVID-19)","Experimental group:Xinguan-2 formula+Standard treatment;Control group:Standard treatment;","Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of br","","","","Yes","0","          ",""
"ChiCTR2000029625","2020-02-17","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                 ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49177","Not Recruiting","No","18.0","90.0","Both","2020-02-17","Target condition:80;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Cai Hongliu","","79 Qingchun Road, Hangzhou, Zhejiang, China","caiicu@163.com","+86 13505811696","The First Affiliated Hospital of Zhejiang University School of Medicine ","Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"";<br>","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)","novel coronavirus pneumonia (COVID-19)","Gold Standard:Clinical outcome;Index test:early&#32;warning&#32;and&#32;prediction&#32;system;","Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;","","","","Yes","0","          ",""
"ChiCTR2000029495","2020-02-17","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period                                                                                    ","","1. Xinhua Affiliated Hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48971","Not Recruiting","No","18.0","70.0","Both","2020-02-03","experimental group:30;	 Control group:30;Control group:30;","Interventional study","Parallel","0.0","China","Min Huang","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","1025823309@qq.com","+86 13307161995","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV); <br>2. virus turned negative after treatment; <br>3. aged 18-70 years old; <br>4. patients with clear consciousness <br>5. Signing the informed con","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; <br>2. Pregnant or lactating women; <br>3. Patients who have mental confusion, who with a history of drug abuse or","novel coronavirus pneumonia (COVID-19)","experimental group:Traditional Chinese Medicine+psychological intervention;	 Control group:Traditional Chinese Medicine;Control group:psychological intervention;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;","","","","Yes","0","          ",""
"ChiCTR2000029493","2020-02-17","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial                                                      ","","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48931","Not Recruiting","No","18.0","70.0","Both","2020-02-03","experimental group 	:50;control group :50;","Interventional study","Parallel","0.0","China","Jixian Zhang","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China ","jxzhang1607@163.com","+86 13377897297","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);<br>2. virus turned negative after treatment;<br>3. Patients diagnosed with pulmonary fibrosis; <br>4. aged 18-70 years old;<br>5. patients with cle","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; <br>2. Pregnant or lactating women;<br>3. Patients who have mental confusion, who with a history of drug abuse or ","novel coronavirus pneumonia (COVID-19)","experimental group 	:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;","","","","Yes","0","          ",""
"ChiCTR2000029804","2020-02-17","Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                       ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49178","Recruiting","No","","","Both","2020-02-12","Case series:100;","Prognosis study","Cohort study","Retrospective study","China","Wu Wenjuan","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","1346801465@qq.com","+86 13397192695","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) ","Inclusion criteria: 1. Patients who meet the requirements of the ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Trial Version 4)"" which issued by the General Office of the National Health Commission.<br>2. ECMO-treated patients with ","Exclusion criteria: 1. Age> 75 years.<br>2. After CPR.<br>3. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Novel Coronavirus Pneumonia (COVID-19)","Case series:NA;","Inpatient mortality;","","","","No","0","          ",""
"ChiCTR2000029769","2020-02-17","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                              ","","Enze Hospital of Taizhou Enze Medical Center (Group)","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49415","Not Recruiting","No","18.0","80.0","Both","2020-02-15","Experimental group:20;Control group:20;","Interventional study","Parallel","0.0","China","Lv Dongqing","","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang, China","lvdq@enzemed.com","+86 13867622009","Enze Hospital of Taizhou Enze Medical Center (Group)","Inclusion criteria: Severe patients (according to any of the following): respiratory distress (RR> 30 beats / min); at rest, means oxygen saturation <= 93%; arterial oxygen pressure (PaO2) / oxygen concentration (FiO2) < = 300 mmHg","Exclusion criteria: Children, pregnant women","novel coronavirus pneumonia (COVID-19)","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","28-day survival;Inflammatory factor levels;","","","","Yes","0","          ",""
"ChiCTR2000029602","2020-02-17","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population                                                                                                 ","","Hubei Provincial Hospital of TCM","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48985","Recruiting","No","18.0","65.0","Both","2020-02-01","Experimental group:300;Control group:300;","Interventional study","Parallel","0.0","China","Xiaolin Tong","","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","Xiaolintong66@sina.com","+86 13910662116","Hubei Provincial Hospital of TCM","Inclusion criteria: 1. Conforming to the diagnostic criteria for the above close contacts;<br>2. Aged between 18 and 65 years old;<br>3. Signing the generalized informed consent form.  (The intervention objects is incorporated in the clinical study as d","Exclusion criteria: 1. Severe or critically severe patients;<br>2. Clear evidence of bacterial infection; <br>3. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affec","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated ","","","","No","0","          ",""
"ChiCTR2000029600","2020-02-17","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                ","","The Third People's Hospital of Shenzhen","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49042","Recruiting","No","16.0","75.0","Both","2020-01-30","Group A:30;Group B:30;Group C:30;","Interventional study","Non randomized control","0.0","China","Liu Yingxia","","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","yingxialiu@hotmail.com","+86 755 61238922","The Third People's Hospital of Shenzhen","Inclusion criteria: 1. 16 to 75 years of age, male or female;<br>2. Respiratory or blood samples tested positive for novel coronavirus;<br>3. Within 7 days of onset: Onset is defined as body temperature exceeding 38 degree C (armpit temperature) or at l","Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;<br>2. Patient refuses to receive invasive tracheal support (if needed);<br>3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfe","novel coronavirus pneumonia (COVID-19)","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;","","","","No","0","          ",""
"ChiCTR2000029768","2020-02-17","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate","","Zhongnan Hospital of Wuhan University","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49131","Recruiting","No","18.0","75.0","Both","2020-02-12","experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Jun Lin","","169 Donghu Road, Wuchang District, Wuhan, Hubei ","wdznyy@126.com","+86 13971156723","Zhongnan Hospital of Wuhan University ","Inclusion criteria: 1. Aged 18-75 years male or female;<br>2. Body weight 40-100 kg and BMI >= 18kg/m2;<br>3. Been Confirmed with commom 2019-nCoV pneumonia inpatient;<br>4. With fever, respiratory tract and other symptoms, imaging shows pneumonia;<br","Exclusion criteria: 1. Infected with other viruses such as HCV, HIV, and syphilis;<br>2. Used non-steroidal anti-inflammatory drugs within 3 days before enrollment;<br>3. Have severe liver disease;<br>4. Those who are known to be allergic to the test d","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","Time to Clinical recovery;","","","","No","0","          ",""
"ChiCTR2000029754","2020-02-17","Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People                                                                                                                                                                             ","","West China Hospital, Sichuan University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49370","Recruiting","No","","","Both","2020-02-10","Epilepsy group:500;Health Control group:1000;","Observational study","Factorial","N/A","China","Chen Lei","","37 Guoxuexiang, Wuhou District, Chengdu, Sichuan, China","leilei_25@126.com","+86 18980605819","West China Hospital, Sichuan University","Inclusion criteria: Long-term follow-up of patients with epilepsy and healthy subjects in the natural population cohort study of west China hospital, sichuan university.","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;<br>2. Patients and healthy people who are not willing to participate in the survey.","Epilepsy, Chronic diseases, Novel Coronavirus Pneumonia (COVID-19)","Epilepsy group:N/A;Health Control group:N/A;","Physical and mental health;","","","","No","0","          ",""
"ChiCTR2000029432","2020-02-17","A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                      ","","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48881","Not Recruiting","No","","","Both","2020-02-01","Case series:72;","Interventional study","Sequential","4.0","China","Zhongqi Yang, Minyong Wen","","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","yang_zhongqi@163.com","+86 13688867618","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","Inclusion criteria: 1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the ""Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version ","Exclusion criteria: 1. Patients with severe novel coronavirus pneumonia;<br>2. Patients with severe basic diseases;<br>3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to st","novel coronavirus pneumonia (COVID-19)","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more t","Time for body temperature recovery;Chest X-ray absorption;","","","","Yes","0","          ",""
"ChiCTR2000029431","2020-02-17","Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                        ","","Affiliated Zhongshan Hospital of Dalian University","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48907","Recruiting","No","","","Both","2020-01-29","A:15;B:15;C:15;","Interventional study","Parallel","0.0","China","Dewei Zhao","","6 Jiefang Street, Dalian, Liaoning, China ","zhaodewei2016@163.com","+86 0411-62893509","Affiliated Zhongshan Hospital of Dalian University","Inclusion criteria: 1. 2019-nCoV infected patients treated at Affiliated Zhongshan Hospital of Dalian University and Zhongnan Hospital of Wuhan University from January 2020 to December 2020<br>2. nCoV nucleic acid positive;<br>3. Aged >=18 years;<br>4.","Exclusion criteria: 1. Those with allergies;<br>2. Patients with a history of severe cardio-cerebral vascular disease, diabetes, mental and neurological diseases, severe liver and renal insufficiency;<br>3. History of hip or knee trauma or surgery;<br>","novel coronavirus pneumonia (COVID-19)","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","CT of lung;CT and MRI of hip;","","","","No","0","          ",""
"ChiCTR2000030173","2020-02-25","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration                                                                                                     ","","Hunan yuanpin Cell Biotechnology Co., Ltd","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49229","Not Recruiting","No","18.0","70.0","Both","2020-02-17","Experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Xue Zhigang","","102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China","xuezg@tongji.edu.cn","+86 15000285942","Hu'nan Yuanpin Cell Biotechnology Co., Ltd","Inclusion criteria: 1. Aged 18-60 years old;<br>2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia;<br>3. Voluntarily sign the informed consent t","Exclusion criteria: 1. History of tumor;<br>2. Vascular embolism and pulmonary hypertension;<br>3. Suspected or established history of alcohol, drug or drug abuse;<br>4. Female patients of child-bearing age who are pregnant, breast-feeding or have a re","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","pulmonary function;Novel coronavirus pneumonic nucleic acid test;","","","","No","0","          ",""
"ChiCTR2000030166","2020-02-25","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                    ","","The 5th Medical Center Chinese PLA General Hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49696","Not Recruiting","No","18.0","","Both","2020-02-25","Control group:10;Investigation group:10;","Interventional study","Parallel","0.0","China","Yanling Zhao","","100 West Fourth Ring Road, Fengtai District, Beijing, China","zhaoyl2855@126.com","+86 13681208998","The 5th Medical Center Chinese PLA General Hospital","Inclusion criteria: Inclusion of case criteria (pneumonia diagnosis and treatment protocol for COVID-19 (trial 6th edition))<br>1. Common type patient: with fever, respiratory tract and other symptoms, and imaging findings of pneumonia.<br>2. Severe pat","Exclusion criteria: 1. The patient has other immune system, blood system, heart, liver, kidney and other important organs of the disease;<br>2. Accompanied by chronic diseases, such as malignant tumors, chronic obstructive pulmonary disease;<br>3. have ","Novel Coronavirus Pneumonia (COVID-19)","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recom","CT scan of the lungs;Nucleic acid detection of throat secretion;","","","","Yes","0","          ",""
"ChiCTR2000029572","2020-02-17","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial                                                                          ","","Xiangyang First People's Hospital","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=41760","Recruiting","No","18.0","","Both","2020-02-05","control group:15;experimental group:15;","Interventional study","Parallel","0.0","China","Pei Bei","","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China ","xyxzyxzh@163.com","+86 18995678520","Xiangyang First People's Hospital ","Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial","Exclusion criteria: 1. Have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;<br>2. Other circu","novel coronavirus pneumonia (COVID-19)","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","PSI;","","","","Yes","0","          ",""
"ChiCTR2000029559","2020-02-17","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)                                                                                                                                                                             ","","Renmin Hospital of Wuhan University","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48880","Recruiting","No","30.0","65.0","Both","2020-01-31","experimental group 1:100;experimental group 2:100;Placebo control group:100;","Interventional study","Parallel","4.0","China","Zhang Zhan","","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","doctorzhang2003@163.com","+86 18962567610","Renmin Hospital of Wuhan University","Inclusion criteria: Patients with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form.","Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.","novel coronavirus pneumonia (COVID-19)","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;","","","","No","0","          ",""
"ChiCTR2000029751","2020-02-17","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                      ","","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49354","Recruiting","No","","","Both","2020-02-01","Suspected patient control group:100;Suspected patient Treatment group:100;Common NCP patient control group:50;Common NCP patient Treatment group:50;Severe NCP patient:50;","Observational study","Non randomized control","N/A","China","Mao Wei","","54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang, China","maoweilw@163.com","+86 0571-87068001","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","Inclusion criteria: 1. Patients diagnosed with suspected or confirmed NCP (divided into ordinary type and severe type according to their clinical classification);<br>2. Be between 18-85 years of age;<br>3. Informed consent and signed informed consent.","Exclusion criteria: 1. Patients with severe primary diseases such as heart, lung, liver, kidney, brain, and hematopoietic system;<br>2. pregnant or lactating women;<br>3. Patients with mental illness;<br>4. Those who are participating in other clinical","novel coronavirus pneumonia (COVID-19)","Suspected patient control group:Routine respiratory disease treatment;Suspected patient Treatment group:Oral Chinese medicine treatment based on control group;Common NCP patient control group:treatment according to the guideline;Common NCP patient Treatme","blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;","","","","No","0","          ",""
"ChiCTR2000029735","2020-02-17","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                   ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49279","Recruiting","No","","","Both","2020-01-26","non-severe group and severe gorup:500;","Observational study","Factorial","N/A","China","Min Xie","","1095 Jiefang Avenue, Wuhan, Hubei, China","xie_m@126.com","+86 18602724678","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: SARI<br>1. An ARI with history of fever or measured temperature >= 38 degree C and cough; onset within the last ~10 days; and requiring hospitalization. However, the absence of fever does NOT exclude viral infection.<br>2. Surveillan","Exclusion criteria: Researchers believe that patients are not suitable for any other situation in this study.","Novel Coronavirus Pneumonia (COVID-19)","non-severe group and severe gorup:N/A;","incidence;mortality;","","","","No","0","          ",""
"ChiCTR2000029544","2020-02-17","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy                          ","","The First Hospital Affiliated to Zhejiang University's Medical School","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49013","Not Recruiting","No","18.0","75.0","Both","2020-02-04","Experimental group 1:10;Experimental group 2:10;Control group:10;","Interventional study","Parallel","0.0","China","Qiu Yunqing","","79 Qingchun Road, Hangzhou, Zhejiang, China","qiuyq@zju.edu.cn","+86 13588189339","The First Hospital Affiliated to Zhejiang University's Medical School","Inclusion criteria: 1. 18 to 75 years of age, male or female, willing to sign informed consent;<br>2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain reaction (RT-PCR)-based diagnostic assay;","Exclusion criteria: 1. Allergic constitution, known to be allergic to balosavir or farpiravir or pharmaceutical excipients;<br>2. Body weight <40 kg;<br>3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mec","novel coronavirus pneumonia (COVID-19)","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","Time to viral negativity by RT-PCR;Time to clinical improvement;","","","","Yes","0","          ",""
"ChiCTR2000029541","2020-02-17","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                      ","","Zhongnan Hospital of Wuhan University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48992","Not Recruiting","No","18.0","65.0","Both","2020-02-10","DRV/c group:40;LPV/r group:40;other group:20;","Interventional study","Parallel","N/A","China","Wang Xinghuan/Ke Hengning ","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","wangxinghuan@whu.edu.cn","+86 18971387168/+86 15729577635","Zhongnan Hospital of Wuhan University","Inclusion criteria: 1. Aged 18-65 years;<br>2. been Confirmed with 2019-nCoV pneumonia, hospitalized or will be hospitalized;<br>3. Sign the ICF;<br>4. no more than 10 days from the occurrence of relevant clinical symptoms to the diagnosis been confirm","Exclusion criteria: 1. Allergic history to study medicines;<br>2. ALT/AST >5 UNL or Child-Pugh Class C;<br>3. Severely ill patients with life expectance <48 hours;<br>4. Contraindication of DRV or thymosin;<br>5. Pregnancy testing positive for child-b","novel coronavirus pneumonia (COVID-19)","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 m","Time to conversion of 2019-nCoV RNA result from RI sample;","","","","Yes","0","          ",""
"ChiCTR2000030118","2020-02-25","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                         ","","Shenzhen national medicine inheritance medical research institute co. LTD","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49594","Not Recruiting","No","","","Both","2020-02-24","Experimental group:60;Control group:60;","Interventional study","Parallel","0.0","China","Yuan Yongming","","Room 18A 03-2, Anlian Building, 4018 Jintian Road, Fuzhong Community, Lianhua Street, Futian District, Shenzhen, Guangdong, China","64699629@qq.com","+86 18664556429","Shenzhen national medicine inheritance medical research institute co. LTD","Inclusion criteria: (1) All patients were diagnosed with a new type of coronavirus pneumonia;<br>(2) Clear mind, cooperation and communication; <br>(3) Men and women aged 18 and 80 years; <br>(4) informed consent has been signed and is willing to be as","Exclusion criteria: (1) with severe liver or kidney failure or other serious underlying diseases; <br>(2) Pregnant and lactating women; <br>(3) Persons who are participating in other clinical trials.","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;","","","","Yes","0","          ",""
"ChiCTR2000030116","2020-02-25","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)                                                                               ","","The First Affiliated Hospital of Nanchang University","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49901","Recruiting","No","18.0","75.0","Both","2020-02-01","Two groups:16;","Interventional study","Dose comparison","N/A","China","Zhang Wei","","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","zhangweiliuxin@163.com","+86 13707089183","The First Affiliated Hospital of Nanchang University","Inclusion criteria: Patients are eligible for admission if they meet all of the following criteria within 5-7 days of their first ICU admission. <br>1) Aged 18-75 years; <br>2) The patient meets the ARDS diagnostic standard (Berlin standard) and needs i","Exclusion criteria: 1) ARDS caused by other viral infections; <br>2) ARDS caused by other non-viral infections (such as trauma); <br>3) WHO grade III or IV pulmonary hypertension; <br>4) Patients with malignant tumors of the lungs and other systems; <","Novel Coronavirus Pneumonia (COVID-19)","Two groups:Different stem cell doses;","Time to leave ventilator on day 28 after receiving MSCs infusion;","","","","No","0","          ",""
"ChiCTR2000029734","2020-02-17","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                  ","","The First People's Hospital of Huaihua","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48868","Recruiting","No","","","Both","2020-02-08","Case series:40;","Observational study","Sequential","N/A","China","Chengfeng Qiu","","144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China","qiuchengfeng0721@163.com","+86 14786531725","The First People's Hospital of Huaihua","Inclusion criteria: Patients who are positive for novel coronary virus detected by RC-PCR and  second-generation sequencing.","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:N/A;","Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;","","","","No","0","          ",""
"ChiCTR2000029621","2020-02-17","Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                  ","","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49165","Recruiting","No","18.0","","Both","2020-02-07","Experimental group:190;Control group:190;","Interventional study","Parallel","4.0","China","Qu Jieming","","197 Second Ruijin Road, Huangpu District, Shanghai, China","jmqu0906@163.com","+86 21 64370045","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","Inclusion criteria: 1. Sign the informed consent form;<br>2. Aged >=18 years;<br>3. Subjects diagnosed as 2019-nCoV pneumonia;<br>(1) Detection of 2019-nCoV nucleic acid positive by RT-PCR in respiratory tract or blood samples;<br>(2) The virus gene s","Exclusion criteria: 1. Critical type: If one of the following conditions is met<br>(1) Respiratory failure occurs and mechanical ventilation is needed;<br>(2) Shock occurred;<br>(3) Patients with other organ failure need ICU monitoring treatment;<br>2","novel coronavirus pneumonia (COVID-19)","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","Virus negative conversion rate in the first week;","","","","Yes","0","          ",""
"ChiCTR2000029487","2020-02-17","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children                                                                                                                                                     ","","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48965","Not Recruiting","No","","","Both","2020-02-10","Experimental group:100;Control group:100;","Prevention","Case-Control study","N/A","China","Su Wen","","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","784404524@qq.com","+86 13659897175","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Inclusion criteria: Healthy children between the ages of 1 and 18 who meet the TCM constitutional doctrine:<br>(1) Main features: moderate body shape, ruddy complexion, energetic, etc .;<br>(2) Common manifestations: Symmetric body shape, complexion, mo","Exclusion criteria: 1. Clinical suspected or confirmed cases [Refer to the recommendations for diagnosis and treatment of 2019-nCoV infection in children in Hubei Province (trial version 1)]<br>2. Those who have received other traditional Chinese medicin","novel coronavirus pneumonia (COVID-19) in children","Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;","body temperature;Whole blood count and five classifications;C-reactive protein;","","","","Yes","0","          ",""
"ChiCTR2000029468","2020-02-17","A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study                                                    ","","Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48919","Not Recruiting","No","18.0","80.0","Both","2020-02-01","experimental group:60;Historical Control:60;","Interventional study","Non randomized control","N/A","China","Jiang Hua","","32 Second Section, First Ring Road West, Chengdu, Sichuan, China","cdjianghua@qq.com","+86 028 87393881","Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital","Inclusion criteria: 1. diagnosis of 2019-new coronavirus (2019-nCoV) pneumonia;<br>2. adult patients aged 18-80 years old.","Exclusion criteria: 1. ARDS was developed after infection without antiviral treatment;<br>2. suffering from HBV, HIV, pancreatitis, intrahepatic bile duct stones or having the previous history mentioned above ;<br>3. severe heart, liver, kidney and resp","novel coronavirus pneumonia (COVID-19)","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","Patient survival rate;","","","","No","0","          ",""
"ChiCTR2000030093","2020-02-25","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)                           ","","The Second Hospital of Shanxi Medical University","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49932","Not Recruiting","No","18.0","65.0","Both","2020-03-01","1:30;2:30;","Interventional study","Non randomized control","N/A","China","Tian Feng","","382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, China","tflook@163.com","+86 13934570253","The Second Hospital of Shanxi Medical University","Inclusion criteria: Including front-line medical staff for COVID-19 epidemic prevention and control, including front-line medical staff responsible for epidemic prevention and control in Wuhan or other regions, and front-line staff responsible for epidemi","Exclusion criteria: With other serious physical or mental illnesses.","Mental health; Novel coronavirues pneumonia (COVID-19)","1:Simplify cognitive behavior;2:Supportive psychotherapy;","State anxiety;","","","","Yes","0","          ",""
"ChiCTR2000030084","2020-02-25","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression                                                  ","","The First Hospital of Shanxi Medical University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49952","Recruiting","No","18.0","75.0","Both","2020-02-24","Psychological Intervention Group:90;Control Group :90;","Interventional study","Parallel","0.0","China","Xu Yong","","85 Jiefang Road South, Yingze District, Taiyuan, Shanxi, China","xuyongsmu@vip.163.com","+86 18234016125","The First Hospital of Shanxi Medical University","Inclusion criteria: 1. Age between 18 and 75 years old (including threshold), regardless of gender;<br>2. The patient under isolation observation is diagnosed with mild or common type of 2019-nCoV acute respiratory disease and can cooperate to complete c","Exclusion criteria: 1. In the six months before the diagnosis of 2019-nCoV acute respiratory disease, the patient was clearly diagnosed as a psychiatric disorder, including depression, bipolar disorder and so on; <br>2. Patients with psychotic symptoms;","novel coronavirus pneumonia (COVID-19) with mild to moderate anxiety and depression","Psychological Intervention Group:""Intelligent Psychosomatic Regulation System"" Intervention;Control Group :General Treatment ;","the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;","","","","Yes","0","          ",""
"ChiCTR2000029609","2020-02-17","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                ","","The Fifth Affiliated Hospital of Sun Yat-Sen University","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49145","Not Recruiting","No","18.0","80.0","Both","2020-02-10","mild-moderate chloroquine group:59;mild-moderate Lopinavir/ritonavir group:59;mild-moderate combination group:59;severe-chloroquine group :14;severe- Lopinavir/ritonavir group:14;","Interventional study","Non randomized control","4.0","China","Hong Shan","","52 Meihua Road East, Zhuhai, Guangdong, China","shanhong@mail.sysu.edu.cn","+86 0756 2528573","The Fifth Affiliated Hospital of Sun Yat-Sen University","Inclusion criteria: 1. Aged >=18 years old; <br>2. Patients has been diagnosed with 2019-nCoV pneumonia according to the fifth version of 2019-nCoV pneumonia management guideline made by the national health commission of the People's Repulic of China.<b","Exclusion criteria: 1. Pregnant woman patients;<br>2. Documented allergic history to any of chloroquine phosphate, ritonavir and lopinavir;<br>3. Documented history of hematological system diseases;<br>4. Documented history of chronic liver and kidney ","novel coronavirus pneumonia (COVID-19)","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate","virus nucleic acid negative-transforming time;","","","","Yes","0","          ",""
"ChiCTR2000029606","2020-02-17","Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                   ","","The First Affiliated Hospital, College of Medicine, Zhejiang University","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49146","Recruiting","No","1.0","99.0","Both","2020-01-25","experimental group A:18;control gorup A:15;Experimental Group B1:10;Experimental Group B2:10;Control Gorup A:10;","Interventional study","Parallel","0.0","China","Lanjuan Li /Xiaowei Xu/Charile Xiang","","79 Qingchun Road, Hangzhou, Zhejiang, China","ljli@zju.edu.cn","+86 0571-87236426","The First Affiliated Hospital, College of Medicine, Zhejiang University","Inclusion criteria: 1. Diagnosed as novel coronavirus pneumonia (NCP) Patient:<br>1) Basis of diagnostic criteria: ""Notice on Printing and Distributing Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Implementation Fourth Edit","Exclusion criteria: 1. Pregnant or lactating women;<br>2. There are comorbidities that affect the judgment of the efficacy, such as those with malignant tumors or long-term immunosuppressants;<br>3. The investigator believes that the patient has other c","Novel Coronavirus Pneumonia (COVID-19)","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental","Mortality in patients;","","","","No","0","          ",""
"ChiCTR2000029437","2020-02-17","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","","Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48913","Not Recruiting","No","","","Both","2020-02-03","Case series:300;","Observational study","Single arm","N/A","China","Xia Wenguang, An Changqing, Zhang Boli","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","DOCXWG@16.COM","+86 13902020873","Hubei integrated hospital of traditional Chinese and Western Medicine","Inclusion criteria: Inpatient patients diagnosed as neumonia caused by new coronavirus infection.","Exclusion criteria: Doctor's judgment is not suitable for the study.","novel coronavirus pneumonia (COVID-19)","Case series:according to guidelines;","all available outcome;","","","","Yes","0","          ",""
"ChiCTR2000029435","2020-02-17","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population                                                                                                               ","","Wuhan 1st Hospital","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48827","Not Recruiting","No","18.0","60.0","Both","2020-02-01","Community exposure TCM intervention group:20;Community exposure control group:20;Hospital exposure TCM intervention group:20;Hospital exposure control group:20;Community suspected TCM intervention group:20;Community suspected control group:20;Hospital su","Interventional study","Parallel","0.0","China","Wei Li","","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","whsdyyykjc@126.com","+86 13163283819","Wuhan 1st Hospital","Inclusion criteria: 1. aged 18 to 60 years<br>2. to be confirmed with a exposure history of diagnosed population within last 14 days;<br>3. with fever, positive results of blood routine examination and positive findings in CT examination, any two in thr","Exclusion criteria: 1. Pregnancy or lactation;<br>2. Previous serious chronic basic diseases;<br>3. Previous allergy to traditional Chinese medicine;<br>4. Newly diagnosed 2019-nCOV pneumonia.","novel coronavirus pneumonia (COVID-19)","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM interventi","Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;","","","","Yes","0","          ",""
"ChiCTR2000030043","2020-02-25","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                                                   ","","Peking University Third Hospital","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49866","Not Recruiting","No","18.0","75.0","Both","2020-02-21","Experimental:150;control:150;","Interventional study","Parallel","4.0","China","Ma Penglin","","49 North Huayuan Road, Haidian District, Beijing, China","mapenglin1@163.com","+86 13810339898","Peking University Third Hospital ","Inclusion criteria: 1. Confirmed and suspected cases of pneumonia from novel coronavirus infection;<br>2. Meet the diagnostic criteria for community - acquired pneumonia;<br>3. Clinical classification is ""heavy"" or ""critical"";<br>4. Aged 18 to 75 years","Exclusion criteria: 1. Pregnancy or lactating women;<br>2. People with allergies or allergies to Shenfu injection and its components;<br>3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases tha","Novel Coronavirus Pneumonia (COVID-19)","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","pneumonia severity index (PSI);Incidence of new organ dysfunction;","","","","Yes","0","          ",""
"ChiCTR2000030041","2020-02-25","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)                                                                                                                              ","","Zhongnan Hospital of Wuhan University","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49891","Not Recruiting","No","18.0","","Both","2020-02-25","Case series:40;","Interventional study","Single arm","N/A","China","Cheng Zhenshun","","169 Donghu Road, Wuhan, Hubei, China ","chzs1990@163.com","+86 02767812787","Zhongnan Hospital of Wuhan University ","Inclusion criteria: (1) Aged >=18 years old inpatient;<br>(2) novel coronavirus nucleic acid positive was detected by real-time fluorescent RT-PCR in throat swabs;<br>(3) The clinical types were common type or severe type;<br>(4) Informed consent has b","Exclusion criteria: (1) It is known or suspected that it is allergic to the components of azvudine tablets;<br>(2) Light or severe patients;<br>(3) Patients with dysabsorption syndrome, or any other condition that affects gastrointestinal absorption, or","Novel Coronavirus Pneumonia (COVID-19)","Case series:FNC;","The novel coronavirus nucleic acid negative rate;","","","","Yes","0","          ",""
"ChiCTR2000029430","2020-02-17","Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)","An epidemiology study for TCM syndrome  of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                              ","","Hubei Integrated Hospital of Traditional Chinese and Western Medicine","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48902","Not Recruiting","No","18.0","90.0","Both","2020-02-03","Case series:600;","Observational study","Sequential","N/A","China","ZHANG ZHONGDE, ZHANG BOLI","","10 Poyang Lake Road, Jinghai District, Tianjin, China","ZJHTCM@FOXMAIL.COM","+86 13902020873","Tianjin University of Traditional Chinese Medicine","Inclusion criteria: Patients with Confirmed 2019-nCoV infected pneumonia","Exclusion criteria: NA","novel coronavirus pneumonia (COVID-19)","Case series:Nil;","TCM syndroms;","","","","Yes","0","          ",""
"ChiCTR2000029400","2020-02-17","Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                               ","","China Academy of Chinese Medical Sciences","2020-01-29","2020-01-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48824","Recruiting","No","18.0","","Both","2020-01-29","Group A:20;Group B:20;Group C:20;","Interventional study","Non randomized control","0.0","China","Huang Luqi","","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","huangluqi01@126.com","+86 010-64089801","China Academy of Chinese Medical Sciences","Inclusion criteria: 1) Comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the ""Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)"";<br>2) Agree to participate in t","Exclusion criteria: 1) Patients with particularly severe pneumonia caused by novel coronavirus infection.<br>2) Patients whose initial onset time exceeds 5 days.<br>3) Patients with severe primary respiratory disease.<br>4) It is difficult to administe","novel coronavirus pneumonia (COVID-19)","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","the rate of remission;","","","","Yes","0","          ",""
"ChiCTR2000029605","2020-02-17","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                   ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49051","Recruiting","No","18.0","","Both","2020-02-06","Low dose group:100;Medium dose of group:100;High dose of group:100;Control group:100;","Interventional study","Parallel","4.0","Wuhan","Wang Daowen, Zhao Jianping","","1095 Jiefang Avenue, Wuhan, Hubei, China","dwwang@tjh.tjmu.edu.cn","+86 13971301060","Department of Cardiovascular Medicine, Tongji Hospital","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Above 18 years old (inclusive);<br>3. Voluntarily sign written informed consent. ","Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;<br>2. Estimated Time of Death is less than 48 hours;<br>3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic dis","novel coronavirus pneumonia (NCP)","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Co","Time to disease recovery;","","","","No","0","          ",""
"ChiCTR2000029603","2020-02-17","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)                                              ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49075","Recruiting","No","18.0","75.0","Both","2020-02-06","Experimental group:80;Control group:80;","Interventional study","Parallel","0.0","China","Qiu Yunqing","","79 Qingchun Road, Hangzhou, Zhejiang, China","qiuyq@zju.edu.cn","+86 13588189339","The First Affiliated Hospital of Zhejiang University School of Medicine","Inclusion criteria: 1. Aged 18-75 years old;<br>2. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnostic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infe","Exclusion criteria: 1. Patients with severe 2019-nCoV pneumonia met one of the following conditions: respiratory distress, RR >= 30 times / min; or SaO2 / SpO2 <= 93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxyge","novel coronavirus pneumonia (COVID-19)","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2<= 93% without oxygen supplementation, PaO2/FiO2 <= 300mmHg or RR <=30 breaths per minute.;","","","","Yes","0","          ",""
"ChiCTR2000029558","2020-02-17","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province                                                                                               ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48792","Recruiting","No","","","Both","2020-01-29","single arm:200;","Interventional study","Single arm","0.0","China","Xie Chunguang","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","xcg718@aliyun.com","+86 18980880132","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: Patients who meet the suspected and confirmed diagnostic criteria for the 2019-nCoV pneumonia version 4.0 of the National Health and Medical Commission (released 2020.01.27).","Exclusion criteria: No exclusion criteria.","novel coronavirus pneumonia (COVID-19)","single arm:Chinese medicine treatment combined with western medicine treatment;","blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;","","","","No","0","          ",""
"ChiCTR2000029548","2020-02-17","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients                                             ","","The First Affiliated Hospital, Zhejiang University School of Medicine","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49015","Not Recruiting","No","18.0","75.0","Both","2020-02-04","A:10;B:10;C:10;","Interventional study","Parallel","0.0","China","Yunqing Qiu","","79 Qingchun Road, Hangzhou, Zhejiang, China","qiuyq@zju.edu.cn","+86 13588189339","The First Affiliated Hospital, Zhejiang University School of Medicine","Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent;<br>2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain<br>reaction (RT-PCR)-based diagnostic a","Exclusion criteria: 1. Hypersensitive to study drug;<br>2. Body weight <40 kg;<br>3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due t","novel coronavirus pneumonia (COVID-19)","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipira","Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2<2 for 24 hours.;","","","","Yes","0","          ",""
"ChiCTR2000030034","2020-02-25","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial                                                                                                                            ","","Tongde Hospital of Zhejiang Province","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49647","Recruiting","No","18.0","85.0","Both","2020-02-07","Experimental group:88;Control group:44;","Interventional study","Parallel","N/A","China","Kequn Chai","","234 Gucui Road, Xihu District, Hangzhou, Zhejiang, China","ckqmzygzs@163.com","+86 13906503739","Tongde Hospital of Zhejiang Province","Inclusion criteria: (1) Patients in accordance with the diagnostic criteria of ""Quick reference guide for diagnosis and treatment of novel coronavirus pneumonia(2019-nCoV)(Standard Edition)"" and ""Diagnostic and treatment protocols of novel coronavirus pne","Exclusion criteria: (1) Diagnosed with other known viral pneumonia,like influenza virus, parainfluenza virus, adenovirus, respiratory syncytical virus, rhinovirus, human metapneumovirus and SARS coronavirus, etc.;<br>(2) Diagnosed with mycoplasma pneumon","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;","","","","No","0","          ",""
"ChiCTR2000030032","2020-02-25","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions                                                                                                                      ","","Xi'an Chest Hospital","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49816","Recruiting","No","1.0","90.0","Both","2020-02-10","Case series:20;","Observational study","Sequential","0.0","China","Huang Yi","","Xi'an Chest Hospital, East Section of Hangtian Avenue, Chang'an District, Xi'an, Shaanxi, China","huang-yi-1980@163.com","+86 13319184133","Xi'an Chest Hospital","Inclusion criteria: 1. novel coronavirus: <br>(1) 1 days before onset, 14 had travel history or residence history in Wuhan or other areas with local cases;<br>(2) during the 14 days before onset, patients with fever or respiratory symptoms from Wuhan or","Exclusion criteria: 1. Exclude participants who disagree;<br>2. Exclude those who cannot cooperate.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;","","","","No","0","          ",""
"NCT04244591","2020-02-24","Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure","Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial","Steroids-SARI","Peking Union Medical College Hospital","2020-01-23","2020-01-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04244591","Recruiting","No","18 Years","N/A","All","2020-01-26","80.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","China"," ","Bin Du, MD","","dubin98@gmail.com","8610-6915-5036","","<br>        Inclusion Criteria:<br><br>          -  Adult<br><br>          -  PCR confirmed noval coronavirus infection<br><br>          -  Symptoms developed more than 7 days<br><br>          -  PaO2/FiO2 < 200 mmHg<br><br>          -  Positiv","","Coronavirus Infections;Respiratory Infection Virus","Drug: methylprednisolone therapy;Other: Standard care","Lower Murray lung injury score;Lower Murray lung injury score","","","","Yes","0","          ",""
"ChiCTR2000030185","2020-02-25","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)                                                                                            ","","West China Hospital of Sichuan University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50058","Recruiting","No","","","Both","2020-02-24","Target condition:40;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Wanhong Yin","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","doctorwhy@126.com","+86 13518106758","Department of Critical Care Medicine, West China Hospital of Sichuan University ","Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus. ","Exclusion criteria: none","novel coronavirus pneumonia (COVID-19)","Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical&#32;care&#32;ultrasound&#32;examination;","28day mortality;","","","","Yes","0","          ",""
"ChiCTR2000029461","2020-02-17","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)                                                                                          ","","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48927","Not Recruiting","No","18.0","70.0","Both","2020-02-03","experimental group:50;Control group:50;","Interventional study","Parallel","0.0","China","Wenguang Xia","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China ","docxwg@163.com","+86 13377897278","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine ","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);The classification was judged as common type;<br>2. aged 18-70 years old;<br>3. patients with clear consciousness;<br>4. Signing the informed consent","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; <br>2. Pregnant or lactating women;<br>3. Patients who have mental confusion, who with a history of drug abuse or ","Novel Coronavirus Pneumonia (COVID-19)","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","pulmonary function;Antipyretic time;Time of virus turning negative;","","","","Yes","0","          ",""
"ChiCTR2000029460","2020-02-17","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                         ","","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48930","Not Recruiting","No","18.0","70.0","Both","2020-02-02","experimental group:50;Control group:50;","Interventional study","Parallel","0.0","China","Chanjuan Zheng","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China ","chanjuanzheng@163.com","+86 18971317115","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);<br>2. virus turned negative after treatment;<br>3. aged 18-70 years old;<br>4. patients with clear consciousness<br>5. Signing the informed consent","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; <br>2. Pregnant or lactating women;<br>3. Patients who have mental confusion, who with a history of drug abuse or ","novel coronavirus pneumonia (COVID-19)","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;","","","","Yes","0","          ",""
"NCT04259892","2020-02-24","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Cov-CONTACT","Institut National de la Sant Et de la Recherche Mdicale, France","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04259892","Recruiting","No","N/A","N/A","All","2020-02-04","300.0","Observational","","N/A","France"," ; ; ","Xavier Duval, MD;Xavier Duval, MD;Xavier Duval, MD","",";xavier.duval@aphp.fr;xavier.duval@aphp.fr",";01 40 25 71 48;01 40 25 71 48","Institut National de la Sant Et de la Recherche Mdicale, France;","<br>        Inclusion Criteria:<br><br>          -  High/moderate risk contact with a laboratory-confirmed 2019-nCoV case<br><br>          -  Undergoing standard sanitary surveillance by Sant Publique France<br><br>          -  Written informed c","","Coronavirus","Biological: 2019-nCoV PCR","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab","","","","Yes","0","          ",""
"NCT04268537","2020-02-24","Immunoregulatory Therapy for 2019-nCoV","Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","","Southeast University, China","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04268537","Not recruiting","No","18 Years","N/A","All","2020-02-10","120.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 2","","","","","","","","<br>        Inclusion Criteria:<br><br>          1. Adult SARI patients with 2019-ncov infection confirmed by PCR;<br><br>          2. Absolute value of lymphocytes < 0. 6x 109/L;<br><br>          3. Severe respiratory failure within 48 hours and r","","2019 nCoV, PD-1","Drug: PD-1 blocking antibody+standard treatment;Drug: Thymosin+standard treatment;Other: standard treatment","lung injury score","","","","Yes","0","          ",""
"ChiCTR2000030179","2020-02-25","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)                                                                                                                                  ","","The First Affiliated Hospital of Nanchang University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50059","Recruiting","No","18.0","65.0","Both","2020-02-24","Experimental group:50;Control group:50;","Interventional study","Parallel","New Treatment Measure Clinical Study","China","Le Aiping","","17 Yongwai Main Street, Nanchang, Jiangxi, China","leaiping@126.com","+86 13707089009","The First Affiliated Hospital of Nanchang University ","Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;<br>2) aged 18 to 65 years;<br>3) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect ","Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;<br>2) Allergic constitution, allergic to plasma or drugs;<br>3) Being too old with severe underlying diseases that affect survival, including uncontrolled clinically s","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Cure rate;Mortality;","","","","Yes","0","          ",""
"ChiCTR2000030016","2020-02-25","Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection                                                     ","","Guangxi medical uniwresity","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49799","Recruiting","No","18.0","80.0","Both","2020-02-04","1:30;2:30;","Interventional study","Parallel","4.0","China","Chaoqian Li","","6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China","2534776680@qq.com","+86 13807887867","Department of respiratory medicine, the First Affiliated Hospital of Guangxi Medical University","Inclusion criteria: Patients aged >=18 years with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent.","Exclusion criteria: 1. Pregnant women;<br>2. Patients with a history of angina pectoris, myocardial infarction and other serious cardiovascular diseases;<br>3. The researchers judged that this study was not in the interests of patients.","Novel Coronavirus Pneumonia (COVID-19)","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme","","","","No","0","          ",""
"ChiCTR2000030007","2020-02-25","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49619","Not Recruiting","No","15.0","80.0","Both","2020-02-03","Experimental group:100;Control group:100;","Interventional study","Parallel","0.0","China","Nanshan Zhong","","151 Yanjiang Road, Yuexiu District, Guangzhou","linling@gird.cn","+86 13902233092","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: 1. Patients aged  15-80 years,diagnosed with mild, common, and severe novel coronavirus pneumonia in accordance with the diagnostic criteria for the diagnosis and treatment of novel coronavirus pneumonia issued by the National Health C","Exclusion criteria: 1. Combining basic diseases such as hypertension, diabetes, and coronary heart disease;<br>2. Malignant tumor or with a history of malignant tumor;<br>3. pregnant or lactating women;<br>4. suffer from severe mental illness;<br>5. H","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;","","","","No","0","          ",""
"ChiCTR2000030167","2020-02-25","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                  ","","Renmin Hospital of Wuhan University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49567","Not Recruiting","No","18.0","75.0","Both","2020-03-02","Experimental Group:40;Control Group:40;","Interventional study","Parallel","0.0","China","Qianxue Chen","","99 Jiefang Road, Wuchang District, Wuhan, Hubei, China","chenqx666@whu.edu.cn","+86 027-88041911-82237","Renmin Hospital of Wuhan University","Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;<br>(2) Inpatients aged 18 to 75 years;<br>(3) Voluntarily receive treatment with the drug and sign informed consent. Th","Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;<br>(2) Preparing pregnant, pregnant and lactating women;<br>(3) Patients with allergies (referring to allergie","Novel Coronavirus Pneumonia (COVID-19)","Experimental Group:Conventional Treatment & Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks)","CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;","","","","Yes","0","          ",""
"ChiCTR2000030165","2020-02-25","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                         ","","Tianjin University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49947","Recruiting","No","18.0","80.0","Both","2020-02-24","control group:30;mild ill patients:15;severe/critical ill patients:15;","Interventional study","Factorial","0.0","China","Yu Hongzhi","","890 Jin'gu Road, Jinnan District, Tianjin, China","ykb@tju.edu.cn","+86 22 58830026","Haihe hospital, Tianjin University","Inclusion criteria: (1) Confirmed patients (or legal guardian) sign a written informed consent form;<br>(2) Aged from 18 to 80 years, male or female;<br>(3) Patients with positive detection of 2019 Novel Coronavirus Pneumonia fluorescence RT-PCR in resp","Exclusion criteria: 1) Patients who may be transferred to other hospitals that are not included in the trial within 72 hours; <br>2) G-6PD defect (Favism); <br>3) Pregnancy, especially early pregnancy; <br>4) Patients who continually use immunosuppress","Novel Coronavirus Pneumonia (COVID-19)","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;","","","","Yes","0","          ",""
"ChiCTR2000029459","2020-02-17","The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                    ","","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48929","Not Recruiting","No","18.0","70.0","Both","2020-02-03","experimental group:50;control group:50;","Interventional study","Parallel","0.0","China","Wenguang Xia","","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China ","docxwg@163.com","+86 13377897278","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);<br>2. virus turned negative after treatment;<br>3. aged 18-70 years old;<br>4. patients with clear consciousness;<br>5. Signing the informed consen","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; <br>2. Pregnant or lactating women;<br>3. Patients with mental confusion, with a history of drug abuse or dependen","new coronavirus pneumonia (COVID-19)","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","pulmonary function;St Georges respiratory questionnaire, SGRQ;","","","","Yes","0","          ",""
"ChiCTR2000029439","2020-02-17","Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                                                                                         ","","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese MedHubei integrated traditional Chinese and Western Medicine Hospital","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48904","Not Recruiting","No","","","Both","2020-02-02","control group:60;experimental group:60;","Interventional study","Parallel","0.0","China","WANG YUGUANG, LI XUCHENG, ZHANG BOLI","","23 Back Street of Art Gallery, Dongcheng District, Beijing/11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","ZJHTCM@FOXMAIL.COM","+86 13902020873","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","Inclusion criteria: 1) patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);<br>2) The classification was judged as common type;<br>3) Informed consent.","Exclusion criteria: 1) Pregnant or lactating women;<br>2) Severe basic diseases that affect survival;<br>3) Other problems thant doctor's judgment is not suitable for the study;<br>4) Patients have difficulty in taking TCM standard decoctions.","novel coronavirus pneumonia (COVID-19)","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","Antipyretic time;Time of virus turning negative;","","","","Yes","0","          ",""
"ChiCTR2000030000","2020-02-25","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)                                                         ","","Nanchang Ninth Hospital","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49748","Recruiting","No","18.0","75.0","Both","2020-02-16","Ganovo / ritonavir group:10;Pegasys group:10;Novaferon group:10;Coriolus group:10;Comparator:10;","Interventional study","Non randomized control","4.0","China","Hongyi Chen","","167 Hongdu Middle Avenue, Qingshanhu District, Nanchang, Jiangxi, China","Chenhongyi8660@163.com","+86 13807088660","Nanchang Ninth Hospital ","Inclusion criteria: 1. Aged 18-75 years old;<br>2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 <93% in resting state; or arterial partial pressure of oxygen (PaO2) / concent","Pneumonia caused by new coronavirus","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;","","","","No","0","          ",""
"ChiCTR2000029956","2020-02-25","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)                                                                                                                                                     ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49618","Not Recruiting","No","","","Both","2020-02-18","Experimental group:60;Control group:60;","Interventional study","Parallel","N/A","China","Tang Jianyuan","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","tangjianyuan163@163.com","+86 13910768464","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: cured patients of 2019 novel coronavirus.","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;","","","","Yes","0","          ",""
"ChiCTR2000030164","2020-02-25","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU                                                                                                                                                                              ","","Wuhan Jin Yin-tan hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49983","Not Recruiting","No","","","Both","2020-02-24","Case series:10;","Observational study","Sequential","N/A","China","You Shang","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","you_shang@126.com","+86 15972127819","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: All patients with SARS-CoV-2 pneumonia in the ICU","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","Case series:N/A;","the daily treatment intensity;","","","","Yes","0","          ",""
"ChiCTR2000030113","2020-02-25","Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir                                                                                                    ","","The Third People's Hospital of Shenzhen","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49988","Recruiting","No","16.0","75.0","Both","2020-02-22","Control group:15;Experimental group:15;","Interventional study","Parallel","0.0","","Liu Yingxia","","29 Bulan Road, Logngang District, Shenzhen, Guangdong, China","yingxialiu@hotmail.com","+86 755 61238922","Shenzhen the 3rd People's Hospital","Inclusion criteria: 1. 16 to 75 years of age, male or female;<br>2. Respiratory or blood samples tested positive for novel coronavirus;<br>3. A novel coronavirus nucleic acid was detected in respiratory or anal swabs after 10 days of standard treatment ","Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;<br>2. Patient refuses to receive invasive tracheal support (if needed);<br>3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfe","novel coronavirus pneumonia (COVID-19)","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;","","","","No","0","          ",""
"ChiCTR2000030117","2020-02-25","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                    ","","Shanghai Public Health Clinical Center","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49762","Recruiting","No","18.0","70.0","Both","2020-02-15","Combination therapy group:232;Conventional treatment group:116;","Interventional study","Parallel","4.0","China","Hongzhou Lu","","9th Floor, Block 3, Lufthansa Center, 16 Xinyuanli Street, Chaoyang District, Beijing, China","luhongzhou@shphc.org.cn","+86 21-37990333","Jiangxi Qingfeng Pharmaceutical Co., Ltd.","Inclusion criteria: 1. Aged 18-70 years old;<br>2. Meet the diagnostic criteria for confirmed cases in the diagnosis and treatment plan of new coronavirus-infected pneumonia (trial version 5); and the clinical symptoms before admission or screening must ","Exclusion criteria: 1. Allergic constitution (persons who are allergic to more than 2 kinds of substances), people who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test d","Novel Coronavirus Pneumonia (COVID-19)","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Clinical recovery time;","","","","No","0","          ",""
"ChiCTR2000030115","2020-02-25","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients                                         ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49964","Not Recruiting","No","18.0","","Both","2020-02-27","Case series:50;","Observational study","Single arm","N/A","China","Wang Shaogang","","1095 Jiefang Avenue, Wuhan, Hubei, China","lingqing1985@163.com","+86 15827257012","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged >=18 years;<br>2. Severed COVID-19 patients, matched the requirements of <COVID-19 diagnosis and treatment programme (trial sixth edition)> launched by NHC, which is meeting any of the following:<br>RR>=30 times/min;<br>Rest","Exclusion criteria: 1. Patients who have been treated with glucocorticoids;<br>2. Patients who have received invasive ventilator-assisted ventilation treatment;<br>3. Patients with shock;<br>4. Patients combined with organ failure and needed ICU monito","Novel Coronavirus Pneumonia (COVID-19)","Case series:Basic symptomatic therapy combined with glucocorticoid therapy;","Cortisol;ACTH;Form of Adrenal tissue;","","","","Yes","0","          ",""
"ChiCTR2000029781","2020-02-25","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                           ","","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49138","Recruiting","No","18.0","","Both","2020-02-14","experimental group:80;control group:80;","Interventional study","Parallel","4.0","China","Xin Zheng","","1277 Jiefang Avenue, Wuhan, Hubei","Xin11@hotmail.com","+86 18602724981","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: 1) Aged >= 18 years;            <br>2) In line with the diagnostic criteria of ""new coronavirus pneumonia diagnosis program"", the patient was diagnosed as pneumonia infected by the new coronavirus;<br>3) Severe pneumonia index (PSI) ","Exclusion criteria: 1)One of the following conditions:<br>Respiratory distress, RR >= 30 times/min;<br>At rest, oxygen saturation is less than 93%;<br>Atrial  arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) <= 300mmHg (1mmHg=0.13","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","Disappearance rate of fever symptoms;","","","","Yes","0","          ",""
"ChiCTR2000029740","2020-02-25","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)                                                                                                        ","","The First Hospital of Peking University","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49317","Recruiting","No","16.0","99.0","Both","2020-02-11","hydroxychloroquine group:54;control group:24;","Interventional study","Parallel","4.0","China","Zhuoli Zhang","","8 Xishiku Street, Beijing, China","zhuoli.zhang@126.com","+86 13901094780","The First hospital of Peking University","Inclusion criteria: Patients with novel coronavirus infection who agreed to participate in this trial and signed the informed consent form. The diagnose criteria was according to Diagnostic and treatment protocol of COVID-19 pneumonia published by Chinese","Exclusion criteria: Patients who is enrolled in other clinical trial<br>who had diagnosed as macular degeneration of retinawere or defects of visual field;<br>who was allergic to 4-aminoquinoline compounds or is prescribed any drug had interactions with","Novel Coronavirus Pneumonia (COVID-19)","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;","","","","Yes","0","          ",""
"ChiCTR2000030096","2020-02-25","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)                                                                                                                           ","","Peking University First Hospital","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49794","Not Recruiting","No","16.0","","Both","2020-02-17","Case series:120;","Observational study","Sequential","N/A","China","Hong Zhao","","8 Xi-Shi-Ku Street, Xicheng District, Beijing, China","zhaohong_pufh@bjmu.edu.cn","+86 13810765943","Peking University First Hospital","Inclusion criteria: 1. COVID-19 diagnosed based on the interim guidelines of the World Health Organization;<br>2. Excess specimens for clinical testing (sputum, nasopharyngeal swabs, blood specimens, urine, anal swabs).<br>3. Sign the informed consent f","Exclusion criteria: The doctor believes that the subject is not suitable to continue the clinical study;","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","SARS-CoV2 Nucleic Acid Quantification;","","","","No","0","          ",""
"ChiCTR2000030094","2020-02-25","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages                                                                                                                  ","","Chengdu University of Traditional Chinese Medicine","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49970","Not Recruiting","No","16.0","50.0","Female","2020-03-01","Adolescent group:50;Childbearing group:100;Climacterium group:50;","Observational study","Factorial","N/A","China","Hua Lu","","37 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China ","1924238034@qq.com","+86 18980880525","Chengdu University of Traditional Chinese Medicine","Inclusion criteria: 1. aged between 16 and 50 years;<br>2. no history of gynecological diseases before;<br>3. willing to join this research and sign an informed consent form.","Exclusion criteria: 1. pregnancy or lactation;<br>2. history of psychiatric disorders(serious anxiety and depression,schizophrenia);<br>3. take sedatives in the past week.","Novel Coronavirus Pneumonia (COVID-19)","Adolescent group:NA;Childbearing group:NA;Climacterium group:NA;","menstruation changes;TCM body constitution score;","","","","Yes","0","          ",""
"ChiCTR2000030092","2020-02-25","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques                                                                                                                              ","","Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49880","Recruiting","No","","","Both","2020-02-12","Severe group:200;Critical group:200;Light group:200;Common group:200;","Observational study","Factorial","0.0","China","Mingxing Xie","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","xiemx@hust.edu.cn","+86 13607108938","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19) ","Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.","Novel Coronavirus Pneumonia (COVID-19)","Severe group:None;Critical group:none;Light group:None;Common group:None;","M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","","","","No","0","          ",""
"ChiCTR2000030090","2020-02-25","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students                                                                                               ","","West China Hospital, Sichuan University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49910","Not Recruiting","No","15.0","35.0","Both","2020-02-22","Exercise prescription group:200;Control group:200;","Interventional study","Parallel","N/A","China","XIONG YAN","","363 Furong Avenue, Wenjing District, Chengdu, Sichuan, China","luyibingli@163.com","+86 18328737998","West China Hospital, Sichuan University ","Inclusion criteria: All students from China University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent. ","Exclusion criteria: None","Novel Coronavirus Pneumonia (COVID-19)","Exercise prescription group:Exercise prescription;Control group:None;","Mood index;","","","","Yes","0","          ",""
"ChiCTR2000029381","2020-02-17","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                           ","","The First Affiliated Hospital of Guangzhou Medical University","2020-01-27","2020-01-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48768","Not Recruiting","No","18.0","75.0","Both","2020-01-24","Group 1:200;Group 2:200;","Interventional study","Non randomized control","4.0","China","Zhong Nanshan / Song Yuanlin/Qiu Haibo/Li Yimin/Liu Xiaoqinqing","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","ylsong70@163.com","+86 020 34294311","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: 1. New coronavirus-infected pneumonia confirmed by pathogenic detection;<br>2. Meet the diagnostic criteria for community-acquired pneumonia (based on 2019 ATS/IDSA diagnostic criteria);<br>3. Pneumonia Severity Index (PSI) III-V or ","Exclusion criteria: 1. Pregnancy or lactating women;<br>2. People with allergies or allergies to Xuebijing injection and its components;<br>3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases ","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","pneumonia severity index (PSI);","","","","No","0","          ",""
"NCT04269525","2020-02-24","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","","ZhiYong Peng","2020-02-07","2020-02-07","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04269525","Recruiting","No","18 Years","75 Years","All","2020-02-06","10.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 2","China"," ; ; ","XingHuan Wang, professor;XingHuan Wang, professor;XingHuan Wang, professor","",";znyylcsy@126.com;",";18971387168;","Wuhan University;","<br>        Inclusion Criteria:<br><br>          -  18-75 years old ,no gender restriction<br><br>          -  According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV<br>             infection(Trial Version 4), patients are d","","Pneumonia, Viral;Pneumonia, Ventilator-Associated","Biological: UC-MSCs","Oxygenation index","","","","Yes","0","          ",""
"ChiCTR2000030046","2020-02-25","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)                                                                                    ","","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49861","Recruiting","No","18.0","80.0","Both","2020-02-07","Case series:10;","Interventional study","Single arm","0.0","China","Bende Liu","","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","liubende99@outlook.com","+86 13907191851","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","Inclusion criteria: 1. Inpatients aged 18 to 80 years old, male or female;<br>2. Confirmed patient diagnosed according to the guideline for Diagnosis and Treatment for COVID-19 (5th version), whose clinical classification is common or severe case;<br>Cl","Exclusion criteria: 1. Previous or current allergic history to human plasma protein products or excipients (sodium citrate) contained in this product;<br>2. Patients diagnosed as severe COVID-19;<br>3. Patients diagnosed as infection of influenza virus,","Novel Coronavirus Pneumonia","Case series:Anti-2019-nCoV virus inactivated plasma;","The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine ami","","","","No","0","          ",""
"ChiCTR2000030030","2020-02-25","A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)","The risk factor and prognosis of acute kidney injury in novel coronavirus pneumonia (COVID-19)                                                                                                                                                                 ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49841","Recruiting","No","","","Both","2020-02-20","Case series:2000;","Observational study","Sequential","Retrospective study","China","Gang Xu","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","xugang@tjh.tjmu.edu.cn","+86 13507181312","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: COVID-19 patients admitted to Tongji Hospital ,Tongji Medical College, Huazhong University of Science and Technology","Exclusion criteria: age<18 year; missing baseline and follow-up data","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Acute kidney injury;","","","","Yes","0","          ",""
"ChiCTR2000030188","2020-02-25","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)                                                                                                                                       ","","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50025","Recruiting","No","18.0","","Both","2020-02-15","Experimental group:80;Control group:40;","Interventional study","Parallel","N/A","China","Donghui Huang","","53 Jidajingle Road, Zhuhai, Guangdong, China","13600001163@139.com","+86 0756-3325892","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","Inclusion criteria: (1) Comply with the diagnostic criteria for COVID-19 in the ""Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 5)"", meet the the criteria of severe and critical type;<br>(2) Agree to pa","Exclusion criteria: (1) It is difficult to administer to patients by oral or nasal feeding;<br>(2) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for st","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;","","","","No","0","          ",""
"ChiCTR2000030170","2020-02-25","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)                                                                                             ","","Shanghai Public Health Clinical Center","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50017","Recruiting","No","50.0","100.0","Both","2020-02-15","severe NCP group:8;Acute exacerbation NCP group:8;","Interventional study","Factorial","0.0","China","Lu Hongzhou","","2901 Caolang Road, Jinshan District, Shanghai, China","luhongzhou@shphc.org.cn","+86 18930810088","Shanghai Public Health Clinical Center","Inclusion criteria: (1) Inpatients aged 50 and over, regardless of gender, voluntarily signed informed consent;<br>(2) Persons diagnosed with 2019-nCoV infection: respiratory specimens or blood specimens are tested positive for 2019-nCoV nucleic acid by ","Exclusion criteria: Exclusion criteria for the severe NCP group were the same as those for the acutely exacerbated NCP group:<br>1. Have a history of drug dependence or substance abuse;<br>2. female patients who are pregnant or lactating;<br>3. People ","Novel Coronavirus Pneumonia (COVID-19)","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the even","Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;","","","","No","0","          ",""
"ChiCTR2000030058","2020-02-25","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                  ","","Renmin Hospital of Wuhan University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49831","Not Recruiting","No","18.0","70.0","Both","2020-03-10","Experimental group :100;Control group:100;","Interventional study","Parallel","3.0","China","Ke Hu","","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","hukejx@163.com","+86 18971035988","Renmin Hospital of Wuhan University","Inclusion criteria: 1. aged 18-70 years male or female;<br>2. 2019 new coronavirus nucleic acid test positive;<br>3. meet the national diagnosis criteria;<br>4. subjects onset within 8 days (severe cases can be delayed to 14 days);<br>5. subjects or a","Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or absorbing in oral medication;<br>2. pregnant and nursing women;<br>3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral","Novel Coronavirus Pneumonia (COVID-19)","Experimental group :Oral leflunomide;Control group:Oral placebo;","The days from positive to negative for viral nucleic acid testing;","","","","Yes","0","          ",""
"ChiCTR2000030056","2020-02-25","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                        ","","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49904","Not Recruiting","No","","","Both","2020-02-23","case series:100;","Observational study","Sequential","N/A","China","Qingping Wu","","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China ","wqp1968@163.com","+86 13971605283","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","Inclusion criteria: 1. In line with the diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diagnosis and etiological diagnosis;<","Exclusion criteria: Patients who refuse to sign informed consent form","Novel Coronavirus Pneumonia (COVID-19)","case series:none;","ICU hospitalization days;Death rate;","","","","Yes","0","          ",""
"ChiCTR2000030029","2020-02-25","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49824","Not Recruiting","No","18.0","75.0","Both","2020-02-20","Case series:20;","Interventional study","Single arm","0.0","China","Shentu Jianzhong?Wu Lihua","","79 Qingchun Road, Hangzhou, Zhejiang, China ","stjz@zju.edu.cn","13957111817.0","The First Affiliated Hospital of Zhejiang University School of Medicine","Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent; <br>2. Patients with novel coronavirus infection pneumonia were confirmed by epidemiology and clinical symptoms. The diagnostic criteria refer to ""Pneumoniti","Exclusion criteria: 1. Hypersensitive to suramin or 2 or more drugs or food; <br>2. Body weight <40 kg; <br>3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or","Novel Coronavirus Pneumonia (COVID-19)","Case series:Suramin( IV.);","clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;","","","","No","0","          ",""
"ChiCTR2000030027","2020-02-25","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial                                                                                     ","","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49852","Recruiting","No","18.0","","Both","2020-02-20","Case series:60;","Interventional study","Single arm","N/A","China","Yao-sheng Zhang/Ting-rong Huang/Chun-yan Ji/Jian-wei Shang  ","","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China","ysz3129@163.com","+86 18610329658","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China","Inclusion criteria: 1. Meet the diagnostic criteria of the ""New Coronavirus Pneumonia Diagnosis and Treatment Scheme"" and patients diagnosed with new coronavirus infection; <br>2. Meet the diagnostic criteria for severe cases in the ""Plan"", namely: respi","Exclusion criteria:  People with allergies and allergies to experimental drugs; ","Novel coronavirus pneumonia (COVID-19)","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;","","","","Yes","0","          ",""
"ChiCTR2000030138","2020-02-25","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                              ","","Chinese PLA General Hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50004","Not Recruiting","No","16.0","75.0","Male","2020-02-24","Experimental group:30;Control group:30;","Interventional study","Parallel","2.0","China","Jian Bo and Chuanzhu Li","","28 Fuxing Road, Haidian Distract, Beijing, China","boj301@sina.com","+86 13801257802","Chinese PLA General Hospital","Inclusion criteria: Subjects who met all of the following conditions entered the trial:<br>1. Male or female patients aged 16 to 75 years;<br>2. willing to sign informed consent;<br>3. Based on the criteria for suspected cases of COVID-19 infection, sp","Exclusion criteria: Subjects who meet one of the following conditions will not be eligible for the trial:<br>1. pregnant or lactating women;<br>2. Malignant tumors, patients with other severe systemic diseases and mental illness;<br>3. Those who have r","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","Clinical index;","","","","Yes","0","          ",""
"ChiCTR2000030137","2020-02-25","Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)","The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                    ","","The Second Affiliated Hospital of Xi'an Jiaotong University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50007","Not Recruiting","No","15.0","60.0","Both","2020-02-24","Case series:130;","Observational study","Single arm","0.0","China","Gong Shouping","","157 West 5th Road, Xi'an, Shaanxi, China","shpingg@126.com","+86 13709206398","The Second Affiliated Hospital of Xi'an Jiaotong University","Inclusion criteria: Healthcare-personnel who are working for treating COVID-19","Exclusion criteria: disagree to consent or infected with COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Case series:Humanistic care;","Self-rating depression scale;","","","","Yes","0","          ",""
"ChiCTR2000030033","2020-02-25","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)                                                                                                         ","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49703","Not Recruiting","No","18.0","80.0","Both","2020-02-24","Intervention group 1:276;Intervention group 2:276;Control group:276;","Interventional study","Parallel","New Treatment Measure Clinical Study","Chinese","Feng WANG","","151 Yanjiang Road, Guangzhou, Guangdong, China","412475734@qq.com","+86 13710801606","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: 1. Aged 18 to 80 years (inclusive);<br>2. People who had ineffective protection, i.e.:<br>1) living, studying, working together with, or having close contacts with confirmed cases and positive testers, such as working at close distan","Exclusion criteria: 1. The physician decides that participating in this study is not in the best interest of the subject or that there exist a circumstance in which the agreed protocol cannot be safely followed;<br>2. People who have allergic reactions o","Novel Coronavirus Pneumonia (COVID-19)","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral ""Wu-Zhi-Fang-Guan-Fang"" decoction;Control group:Routine quarantine measures;","Proportion of COVID-19 close contacts who have developed as confirmed cases;","","","","Yes","0","          ",""
"ChiCTR2000030017","2020-02-25","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)                                                                                                             ","","Department of Ultrasound Imaging, Renmin Hospital of Wuhan University","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49798","Recruiting","No","","","Both","2020-02-17","Severe group:100;Non-severe group:100;","Observational study","Factorial","0.0","China","Qing Zhou","","238 Jiefang Road, Wuhan, Hubei, China ","qingzhou.wh.edu@hotmail.com","+86 13971358226","Renmin Hospital of Wuhan University","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)","Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.","Novel Coronavirus Pneumonia (COVID-19)","Severe group:None;Non-severe group:None;","Death;Recovered;Discharged;","","","","No","0","          ",""
"ChiCTR2000030136","2020-02-25","Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)                                                                                                           ","","the Second Affiliated hospital of Xi'an Jiaotong University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50005","Not Recruiting","No","0.0","90.0","Both","2020-02-24","Humanistic care:100;Control group:30;","Interventional study","Non randomized control","0.0","China","Gong Shouping","","157 West 5th Road, Xi'an, Shaanxi, China","shpingg@126.com","+86 13709206398","the Second Affiliated hospital of Xi'an Jiaotong University","Inclusion criteria: Inpatients with 2019 Novel Coronavirus infection in the severe case section running by national medical team from the Second Affiliated hospital of Xian Jiaotong University","Exclusion criteria: Patients can not follow-up;<br>Investigator considering inappropriate","Coronavirus Disease 2019","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","recovery time;","","","","Yes","0","          ",""
"ChiCTR2000030102","2020-02-25","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                 ","","Tianjin Huanhu Hospital","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49747","Recruiting","No","18.0","80.0","Both","2020-02-24","control group with common NCP:30;experimental group with common NCP:30;experimental group with severe NCP:30;control group with severe NCP:30;experimental group with critical NCP:30;control group with critical NCP:30;","Interventional study","Parallel","0.0","China","Xiaoguang Tong","","6 Jizhao Road, Jinnan District, Tianjin","Tongxg@yahoo.com","+86 13820088121","Tianjin Huanhu Hospital","Inclusion criteria: 1. Aged 18-80 years;<br>2. Within 1 week of onset;<br>3. Meet the diagnostic criteria of common, severe and critical NCP, according to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (Trial Version 6)"".<b","Exclusion criteria: 1. Any situation that does not allow the program to proceed safely; <br>2. The patient may be transferred to a non-participating hospital within 72 hours; <br>3. Those who have continued to use immunosuppressive agents or organ trans","Novel Coronavirus Pneumonia (COVID-19)","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:","Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: complet","","","","Yes","0","          ",""
"NCT04270383","2020-03-02","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","","Beijing Children's Hospital","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04270383","Not recruiting","No","N/A","18 Years","All","2020-02-15","500.0","Observational","","Phase 1","China"," ; ; ; ; ","Kunling Shen, MD,PhD;Tianyou Wang, MD,PhD;Baoping Xu, MD,PhD;Baoping Xu, MD,PhD;Lina Wang","",";;;xubaopingbch@163.com;",";;;861059616308;","Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;","<br>        1. For the 2019-nCoV infection group<br><br>             Inclusion Criteria:<br><br>             Diagnosed with 2019-nCoV infection (with direct laboratory evidence).<br><br>               1. Respiratory or blood samples tested positive","","2019-nCoV","","The cure rate of 2019-nCoV.;The improvement rate of 2019-nCoV.;The incidence of long-term adverse outcomes.","","","","Yes","0","          ",""
"NCT04273646","2020-03-02","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia","","Wuhan Union Hospital, China","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04273646","Not recruiting","No","18 Years","65 Years","All","2020-02-16","48.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ","Yang Jin, MD","","whuhjy@sina.com","8613554361146.0","","<br>        Inclusion Criteria:<br><br>          1. CT image is characteristic of viral pneumonia;<br><br>          2. 2019-ncov infection (positive nucleic acid test) is confirmed by pathogenic test;<br><br>          3. In compliance with the 2019","","2019 Novel Coronavirus Pneumonia;COVID-19","Biological: UC-MSCs;Drug: Placebo","Pneumonia severity index;Oxygenation index (PaO2/FiO2)","","","","Yes","0","          ",""
"NCT04275947","2020-03-02","The COVID-19 Mobile Health Study (CMHS)","The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp","CMHS","Chinese Alliance Against Lung Cancer","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04275947","Recruiting","No","18 Years","90 Years","All","2020-02-14","450.0","Observational","","N/A","China"," ; ; ","Chunxue Bai;Chunxue Bai;Chunxue Bai","",";bai.chunxue@zs-hospital.sh.cn;",";+8618621170011?;","Shanghai Respiratory Research Institution;","<br>        Inclusion Criteria:<br><br>          -  High risk of COVID-19<br><br>          -  RT-PCR test result of SAR2-CoV-19<br><br>        Exclusion Criteria:<br><br>          -  Not available for RT-PCR test result of SAR2-CoV-19<br>      ","","COVID-19","Other: nCapp, a cell phone-based auto-diagnosis system","Accuracy of nCapp COVID-19 risk diagnostic model","","","","Yes","0","          ",""
"ChiCTR2000030420","2020-03-02","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                            ","","Institute of Integrative Medicine of Dalian Medical University, Dalian, China.","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50286","Not Recruiting","No","","","Both","2020-03-01","Control group:30;Experimental group:30;","Interventional study","Parallel","N/A","China","Dong Shang","","9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China","shangdongdalian@163.com","+86 18098875933","Institute of Integrative Medicine of Dalian Medical University","Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;<br>2) be able to understand the content of this study, and have the ability of normal communication and understanding;<br>3) voluntarily participate in this study and obta","Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities;<br>2) patients with mental illness or adverse reactions caused by drugs;<br>3) patients with serious diseases such as cardiovascular, cerebrovascula","Novel Coronavirus Pneumonia (COVID-19)","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medic","Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;","","","","Yes","0","          ",""
"ChiCTR2000030012","2020-02-25","Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)","Development of 2019-nCoV  therapeutic antibody                                                                                                                                                                                                                 ","","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49718","Not Recruiting","No","18.0","60.0","Both","2020-02-19","Case series:20;","Treatment study","Sequential","0.0","China","XiaoWang Qu","","102 Luo-Jia-Jing, Beihu District, Chenzhou, Hu'nan, China","quxiaowang@163.com","+86 15526272595","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","Inclusion criteria: 1)2019-nCoV-cured patients that over 18 years of age<br>2)Sign informed consent. ","Exclusion criteria: NA","Novel Coronavirus Pneumonia (COVID-19)","Case series:NA;","NA;","","","","Yes","0","          ",""
"ChiCTR2000030010","2020-02-25","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)                                              ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49777","Not Recruiting","No","18.0","70.0","Both","2020-02-19","Experimental group:50;Control group:50;","Interventional study","Parallel","N/A","China","Zhang Dingyu","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","1813886398@qq.com","+86 13507117929","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) ","Inclusion criteria: 1. Aged 18 to 70 years old, inpatients, male or female;<br>2. Patients with severe novel coronavirus infection: According to the ""Pneumonitis Diagnosis and Treatment Guideline for the Novel Coronavirus Infection (Trial Version 5)"", cl","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:<br>1) Respiratory failure occurs and requires mechanical ventilation;<br>2) Shock occurs;<br>3) Combined failure of ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","","","","Yes","0","          ",""
"ChiCTR2000030089","2020-02-25","A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                                ","","Shanghai Changzheng Hospital","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49889","Not Recruiting","No","","","Both","2020-02-28","Experimental group:30;Control group:30;","Interventional study","Parallel","4.0","China","Huji Xu","","415 Fengyang Road, Huangpu District, Shanghai, China","xuhuji@smmu.edu.cn","+86 13671609764","Shanghai Changzheng Hospital","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:<br>1. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;<br>2. Ch","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;<br>2. Pregnant or lactating women;<br>3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50;<br>4. Expected survival is less than 1 week;<br>5. Patients diagn","Novel Coronavirus Pneumonia(COVID-19)","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","TTCI (Time to Clinical Improvement);","","","","Yes","0","          ",""
"ChiCTR2000030088","2020-02-25","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                ","","The Sixth Medical Center of PLA General Hospital","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49902","Not Recruiting","No","18.0","80.0","Both","2020-03-01","Experimental group:20;Control group:20;","Interventional study","Parallel","0.0","China","Lianru Gao","","6 Fucheng Road, Haidian District, Beijing, China","lianru666@163.com","+86 18600310121","The Sixth Medical Center of PLA General Hospital","Inclusion criteria: 1) age 18-80 years old, regardless of gender: 2) the diagnosis criteria of severe nCoV pneumonia in line with the 6th edition of China's new coronavirus pneumonia diagnosis scheme: a.B. Real-time fluorescence rt-pcr of respiratory trac","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;","","","","Yes","0","          ",""
"ChiCTR2000030390","2020-03-02","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology                                                                                                              ","","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50224","Recruiting","No","","","Both","2020-01-01","Target condition:3000;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","China","Kunlun He","","28 Fuxing Road, Haidian District, Beijing, China","hekl301@aliyun.com","+86 010 66939107","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","Inclusion criteria: 1. confirmed clinical records in the database of the hospital;<br>2. inpatients have confirmed clinical diagnosis and relevant laboratory tests;<br>3. the CT images are complete, the image quality meets the diagnostic and measurement","Exclusion criteria: The cases of artifacts caused by poor breath-holding coordination or operator factors are excluded ","Novel coronavirus pneumonia (COVID-19)","Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic&#32;Assistance&#32;Decision&#32;Support&#32;System;","CT;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030363","2020-03-02","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome                                                                                                                                               ","","Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","2020-02-29","2020-02-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49984","Recruiting","No","0.0","18.0","Both","2020-02-23","Monitor cases, suspected cases and diagnosed cases:120;","Observational study","Sequential","N/A","China","Yan Hao; Xiaoping Luo","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","haoyaner@163.com","+86 13971679960","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: This study intends to select surveillance cases, suspected cases, and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the Department of Pediatrics, Tongji Hospital from December 2019 to June 2020.<br>1. Epidemi","Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;<br>(2) Exclude pneumonia caused by atypical microor","Novel Coronavirus Pneumonia (COVID-19)","Monitor cases, suspected cases and diagnosed cases:No;","Epidemiological characteristics;clinical features;Treatment outcome;","","","","No","0","          ",""
"ChiCTR2000030015","2020-02-25","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women                                                                                                                             ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49800","Recruiting","No","","","Female","2020-02-19","Case series:300;","Basic Science","Sequential","0.0","China","Shixuan Wang","","1095 Jiefang Avenue, Wuhan, Hubei, China","sxwang@tjh.tjmu.edu.cn","+86 027-83663078","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Female of after menarche;<br>2. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of hubei province: including clinical diagnos","Exclusion criteria: Patients who the researchers determined not suitable for this study.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","menstruation changes;","","","","No","0","          ",""
"ChiCTR2000030008","2020-02-25","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak                                                                                                       ","","The Fifth Affiliated Hospital of Sun Yat-Sen University","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49426","Recruiting","No","18.0","65.0","Both","2020-02-12","Case series:100;","Observational study","Sequential","N/A","China","Jing Liu","","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China.","liujing25@mail.sysu.edu.cn","+86 13844021812","The Fifth Affiliated Hospital of Sun Yat-Sen University","Inclusion criteria: 1. Volunteer to participate in the study and sign informed consent;<br>2. Aged 18-65 years, male or female;<br>3. Weight >= 40kg and <=100kg, and BMI >= 18kg/m2;<br>4. Medical staff during the novel coronavirus (COVID-19) outbreak.","Exclusion criteria: 1. Plan for pregnant,breast-feeding or pregnant;<br>2. Hospitalized for other reasons within 14 days before the election;<br>5. Combined with serious diseases of heart, lung, brain, liver, kidney, blood system;<br>6. Has fever, runn","anxiety and depression; novel coronavirus pneumonia (COVID-19)","Case series:Nil;","psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;","","","","No","0","          ",""
"ChiCTR2000029996","2020-02-25","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                          ","","Beijing Chaoyang Hospital, Capital Medical University","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49510","Recruiting","No","18.0","","Both","2020-02-20","Low-dose group:20;Middle-dose group:20;High-dose group:20;","Interventional study","Parallel","2.0","China","Zhaohui Tong","","8 Workers Stadium Road South, Chaoyang District, Beijing","13910930309@163.com","+86 13910930309","Beijing Chaoyang Hospital, Capital Medical University","Inclusion criteria: 1. Voluntarily sign the Consent Form;<br>2. Male or female aged 18 and over;<br>3. According to the ""Diagnosis and Treatment Scheme for Pneumonia of Novel coronavirus pneumonia Infection-Trial Fifth Edition"", inpatient diagnosed with","Exclusion criteria: 1. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;<br>2. Males or females who have a birth plan or are unwilling to take ","Novel Coronavirus Pneumonia  (COVID-19)","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration ","Time to Clinical Recovery;","","","","Yes","0","          ",""
"ChiCTR2000029995","2020-02-25","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","Study on anxiety of different populations under novel coronavirus (COVID-19) infection                                                                                                                                                                         ","","Shanghai General Hospital of Shanghai Jiaotong University","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49418","Recruiting","No","","","Male","2020-02-20","pneumonia patients group:100;medical staff group:100;","Observational study","Factorial","N/A","China","Jiang Hong","","650 Xinsongjiang Road, Songjiang District, Shanghai, China","jhong.pku@163.com","+86 15301655562","Shanghai General hospital of Shanghai Jiaotong University","Inclusion criteria: 1. First-line medical staff: doctors and nurses who enter the fixed-point pneumonia treatment hospital in Hubei Province for first-line clinical work, or clinical doctors and nurses who have treated COVID19 pneumonia cases in local des","Exclusion criteria: 1. Patients who have been admitted to the hospital for reasons other than pneumonia<br>2. Patients with mental illness have been identified or have been clearly diagnosed with emotional disorders<br>3. Minors","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","pneumonia patients group:N/A;medical staff group:N/A;","Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;","","","","Yes","0","          ",""
"ChiCTR2000030087","2020-02-25","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)                                                                                                                                                     ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49919","Recruiting","No","","","Both","2020-02-12","Light group:200;Common group:200;Severe group:200;Critical group:200;","Observational study","Factorial","0.0","China","Mingxing Xie","","1277 Jiefang Avenue, Wuhan, Hubei, China","xiemx@hust.edu.cn","+86 13607108938","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: The COVID-19 patients are confirmed according to the novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) issued by the National Health Protection Commission and the Chinese medicine administration.","Exclusion criteria: 1. Previous cheset trauma and surgery;<br>2. Previous severe emphysema and chronic obstructive pulmonary disease.","Novel Coronavirus Pneumonia (COVID-19)","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;","","","","No","0","          ",""
"ChiCTR2000030086","2020-02-25","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae                                                            ","","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49934","Recruiting","No","","","Both","2020-02-24","general anesthesia group vs. intraspinal anesthesia group:30;Health care goup:180;","Observational study","Factorial","Retrospective study","China","Haifa Xia, Xiangdong Chen","","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China ","xiangdongchen2013@163.com","+86 15071096621","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","Inclusion criteria: 1) The NCP puerperae undergoing cesarean section (The diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diag","Exclusion criteria: Medical staff with contact history outside the operating room.","Novel Coronavirus Pneumonia (COVID-19)","general anesthesia group vs. intraspinal anesthesia group:N/A;Health care goup:N/A;","CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;","","","","Yes","0","          ",""
"ChiCTR2000029994","2020-02-25","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial                                                                              ","","Shanghai University of TCM","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49309","Not Recruiting","No","18.0","80.0","Both","2020-02-19","Control group:100;Experimental group:100;","Interventional study","Parallel","0.0","China","Fang Lei","","1200 Cailun Road, Pudong New District, Shanghai, China","fanglei586@126.com","+86 021-51323092","Faculty of Rehabilitation Medicine, Shanghai University of Chinese Medicine","Inclusion criteria: (1) Meet NCP critical diagnosis criteria;<br>(2) Volunteer to participate in this study, cooperate with examination and treatment;<br>(3) The selected patients were basically stable, conscious and cooperative;<br>(4) No serious ment","Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;<br>2. Pregnant or lactating women;<br>3. Pa","Novel Coronavirus Pneumonia (COVID-19)","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","lung function;ADL;6min walk;","","","","Yes","0","          ",""
"ChiCTR2000029978","2020-02-25","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)                                                                                                                             ","","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49702","Not Recruiting","No","18.0","60.0","Both","2020-02-21","Control group:93;Experimental group:93;","Interventional study","Parallel","0.0","China","Fang Min","","110 Ganhe Road, Hongkou District, Shanghai, China","fangmin19650510@163.com","+86 18930568005","Tuina Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","Inclusion criteria: 1. Aged 18 to 60 years old;<br>2. Inpatients who meet the diagnostic criteria for mild, general and neonatal pneumonia in western medicine, and early and recovery stages of traditional Chinese medicine;<br>3. Understand and agree to ","Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;<br>2. Pregnant or lactating women;<br>3. Pa","Novel Coronavirus Pneumonia (COVID-19)","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Length of hospital stay;","","","","Yes","0","          ",""
"ChiCTR2000029960","2020-02-25","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province                                                                                                               ","","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49639","Not Recruiting","No","","","Both","2020-02-28","Control group:30;Experimental group:70;","Interventional study","Non randomized control","0.0","China","CHEN Xinyu","","95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","chenxinyuchen@163.com","+86 13807312410","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.","Exclusion criteria: pregnant or lactating women","Novel Coronavirus Pneumonia (COVID-19)","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","TCM syndrome;","","","","Yes","0","          ",""
"ChiCTR2000029959","2020-02-25","Clinical observation and research of  Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns","Clinical observation of the novel coronavirus pneumonia (COVID-19) in neonatal                                                                                                                                                                                 ","","West China Second Hospital, Sichuan University","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49636","Recruiting","No","0.0","1.0","Both","2020-01-25","COVID-19 pregnant women and normal pregnant women and infants born to them:30;","Observational study","Factorial","N/A","China","Jun Tang","","20 Third Section, Renmin Road South, Chengdu, Sichuan, China","tj1234753@sina.com","+86 18180609287","West China Second Hospital, Sichuan University, Chengdu, China","Inclusion criteria: 1. The neonates delivered by the mother who were suspected or confirmed infection of COVID-19;<br>2. The newborn,whose mother had no diagnosis of COVID-19 before delivery, had a history of epidemiological exposure (including diagnosis","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 pregnant women and normal pregnant women and infants born to them:None;","CoVID-19 Perinatal Outcomes;","","","","No","0","          ",""
"ChiCTR2000030331","2020-03-02","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui                                                                                                                                              ","","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50271","Recruiting","No","0.0","120.0","Both","2020-02-01","Case series:498;","Epidemilogical research","Sequential","N/A","China","Weng Jianping","","17 Lujiang Road, Luyang District, Hefei, Anhui, China","wengjp@ustc.edu.cn","+86 0551-62286223","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China","Inclusion criteria: Patients confirmed to be infected with SARS-CoV-2.","Exclusion criteria: 1. Patients who refused to participate in the project; <br>2. Patients developed symptoms caused by other pathogens rather than the SARS-CoV-2, and there was no evidence show that patients were infected with SARS-CoV-2.","COVID-19","Case series:NA;","","","","","No","0","          ",""
"ChiCTR2000030322","2020-03-02","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients                                                                                                                                                                ","","Xinyang Central Hospital","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50240","Recruiting","No","18.0","90.0","Both","2020-02-01","Light and common type group:80;Severe group:40;Western medicine treatment group:30;Chinese and western medicine combined treatment group:30;Non-invasive mechanical ventilation group:15;Nasal high flow oxygen therapy group:15;","Observational study","Factorial","0.0","China","Lu Yibin","","1 Siyi Road, Shihe District, Xinyang, He'nan, China","luyb6810@163.com","+86 13937642780","Xinyang Central Hospital","Inclusion criteria: According to the ""Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)"" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with p","Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;<br>2. Pregnant or lactating patients.","Novel Coronavirus Pneumonia (COVID-19);U07.100x001","Light and common type group:Conventional treatment;Severe group:Conventional treatment;Western medicine treatment group:Give routine western medicine treatment;Chinese and western medicine combined treatment group:Traditional Chinese medicine is combined ","Epidemiological and clinical characteristics;","","","","No","0","          ",""
"ChiCTR2000030054","2020-02-25","A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)                                                                                        ","","Zhongshan Hospital Affiliated to Xiamen University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49869","Not Recruiting","No","18.0","75.0","Both","2020-02-22","Hydroxychloroquine sulfate gloup:40;Chloroquine phosphate gloup:40;Control group:20;","Interventional study","Parallel","0.0","China","Yin Zhenyu","","Room 507, Xianyue Haijing Building, 195 Xianyue Road, Siming Square, Xiamen, Fujian, China","Yinzy@xmu.edu.cn","+86 13950120518","Zhongshan Hospital Affiliated to Xiamen University","Inclusion criteria: 1. Aged 18-75 years old;<br>2. RT-PCR positive for 2019-nCoV or Confirmed lung involvement with chest imaging;<br>3. The clinical symptoms are slight, and there is no obvious manifestation of pneumonia (mild disease) or clinical symp","Exclusion criteria: 1. Investigator makes a decision that trial participation is not in patients' best interest, or any condition that does not allow the protocol to be followed safely;<br>2. As judged by investigator historic or current diseases that ma","Novel Coronavirus Pneumonia (COVID-19)","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel","Clinical recovery time;","","","","Yes","0","          ",""
"ChiCTR2000030039","2020-02-25","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)                                                                                                                                                    ","","Affiliated Hospital of Xuzhou Medical University","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49544","Recruiting","No","18.0","60.0","Both","2020-05-31","Experimental group:30;control group:60;","Interventional study","Non randomized control","N/A","China","Xuebing Yan","","9 Kunpeng Road, Gulou District, Xuzhou, Jiangsu, China","yxbxuzhou@126.com","+86 15205215685","Affiliated Hospital of Xuzhou Medical University","Inclusion criteria: 1. The diagnosis conforms to the diagnostic criteria of ""pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5)"";<br>2. Clinical classification is normal,severe or critical;<br>3. Subject aged >=18 ","Exclusion criteria: 1. Highly allergic constitution or history of severe allergy, especially plasma allergy;<br>2. The doctor believes that there are other reasons not to include the healer.","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;","","","","Yes","0","          ",""
"ChiCTR2000029866","2020-02-25","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics                                                                                                                                                    ","","Enze Hospital of Taizhou Enze Medical Center (Group)","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49519","Recruiting","No","18.0","85.0","Both","2020-02-17","Target condition:120;Difficult condition:0","Diagnostic test","Factorial","Retrospective study","China","Lyu Dongqing","","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang ","lvdq@enzemed.com","+86 13867622009","Enze Hospital of Taizhou Enze Medical Center (Group) ","Inclusion criteria: 1. Aged >18 years; <br>2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV; <br>3. Lung involvement confirmed with chest imaging.","Exclusion criteria: Pregnant women.","novel coronavirus pneumonia (COVID-19)","Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early&#32;warning&#32;and&#32;prediction&#32;system.;","Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000029865","2020-02-25","Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients","Clinical characteristics and outcomes of cardiovascular disease patients infected by COVID-19 in Wuhan, China: a descriptive study                                                                                                                             ","","Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49545","Recruiting","No","","","Both","2020-02-20","common group:400;severe group:400;critical group:400;","Observational study","Factorial","N/A","China","Peng Yudong","","1277 Jiefang Avenue, Wuhan, Hubei, China","am-penicillin@163.com","+86 13886157176","Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: All patients who were diagnosed as COVID-19 according to the interim guidance of China National Health Commission (NHC)  were screened in this study. CVD included hypertension, coronary heart disease or/and heart failure confirmedly di","Exclusion criteria: 1. Aged <18 years;<br>2. Patients with systemic disease and severe liver and kidney dysfunction were excluded. ","Novel Coronavirus Pneumonia  (COVID-19)","common group:N/A;severe group:N/A;critical group:N/A;","blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;","","","","Yes","0","          ",""
"ChiCTR2000030006","2020-02-25","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                          ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49737","Recruiting","No","","","Both","2020-02-19","Experimental group:30;Control group:30;","Interventional study","Parallel","N/A","China","Chen Xiangdong","","1277 Jiefang Avenue, Wuhan, Hubei, China","xiangdongchen2013@163.com","+86 15071096621","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: (1) In line with ethics, sign a written informed consent form;<br>(2) Patients with positive detection of new coronavirus nucleic acid;<br>(3) Chest CT confirmed pulmonary lesions;<br>(4) Hospitalized patients with fever or respirat","Exclusion criteria: (1) Hyperthyroidism; <br>(2) Favism; <br>(3) Pregnancy; <br>(4) Abnormal coagulation, thrombocytopenia, active bleeding;<br>(5) People with medical ozone allergy or hypersensitivity; <br>(6) Severe anemia; <br>(7) Hypocalcemia; ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","Recovery rate;","","","","Yes","0","          ",""
"ChiCTR2000030001","2020-02-25","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial                                                                                                       ","","Health commission of Heilongjiang province","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49723","Recruiting","No","18.0","","Both","2020-02-15","Experimental group:120;Control group:120;","Interventional study","Parallel","3.0","China","Baofeng Yang","","194 Xuefu Road, Nangang District, Harbin, Heilongjiang, China","yangbf@ems.hrbmu.edu.cn","+86 133 0451 2381","Heilongjiang Province hospital","Inclusion criteria: (1) Adult aged >=18 years and agrees to sign the informed consent;<br>(2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR;<br>(3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in th","Exclusion criteria: (1) The PI considers that the patient is not suitable to participate the study or  the patient may be unsafe if he participate the study;<br>(2) Patients with serious liver disease, grade C according to child-pugh;<br>(3) Patients wi","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Time to Clinical recovery;","","","","No","0","          ",""
"ChiCTR2000030314","2020-03-02","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)                                                                                                                 ","","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50248","Not Recruiting","No","1.0","15.0","Both","2020-02-28","Case series:40;","Interventional study","Single arm","0.0","","Rui Pan","","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China","55815147@qq.com","+86 13986394739","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Inclusion criteria: 1. Confirmed or clinically diagnosed cases;<br>2. Aged > 1 year;<br>3. Volunteers.","Exclusion criteria: 1.With vomiting, diarrhea or other contraindications;<br>2.refuse to traditional Chinese medicine.","pediatric COVID19","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","temperature;respiratory symptoms;","","","","Yes","0","          ",""
"ChiCTR2000030305","2020-03-02","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)                                                                          ","","Li Caixia","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50223","Not Recruiting","No","18.0","90.0","Both","2020-03-09","Case series:20;","Observational study","Single arm","0.0","China","Li Caixia","","N1 Shangcheng Road, Yiwu, Zhejiang, China","li_caixia@zju.edu.cn","+86 15268118258","The Fourth Affiliated Hospital of Zhejiang University School of Medicine","Inclusion criteria: Adult patients with confirmed 2019-nCoV","Exclusion criteria: Severe liver and kidney damage, pulmonary tuberculosis, congenital heart disease, autoimmune disease, interstitial pneumonia, bacterial pneumonia, malignant tumor, history of psychiatric disease","Novel Coronavirus Pneumonia (COVID-19)","Case series:traditional Chinese medicine;","blood RNA;","","","","Yes","0","          ",""
"ChiCTR2000030021","2020-02-25","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients                                                                                                                      ","","Department of respiratory and critical care medicine, Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49690","Recruiting","No","","","Both","2020-02-20","Case series:10;","Observational study","Sequential","Retrospective study","China","Zhou Min","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","minzhou@tjh.tjmu.edu.cn","+86 15002749377","Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Diagnostic criteria refers to the WHO standards, including clinically diagnosed cases and laboratory confirmed cases","Exclusion criteria: Pneumonia caused by other pathogens","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical characteristics;","","","","Yes","0","          ",""
"ChiCTR2000030020","2020-02-25","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)                                                                                                                                  ","","Second Hospital of University of South China, Hengyang","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49812","Recruiting","No","18.0","70.0","Both","2020-02-06","Case series:20;","Interventional study","Sequential","N/A","China","Luo Zhigang","","35 Jiefang Avenue, Zhengxiang District, Hengyang, Hu'nan, China","706885399@qq.com","+86 13907342350","Second Hospital of University of South China, Hengyang","Inclusion criteria: (1) Age 18-70 years<br>(2) Clinical symptoms, signs, and lung CT suggest changes in lung inflammation. Patients diagnosed with new type of coronavirus pneumonia combined with more than one nucleic acid test<br>(3) Clinical symptoms, ","Exclusion criteria: (1) Subject has a history of tumor<br>(2) Female patients of childbearing age during pregnancy, lactation or recent birth planning<br>(3) Highly allergic constitution or history of severe allergies<br>(4) Coagulation disorders such ","Novel Coronavirus Pneumonia (COVID-19)","Case series:mesenchymal stem cells therapy;","Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);","","","","No","0","          ",""
"ChiCTR2000030262","2020-03-02","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                            ","","Shanghai Public Health Clinical Center","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50136","Recruiting","No","18.0","70.0","Both","2020-02-01","Group 2:10;Group 3:10;Group 1:10;","Interventional study","Sequential","0.0","China","Jianqing Xu","","2901 Caolang Road, Jinshan District, Shanghai, China","xujianqing@shphc.org.cn","+86 18964630206","Shanghai Public Health Clinical Center ","Inclusion criteria: 1. Aged from 18 to 70 years old;<br>2. According with the clinical diagnosis of viral pneumonia symptoms,including fever, Low white blood cells or platelets infiltration shadow in CT;<br>3. Positive result for  nucleic acid of 2019-n","Exclusion criteria: 1. Pneumonia caused by other viruses, except for 2019-nCov;<br>2. Clear bacterial infection;<br>3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study;<br>4. There are serious non-infecti","Novel Coronavirus Pneumonia (COVID-19)","Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;","Viral load;Clinical features;Inflammation;Pulmonary imaging;","","","","No","0","          ",""
"ChiCTR2000030260","2020-03-02","Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment                                                                                                ","","Ganzi Hospital of West China Hospital, Sichuan University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50130","Not Recruiting","No","","","Both","2020-02-27","Experimental group:10;Control group:10;","Interventional study","Parallel","0.0","China","Lijia Deng","","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","27216302@qq.com","+86 17723451376","Ganzi Hospital of West China Hospital, Sichuan University","Inclusion criteria: 1. novel coronavirus pneumonia patients with nutritional malnutrition diagnosed by nutritional assessment;<br>2. enteral nutrition support treatment for at least 5 days;<br>3. No use of Fat emulsion taboo;","Exclusion criteria: 1. No malnutrition;<br>2. Patients who had received antiviral drugs, immunosuppressive drugs and cytotoxic drugs 2 weeks before diagnosis;<br>3. patients with hypertriglyceridemia (TG): Serum TG > 3.0mmol/l;<br>4. patients with seve","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;","","","","Yes","0","          ",""
"ChiCTR2000030019","2020-02-25","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp                                                                                                                                                   ","","Zhongshan Hospital Fudan University","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49768","Not Recruiting","No","18.0","90.0","Both","2020-02-28","Training:150;Vaidation:450;","Observational study","Factorial","N/A","China","Chunxue Bai","","180 Fenglin Road, Xuhui District, Shanghai, China","bai.chunxue@zs-hospital.sh.cn","+86 18621170011","Zhongshan Hospital Fudan University","Inclusion criteria: 1. Aged 18-90 years;<br>2. With risk factor of COVID-19;<br>3. Access to nCapp platform;<br>4. to be able to complete a 1 year follow up.","Exclusion criteria: Unable to access the nCapp platform","Novel Coronavirus Pneumonia (COVID-19)","Training:None;Vaidation:None;","Accuracy;","","","","Yes","0","          ",""
"ChiCTR2000030004","2020-02-25","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Effect of New Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students                                                                                                                                                                        ","","West China Hospital, Sichuan University","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49783","Not Recruiting","No","16.0","30.0","Both","2020-02-20","college students:150000;","Observational study","Sequential","N/A","China","Tao Li","","28 South Dianxin Street, Wuhou District, Chengdu, Sichuan, China ","xuntao26@hotmail.com","+86 18980601817","West China Hospital, Sichuan University","Inclusion criteria: All students from Sichuan University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent.","Exclusion criteria: None","Novel Coronavirus Pneumonia","college students:none;","Mental health status;","","","","Yes","0","          ",""
"ChiCTR2000029999","2020-02-25","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)                                                                                                                    ","","Shanghai 10th people's hospital","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49717","Not Recruiting","No","18.0","100.0","Both","2020-02-20","Mild Group:30;Severe Group:30;","Interventional study","Factorial","0.0","China","Peng Hu","","301 Yanchang Middle Road, Shanghai, China","18917683122@189.cn","+86 18917683122","Shanghai 10th People's Hospital, Tongji University","Inclusion criteria: 1. aged >=18 years;<br>2. Gender limitation;<br>3. Patients must be able to sign informed consent and understand the possible risks of microecological intervention;<br>4. Be willing to provide stool and blood samples on time.","Exclusion criteria: 1. patients with dysphagia or gastrointestinal obstruction;<br>2. Patients with autoimmune diseases, or with extremely low immunity, or with other diseases requiring systemic use of immunosuppressive drugs or hormone therapy;<br>3. H","novel coronavirus pneumonia","Mild Group:probiotics;Severe Group:probiotics;","gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;We","","","","Yes","0","          ",""
"ChiCTR2000029992","2020-02-25","A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                 ","","Zhongshan Hospital Affiliated to Xiamen University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49574","Not Recruiting","No","18.0","75.0","Both","2020-02-17","Chloroquine phosphate gloup:40; Hydroxychloroquine sulfate gloup:40;Routine treatment group:20;","Interventional study","Parallel","4.0","China","Yin Zhenyu","","201-209 Hubin Road South, Siming District, Xiamen, Fujian","Yinzy@xmu.edu.cn","+86 13950120518","Zhongshan Hospital Affiliated to Xiamen University","Inclusion criteria: 1. The age at the time of signing the informed consent is >= 18 years old and <= 75 years old, both male and female; <br>2. The change of typical viral pneumonia in lung was detected by RT-PCR test of novel coronavirus nucleic acids o","Exclusion criteria: 1. In the opinion of the researchers, the participation of the trial is not in the best interests of the patients, or any situation is not in line with the situation that the trial scheme is allowed to be followed safely;<br>2. Accord","Novel Coronavirus Pneumonia (COVID-19)","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel","Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;","","","","No","0","          ",""
"ChiCTR2000029851","2020-02-25","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)                                                                                 ","","Zhongshan Hospital, Fudan University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49534","Recruiting","No","35.0","74.0","Both","2020-02-19","control group:34;Experience group:34;","Interventional study","Parallel","4.0","China","Junbo Ge","","180 Fenglin Road, Xuhui District, Shanghai, China","jbge@zs-hospital.sh.cn","-64041925.0","Zhongshan Hospital, Fudan University","Inclusion criteria: 1. Severe patients diagnosed with novel coronavirus pneumonia (COVID-19);<br>2. Aged 35 years old to 74 years old;<br>3. Patients or authorized family members volunteered to participate in this study and signed informed consent.<br>","Exclusion criteria: 1. Involving in other drug clinical trial;<br>2. Pregnant or breastfeeding;<br>3. Presence of other serious diseases that may be life threatening, such as cancer;<br>4. Expected life is less than 24 hours;<br>5. Allergy to ALA or d","Novel Coronavirus Pneumonia (COVID-19)","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","SOFA;","","","","Yes","0","          ",""
"NCT04252664","2020-03-02","Mild/Moderate 2019-nCoV Remdesivir RCT","A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.","","Capital Medical University","2020-01-31","2020-01-31","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04252664","Recruiting","No","18 Years","N/A","All","2020-02-12","308.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","China"," ; ","Bin Cao, Professor;Ying Liu","","caobin@zryhyy.com.cn;","+01084206264;","","<br>        Inclusion Criteria:<br><br>          1. Age =18 years at time of signing Informed Consent Form<br><br>          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.<br><br>          3. Lung involvement confirmed with chest imaging","","2019-nCoV","Drug: Remdesivir;Drug: Remdesivir placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","","","","Yes","0","          ",""
"ChiCTR2000030003","2020-02-25","Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                              ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49770","Not Recruiting","No","","","Both","2020-02-19","Group 1:120;Group 2:240;Group 3:120;","Interventional study","Parallel","N/A","China","Tang Jianyuan","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","tangjianyuan163@163.com","+86 13910768464","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: (1) Patients with mild who are in compliance with the ""Pneumonitis Diagnosis and Treatment Program for COVID-19(Trial Fifth Edition)"" (released on 2020.2.4);<br>(2) Aged more than 18 years old;<br>(3) Informed consent of the patient.","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;","","","","Yes","0","          ",""
"ChiCTR2000030002","2020-02-25","Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)                                                                                                                                              ","","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49738","Recruiting","No","18.0","85.0","Both","2020-02-15","control group:30;Experience group:30;","Interventional study","Parallel","4.0","China","Hongliang He","","17 Lujiang Road, Luyang District, Hefei, Anhui, China","44271370@qq.com","+86 15956927046","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital) ","Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia;<br>2. Aged 18 to 85 years;<br>3. IL-1 elevated (using Elisa method, using the same compan","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;<br>2. Pregnant or lactating women;<br>3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50;<br>4. Expected life<1 week;<br>5. Definite diagnosis of asthma-re","Novel Coronavirus Pneumonia (COVID-19)","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","cure rate;","","","","No","0","          ",""
"ChiCTR2000029990","2020-02-25","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)                                                                                                                                              ","","Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49674","Recruiting","No","","","Both","2020-01-30","experimental group:60;control group:60;","Interventional study","Parallel","43862.0","China","Robert Chunhua Zhao/Ronghua Jin","","5 Shantiao Street, Dongdan, Dongcheng District, Beijing, China","zhaochunhua@vip.163.com","+86 010-65125311","institute of basic medicine, Chinese Academy of medical sciences","Inclusion criteria: 1. Male or female, 18-95 years old;<br>2. 2019 new coronavirus nucleic acid test positive;<br>3. Diagnosed as moderate to severe cases of new coronavirus pneumonia in 2019, which meets the following clinical manifestations:<br>4. Wi","Exclusion criteria: 1. Malignant disease in the past five years;<br>2. The clinical prediction is that there is no hope for survival, only cases of hospice care, or cases of deep coma that do not respond to supportive treatment measures within three hour","pneumonitis caused by novel coronavirus","experimental group:mesenchymal stem cells;control group:saline;","Improved respiratory system function (blood oxygen saturation) recovery time;","","","","No","0","          ",""
"ChiCTR2000029981","2020-02-25","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions                                                                                                                                                      ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49692","Recruiting","No","18.0","","Female","2020-02-18","Target condition:60;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Shixuan Wang","","1095 Jiefang Avenue, Wuhan, Hubei, China","sxwang@tjh.tjmu.edu.cn","+86 02783663078","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Inclusion criteria: 1. Aged >=18 years old female;<br>2. A history of fertility or sexual activity<br>3. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic cri","Exclusion criteria: Patients that the researchers determined not suitable for this study","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab","SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000030255","2020-03-02","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome                                                                                                                                          ","","Shanghai University of Traditional Chinese Medicine","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50089","Not Recruiting","No","18.0","75.0","Both","2020-03-01","Routine treatment +  Jing-Yin Granule:200;Routine treatment :100;","Interventional study","Parallel","4.0","China","Liu Hua/Wang Qian","","1200 Cailun Road, Zhangjiang Hi-TechPark, Pudong New Area, Shanghai, China","yyliuhua@126.com","+86 18930568010","Shanghai University of Traditional Chinese Medicine","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia, clinical classification is ordinary or heavy;<br>2. TCM syndrome differentiation is wind-heat syndrome;<br>3. Aged between 18-75 years old, regardless of gender;<br>4. V","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital h","Novel Coronavirus Pneumonia (COVID-19)","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day 	;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Clearance rate and time of main symptoms (fever, fatigue, cough);","","","","Yes","0","          ",""
"ChiCTR2000030253","2020-03-02","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid                                                                                                                                                           ","","Ganzi Hospital of West China Hospital, Sichuan University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50143","Not Recruiting","No","","","Both","2020-02-27","Target condition:30;Difficult condition:30","Diagnostic test","Cross-sectional","1.0","China","Lijia Deng","","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","27216302@qq.com","+86 17723451376","Ganzi Hospital of West China Hospital, Sichuan University","Inclusion criteria: suspected infection and Confirmed novel coronavirus patients","Exclusion criteria: Non Novel coronavirus suspected infection and Confirmed patients","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection&#32;of&#32;viral&#32;nucleic&#32;acids&#32;in&#32;eye&#32;swabs,&#32;throat&#32;swabs,&#32;oral&#32;saliva,&#32;feces,&#32;urine&#32;and&#32;plasma;","SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000029989","2020-02-25","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)                                                                              ","","Chinese PLA General Hospital","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49720","Not Recruiting","No","60.0","","Both","2020-02-20","experimental group.:150;Control group:150;","Interventional study","Parallel","4.0","China","Feng Cao","","28 Fuxing Road, Haidian District, Beijing, China","fengcao8828@163.com","+86 13911798280","Chinese PLA General Hospital","Inclusion criteria: 1. Aged >=60 years;<br>2. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"";<br>3. Those without broad","Exclusion criteria: 1. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;<br>2. Patients with eye diseases (such as cataract, conjunctivitis, glaucoma)<br>3. Severe liver disease (such as  AST > 3 ULN);<br>4. Patients","Novel Coronavirus Pneumonia (COVID-19)","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;","","","","Yes","0","          ",""
"ChiCTR2000029988","2020-02-25","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                      ","","Zhongnan Hospital of Wuhan University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49218","Recruiting","No","18.0","70.0","Both","2020-02-13","Experimental group:40;Control group:40;","Interventional study","Parallel","4.0","China","Zhao Yan","","169 Donghu Road, Wuhan, Hubei, China","doctoryanzhao@whu.edu.cn","+86 13995577963","Zhongnan Hospital of Wuhan University","Inclusion criteria: 1) Male and female, 18-70 years old;<br>2) Severe patients (in any case: respiratory distress, RR >= 30 times / min; in resting state, oxygen saturation <= 93%; PaO2 / FiO2 <= 300MMHG);<br>3) Within 12 days after illness onset;<br>4","Exclusion criteria: 1) Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;<br>2) Pregnant and lactating women;<br>3) The subjects received specific antiviral drugs such as lop","Novel Coronavirus Pneumonia  (COVID-19)","Experimental group:Chloroquine Phosphate;Control group:No;","Time to Clinical Recovery;","","","","No","0","          ",""
"ChiCTR2000029974","2020-02-25","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)                                                             ","","Qingdao East Sea Pharmaceutical Co., Ltd.","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49321","Recruiting","No","18.0","","Both","2020-02-09","Experimental group:150;Control group:150;","Interventional study","Parallel","0.0","China","Dong Liang","","1377 Jiao-Zhou-Wan Road West, Yinzhou Street, Huangdao District, Qingdao, Shandong, China","dl5506@126.com","+86 18560082787","Qilu Hospital of Shandong University","Inclusion criteria: 1. Patients or his/her legal representatives agreed to participate the study and signed the informed consent. <br>2. Those diagnosed with mild or moderate novel coronavirus pneumonia (NCP) or those with severe NCP but can take medicin","Exclusion criteria: 1. The serious NCP patients who can neither swallow medicines nor take medicine via stomach tube, and the critical serious NCP patients;<br>2. Those with severe hypo-immunity due to, but not limited to, one of the following reasons:<","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","Time to Clinical recovery;Butyrate in feces;","","","","No","0","          ",""
"ChiCTR2000029803","2020-02-25","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)                                                        ","","Renmin Hospital of Wuhan University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49428","Not Recruiting","No","18.0","60.0","Both","2020-02-20","A1:80;A2:80;B1:80;B2:80;","Interventional study","Parallel","0.0","China","Zhan Zhang","","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","doctorzhang2003@163.com","+86 18062567610","Renmin Hospital of Wuhan University","Inclusion criteria: 1. 18 years old <= age <= 60 years old when screening, not limited to men and women;<br>2. Who are in close contact with suspected cases, confirmed cases, and positive test of new coronavirus nucleic acid, and those who have not taken","Exclusion criteria: 1. The physician decides that participating in the trial is not in the best interest of the patient, or does not meet any conditions for safe follow-up in the protocol;<br>2. People with heart disease such as cardiac block;<br>3. Peo","Novel Coronavirus Pneumonia  (COVID-19)","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;","","","","Yes","0","          ",""
"ChiCTR2000030219","2020-03-02","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                         ","","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50110","Recruiting","No","8.0","91.0","Both","2020-01-21","Case series:120;","Interventional study","Sequential","New Treatment Measure Clinical Study","China","Bi Ying-fei","","88 Changling Road, Xiqing District, Tianjin, China","yingfei1981@163.com","+86 13920648942","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Inclusion criteria: 1) Any age;<br>2) Meet the diagnostic standard of COVID-19;<br>3) Voluntarily accept TCM syndrome differentiation treatment;<br>4) Agree to sign informed consent.","Exclusion criteria: 1) Liver and kidney dysfunction (alt, AST > 2 times the upper limit of normal reference value or / and serum creatinine > 2 times the upper limit of normal reference value);<br>2) Psychosis, or cognitive impairment;<br>3) Those who a","Novel Coronavirus Pneumonia (COVID-19)","Case series:Integration of traditional Chinese and Western Medicine;","Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;","","","","No","0","          ",""
"ChiCTR2000030091","2020-03-02","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)                                                                                           ","","West China Hospital, Sichuan University","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49914","Not Recruiting","No","15.0","35.0","Both","2020-02-22","Experimental group:100;Control group:100;","Interventional study","Parallel","N/A","China","XIONG YAN","","363 Furong Avenue, Wenjing District, Chengdu, Sichuan ","luyibingli@163.com","+86 18328737998","West China Hospital, Sichuan University","Inclusion criteria: Nursing student will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent. ","Exclusion criteria: NONE","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Exercise prescription;Control group:none;","Mood index;","","","","No","0","          ",""
"ChiCTR2000029985","2020-02-25","Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)","Study on mental health status and influencing factors of nurses during epidemic prevention of Novel coronavirus pneumonia (COVID-19)                                                                                                                           ","","Sichuan Academy of Medical Sciences & Sichuan Provincial Peoples Hospital","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49711","Recruiting","No","22.0","55.0","Both","2020-02-10","Case series:1853;","Observational study","Sequential","N/A","China","Caixia Xie","","32 West Second Section, First Ring Road, Chengdu, Sichuan, China","8999578@qq.com","+86 13699093647","Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital","Inclusion criteria: (1) nurses with working years >=1 year;<br>(2) registered nurses who are qualified to practice;<br>(3) nurses who volunteered to participate in this study.","Exclusion criteria: (1) advanced and trainee nurses; <br>(2) nurses during the investigation period due to leave (sickness, affairs, pregnancy, etc.) reasons not post.","NO","Case series:Nil;","HSCS;SCSQ;GHQ-12;","","","","No","0","          ",""
"ChiCTR2000029972","2020-02-25","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                   ","","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49664","Recruiting","No","18.0","65.0","Both","2020-02-17","Experimental group:20;control:20;","Interventional study","Parallel","N/A","China","Chen Hong","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","chenhong1129@hotmail.com","+86 13296508243","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: (1) Aged 18-65 years;<br>(2) Virus nucleic acid test is positive;<br>(3) Lung CT showed multiple patchy, lumpy ground glass opacity(GGO) or consolidation in both lungs.","Exclusion criteria: (1) Positive for other pathogens such as A, B, Mycoplasma, Adenovirus;<br>(2) Respiratory failure occurs, requiring mechanical ventilation;<br>(3) People with metal or pacemaker;<br>(4) active tuberculosis;<br>(5) Massive pulmonary","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;","","","","Yes","0","          ",""
"ChiCTR2000029780","2020-02-25","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49220","Recruiting","No","18.0","","Both","2020-02-14","experimental group:80;control group:80;","Interventional study","Parallel","4.0","China","Xin Zheng","","1277 Jiefang Avenue, Wuhan, Hubei, China","Xin11@hotmail.com","+86 18602724981","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: 1) Aged >= 18 years;<br>2) In line with the diagnostic criteria of ""new coronavirus pneumonia diagnosis program"", the patient was diagnosed as pneumonia infected by the new coronavirus;<br>3) Severe pneumonia index (PSI) class for II","Exclusion criteria: 1)One of the following conditions:<br>Respiratory distress, RR >= 30 times/min;<br>At rest, oxygen saturation is less than 93%;<br>Artial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) <= 300mmHg (1mmHg=0.133","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","Recovery time;","","","","Yes","0","          ",""
"NCT04257656","2020-03-02","Severe 2019-nCoV Remdesivir RCT","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.","","Capital Medical University","2020-01-31","2020-01-31","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04257656","Recruiting","No","18 Years","N/A","All","2020-02-06","453.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","China"," ","Bin Cao, Professor","","caobin@zryhyy.com.cn","1084206264.0","","<br>        Inclusion Criteria:<br><br>          1. Age =18 years at time of signing Informed Consent Form<br><br>          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.<br><br>          3. Lung involvement confirmed with chest imaging","","2019-nCov;Remdesivir","Drug: Remdesivir;Drug: Remdesivir placebo","Time to Clinical Improvement (TTCI) [Censored at Day 28]","","","","Yes","0","          ",""
"ChiCTR2000030042","2020-03-02","Cancelled due to lack of patient                                                                A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&","A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                            ","","Chongqing Liangjiang New Area first people's Hospital","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49899","Recruiting","No","14.0","99.0","Both","2020-02-21","Case series:240;","Observational study","Sequential","Retrospective study","China","Chen Hao","","116 North Street, Guixi Street, Dianjiang, Chongqing, China","1041863309@qq.com","+86 023 61103649","Chongqing Dianjiang County People's Hospital","Inclusion criteria: Novel coronavirus pneumonia real-time fluorescence RT-PCR virus nucleic acid detection cases were detected in all centers.","Exclusion criteria: 1) Children (less than 14 years old);<br>2) lack of important case information (such as blood routine, C-reactive protein, epidemic history, chest CT, etc.).","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","ROC;calibration curve;","","","","Yes","0","          ",""
"ChiCTR2000029975","2020-03-02","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                        ","","The First Hospital of Jilin University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49592","Not Recruiting","No","18.0","","Both","2020-02-24","Experimental group:10;","Interventional study","Single arm","4.0","China","Hua Shucheng","","71 Xinmin Street, Changchun, Jilin, China","shuchenghua@126.com","+86 13756661209","The First Hospital of Jilin University","Inclusion criteria: A novel coronavirus pneumonia patient who was more than 18 years old and agreed to participate in the trial and signed informed consent.","Exclusion criteria: 1. Known to be allergic to hydroxychloroquine or 4-aminoquinoline;<br>2. Patients with severe renal insufficiency (EGFR < = 30 ml / min / 1.73 m2) and RRT;<br>3. Severe liver disease (child Pugh score > =C,Ast > 5 times of the upper ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Chloroquine phosphate;","viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;","","","","Yes","0","          ",""
"ChiCTR2000029954","2020-02-25","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                          ","","Hubei Hospital of Traditional Chinese Medicine","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49402","Recruiting","No","","","Both","2020-04-30","Control group:100;Experimental group 1:100;Experimental group 2:100;","Interventional study","Parallel","4.0","China","Yang Yi","","4 Garden Hill, Wuchang District, Wuhan, Hubei, China","153267742@qq.com","+86 18971163518","Hubei Hospital of Traditional Chinese Medicine","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;<br>2. Aged 18 to 65 years;<br>3. The time interval between symptom onset and randomization was within 7 days (the onset of symp","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal r","Novel Coronavirus Pneumonia (COVID-19)","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group","Recovery time;Pneumonia psi score;","","","","Yes","0","          ",""
"NCT04279899","2020-03-02","The Investigation of the Neonates With or With Risk of COVID-19","A Multicenter Observational Study of the Perinatal-neonatal Population With or With Risk of COVID-19 in China","","Children's Hospital of Fudan University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04279899","Recruiting","No","N/A","28 Days","All","2020-02-01","100.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  The neonates with COVID-19,or neonates born by infected mothers<br><br>        Exclusion Criteria:<br><br>          -  The neonates with major anomalies<br>      ","","Neonatal Infection;Perinatal Problems;Infectious Disease","","The death of newborns with COVID-19;The SARS-CoV-2 infection of neonates born to mothers with COVID-19","","","","Yes","0","          ",""
"NCT04256395","2020-03-02","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","Registry Study on the Efficacy of a Self-test and Self-alert Applet in Detecting Susceptible Infection of COVID-19 a Population Based Mobile Internet Survey","COVID-19","Beijing Tsinghua Chang Gung Hospital","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04256395","Recruiting","No","N/A","N/A","All","2020-02-01","300000.0","Observational","","N/A","China"," ; ; ","Jiahong Dong, M.D;Xiaobin Feng, M.D;Xiaobin Feng, M.D","",";fengxiaobin200708@aliyun.com;",";+86 13228683243;","Beijing Tsinghua Changgung Hospital;","<br>        Inclusion Criteria:<br><br>          -  people who lived in or out of China at present and threatened by the infection and<br>             spread of COVID-19<br><br>               -  without gender and age restriction<br><br>          ","","Susceptibility to Viral and Mycobacterial Infection","Other: mobile internet survey on self-test","positive number diagnosed by national guideline in the evaluated population","","","","Yes","0","          ",""
"NCT04273321","2020-03-02","Efficacy and Safety of Corticosteroids in COVID-19","Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","","Beijing Chao Yang Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04273321","Recruiting","No","18 Years","N/A","All","2020-02-14","400.0","Interventional","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ","Bing Sun, MD","","ricusunbing@126.com","86013911151075.0","","<br>        Inclusion Criteria:<br><br>          -  age more than 18 years old<br><br>          -  accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria<br>             of Novel coronavirus pneumonia (COVID-19).<br><","","COVID-19;Novel Coronavirus Pneumonia","Drug: Methylprednisolone","the incidence of treatment failure in 14 days","","","","Yes","0","          ",""
"NCT04273529","2020-03-02","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","","First Affiliated Hospital of Wenzhou Medical University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04273529","Not recruiting","No","18 Years","N/A","All","2020-02-20","100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2",""," ; ","Jinglin Xia, MD;Jinglin Xia, MD","",";xiajinglin@fudan.edu.cn",";0577-55578166","First Affiliated Hospital of Wenzhou Medical University;","<br>        Inclusion Criteria:<br><br>          1. Age =18 years;<br><br>          2. Laboratory (RT-PCR) diagnosis of common patients infected with COVID-19 (refer to the<br>             fifth edition of the Chinese Guidelines for Diagnosis and Tr","","COVID-19 Thalidomide","Drug: thalidomide;Drug: placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","","","","Yes","0","          ",""
"ChiCTR2000029762","2020-03-02","Cancelled due to lack of patient                                                                              Clinical study for the effect and","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                   ","","The First Affiliated Hospital of Chongqing Medical University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49404","Not Recruiting","No","18.0","80.0","Both","2020-02-12","Experimental group:30;Control group:30;","Interventional study","Parallel","4.0","China","Wenxiang Huang","","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China","wenxiang_huang@163.com","+86 13883533808","The First Affiliated Hospital of Chongqing Medical University","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:<br>1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;<br>2. Chinese","Exclusion criteria: Patients with any of the following were excluded from the study:<br>1. Patients with previous allergy to 4-aminoquinoline compounds;<br>2. Patients with previous severe retinal or visual field related diseases;<br>3. Patients with s","Novel Coronavirus Pneumonia  (COVID-19)","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;","","","","Yes","0","          ",""
"ChiCTR2000029760","2020-03-02","Cancelled due to lack of patient                              A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases                                                                                                                     ","","The Second Affiliated Hospital of Chongqing Medical University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49369","Not Recruiting","No","","","Both","2020-02-12","Experimental group:120;Control group:120;","Interventional study","Parallel","4.0","China","Huawei Mao","","136 Second Zhongshan Road, Yuzhong District, Chongqing, China","maohwei@qq.com","+86 13928459556","Chongqing Medical University","Inclusion criteria: 1. Informed consent offered;<br>2. Confirmed infection with 2019-nCoV by RT-PCR;<br>3. Compliance with the intervention of study.","Exclusion criteria: 1. Known allergic to hydroxychloroquine or 4-aminoquinoline;<br>2. Severe renal impairment (eGFR <= 30 mL/min/1.73 m2), and those with RRT;<br>3. Severe liver disease (Child Pugh score >= C, AST>5 times upper limit);<br>4. Pre-exist","novel coronavirus pneumonia (COVID-19)","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","Time to clinical recovery;","","","","Yes","0","          ",""
"ChiCTR2000030433","2020-03-02","Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)                                                                                                             ","","The First Affiliated Hospital of Fujian Medical University","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50273","Not Recruiting","No","","","Both","2020-03-01","one group:80;","Interventional study","Single arm","1.0","China","Nijun","","20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","nijun1000@126.com","+86 19890572216","The First Affiliated Hospital of Fujian Medical University","Inclusion criteria: 1. aged between 18-70 years old;<br>2. clinical dignosied 2019-nCov pneumonia and clinical recovery,diagnostic criteria according to the   2019-nCov pneumonia-6th edition;<br>3. Cured within one month of discharge;<br>4. consious,em","Exclusion criteria: 1. Heart rate: heart rate <40 or >130 times/min;<br>2. New myocardial ischemia or arrhythmia;<br>3. Severe liver and kidney dysfunction or the appearance of new progressive liver and kidney dysfunction;<br>4. Oxygen saturation <=93%","2019-nCov pneumonia","one group:Rehabilitation Lung Health Eight - Stage Exercise ;","PCL;HRQL;IPAQ;PASE;","","","","Yes","0","          ",""
"ChiCTR2000030418","2020-03-02","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                     ","","The First Affiliated Hospital of Fujian Medical University","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50341","Recruiting","No","18.0","80.0","Male","2020-03-01","Group 1:40;Group 2:40;","Interventional study","Parallel","N/A","China","Ni Jun","","20 Chazhong Road, Fuzhou, Fujian, China","nijun1000@126.com","+86 19890572216","The First Affiliated Hospital of Fujian Medical University","Inclusion criteria: 1. Aged 18-80 years;<br>2. Meet the diagnostic criteria of ""New Coronavirus Infected Pneumonia Sixth Edition"";<br>3. Blood pressure 90-150 / 60-100mmHg, respiratory rate 12-20 beats / min, heart rate 60-100 beats / min;<br>4. Extrem","Exclusion criteria: 1. Heart rate: Heart rate <40 or> 130 beats / min;<br>2. New onset of myocardial ischemia or arrhythmia;<br>3. Blood pressure: mean arterial pressure (MAP) <65mmHg or> 110mmHg;<br>4. Body temperature: >=38.5 degree C;<br>5. Blood o","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;","","","","Yes","0","          ",""
"NCT04275245","2020-03-02","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","","Tang-Du Hospital","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04275245","Recruiting","No","18 Years","75 Years","All","2020-02-03","20.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1/Phase 2","China"," ; ","Jianqi Lian, MD;Sicao Li","","liangjq@fmmu.edu.cn;","+86-13571892829;+86-029-84777631","","<br>        Inclusion Criteria:<br><br>          -  Men and women aged 18 to 75 years (inclusive)<br><br>          -  In line with the new coronavirus infection pneumonia diagnosis and treatment plan<br>             (trial version 4) issued by the H","","2019-nCoVs Infection Pneumonia","Drug: Meplazumab for Injection","2019 nCoV nucleic acid detection","","","","Yes","0","          ",""
"NCT04275388","2020-03-02","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia","","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04275388","Not recruiting","No","18 Years","70 Years","All","2020-02-14","348.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A",""," ","Hongzhou Lu, Master","","lunliweiyuanhui2009@126.com","021-37990333","","<br>        Inclusion Criteria:<br><br>          1. Aged between 18 and 70 years, extremes included, male or female<br><br>          2. Fever (armpit temperature =37.3  C, or mouth temperature =38.0  C, or anal or ear<br>             temperature","","2019 Novel Coronavirus Pneumonia","Drug: Xiyanping injection;Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Clinical recovery time","","","","Yes","0","          ",""
"NCT04279197","2020-03-02","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu","A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","","ShuGuang Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04279197","Recruiting","No","18 Years","65 Years","All","2020-02-15","136.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ","Phase 2","China"," ; ","Chenghai Liu, PhD;Chenghai Liu, PhD","","chenghailiu@hotmail.com;","8621-20256521;","","<br>        Inclusion Criteria:<br><br>          -  Patients with pulmonary fibrosis after standard treatment of COVID-19<br><br>          -  Age 18-65<br><br>          -  2019-nCoV nucleic acid negative in respiratory tract or blood samples were d","","Pulmonary Fibrosis Due to 2019-nCoV","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet;Drug: N-acetylcysteine+Placebo","High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco","","","","Yes","0","          ",""
"NCT04280588","2020-03-02","Fingolimod in COVID-19","Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","","First Affiliated Hospital of Fujian Medical University","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04280588","Recruiting","No","18 Years","80 Years","All","2020-02-22","30.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","China"," ; ","Ying Fu;Wan-Jin Chen, MD","","fuying1995@163.com;wanjinchen75@fjmu.edu.cn","+86;+1386061359","","<br>        Inclusion Criteria:<br><br>          -  The patients who were diagnosed with the common type of NCP (including severe risk<br>             factors) and severe cases of new coronavirus pneumonia;<br><br>          -  Aged 18 to 85 years;<","","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","The change of pneumonia severity on X-ray images","","","","Yes","0","          ",""
"ChiCTR2000030432","2020-03-02","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic                                                                                                        ","","The First Affiliated Hospital of Fujian Medical University","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50268","Not Recruiting","No","20.0","45.0","Both","2020-03-02","Case series:40;Control group:40;","Interventional study","Parallel","0.0","China","RongJin Lin","","20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","nplrj@126.com","+86 13809508580","The First Affiliated Hospital of Fujian Medical University","Inclusion criteria: (1) Aged 20-45 years old;<br>(2) Understand and willing to participate in this clinical trial and provide signed informed consent.","Exclusion criteria: Patients with severe cardiovascular disease, lung disease, sleep disorder, psychological disease, musculoskeletal system disease and other sports contraindications.","Novel Coronavirus Pneumonia (COVID-19)","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","PCL;PSQI;FSI;","","","","Yes","0","          ",""
"ChiCTR2000030398","2020-03-02","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                 ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50173","Not Recruiting","No","18.0","75.0","Both","2020-02-27","Experimental group:170;Control group:170;","Interventional study","Parallel","N/A","China","Zhang Dingyu","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","1813886398@qq.com","+86 13507117929","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Inclusion criteria: 1. Aged 18 to 75 years men and women;<br>2. Inpatients with novel coronavirus(SARS-CoV-2) infection confirmed by PCR;<br>3. Agree and sign the informed consent form.","Exclusion criteria: 1. Cannot take medicine by mouth;<br>2. Those who are allergic to bismuth potassium citrate capsules or who have taken bismuth preparations within 1 month;<br>3. Critical patients meet one of the following conditions:<br>(1) Respira","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potas","Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;","","","","No","0","          ",""
"NCT04273581","2020-03-02","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","","First Affiliated Hospital of Wenzhou Medical University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04273581","Not recruiting","No","18 Years","N/A","All","2020-02-18","40.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2",""," ; ","Jinglin Xia, MD;Jinglin Xia, MD","",";xiajinglin@fudan.edu.cn",";0577-55578166","First Affiliated Hospital of Wenzhou Medical University;","<br>        Inclusion Criteria:<br><br>          1. Age =18 years;<br><br>          2. The laboratory (RT-PCR) confirmed the diagnosis of severe patients infected with<br>             CoVID-19 (refer to the fifth edition of the Chinese diagnosis and","","COVID-19 Thalidomide","Drug: placebo;Drug: Thalidomide","Time to Clinical Improvement (TTCI)","","","","Yes","0","          ",""
"NCT04274322","2020-03-02","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC)","","Peking University Third Hospital","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04274322","Not recruiting","No","18 Years","N/A","All","2020-02-01","100.0","Observational","","N/A",""," ","Qinggang Ge, M.D.","","qingganggelin@126.com","86-10-82266699","","<br>        Inclusion Criteria:<br><br>          -  Admitted to intensive care unit (ICU), Peking University Third Hospital since Feb 2020<br><br>          -  Adult (aged over 18 years)<br><br>          -  Anticipate a length of ICU stay (LOS) of m","","Critically Ill;Coronavirus Infections","Other: Nutrition support","28-day all cause mortality","","","","Yes","0","          ",""
"NCT04275414","2020-03-02","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","BEST-CP","Qilu Hospital of Shandong University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04275414","Recruiting","No","18 Years","80 Years","All","2020-02-01","20.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","China"," ; ; ","Yuguo Chen, Dr;Jiaojiao Pang, Dr;Jiaojiao Pang","",";jiaojiaopang@126.com;jiaojiaopang@126.com",";(086)0531-82166843;(086)0531-82166843","Qilu Hospital of Shandong University;","<br>        Inclusion Criteria:<br><br>          1. Age 18 to 80.<br><br>          2. Confirmed COVID-19 diagnosis(including the clinically confirmed cases in Hubei).<br><br>          3. Accord with any of the following: ? Respiratory distress, RR ","","Coronavirus Infections","Drug: Bevacizumab Injection","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio","","","","Yes","0","          ",""
"ChiCTR2000030386","2020-03-02","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                              ","","Hu'nan university of chinese medicine","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50323","Not Recruiting","No","0.0","0.0","Both","2020-03-01","Case series:1000;","Interventional study","Sequential","0.0","China","Xiaorong Chang","","Hanpu Science and Teaching Road, Yuelu District, Changsha, Hu'nan, China","xrchang1956@163.com","+86 0731 88458187","Hu'nan University of Chinese Medicine","Inclusion criteria: Moxibustion intervention study plan for 14 days of NCP close contact with forced home isolation:<br>Participants inclusion criteria:<br>1. Aged 18 to 75 years old;<br>2. Those that meet one or more of the following:<br>(1)In the pa","Exclusion criteria: (1) Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system;<br>(2) Those with malignant changes in the lungs;<br>(3) Persons with a mental, intellectual or language impairment;<br>(4) preg","Novel Coronavirus Pneumonia (COVID-19)","Case series:moxibustion;","mood assessment;","","","","Yes","0","          ",""
"ChiCTR2000030382","2020-03-02","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet                                                                    ","","Hubei Provincial Hospital of TCM","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50325","Recruiting","No","18.0","65.0","Both","2020-03-01","Case series:50;","Observational study","Single arm","0.0","China","Zhongyu Zhou","","4 Huayuan Hill, Wuchang District, Wuhan, Hubei, China","2209447940@qq.com","+86 18672308659","Hubei Provincial Hospital of TCM","Inclusion criteria: 1. Meet the diagnostic criterias for novel coronavirus pneumonia during the medical observation period, light type (the syndrome of cold and damp stagnating lungs), ordinary type (the syndrome of lung block by cold and damp), and recov","Exclusion criteria: 1. If the researcher judges that a previous or current disease may affect the outcome of participating in the trial or study: severe lung disease, diabetes, cardiovascular and cerebrovascular disease, liver and kidney disease, malignan","Novel coronavirus pneumonia (COVID-19)","Case series:routine treatment+indirect moxibustion;","pulmonary iconography;","","","","Yes","0","          ",""
"ChiCTR2000030389","2020-03-02","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)                                                                                            ","","Hubei Provincial Hospital Of TCM","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50278","Recruiting","No","18.0","","Both","2020-02-29","Exposure group:60;Control group:60;","Observational study","Non randomized control","0.0","China","Jianzhong Liu","","4 Garden Hill, Wuchang District, Wuhan, Hubei, China","ljzwd@163.com","+86 13307173928","Hubei Provincial Hospital of TCM","Inclusion criteria: Patients with Novel coronavirus pneumonia who are mainly admitted to hospitals in Hubei Province and whose temperature is normal for at least 5 days after treatment, whose vital signs are stable (including to be discharged) or who have","Exclusion criteria: 1. Other pneumonia;<br>2. Known to be allergic to traditional Chinese medicine ingredients, or patients with allergies;<br>3. Women during lactation and pregnancy, or have a positive urine pregnancy test.","Novel Coronavirus Pneumonia (COVID-19)","Exposure group:Western medicine routine treatment+triple energizer treatment;Control group:Conventional medicine routine treatment;","Lung CT;TCM symptoms;","","","","No","0","          ",""
"ChiCTR2000030387","2020-03-02","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                     ","","Tongji Hospital of Tongji University","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50329","Recruiting","No","","","Both","2020-03-01","Mild group:100;Serere group:30;","Observational study","Factorial","Retrospective study","China","Ziqiang Zhang","","389 Xincun Road, Putuo District, Shanghai, China","zzq1419@126.com","+86 18721335536","Tongji Hospital of Tongji University","Inclusion criteria: According to the ""Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)"" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with p","Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;<br>2. Pregnant or lactating patients;<br>3. Cancer patients.","Novel Coronavirus Pneumonia (COVID-19)","Mild group:Conventional treatment;Serere group:intensive care;","Epidemiological and clinical characteristics;","","","","Yes","0","          ",""
"ChiCTR2000030334","2020-03-02","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)                                                                                                                                                                             ","","Nanjing Second Hospital","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49491","Recruiting","No","0.0","100.0","Both","2020-02-19","Target condition:25;Difficult condition:25","Diagnostic test","Factorial","0.0","China","Yongxiang Yi","","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China ","ian0126@126.com","+86 13338628626","Nanjing Second Hospital ","Inclusion criteria: 1. Age is not limited; <br>2. Confirmed group:clinical diagnosis is in accordance with the ""Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)"" on the diagnosis of a new type of coron","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;","SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030333","2020-03-02","A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)                                                                                                  ","","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48801","Recruiting","No","18.0","","Both","2020-03-04","Pirfenidone group:147;Control group:145;","Interventional study","Parallel","0.0","China","Huilan Zhang","","1095 Jiefang Avenue, Wuhan, Hubei, China","huillanz_76@163.com","+86 15391532171","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","Inclusion criteria: 1. First diagnosis of novel coronavirus infection<br>2. Epidemiological history Travel history or residence history of Wuhan City within two weeks before the onset of illness; or patients who have had fever from Wuhan with respiratory","Exclusion criteria: 1. AST and ALT> 1.5 x ULN at visit 1;<br>2. bilirubin> 1.5 x ULN at visit 1;<br>3. At visit 1, calculated by CockcroftGault formula, creatinine clearance <30 mL / min;<br>4. Patients with potential chronic liver disease (Child Pu","Novel Coronavirus Pneumonia (COVID-19)","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;","","","","Yes","0","          ",""
"NCT04279782","2020-03-02","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit","","Third Affiliated Hospital, Sun Yat-Sen University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04279782","Recruiting","No","N/A","N/A","All","2020-01-20","100.0","Observational","","Phase 1","China"," ; ; ","Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor","",";xwx1983@163.com;pzp33@hotmail.com",";+8613760783281;+8613533978874","Third Affiliated Hospital of Sun Yat-sen University;","<br>        Inclusion Criteria:<br><br>          1. Epidemiological history including resident of Hubei province, or travel history to<br>             Hubei province or exposure to suspected patients in the past two weeks.<br><br>          2. Sympto","","Coronavirus","Other: Comprehensive treatment","Survival rate","","","","Yes","0","          ",""
"NCT04279795","2020-03-02","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients","","Third Affiliated Hospital, Sun Yat-Sen University","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04279795","Recruiting","No","N/A","N/A","All","2020-01-20","20.0","Observational","","Phase 1","China"," ; ; ","Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor","",";xwx1983@163.com;pzp33@hotmail.com",";+8613760783281;+8613533978874","Third Affiliated Hospital of Sun Yat-sen University;","<br>        Inclusion Criteria:<br><br>          1. Epidemiological history including resident of Hubei province, or travel history to<br>             Hubei province or exposure to suspected patients in the past two weeks.<br><br>          2. Sympto","","Coronavirus","","Positive rate of 2019 Novel Coronavirus RNA","","","","Yes","0","          ",""
"NCT04280224","2020-03-02","NK Cells Treatment for Novel Coronavirus Pneumonia","Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","","Xinxiang medical university","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04280224","Recruiting","No","18 Years","65 Years","All","2020-02-20","30.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1","China"," ; ","ZHU, Professor;GUO, Professor","","wulingzhu@xxmu.edu.cn;guomh@163.com","00863733029089;00863734402517","","<br>        Inclusion Criteria:<br><br>          -  1. Male or female, aged at 18 years-65 years old<br><br>          -  2. Pneumonia that is judged by chest radiograph or computed tomography<br><br>          -  3. Laboratory confirmation of NCP in","","Novel Coronavirus Pneumonia","Biological: NK Cells","Improvement of clinical symptoms including duration of fever;Improvement of clinical symptoms including respiratory frequency;Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0","","","","Yes","0","          ",""
"ChiCTR2000030442","2020-03-02","Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)                                                                                                                            ","","the Second Affiliated hospital of Xi'an Jiaotong University","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50380","Not Recruiting","No","20.0","90.0","Male","2020-03-05","Case series:100;","Interventional study","Non randomized control","0.0","","Ma Xiaorong","","157 West 5th Road, Xi'an, Shaanxi, China","maxr0910@163.com","+86 13992856156","the Second Affiliated hospital of Xi'an Jiaotong University","Inclusion criteria: severe case of COVID-19","Exclusion criteria: Allergy to any medicine<br>Pregnancy","Coronavirus Disease 2019","Case series:Combination of Tocilizumab, IVIG and CRRT;","Inhospital time;","","","","Yes","0","          ",""
"ChiCTR2000030424","2020-03-02","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","","Henan Provincial People's Hospital","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50174","Not Recruiting","No","18.0","","Both","2020-03-02","Case series:30;","Interventional study","Single arm","0.0","China","Shao Fengmin","","7 Weiwu Road, Jinshui District, Zhengzhou, He'nan, China","guyuesunny@163.com","+86 15037167775","He'nan Provincial People's Hospital","Inclusion criteria: (1) aged >=18 years;<br>(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/lowe","Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;<br>(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;<br>(3) partic","Novel Coronavirus Pneumonia (COVID-19)","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Dia","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;","","","","Yes","0","          ",""
"ChiCTR2000030391","2020-03-02","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients                                                                                                                                                 ","","Lishui Central Hospital","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=30796","Not Recruiting","No","","","Both","2020-03-01","Case series:100;","Observational study","Sequential","Retrospective study","China","Chuxiao Shao","","289 Kuocang Road, Liandu District, Lishui, Zhejiang, China ","scx1818@126.com","+86 0578 2285102","Lishui Central Hospital ","Inclusion criteria: Confirmed cases of novel coronavirus pneumonia","Exclusion criteria: 1. Pneumonia caused by other pathogens; <br>2. Not receiving antiviral treatment.","Novel Coronavirus Pneumonia (COVID-19)","Case series:NA;","cure rate;virus negative rate;time of virus negative;","","","","Yes","0","          ",""
"NCT04286503","2020-03-09","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","","Beijing YouAn Hospital","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04286503","Not recruiting","No","18 Years","75 Years","All","2020-02-23","520.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4",""," ; ","Ronghua Jin;Huiguo Ding","",";dinghuiguo@medmail.com.cn",";+86-13911683832","Beijing YouAn Hospital;","<br>        Inclusion Criteria:<br><br>          1. Subjects or their legal representatives have signed the informed consent form(ICF);<br>             agree not to participate in other clinical studies within 30 days after the last<br>             a","","Novel Coronavirus Infectious Disease (COVID-19)","Drug: Carrimycin;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: basic treatment","Fever to normal time (day);Pulmonary inflammation resolution time (HRCT) (day);Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","","","","Yes","0","          ",""
"ChiCTR2000030581","2020-03-09","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope                                                                                                                   ","","West China Hospital, Sichuan University","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50394","Recruiting","No","18.0","35.0","Both","2020-02-02","Case series:192;","Observational study","Sequential","N/A","China","Yunxia Zuo","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","zuoyunxiahxa@qq.com","+86 18980601541","Department of Anesthesiology, West China School of Medicine, Sichuan University","Inclusion criteria: medical students in anesthesiology department","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:observation;","intrusion;avoidance;","","","","No","0","          ",""
"ChiCTR2000030328","2020-03-02","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50241","Not Recruiting","No","18.0","","Both","2020-03-02","Experimental group:30;Control group:30;","Interventional study","Sequential","4.0","China","Yun Lin","","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China  ","frank0130@126.com","+86 13986268403","Union Hospital, Tongji Medical College, Huazhong University of Science & Technology","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the ""Diagnosis and Treatment Program for COVID-19""(trial version 6th);<br>(2) Patients =18 years of age with tracheal intubation;<br>(3) Agree to participate in the","Exclusion criteria: 1.Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;<br>2.Obstructi","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;","","","","Yes","0","          ",""
"ChiCTR2000030263","2020-03-02","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic                                                                                                                                ","","Beijing Geriatric Hospital","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50140","Not Recruiting","No","","","Both","2020-02-20","Case series:200;","Epidemilogical research","Sequential","N/A","China","Jihui Lyu","","118 Wenquan Road, Haidian District, Beijing, China","lvjihui@139.com","+86 010 62402842","Beijing Geriatric Hospital","Inclusion criteria: staff working in hospital during the epidemic of COVID-19","Exclusion criteria: anyone who are reluctant or unable to answer the questionnaire","psychological status","Case series:N/A;","GHQ-20;","","","","No","0","          ",""
"ChiCTR2000030317","2020-03-02","Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period                                                                                 ","","West China Hospital of Sichuan University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50247","Not Recruiting","No","18.0","79.0","Both","2020-03-01","The experimental group:150;Control group:150;","Interventional study","Parallel","N/A","China","Hu Bing","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China.","hubingnj@163.com","+86 18980601278","West China Hospital of Sichuan University","Inclusion criteria: Patients undergoing painless gastroscopy in our hospital.","Exclusion criteria: 1. Patients undergoing general gastroscopy;<br>2. With trachea dysfunction;<br>3. pregnant women, children, age more than 80 years;<br>4. Patients with difficulty in intubation.","Digestive endoscopy gastroscopy; Novel Coronavirus Pneumonia (COVID-19)","The experimental group:Wear a self-made ""gastroscope mask"" during gastroscopy;Control group:Without self-made ""gastroscope mask"" during gastroscopy;","During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;","","","","Yes","0","          ",""
"ChiCTR2000030315","2020-03-02","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                      ","","Affiliated Hospital of Changchun University of traditional Chinese Medicine","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50255","Recruiting","No","18.0","","Both","2020-01-01","Case series:120;","Observational study","Sequential","0.0","China","Wang Tan","","1478 Gongnong Road, Chaoyang  District, Changchun, Jilin, China ","Wangtan215@sina.com","+86 13756858523","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);<br>2. Aged >= 18 years;<br>3. Patients who voluntarily partic","Exclusion criteria: (1) Known to be allergic to the ingredients contained in the research medication, or patients with allergies;<br>(2) Unwilling to cooperate with the information collector;<br>(3) Patients with mental illness, or cognitive impairment;","novel coronavirus pneumonia (COVID-19)","Case series: Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Critically ill patients (%);Mortality Rate;","","","","No","0","          ",""
"ChiCTR2000030327","2020-03-02","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                 ","","The Second Affiliated hospital of Anhui Medical University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50214","Recruiting","No","","","Both","2020-01-21","Case series:200;","Observational study","Sequential","Retrospective study","China","Zhenhua Zhang","","678 Furong Road, Jingkai District, Hefei, Anhui, China","zzh1974cn@163.com","+86 13215510411","The Second Affiliated hospital of Anhui Medical University","Inclusion criteria: A total of 200 2019-new coronavirus infections were included, regardless of age or sex.","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;","","","","No","0","          ",""
"ChiCTR2000030325","2020-03-02","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang                                                                                        ","","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50227","Not Recruiting","No","","","Both","2020-02-28","Intervention group:500;","Observational study","Sequential","N/A","China","Ming Chen","","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China","55815147@qq.com","+86 13797625096","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Inclusion criteria: 1. Front line medical staff;<br>2. Participate in the prevention and treatment of COVID-19;<br>3. Voluntary to finish psychological survey;<br>4. without psychological history.","Exclusion criteria: 1. refuse to participate in the questionnaire survey<br>2. with mental disorders","psychological health; Novel Coronavirus Pneumonia (COVID-19)","Intervention group:Psychological intervention;","Psychological questionnaire;","","","","Yes","0","          ",""
"ChiCTR2000030261","2020-03-02","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                       ","","Wuxi Fifth People's Hospital","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49963","Not Recruiting","No","","","Both","2020-03-01","Exocrine group:13;Control group:13;","Interventional study","Parallel","0.0","China","Meiping Chu","","1215 Guangrui Road, Wuxi, Jiangsu, China","chump1981@163.com","+86 15052103816","Wuxi Fifth People's Hospital","Inclusion criteria: Patients meet the diagnostic criteria ""Diagnosis and treatment of novel coronavirus pneumonia (trial version fifth)""for suspected cases outside Hubei Province: combined with the following epidemiological and clinical manifestations: ep","Exclusion criteria: (1) Age < 18 or > 65; <br>(2) Patients with severe heart, brain, lung, kidney dysfunction, endocrine disease, hematopoiesis system disease or other serious diseases and psychosis; <br>(3) Pregnant and lactating women.","Novel Coronavirus Pneumonia (COVID-19)","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","Lung CT;","","","","Yes","0","          ",""
"ChiCTR2000030222","2020-03-02","Cancelled due to lack of participants                                        Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People                                                                                                                                                             ","","The Thirteenth People's Hospital of Chongqing","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50048","Not Recruiting","No","60.0","","Both","2020-02-21","the elderly population:658;","Observational study","Sequential","N/A","China","Bin Zhan","","16 Railway New Village, Jiulongpo Districts, Chongqing, China","406302524@qq.com","+86 13678494357","The Thirteenth People's Hospital of Chongqing","Inclusion criteria: subjects who are over 60 years old, and willing to participate in the investigation. ","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;<br>2. Patients and healthy people who are not willing to participate in the survey. ","Geriatrics; Novel Coronavirus Pneumonia (COVID-19)","the elderly population:none;","health status;Mental health status;","","","","No","0","          ",""
"ChiCTR2000030300","2020-03-02","Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study                                                                                 ","","Nanjing Second Hospital","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50022","Recruiting","No","18.0","75.0","Both","2020-02-20","Case series:9;","Interventional study","Non randomized control","1.0","China","Yongxiang Yi","","1-1 Zhongfu Road, Gulou District, Nanjingy, Jiangsu, China","hcm200702@163.com","+86 13584010516","Nanjing Second Hospital","Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;<br>2. According to the new type of coronavirus ","Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;<br>2. The subject suffers from active psychosis, which the researcher believes may interfere","Novel Coronavirus Pneumonia (COVID-19)","Case series:mesenchymal stem cells therapy;","Time to disease recovery;Exacerbation (transfer to RICU) time;","","","","No","0","          ",""
"ChiCTR2000030283","2020-03-02","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)                                                                                                                                                       ","","Xianning Central Hospital","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50119","Recruiting","No","","","Both","2020-02-27","case series:100;","Observational study","Single arm","Retrospective study","China","Kaihu Yu","","228 Jingui Road, Xianning, Hubei, China","2066255602@qq.com","+86 13508649926","Xianning Central Hospital","Inclusion criteria: 1. Patients diagnosed with COVID-19;<br>2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;<br>3. Able to complete the study. ","Exclusion criteria: 1. CT image quality does not meet the analysis criteria;<br>2. Pregnant and lactating women. ","Novel coronavirus pneumonia (COVID-19)","case series:N/A;","imaging feature;","","","","Yes","0","          ",""
"ChiCTR2000030574","2020-03-09","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                       ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49953","Recruiting","No","18.0","90.0","Both","2020-03-08","case series:500;","Observational study","Sequential","0.0","China","Mei Heng","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei","hmei@hust.edu.cn","+86 13886160811","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients;<br>2. Aged 18 to 90 years;<br>3. Sign the written informed consent before the study.  ","Exclusion criteria: 1. Pregnant and lactating women; <br>2. Patients with mental illness.","Novel Coronavirus Pneumonia  (COVID-19)","case series:N/A;","Immunity function;cytokines;viral load;","","","","Yes","0","          ",""
"ChiCTR2000030556","2020-03-09","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","","Anhui Cancer Hospital","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50672","Not Recruiting","No","18.0","-","Both","2020-03-15","Target condition:200;Difficult condition:200","Diagnostic test","Sequential","0.0","China","Hu Liu","","107 Huanhu Road East, Hefei, Anhui, China ","drliuhu@gmail.com","+86 13866175691"," Anhui Cancer Hospital ","Inclusion criteria: COVID-19 group: <br>1. Age> = 18 years old, no gender restriction; <br>2. Patients with covid-19 determined by gold standard; <br>3. Total bilirubin <=1.5 UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (","Exclusion criteria: COVID-19 group: <br>1. Patients without self-awareness; <br>2. Patients who used drugs that can affect metabolism in the past 2 weeks, such as antibiotics (penicillins, erythromycin), hormones (deoxycortisol, dexamethasone), non-ster","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Nucleic acid test;Index test:Nano-nasal&#32;COVID-19&#32;diagnostic&#32;screening&#32;model;","Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000030218","2020-03-02","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                        ","","Fifth People's Hospital of Ganzhou","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50115","Recruiting","No","18.0","","Both","2020-01-22","Experimental group of ordinary COVID-19:30;Control group of ordinary COVID-19:30;Experimental group of severe COVID-19:20;","Interventional study","Parallel","N/A","China","Xie Liangdong","","Chizhuling Fifth People's Hospital, Shuixi Town, Ganzhou, Jiangxi, China","2590410004@qq.com","+86 13707077997","Fifth People's Hospital of Ganzhou","Inclusion criteria: (1) Aged >=18 years;<br>(2) Novel coronavirus pneumonia patients diagnosed by pathogenic testing;<br>(3) The patient himself participated in the study voluntarily, agreed and signed the informed consent.","Exclusion criteria: (1) Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;<br>(2) Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been me","Novel Coronavirus Pneumonia (COVID-19)","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with","Clinical recovery time;Pneumonia Severity Index (PSI) score;","","","","No","0","          ",""
"ChiCTR2000029952","2020-03-02","Cancelled due to lack of patient                         Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing                                                                                                                                                       ","","Chongqing Three Gorges Central Hospital(Chongqing University Three Gorges Hospital  )","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49630","Not Recruiting","No","0.0","79.0","Both","2020-02-17","Case series:0;","Observational study","Sequential","Retrospective study","China","Kaihu Xiao","","165 Xincheng Road, Wanzhou District, Chongqing, China","xiaokh1@163.com","+86 19923204040","Chongqing Three Gorges Central Hospital","Inclusion criteria: All patients diagnosed with novel coronavirus pneumonia by nucleic acid detection.","Exclusion criteria: NO.","COVID-19","Case series:Nil;","Clinical symptoms;Test result;Examination result;","","","","Yes","0","          ",""
"ChiCTR2000030265","2020-03-02","Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)                                                                                                       ","","The First Affiliated Hospital of Harbin Medical University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49691","Not Recruiting","No","","","Both","2020-02-24","High inflammation oXiris CRRT treatment group:10;High inflammation Conventional treatment group:10;Low inflammation conventional treatment group:10;","Interventional study","Parallel","0.0","China","Kaijiang Yu","","23 Youzheng Street, Nangang District, Harbin, Heilongjiang, China","drkaijiang@163.com","+86 13303608899","The First Affiliated Hospital of Harbin Medical University","Inclusion criteria: 1. Aged 18 to 85 years old;<br>2. It conforms to the diagnostic criteria of severe and critical type in ""Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (6th Edition)"";<br>3. Sign the informed consent form.","Exclusion criteria: 1. Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;<br>2. Obstruc","Novel Coronavirus Pneumonia (COVID-19)","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Inflammation factor;","","","","No","0","          ",""
"ChiCTR2000030264","2020-03-02","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","","Department of critical care, Zhongnan Hospital of Wuhan University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50161","Not Recruiting","No","18.0","","Both","2020-02-28","Burnout positive group versus burnout negative group:1000;","Observational study","Sequential","N/A","China","WANG Jing","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","wangjing9279@163.com","+86 18186161668","Department of critical care, Zhongnan Hospital of Wuhan University","Inclusion criteria: All ICU staff involved in the fight against the new coronary pneumonia for at least 1 week","Exclusion criteria: no","job burnout; Novel Coronavirus Pneumonia (COVID-19)","Burnout positive group versus burnout negative group:NO;","no;","","","","Yes","0","          ",""
"ChiCTR2000030542","2020-03-09","A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","A clinical study about the diagnosis and prognosis of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.                                                                  ","","West China Hospital of Sichuan University","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50608","Recruiting","No","","","Both","2020-03-09","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:600;","Observational study","Factorial","Retrospective study","China","Ying binwu","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","binwuying@126.com","+86 18980601655","West China Hospital, Sichuan University","Inclusion criteria: Patients diagnosed with COVID-19<br>Mild group<br>Diagnosed patients classified as mild and ordinary types according to the National Health Commission of the Peoples Republic of China. Report of Novel Coronavirus-Infected Pneumonia i","Exclusion criteria: Participants who are not suitable to be included in the project evaluated by the researchers.","Novel Coronavirus Pneumonia (COVID-19)","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:None;","Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expressi","","","","Yes","0","          ",""
"ChiCTR2000030540","2020-03-09","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy                                                                                                      ","","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50658","Not Recruiting","No","18.0","90.0","Both","2020-03-08","CRRT group:76;Control group:76;","Interventional study","Parallel","0.0","China","Li Shusheng","","1095 Jiefang Avenue, Wuhan, Hubei, China","shushengli16@sina.com","+86 13971086498","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","Inclusion criteria: 1. Adult patients confirmed by 2019-nCov throat swab or other samples of nucleic acid positive; <br>2. Patients with clear manifestations of pulmonary exudation on chest imaging; <br>3. Patients requiring oxygen therapy or mechanical","Exclusion criteria: 1. Patients with cardiopulmonary resuscitation at the end of the disease; <br>2. Pregnant women.","Novel Coronavirus Pneumonia (COVID-19)","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;","","","","Yes","0","          ",""
"ChiCTR2000029900","2020-03-02","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy                                                                                                              ","","Renmin Hospital of Wuhan University","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49377","Not Recruiting","No","18.0","","Both","2020-02-17","Case series:200;","Observational study","Sequential","Retrospective study","China","Yu Jia","","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","yogaqq116@whu.edu.cn","+86 18062586860","Renmin Hospital of Wuhan University","Inclusion criteria: 1. Hospital workers with diagnosis of new coronavirus pneumonia in Wuhan;<br>2. Aged >=18 years old.","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;<br>2. Patients  who are not willing to participate in the survey.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","exposed factors;latent period;preventive measures;","","","","Yes","0","          ",""
"ChiCTR2000029761","2020-03-02","Cancelled due to lack of patient                Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)                                                                                             ","","The First Affiliated Hospital of Chongqing Medical University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49400","Recruiting","No","18.0","80.0","Both","2020-02-13","Low-dose group:60;Medium-dose group:60;High-dose group:60;control group:60;","Interventional study","Parallel","4.0","China","Wenxiang Huang","","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing","wenxiang_huang@163.com","+86 13883533808","The First Affiliated Hospital of Chongqing Medical University","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:<br>1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;<br>2. Chinese","Exclusion criteria: Patients with any of the following were excluded from the study:<br>1. Patients with previous allergy to 4-aminoquinoline compounds;<br>2. Patients with previous severe retinal or visual field related diseases;<br>3. Patients with s","Novel Coronavirus Pneumonia  (COVID-19)","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;","","","","Yes","0","          ",""
"ChiCTR2000030215","2020-03-02","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)                                                                                                                                              ","","The First Affiliated Hospital of Nanchang University, Ten layers pulse Research Institute of traditional Chinese medicine, Nanchang University","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50107","Not Recruiting","No","18.0","65.0","Both","2020-02-26","Experimental group 1:20;Control group (Mild patients):20;Experimental group 2:20;Control group (general patient):20;Experimental group 3:20;Control group (severe patients):20;","Interventional study","Parallel","0.0","China","Shao Yi","","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","freebee99@163.com","+86 13576955700","The First Affiliated Hospital of Nanchang University","Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;<br>2) aged 18 to 65 years;<br>3) The time interval between the onset of symptoms and random enrollment is within 8 d","Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;<br>2) Allergic constitution, allergic to one or more foods or drugs;<br>3) Severe basic diseases affecting survival, including uncontrolled clinically significant hear","Novel Coronavirus Pneumonia (COVID-19)","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kangua","Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node im","","","","Yes","0","          ",""
"ChiCTR2000030196","2020-03-02","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)                                                                                     ","","Central South Hospital of Wuhan University","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49883","Not Recruiting","No","","","Both","2020-02-20","Case series:60;","Interventional study","Single arm","2.0","china","Zhiyong Peng","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","Pengzy5@hotmail.com","+86 18672396028","Central South Hospital, Wuhan University","Inclusion criteria: 1. Patients volunteered to sign the informed consent;<br>2. Patients who were diagnosed with the common type of NCP and severe cases of new coronavirus pneumonia, Referring to the New Coronavirus Pneumonia Diagnosis and Treatment Plan","Exclusion criteria: 1. People with serious or uncontrolled concomitant diseases, including sensory, vascular, heart, liver, kidney, gastric, intestinal, endocrine, etc.;<br>2. Having received Vaccine in the 4 weeks before entry or Planning to receive vac","cytokine release syndrome of new coronavirus pneumonia (COVID-19)","Case series:conventional therapy+tocilizumab;","the relive of CRS;","","","","No","0","          ",""
"ChiCTR2000030492","2020-03-09","Retrospective study for integrate Chinese and conventional medicine  treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Retrospective studyfor integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province                                                                                                              ","","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50549","Not Recruiting","No","","","Both","2020-03-04","Control group:30;Experimental group:170;","Observational study","Non randomized control","Retrospective study","China","CHEN Xinyu","","95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","chenxinyuchen@163.com","+86 13807312410","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.","Exclusion criteria: pregnant or lactating women","Novel Coronavirus Pneumonia (COVID-19)","Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine  treatment;","TCM syndrome;","","","","Yes","0","          ",""
"ChiCTR2000030490","2020-03-09","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)                                                                         ","","Huo-Shen-Shan Hospital","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50487","Recruiting","No","18.0","75.0","Both","2020-02-01","Case series:100;","Interventional study","Single arm","0.0","","Wang Hao","","Zhiyin Aveneu, Caidian District, Wuhan, Hubei, China","wanghaohh@vip.126.com","+86 13901883868","Huo-Shen-Shan Hospital","Inclusion criteria: Must meet all of the following criteria<br>1. aged 18 to 75 years male or female;<br>2. Body Weight 40-100kg, and BMI >=18kg/M2;<br>3. to meet the diagnostic criteria in the fourth edition of the diagnostic protocol for pneumonia ca","Exclusion criteria: 1. according to the clinical classification of severe and critical cases in the sixth edition of Diagnosis and treatment of pneumonia with 2019-ncov infection issued by the National Health Commission.<br>Note: those who comply with an","Novel Coronavirus Pneumonia (COVID-19)","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","Cure rate;","","","","No","0","          ",""
"ChiCTR2000030324","2020-03-02","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)                                                                                                                                         ","","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50231","Not Recruiting","No","","","Both","2020-02-28","Two groups:40;","Interventional study","Non randomized control","0.0","China","Ming Chen","","136 Jingzhou Street, Xiangcheng DIstrict, Xiangyang, Hubei, China","55815147@qq.com","+86 13797625096","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Inclusion criteria: 1. Confirmed or clinically diagnosed cases;<br>2. Aged >= 2 years;<br>3. Volunteers.","Exclusion criteria: 1. With local skin infection, trauma and other contraindications;<br>2. Patients who refuse massage.","Novel Coronavirus Pneumonia (COVID-19); children","Two groups:Chinese massage versus control;","Temperature;Respiratory symptoms;","","","","Yes","0","          ",""
"ChiCTR2000030293","2020-03-02","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                      ","","Shanghai Public Health Clinical Center","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50195","Recruiting","No","16.0","92.0","Both","2020-03-01","Case series:300;","Observational study","Sequential","Retrospective study","China","Feng Li","","2901 Caolang Road, Jinshan District, Shanghai, China","dr_lif08@126.com","+86 18121150282","Shanghai Public Health Clinical Center","Inclusion criteria: 1. be over 18 years of age;<br>2. 2019-nCoV infected patients confirmed by viral nucleic acid testing;<br>3. Subjects and their families (or guardians) have fully read, understood, and signed informed consent.","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:Retrospective analysis;","Clinical indicators;","","","","Yes","0","          ",""
"ChiCTR2000029759","2020-03-02","Retracted due to lack of patient                               A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)                     ","","The Second Affiliated Hospital of Chongqing Medical University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49352","Not Recruiting","No","18.0","80.0","Both","2020-02-15","control group 1:20;control group 2:20;Experimental group:20;","Interventional study","Parallel","0.0","China","Peng Hu","","74 Lingjiang Road, Yuzhong District, Chongqing, China","hp_cq@163.com","+86 13608338064","The Second Affiliated Hospital of Chongqing Medical University","Inclusion criteria: 1. Aged 18- 80 years old; <br>2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia wi","Exclusion criteria: 1. Severe liver disease (such as child Pugh score >= C, AST > 5 times upper limit);<br>2. The patients were allergic to the components in asc09 / ritonavir compound tablets;<br>3. Patients with contraindications specified in the inst","Novel Coronavirus Pneumonia  (COVID-19)","control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","time to recovery.;","","","","Yes","0","          ",""
"ChiCTR2000029386","2020-03-02","Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial","A study on treatment strategies of novel coronavirus pnueumonia patients                                                                                                                                                                                       ","","Chongqing Public Health Medical Center","2020-01-29","2020-01-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48777","Recruiting","No","18.0","","Both","2020-01-29","Experimental group:24;Control group:24;","Interventional study","Parallel","N/A","China","Yaokai Chen","","109 Baoyu Road, Shapingba District, Chongqing, China","yaokaichen@hotmail.com","+86 13638352995","Chongqing Public Health Medical Center","Inclusion criteria: 1. Male or female over 18 years of age;<br>2. Novel coronavirus infection is confirmed by pathogenic detection;<br>3. The diagnosis of severe coronavirus pneumonia will have to meet at least one of the following criteria: <br>(1) Re","Exclusion criteria: 1. Patients are allergic or intolerant to therapeutic drugs;<br>2. Pregnancy or lactating women;<br>3. Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","SOFA score;","","","","Yes","0","          ",""
"ChiCTR2000030022","2020-03-02","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                  ","","First Affiliated Hospital of Anhui Medical University","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49797","Not Recruiting","No","18.0","80.0","Both","2020-02-22","Experimental group:50;Control group:50;","Interventional study","Parallel","4.0","China","Liangdan Sun","","218 Jixi Road, Hefei, Anhui, China","ahmusld@163.com","+86 13856985045","First Affiliated Hospital of Anhui Medical University","Inclusion criteria: (1) Age 18 to 80 years old (including threshold), sex unlimited, inpatient<br>(2) Respiratory specimen were positive for COVID-19 nucleic acid by RT-PCR;<br>(3) Clinical classification is mild or moderate type (with symptoms of fever","Exclusion criteria: (1) Patients with known or suspected to be allergic to the components of the test drug; <br>(2) Patients with known hepatitis B, C, AIDS and other viral infections;<br>(3) Patients with severe or severe clinical classification who ha","Novel coronavirus pneumonia (COVID-19)","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;","","","","Yes","0","          ",""
"ChiCTR2000030013","2020-03-02","A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.                                                                                       ","","Chinese PLA General Hospital","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49796","Not Recruiting","No","","","Both","2020-02-20","Experimental group:300;Control group:150;","Interventional study","Non randomized control","4.0","China","Feng Cao","","28 Fuxing Road, Haidian District, Beijing, China","fengcao8828@163.com","+86 13911798280","Chinese PLA General Hospital","Inclusion criteria: 1. Aged 18 to 70 years old;<br>2. Non-suspected and non-confirmed cases;<br>3. Front-line medical staffs in designated hospitals during the outbreak of pneumonia caused by COVID-19;<br>4. Participate voluntarily and sign the informe","Exclusion criteria: 1. Suspected cases and confirmed cases;<br>2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;<br>3. People who could not complete the study for other reaso","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;","","","","Yes","0","          ",""
"ChiCTR2000030481","2020-03-09","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                      ","","Zhongnan Hospital of Wuhan University","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50453","Recruiting","No","18.0","","Both","2020-03-01","Early corticosteroid intervention group:75;Middle-late corticosteroid intervention group:75;Control group:50;","Interventional study","Parallel","4.0","China","Chen Zhenshun","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","chzs1990@163.com","+86 13627288300","Zhongnan Hospital of Wuhan University","Inclusion criteria: Patients who are more than 18 years are definitely diagnosed with COVID-19. [That is, the diagnosis of 2019-nCoV-infected pneumonia patients was diagnosed according to the diagnostic criteria for novel coronavirus pneumonia diagnosis a","Exclusion criteria: 1. Patients who are allergic to corticosteroid;<br>2. Patients who are diagnosed with adrenal insufficiency;<br>3. Severe immunosuppression, one of the following: infection with human immunodeficiency virus and CD4 cell count below 3","Novel Coronavirus Pneumonia (COVID-19)","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;","","","","No","0","          ",""
"ChiCTR2000030467","2020-03-09","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                   ","","Dalian Medical University, Dalian, China.","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50378","Not Recruiting","No","","","Both","2020-03-01","Control group:30;Experimental group:30;","Interventional study","Parallel","N/A","China","Wei Yao","","9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China","411484335@qq.com","+86 17709877386","Dalian Medical University","Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;<br>2) be able to understand the content of this study, and have the ability of normal communication and understanding;<br>3) voluntarily participate in this study and obta","Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities; <br>2) patients with mental illness or adverse reactions caused by drugs; <br>3) patients with serious diseases such as cardiovascular, cerebrovascu","Novel Coronavirus Pneumonia (COVID-19)","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological int","Psychological status;","","","","No","0","          ",""
"ChiCTR2000029991","2020-03-02","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                                                     ","","The First Affiliated Hospital of Nanchang University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49666","Recruiting","No","18.0","75.0","Both","2020-02-18","Kesuting syrup group:24;Keqing capsule group:24;control group:24;","Interventional study","Parallel","4.0","China","Wei Zhang","","17 Yongwai Main Street, Nanchang, Jiangxi","zhangweiliuxin@163.com","+86 0791-88693401","The First Affiliated Hospital of Nanchang University","Inclusion criteria: 1. Patients withmild and moderate novel coronavirus pneumonia (COVID-19) diagnosed  refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5);<br>2. Patient cough score > 1;<br>3. Aged ","Exclusion criteria: 1. Expected to die within 48 hours;<br>2. Patients with asthma attack, purulent tonsillitis, acute and chronic bronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation; and chest CT confi","novel coronavirus pneumonia (COVID-19)","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","cough;","","","","Yes","0","          ",""
"ChiCTR2000029755","2020-03-02","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)                                                                                                   ","","Tongji Hospital, Tongji Medical College of HUST","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49301","Recruiting","No","18.0","","Both","2020-02-15","experimental group:60;control group:60;","Interventional study","Parallel","4.0","China","Liu Dong","","1095 Jiefang Avenue, Wuhan, Hubei","ld_2069@163.com","+86 13507183749","Institutional Review Board, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ","Inclusion criteria: 1. Patients who  were confirmed diagnosis of 2019-ncov virus pneumonia, according to the ""pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5)"",including clinical symptoms, pulmonary CT manifestat","Exclusion criteria: 1. Patients with severe pneumonia requiring mechanical ventilation and severe new coronavirus infection with pneumonia;<br>2. Death is expected within 48 hours;<br>3. There is clear evidence of bacterial infection in respiratory trac","novel coronavirus pneumonia (COVID-19)","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","Validity observation index;","","","","Yes","0","          ",""
"ChiCTR2000030465","2020-03-09","Cancelled by the investigator                        Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)                                                                                                     ","","The First Affiliated Hospital of Guangzhou University of TCM","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50388","Not Recruiting","No","18.0","90.0","Both","2020-03-02","Group 2:35;Group 1:35;","Interventional study","Parallel","N/A","China","Wu Caineng","","16 Jichang Road, Guangzhou, Guangdong, China  ","wucaineng861010@163.com","+86 13580315308","The First Affiliated Hospital of Guangzhou University of TCM ","Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years); <br>2. Were identified as laboratory-confirmed COVID-19 infection; <br>3. Those who need intubation in ICU, and with no severe hypoxemia.","Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia; 2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle; 3. Those patients has intubated in ICU.","Novel Coronavirus Pneumonia (COVID-19)","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 < 90%;","","","","Yes","0","          ",""
"ChiCTR2000030014","2020-03-09","Cancelled due to lack of patient                               Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients                                                                                                                                    ","","Wuhan Fourth Hospital","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49802","Not Recruiting","No","18.0","65.0","Both","2020-02-19","Experimental group:150;control group:150;","Interventional study","Parallel","0.0","China","CAI YU","","473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China","caiy_kf@163.com","+86 18702745799","Wuhan Fourth Hospital","Inclusion criteria: pneumoniaits were diagnosed by chest CT findings and positive nucleic acid tests","Exclusion criteria: Exclude patients with influenza, adenovirus and other upper respiratory tract infections","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:pulmonary training;control group:Conventional medication;","MRC breathlessness scale;6MWD;","","","","No","0","          ",""
"NCT04252118","2020-03-09","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus","Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus","","Beijing 302 Hospital","2020-01-27","2020-01-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04252118","Recruiting","No","18 Years","70 Years","All","2020-01-27","20.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1","China"," ; ","Lei Shi, MD,PhD;Lei Shi, MD, PhD","","shilei302@126.com;shilei302@126.com","86-10-66933333;86-10-66933333","","<br>        Inclusion Criteria:<br><br>          1. Male or female, aged at 18 years (including) -70 years old<br><br>          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase<br>             chain reaction (RT-","","2019 Novel Coronavirus Pneumonia","Biological: MSCs","Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group","","","","Yes","0","          ",""
"NCT04276987","2020-03-09","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia","A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia","","Ruijin Hospital","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04276987","Not recruiting","No","18 Years","75 Years","All","2020-02-15","30.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1",""," ; ","Jie-ming Qu, MD.,PhD.;Jie-ming Qu, MD.,PhD.","",";jmqu0906@163.com",";+86-21-64370045","Ruijin Hospital, Medical School of Shanghai Jiaotong University Shanghai, China;","<br>        Inclusion Criteria:<br><br>        1.Willingness of study participant to accept this treatment arm, and signed informed<br>        consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Patients with<br>        confirm","","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE);Time to clinical improvement (TTIC)","","","","Yes","0","          ",""
"ChiCTR2000030593","2020-03-09","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study                                                                                                                                  ","","The First Affiliated Hospital, College of Medicine of Zhejiang University","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50228","Not Recruiting","No","18.0","100.0","Both","2020-03-10","Case series:150;","Observational study","Single arm","Retrospective study","China","Xiaoyang Lu","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","luxiaoyang@zju.edu.cn","+86 13605715886","The First Affiliated Hospital, College of Medicine of Zhejiang University","Inclusion criteria: (1) Aged >=18 years;<br>(2) novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (trial version sixth) is diagnosed as new type coronavirus pneumonia common, heavy and critical patients;<br>(3) Patient","Exclusion criteria: (1) Patients allergic to antiviral drugs;<br>(2) Pregnant or lactating women;<br>(3) Patients whose GPT or total bilirubin is higher than the upper limit of normal value before antiviral drug use.","Novel Coronavirus Pneumonia (COVID-19)","Case series:None;","ALT;","","","","Yes","0","          ",""
"ChiCTR2000029728","2020-03-02","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                               ","","Tongji Hospital affiliated to Tongji medical college of HUST","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49250","Not Recruiting","No","18.0","","Both","2020-02-15","Case series:500;","Observational study","Sequential","Retrospective study","China","Liu Dong","","1095 Jiefang Avenue, Wuhan, Hubei, China","ld_2069@163.com","+86 13507183749","Tongji Hospital affiliated to Tongji Medical College of HUST","Inclusion criteria: 1. Staff of tongji hospital willing to participate this study;<br>2. Aged >=18 years.","Exclusion criteria: 1. Meets any contraindications of ARB;<br>2. Meets any contraindications of Jinyebaidu Granule;<br>3. Pregnant women, lactating women, severe renal insufficiency.","novel coronavirus pneumonia (COVID-19)","Case series:Nil;","The proportion of patients diagnosed with 2019-ncov viral pneumonia;","","","","Yes","0","          ",""
"ChiCTR2000029387","2020-03-02","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia                ","","Chongqing Public Health Medical Center","2020-01-29","2020-01-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48782","Recruiting","No","18.0","65.0","Both","2020-01-25","arm A:36;arm B:36;arm C:36;","Interventional study","Parallel","N/A","China","Yaokai Chen","","109 Baoyu Road, Shapingba District, Chongqing, China","yaokaichen@hotmail.com","+86 023-65481658","Chongqing Public Health Medical Center","Inclusion criteria: (1) 1865 years of age; <br>(2) Diagnosed as mild to moderate COVID-19; <br>(3) Be willing to sign informed consent;<br>(4) The clinical assessment and condition of the subject does not influence the completion of the study. ","Exclusion criteria: (1) Patients are diagnosed as a case of severe NCIP;<br>(2) Patients are pregnant or breastfeeding women; <br>(3) Patients have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5UNL or creatinine clearance <50 m","Novel Coronavirus Pneumonia (COVID-19)","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","The time to 2019-nCoV RNA negativity in patients;","","","","No","0","          ",""
"ChiCTR2000030559","2020-03-09","A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)","Retrospective study to assess the safety of in vitro blood purification treatment in critically ill patients with novel coronavirus pneumonia COVID-19                                                                                                         ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50583","Recruiting","No","18.0","","Both","2020-03-07","Case series:12;","Observational study","Sequential","Retrospective study","China","Zhang Huafen","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","zhanghuafen@zju.edu.cn","+86 13757120681","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Inclusion criteria: Critically ill patients with SARS-CoV-2 infection who had perform blood purificationtherapy using artificial liver suppoer system and underwent clustering nusing progremm ","Exclusion criteria: 1) Patient or family member does not agree to sign informed consent;<br>2) Patients with previous or existing history of DVT;<br>3) The investigator believes that the patient has other conditions that are not suitable for enrollment;","Novel Coronavirus Pneumonia (COVID-19)","Case series:clustering nusing progremm;","Unplanned shutdowns;","","","","Yes","0","          ",""
"ChiCTR2000030557","2020-03-09","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)                                                                                                             ","","The Third Affiliated Hospital of the Second Military Medical University","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50667","Recruiting","No","18.0","80.0","Both","2020-03-10","Case series:1030;","Observational study","Sequential","N/A","China","Wang Hongyang","","225 Changhai Road, Yangpu District, Shanghai, China","hywangk@vip.sina.com","+86 13801955367","The Third Affiliated Hospital of the Second Military Medical University","Inclusion criteria: COVID-19 patients were diagnosed and cured as convalescent patients with disappearance of clinical symptoms and convalescent patients who met the discharge criteria after imaging examination and viral nucleic acid test.","Exclusion criteria: 1) < 18 years old or >=80 years old; <br>2) pregnant and lactating women; <br>3) patients with mental illness.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","viral load;virus genotyping;Classification of lymphocytes;","","","","Yes","0","          ",""
"ChiCTR2000029580","2020-03-09","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial                                                                  ","","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49088","Recruiting","No","18.0","75.0","Both","2020-01-31","Experimental group:35;control group:35;","Interventional study","Parallel","0.0","China","Jianfeng Zhou","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","zhougene@medmail.com.cn","+86 027 83665506","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged >= 18 years and <= 75 years;<br>2. Patients clinically diagnosed as novel coronavirus infection; or with positive serum antibodies (IgM or IgG); or with novel coronavirus infection confirmed by PCR; <br>3. Severe/critical pat","Exclusion criteria: 1. Patients with other malignant tumors requiring treatment;<br>2. Severe cardiovascular and metabolic diseases beyond the control of combination with other drugs <br>3. Patients with clinical symptoms of brain dysfunction or serious","novel coronavirus pneumonia (COVID-19)","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","Safety;","","","","No","0","          ",""
"ChiCTR2000029434","2020-03-09","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                             ","","Hebei Yiling Hospital, Renmin Hospital of Wuhan University","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48889","Recruiting","No","18.0","","Both","2020-02-01","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","Interventional study","Parallel","4.0","China","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua","","385 Xinshi Road North, Qiaoxi District, Shijiazhuang, Hebei, China","jiactm@163.com","+86 0311 83855881","Hebei Yiling Hospital","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Above 18 years old (inclusive);<br>3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue);<br>4. Voluntarily sign written i","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital h","Novel Coronavirus Pneumonia  (COVID-19)","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","","","","Yes","0","          ",""
"ChiCTR2000030543","2020-03-09","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)                                                                                                    ","","Central Theater General Hospital of PLA","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50541","Recruiting","No","","","Both","2020-02-14","Case series:35;","Observational study","Sequential","N/A","China","Chen Xiao","","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","cxfn817@163.com","+86 13986156712","Central Theater General Hospital of PLA","Inclusion criteria: All enrolled patients with confirmed NCIP according to both clinical way ( include  symptoms,blood routine test and chest computed tomography) and labotatory way (the revere-transcriptase-polymerase-chain-rection (RT-PCR) reaction from","Exclusion criteria: The patients disagreed for sample collection will be excluded.","Novel Coronavirus Pneumonia (COVID-19)","Case series:reverse transcription polymerase chain reaction;","A cycle threshold value (Ct-value);","","","","No","0","          ",""
"ChiCTR2000030541","2020-03-09","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country                                                                                                                      ","","Xiamen Medical College,Shijiazhuang Medical College","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50623","Not Recruiting","No","16.0","30.0","Both","2020-03-06","Medical students group; Non-medical students group:1300;","Observational study","Sequential","N/A","China","Ye Wan","","1999 Guankou Middle Road, Jimei District, Xiamen, Fujian, China","417433835@qq.com","+86 13806086169","Xiamen Medical College","Inclusion criteria: Full-time college and graduate students are willing to participate in the research.","Exclusion criteria: On-the-job college students and graduate students.","Novel Coronavirus Pneumonia (COVID-19)","Medical students group; Non-medical students group:None;","PSS-14;","","","","Yes","0","          ",""
"ChiCTR2000030290","2020-03-02","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus infection (COVID-19) from two hospitals in China                                                                                       ","","Xiamen University","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50175","Not Recruiting","No","18.0","60.0","Both","2020-02-11","Case series:2000;","Observational study","Sequential","N/A","China","Jiemin Zhu","","Room 222, Alice Lee Building, Xiangan Campus, Xiamen University, Fujian, China","jieminzhu@xmu.edu.cn","+86 15960212649","Xiamen University","Inclusion criteria: The front line nurses who were taking care of the nCoV infected patients in the participating hospitals ","Exclusion criteria: Nurses who were diagnosed with any mental disorders and who were infected by nCoV were excluded from the study. ","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;","","","","No","0","          ",""
"ChiCTR2000030259","2020-03-02","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial                                                                                                ","","Shanghai Changzheng Hospital","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49918","Recruiting","No","18.0","75.0","Both","2020-02-22","Experimental group:30;Control group:30;","Interventional study","Parallel","N/A","China","Junxue Wang","","415 Fengyang Road, Huangpu District, Shanghai, China","docd1@sina.com","+86 18917387623","Shanghai Changzheng Hospital","Inclusion criteria: 1. Aged 18 to 75 years old;<br>2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the current diagnosis and treatment plan for pne","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR <=30 times / min; or SaO2 / SpO2 <=93% in resting state; or arterial partial pressure of oxygen (PaO2) / conc","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","","","","No","0","          ",""
"NCT04276688","2020-03-09","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","","The University of Hong Kong","2020-02-11","2020-02-11","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04276688","Recruiting","No","18 Years","N/A","All","2020-02-10","70.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Hong Kong"," ; ; ","Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP","",";ivanfn@gmail.com;ivanfn@gmail.com",";+862 22554049;852 22554049","The University of Hong Kong;","<br>        Inclusion Criteria:<br><br>          1. Recruited subjects include all adult patients =18 years hospitalised for virologically<br>             confirmed 2019-n-CoV infection.<br><br>          2. NEWS of =1 upon recruitment<br><br>     ","","Novel Coronavirus Infection","Drug: Lopinavir/ritonavir;Drug: Ribavirin;Drug: Interferon Beta-1B","Time to negative NPS","","","","Yes","0","          ",""
"NCT04281693","2020-03-09","A New Screening Strategy for 2019 Novel Coronavirus Infection","Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","","Affiliated Hospital to Academy of Military Medical Sciences","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04281693","Not recruiting","No","N/A","N/A","All","2020-02-01","230.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label). ","N/A","China"," ; ; ","Yan Liu;Xiaotian Sun;Yan Liu, Ph.D.","",";xiaotian-sun@hotmail.com;13911798288@163.com",";+86-01066823480;010-66947473","The Fifth Medical Center of Chinese PLA General Hospital;","<br>        Inclusion Criteria:<br><br>          -  Who agree to participate in the study and sign written informed consent<br><br>        Exclusion Criteria:<br><br>          -  Confirmed NCIP patients<br>      ","","Novel Coronavirus Infection Pneumonia","Diagnostic Test: Standard screening strategy;Diagnostic Test: New screening strategy","Screening accuracy","","","","Yes","0","          ",""
"NCT04282902","2020-03-09","A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","","Huilan Zhang","2020-02-10","2020-02-10","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04282902","Recruiting","No","18 Years","N/A","All","2020-02-04","294.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","China"," ; ","Huilan Zhang, PD;Huilan Zhang, PD","","huilanz_76@163.com;","15391532171;","","<br>        Inclusion Criteria:<br><br>        (1) Age = 18 years. (2) Clinically diagnosed patients with new type of coronavirus<br>        pneumonia include: on the basis of meeting the criteria for suspected cases, one of the<br>        following ","","Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone","Drug: pirfenidone","chest CT;Finger pulse oxygen;blood gas;K-BILD","","","","Yes","0","          ",""
"ChiCTR2000030518","2020-03-09","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial                                                                                                                            ","","The Second Affiliated Hospital of Wenzhou Medical University","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50586","Recruiting","No","18.0","","Both","2020-02-29","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","China","Yuanrong Dai","","109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China","13968888872@163.com","+86 13857715778","the Second Affiliated Hospital of Wenzhou Medical University","Inclusion criteria: (1) Aged 18 years or older, male or female;<br>(2) Real-time fluorescent RT-PCR of pharyngeal swab samples was positive for novel coronavirus nucleic acid;<br>(3) Clinical classification is common or severe;<br>(4) Signed informed c","Exclusion criteria: (1) Known or suspected allergy to the components of zedoary turmeric oil injection, or allergic constitution;<br>(2) Mild and severe patients.<br>(3) Combined with severe liver disease (such as Child-Pugh score >=C, TBIL >=2 times th","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 da","Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start o","","","","No","0","          ",""
"ChiCTR2000030491","2020-03-09","A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City","Comparative Study for Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients in Sichuan Province and Wuhan                                                                                                                          ","","West China Hospital of Sichuan University","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50552","Recruiting","No","","","Both","2020-03-03","Patients in Wuhan versus Sichuan:100;","Observational study","Cross-sectional","0.0","China","Kang Yan","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","Kangyan@scu.edu.cn","+86 18980601566","West China Hospital, Sichuan University","Inclusion criteria: Patients diagnosed with new coronavirus pneumonia","Exclusion criteria: None","Novel Coronavirus Pneumonia (COVID-19)","Patients in Wuhan versus Sichuan:none;","length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;","","","","No","0","          ",""
"ChiCTR2000030258","2020-03-02","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients                                                                                                 ","","The Fourth Affiliated Hospital of Harbin Medical University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49887","Not Recruiting","No","18.0","70.0","Both","2020-02-21","Experimental group:30;Control group:30;","Treatment study","Single arm","0.0","China","Wei Yang","","37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China","hydyangwei@tom.com","+86 13845099775","The Fourth Affiliated Hospital of Harbin Medical University","Inclusion criteria: (1) Adults aged >=18 years understand and agree to sign informed consent;<br>(2) a novel coronavirus infection confirmed by laboratory RT-PCR.<br>(3) Hospitalized patients with fever (axillary temperature >=37.0 degree C) or respirat","Exclusion criteria: (1) novel coronavirus pneumonia is a disease or condition beyond the pneumonia. That is, according to the researchers' judgement, the subjects will be at risk for taking part in the research, or will have an impact on the results of th","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;","temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;","","","","No","0","          ",""
"ChiCTR2000030257","2020-03-02","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","The coagulation function of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                    ","","Puren Hospital of Wuhan City","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50006","Not Recruiting","No","","","Both","2020-03-09","Case series:100;","Observational study","Sequential","Retrospective study","China","Li Jiangping","","1 Benxi Street, Fouth Jianshe Road, Qinshan District, Wuhan, Hubei, China","1078404424@qq.com","+86 18602764053","Puren Hospital of Wuhan City","Inclusion criteria: the diagnosed COVID-19 pneumonia inpatients","Exclusion criteria: blood disease, hepatosis, maglinant tumor, other diseases affecting coagulation function. and taking anticoagulation drugs.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","INR;PT;TT;APTT;FIB;DD;","","","","Yes","0","          ",""
"ChiCTR2000030226","2020-03-02","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study                                                                      ","","The Fourth Hospital of Hebei Medical University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49855","Recruiting","No","","","Both","2020-02-01","Case series:40;","Observational study","Sequential","Retrospective study","China","Zhenjie Hu","","12 Jiankang Road, Shi-Jia-Zhuang, Hebei, China","syicu@vip.sina.com","+86 13933856908","The Fourth Hospital of Hebei Medical University","Inclusion criteria: All patients with 2019 novel coronavirusinfected pneumonia enrolled in this study were diagnosed according to guidance(trial version 5) of China,and met the standard of Heavy or critically ill.","Exclusion criteria: Pregnancy;Sudden death disease, such as fatal heart disease patients.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical characteristics;","","","","No","0","          ",""
"ChiCTR2000030225","2020-03-02","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                     ","","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49945","Not Recruiting","No","18.0","80.0","Both","2020-02-22","Experimental group:93;Control Group:93;","Interventional study","Parallel","0.0","China","Zhou Jia","","110 Ganhe Road, Hongkou District, Shanghai, China","pdzhoujia@163.com","+86 18017306677","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","Inclusion criteria: 1. Aged 18 to 80 years;<br>2. Patients with novel coronavirus pneumonia who were diagnosed as general type or severe type according to the western medicine classification general type, severe type and Chinese medicine classification c","Exclusion criteria: 1. Patients with other serious pulmonary diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, tumor, hematopoiesis, autoimmune diseases, digestive system diseases, skin diseases, psychosis, etc.;<br>2. Patients wh","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatment & Acupuncture;Control Group:Conventional treatment;","Length of hospital stay;Discharge time of general type;Discharge time of severe type;","","","","No","0","          ",""
"ChiCTR2000030489","2020-03-09","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases                                                                                                                                ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50490","Recruiting","No","18.0","70.0","Both","2020-02-01","COVID-2019 patients in Tongji Hospital:250;COVID-2019 patients in Mobile field hospital:250;Medical staff in Tongji Hospital:250;Control:250;","Epidemilogical research","Sequential","0.0","China","Xufang Sun","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","s_1862777@163.com","+86 18627770651","Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. COVID-19 suspected or confirmed patients: meet the following suspected or confirmed case diagnostic criteria; aged between 18 and 70 years old;<br>1.1 Diagnostic criteria for suspected cases;<br>1.1.1 History of Epidemiology:<br>","Exclusion criteria: 1. COVID-19 suspected or confirmed patients:<br>(1) Those who refuse to cooperate;<br>(2) Pregnant women;<br>(3)Patients with mental disorders and cognitive dysfunction.<br>2. non-COVID healthy residents:<br>(1) Those who refuse t","Novel Coronavirus Pneumonia (COVID-19)","COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;","Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;","","","","No","0","          ",""
"ChiCTR2000030484","2020-03-09","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                        ","","Hubei Shiyan Taihe hospital","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50263","Not Recruiting","No","","","Both","2020-02-02","treatment group1:30;treatment group 2:30;control group:30;","Interventional study","Parallel","N/A","China","Jie Luo","","32 Renmin Road South, Shiyan, Hubei, China","182190248@qq.com","+86 0719 8801713","Shiyan Taihe hospital","Inclusion criteria: (1) The novel coronavirus was detected at the age of 18~70 years when signing the informed consent; (2) the nucleic acid test of the pharyngeal test, sputum, lower respiratory tract secretions, blood and so on (RT-PCR detection of the ","Exclusion criteria: ? Doctors decided that it was not in the best interests of the subjects to participate in the study, or there was any situation that could not follow the agreement safely; ? there was a history of pulmonary embolism; ? there were patie","Lung injury","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intraveno","PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or","","","","No","0","          ",""
"NCT04284046","2020-03-09","CT Scores Predict Mortality in 2019-nCoV Pneumonia","CT Scores Predict Mortality in 2019-nCoV Pneumonia","","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04284046","Not recruiting","No","N/A","N/A","All","2020-01-31","39.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  all patients suspected of 2019 novel coronavirus infection.<br><br>        Exclusion Criteria:<br><br>          -  patients' data are not available.<br>      ","","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Other: CT score","7-day mortality","","","","Yes","0","          ",""
"NCT04285190","2020-03-09","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","","Tasly Pharmaceuticals, Inc.","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04285190","Not recruiting","No","18 Years","85 Years","All","2020-02-26","120.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A",""," ; ","Shuiping Zhou, PhD;Yi He, PhD","",";heyi@tasly.com",";86-022-86343860","Tasly Pharmaceutical Group Co., Ltd.;","<br>        Inclusion Criteria:<br><br>          1. Adult male or female patients aged 18-85 years old;<br><br>          2. The newly diagnosed COVID-19 patients who meet the diagnostic criteria set forth in<br>             the ""Guidance of Diagnosi","","Coronavirus Disease 2019;Novel Coronavirus Pneumonia","Drug: T89","The time to oxygen saturation recovery to normal level (=97%);The proportion of patients with normal level of oxygen saturation(=97%)","","","","Yes","0","          ",""
"ChiCTR2000030627","2020-03-09","Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases","Study on the application of convalescent plasma therapy in severe COVID-19                                                                                                                                                                                     ","","The First Affiliated Hospital of Zhengzhou University","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50727","Recruiting","No","","","Both","2020-02-01","Experimental group:15;Control group:15;","Interventional study","Parallel","0.0","China","Guojun Zhang","","1 Jianshe Road East, Zhengzhou, He'nan, China","zlgj-001@126.com","+86 13673665268","The First Affiliated Hospital of Zhengzhou University","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatme","Exclusion criteria: Patients with hypersensitivity to plasma products; patients with severe transfusion reactions in the past; patients with acute pulmonary edema, congestive heart failure, pulmonary embolism, malignant hypertension, polycythemia vera, ex","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","Tempreture;Virus nucleic acid detection;","","","","No","0","          ",""
"ChiCTR2000030223","2020-03-02","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey                                                                                                                                      ","","NA","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50026","Recruiting","No","18.0","100.0","Both","2020-02-20","General population:5000;","Health services reaserch","Sequential","N/A","China","Daisy Dexing Zhang","","4/F, School of Public Health and Primary Care","zhangdxdaisy@cuhk.edu.hk","+852 22528451","JC School Of Public Health And Primary Care, The Chinese University Of Hong Kong","Inclusion criteria: The inclusion criteria are: aged 18 or above; those who can understand Chinese language; be able to give access to the online survey and answer questions. ","Exclusion criteria: Exclusion criterion: those who do not agree to participate. ","Biopsychosocial health; novel coronavirus pneumonia (COVID19)","General population:Health Advice based on survey results;","Quality of life;Socio-demographcis and others;","","","","No","0","          ",""
"ChiCTR2000030162","2020-03-02","Cancelled by the investigator                     Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                                              ","","Cancelled","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49570","Not Recruiting","No","","","Both","2020-03-01","","Interventional study","Parallel","0.0","","Cancelled","","Cancelled","wdxjy@whu.edu","123.0","Cancelled","Inclusion criteria: Cancelled","Exclusion criteria: Cancelled","Cancelled","","Cancelled;","","","","Yes","0","          ",""
"ChiCTR2000030482","2020-03-09","A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)","SARS-CoV-2 Infection on Myocardial Injury and Prognosis: a Multicenter, Long- term Follow-up and Registration Study                                                                                                                                            ","","Peking University First Hospital","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50353","Not Recruiting","No","","","Both","2020-03-06","Case series:8000;","Observational study","Sequential","N/A","China","Yong Huo","","No.8 Xishiku Street, West city District, Peking","drhuoyong@163.com","+86 13901333060","Peking University First Hospital","Inclusion criteria: (1) All confirmed and diagnosed SARS-CoV-2 infection patients (including the clinical diagnosis case of the New Coronavirus Pneumonia HUBEI) (Fifth Edition)<br>(2) Voluntarily agree to enter the trial and sign the written informed con","Exclusion criteria: Patients not suitable for study judged by researchers.","Novel Coronavirus Pneumonia (COVID-19)","Case series:NA;","Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular deat","","","","Yes","0","          ",""
"ChiCTR2000030475","2020-03-09","Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study                                                            ","","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50452","Not Recruiting","No","18.0","","Both","2020-03-04","Case series:19;","Interventional study","Single arm","0.0","China","Xuemei Li","","1 Shuai-Fu-Yuan, Dongcheng District, Beijing, China","lixmpumch@126.com","+86 13911467356","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Inclusion criteria: 1. Written informed consent from patients or representative;<br>2. Aged over 18<br>3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;<br>2019-nCoV diagnosis confirmed by the combination of epidemiol","Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;<br>2. Comorbidities including lupus, vasculitis, APS et al.;<br>3. Concurrent use of","Novel Coronavirus Pneumonia (COVID-19)","Case series:cytokine removal therapy with Cytosorb;","28 day mortality;","","","","Yes","0","          ",""
"ChiCTR2000030579","2020-03-09","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                            ","","Shandong Provincial Hospital","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50692","Not Recruiting","No","","","Both","2020-02-15","Case series:200;","Observational study","Sequential","Retrospective study","China","Jiang Shujuan","",", Jinan, Shandong,Shandong,PR China","docjiangshujuan@163.com","+86 15168887199","Department of Respiratory Medicine, Shandong Provincial Hospital","Inclusion criteria: 1. Patients who were diagnosed with novel coronavirus pneumonia by the nucleic acid test;<br>2. Patients who agreed to enrollment.","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","clinic outcome;","","","","No","0","          ",""
"ChiCTR2000030578","2020-03-09","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                  ","","Shandong Provincial Hospital","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50690","Not Recruiting","No","","","Both","2020-03-07","Experimental group:20;Control group:20;","Interventional study","Parallel","N/A","China","Liu Yi","","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China ","15168888626@163.com","+86 18660117915","Shandong Provincial Hospital","Inclusion criteria: Patients with new type of coronavirus pneumonia admitted to the designated hospital of Jinan City have the same diagnostic criteria as ""Pneumonitis diagnosis and treatment plan for new type of coronavirus infection (latest version)<br","Exclusion criteria: (1) Chronic obstructive pulmonary disease; <br>(2) Cardiorenal insufficiency; <br>(3) Pregnant women","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;","","","","No","0","          ",""
"ChiCTR2000029899","2020-03-02","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial                        ","","Peking University Third Hospital","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49536","Recruiting","No","18.0","","Both","2020-02-17","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","Interventional study","Parallel","4.0","China","Shen Ning","","49 Huayuan Road North, Haidian District, Beijing, China","shenning1972@126.com","+86 15611908958","Peking University Third Hospital","Inclusion criteria: 1. Aged >=18 years at time of signing Informed Consent Form;<br>2. Patients with confirmed cases meeting the following criteria<br>(1) Epidemiology history;<br>(2) Clinical manifestations (epidemiological history and in accordance w","Exclusion criteria: 1. Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;<br>2. Patients with server diseases of the blood system;<br>3. Patients with identified severe liver disease, underlying cirrhosis or alanine aminotra","Novel Coronavirus Pneumonia (COVID-19)","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","Time to Clinical Recovery, TTCR;","","","","Yes","0","          ",""
"ChiCTR2000029898","2020-03-02","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial                                 ","","Peking University Third Hospital","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49482","Recruiting","No","18.0","75.0","Both","2020-02-17","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","Interventional study","Parallel","4.0","China","Shen Ning","","49 Huayuan Road North, Haidian District, Beijing, China","shenning1972@126.com","+86 15611908958","Peking University Third Hospital","Inclusion criteria: 1.  Age 18 to 75 Yearsmale or female subjects<br>2.  Diagnosed with COVID-19,according to ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Pilot  Sixth Edition);<br>3.  Sever COVID-19, except shock and ICU care wit","Exclusion criteria: 1 Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;<br>2 Patients with server diseases of the blood system;<br>3 Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransf","Novel Coronavirus Pneumonia (COVID-19)","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","TTCI (Time to Clinical Improvement);","","","","Yes","0","          ",""
"NCT04288713","2020-03-16","Eculizumab (Soliris) in Covid-19 Infected Patients","Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.","SOLID-C19","Hudson Medical","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04288713","Not recruiting","No","18 Years","N/A","All","2020-03-01","","Expanded Access","","Phase 2",""," ","Thomas C Pitts, M.D.","","Drpitts@hudsonmedical.com","6465967386.0","","<br>        Inclusion Criteria:<br><br>          -  COVID-19 positive patients over the age of 18.<br><br>        Exclusion Criteria:<br><br>          -  Patients who are currently intubated.<br>      ","","Coronavirus","Drug: Eculizumab","","","","","Yes","0","          ",""
"NCT04292327","2020-03-16","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)","2019-nCoV","Fujian Provincial Hospital","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04292327","Not recruiting","No","18 Years","75 Years","All","2020-01-01","400.0","Observational","","Phase 2/Phase 3","China"," ","Xiuling Shang","","","","Fujian Provincial Hospital","<br>        Inclusion criteria.<br><br>          1. 2019-nCov (SARA-Cov-2) nucleic acid positive detected by PCR.<br><br>          2. Older than 18 years old and younger than 75 years old.<br><br>          3. Meet the diagnostic criteria of COVID-1","","Pneumonia Caused by Human Coronavirus","","Mortality;The time interval of Nucleic acid detection become negative","","","","Yes","0","          ",""
"NCT04295551","2020-03-16","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04295551","Not recruiting","No","18 Years","100 Years","All","2020-03-14","80.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","","","","","","","","<br>        Inclusion Criteria:<br><br>          1. Aged >=18 years;<br><br>          2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;<br><br>          3. The patient himself participated in the study voluntarily, agreed and","","COVID-19","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection;Drug: Lopinavir/ritonavir treatment","Clinical recovery time","","","","Yes","0","          ",""
"NCT04296643","2020-03-16","Medical Masks vs N95 Respirators for COVID-19","Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","","McMaster University","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04296643","Not recruiting","No","18 Years","N/A","All","2020-04-01","576.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). ","N/A",""," ; ","Mark B Loeb;Mark Loeb, MD","",";loebm@mcmaster.ca",";9053340010","McMaster University;","<br>        Inclusion Criteria:<br><br>          -  Nurses who work > 37 hours per week in medical, emergency, pediatric units<br><br>        Exclusion Criteria:<br><br>          -  Nurses with one or more comorbidities<br><br>          -  Nurses","","Coronavirus;N95;Medical Mask","Device: Medical Mask;Device: N95 respirator","RT-PCR confirmed COVID-19 infection","","","","Yes","0","          ",""
"ChiCTR2000030464","2020-03-09","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                               ","","The Third Xiangya Hospital, Central South University","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50382","Recruiting","No","","","Both","2020-03-03","Case series:200;","Epidemilogical research","Sequential","Retrospective study","","Chengxian Guo","","138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","gchxyy@163.com","+86 0731-88618338","The Third Xiangya Hospital, Central South University","Inclusion criteria: Novel Coronavirus Pneumonia (COVID-19) patients","Exclusion criteria: NO","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical characteristics;","","","","Yes","0","          ",""
"ChiCTR2000030163","2020-03-09","A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","The Real World Study to Evaluate the Added Treatment Effectiveness of Comprehensive Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19)                                                                                                    ","","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50031","Not Recruiting","No","0.0","100.0","Both","2020-02-25","Case series:256;","Observational study","Sequential","N/A","China","Bin Li","","110 Ganhe Road, Hongkou District, Shanghai, China","18930568129@163.com","+86 18930568129","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","Inclusion criteria: Observational study, no inclusion criteria","Exclusion criteria: Observational study, no exclusion criteria","Novel Coronavirus Pneumonia (COVID-19)","Case series:NA;","cure rate;duration of hospitalization;days of treatment;","","","","Yes","0","          ",""
"ChiCTR2000030564","2020-03-09","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)                                                                                                                                                                               ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50653","Recruiting","No","0.0","18.0","Both","2020-03-15","monitor cases, suspected cases and diagnosed cases:120;","Observational study","Sequential","N/A","China","Yan Hao; Xiaoping Luo","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","haoyaner@163.com","+86 13971679960","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: This study intends to select surveillance cases, suspected cases and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the department of Pediatrics in Tongji Hospital from December 2019 to June 2020.<br>1. Epidem","Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;<br>(2) Exclude pneumonia caused by atypical microo","Novel Coronavirus Pneumonia (COVID-19)","monitor cases, suspected cases and diagnosed cases:Provide psychological intervention for children with severe stress response;","Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;","","","","Yes","0","          ",""
"ChiCTR2000030544","2020-03-09","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                              ","","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50134","Not Recruiting","No","14.0","90.0","Both","2020-02-24","Case series:1500;","Observational study","Sequential","Retrospective study","China","Minghao Fang","","1095 Jiefang Avenue, Wuhan, Hubei, China","Fangmh@tjh.tjmu.edu.cn","+86 15071157405","Emergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Inclusion criteria: 1. Have any of the following epidemiological history: <br>(1) travel history or residence history of Wuhan and surrounding areas, or other communities with case reports within 14 days before the onset of illness; <br>(2) close contac","Exclusion criteria: 1) <14 years of age;<br>2) pregnant women;<br>3) ICU hospital stay <24 hours;<br>4) The necessary clinical information is incomplete.","2019 novel coronavirus pneumonia(COVID-19)","Case series:no;","in-ICU mortality;mortality of 28 days;","","","","No","0","          ",""
"ChiCTR2000029993","2020-03-09","A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study                                       ","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49435","Recruiting","No","18.0","","Both","2020-02-20","group A:20;control group:20;","Interventional study","Parallel","0.0","China","Ye Feng/ Yang Zifeng/ Xu Xuyan/ Zhu Jun/ Jiang Lihong/ Zhang Yunhui/ Yuan Bing/ Chen Shi/ Fan Jie","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","yefeng@gird.cn","+86 13710494278; +86 13622273918","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: 1. Aged>= 18, male or female;<br>2. Fever, axillary temperature > 37.3 degrees;<br>3. Consistent with the clinical diagnosis of COVID-19 mild, normal, severe case;<br>4. Patients who sign informed consent form freely and voluntarily","Exclusion criteria: 1. Critical case with the following situation:<br> i. Patients with respiratory failure and needing mechanical ventilation;<br> ii. Patients with shock;<br> iii. Patients with other organ failures and needing ICU monitoring and trea","Novel Coronavirus Pneumonia (COVID-19)","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Main symptom relief time;","","","","Yes","0","          ",""
"ChiCTR2000029638","2020-03-09","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                    ","","West China Hospital, Sichuan University","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49224","Recruiting","No","18.0","75.0","Both","2020-02-03","Treatment group:50;Control group:50;","Interventional study","Parallel","0.0","China","Lunxu Liu","","No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, 610041, P.R China","lunxu_liu@aliyun.com","+86 18980601525","West China Hospital, Sichuan University","Inclusion criteria: (1) Aged 18 to 75 years old;<br>(2) Real-time fluorescent RT-PCR for respiratory or blood specimens to detect novel coronavirus nucleic acid positive;<br>(3) The sequence of virus genes in respiratory or blood samples was highly homo","Exclusion criteria: (1) Combining basic diseases such as hypertension, diabetes, and coronary heart disease,which were judged unsuitable for inclusion in the trial by researchers.<br>(2) Malignant tumor or with a history of malignant tumor;<br>(3) pregn","Novel Coronavirus Pneumonia (COVID-19)","Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","Clinical symptoms;Blood routine;Biochemical and myocardial enzymes;C-reactive protein;Erythrocyte sedimentation rate;Inflammatory cytokines;Chest CT;Etiology Inspection;Vital signs;","","","","No","0","          ",""
"ChiCTR2000030494","2020-03-09","Early risk stratification of the Novel coronavirus infected diseases (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","Early risk stratification of the coronavirus disease 2019 (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)                                                                                                                                  ","","West China Hospital, Sichuan University","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50077","Not Recruiting","No","18.0","100.0","Both","2020-03-01","Novel coronavirus pneumonia:600;","Observational study","Sequential","Retrospective study","China","Rui Zeng","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan","dongze.li@ymail.com","+86 028-85423248","Department of emergency Medicine, West China Hospital, Sichuan University ","Inclusion criteria: 1. Aged >18 years old;<br>2. patients diagnosed COVID-19.","Exclusion criteria: 1. Patients without complete clinical data;<br>2. Give up treatment and discharge patients automatically.","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia:none;","In-hospital mortality;Hospital mortality;","","","","No","0","          ",""
"ChiCTR2000030493","2020-03-09","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)                                                                                                                      ","","Renmin Hospital of Wuhan University","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50547","Not Recruiting","No","18.0","65.0","Both","2020-03-04","cross-sectional study:1300;","Observational study","Sequential","N/A","China","Zhongyuan Xia","","238 Jiefang Road, 99 Zhangzhidong Raod, Wuchang, Hubei, China  ","wenqin-1987@163.com","+86 13808628560","Renmin Hospital of Wuhan University","Inclusion criteria: (1) Chinese residents who experienced the noval coronavirus;<br>(2) People aged between 18 and 65 years old;<br>(3) People have electronic social software such as WeChat, QQ and Email.","Exclusion criteria: (1)People who complicated with mental illness<br>(2) people who can't use smart phones<br>(3)people who can't recognize or clearly read Chinese characters<br>(4)people who can't understand Chinese characters","sleep disorders","cross-sectional study:no;","Pittsburgh sleep quality index;","","","","Yes","0","          ",""
"NCT04299711","2020-03-16","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019: A Longitudinal Study Protocol","","University of Macau","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04299711","Not recruiting","No","10 Years","19 Years","All","2020-10-15","3428.0","Observational","","N/A","","","","","","","","<br>        Inclusion Criteria:<br><br>          1. age range: 10-19;<br><br>          2. full-time students in these targets high or middle schools;<br><br>          3. nationality: China;<br><br>          4. exposure context: COVID-19;<br><br","","Mental Disorder","Other: Exposed to the novel coronavirus disease 2019","The prevalence and incidence changes of common mental disorders","","","","Yes","0","          ",""
"ChiCTR2000030897","2020-03-16","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)                                                                                             ","","HwaMei Hospital, University of Chinese Academy of Sciences","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50462","Recruiting","No","","","Both","2020-02-10","Control group:10;Experimental group:10;","Interventional study","Parallel","N/A","China","Honghua Ye","","41 Xibei Street, Haisu District, Ningbo, Zhejiang, China ","yehonghua@medmail.com.cn","+86 13505743664","HwaMei Hospital, University of Chinese Academy of Sciences ","Inclusion criteria: 1. Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission. Criteria for diagnosis (meet all the following criter","Exclusion criteria: 1. Gestational female patients;<br>2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage;<br>3. Patients with known psychiatric disorders;<br>4. Patients wi","Novel Coronavirus Pneumonia (COVID-19)","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","serum albumin;siderophilin;prealbumin;lung CT scanning result;","","","","No","0","          ",""
"ChiCTR2000029579","2020-03-09","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance                                                                                                                                       ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49045","Recruiting","No","18.0","75.0","Both","2020-01-31","Case series:200;","Observational study","Sequential","0.0","China","Jianfeng Zhou","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","zhougene@medmail.com.cn","+86 027-83665506","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1.No age restriction.<br>2. Clinically confirmed 2019-nCoV infected patients.<br>3. Patients with willingness and ability to sign the informed consent.","Exclusion criteria: 1. Patients without any clinical and chest radiographic findings.<br>2. Patients not providing written informed consent.","novel coronavirus pneumonia (COVID-19)","Case series:Nil;","Cytokines;","","","","No","0","          ",""
"ChiCTR2000029433","2020-03-09","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)                                                                                                    ","","Hebei Yiling Hospital?Renmin Hospital of Wuhan University","2020-02-01","2020-02-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48898","Not Recruiting","No","18.0","","Both","2020-02-01","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","Interventional study","Parallel","4.0","China","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua","","385 North Xinshi Road, Qiaoxi District, Shijiazhuang, Hebei, China","jiactm@163.com","+86 0311-83855881","Shijiazhuang Yiling Pharmaceutical Co., Ltd.","Inclusion criteria: 1. Those who meet the diagnostic criteria for suspected cases in the diagnosis and treatment scheme;<br>2. Over 18 years old (including 18 years old), male or female;<br>3. At the time of enrollment, the patient had any of the main s","Exclusion criteria: 1. Respiratory tract infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease, abnormal lung developm","suspected novel coronavirus pneumonia (COVID-19)","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","","","","Yes","0","          ",""
"ChiCTR2000029829","2020-03-02","Cancelled due to lack of patient                                 Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                   ","","Chongqing Three Gorges Central Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49520","Not Recruiting","No","0.0","90.0","Both","2020-02-15","Case series:40;","Observational study","Sequential","Retrospective study","China","Wang Hailong","","165 Xincheng Road, Wanzhou, Chongqing, China","wangjinlong2007666@163.com","+86 15923859880","Three Gorges Central Hospital","Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital ","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:No;","Worsening condition;Death;Heart fatty acid binding protein;","","","","Yes","0","          ",""
"ChiCTR2000030552","2020-03-09","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)                                                                                                                      ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49708","Recruiting","No","18.0","90.0","Both","2020-03-08","Case series:70;","Observational study","Sequential","0.0","China","Li Shusheng","","1095 Jiefang Avenue, Wuhan, Hubei.","shushengli16@sina.com","+86 13971086498","Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged > 18 years; <br>2. COVID-19 coronavirus nucleic acid positive (including throat swabs, sputum, bronchoalveolar lavage fluid, stool and other specimens); <br>3. Chest imaging has clear viral pneumonia changes; <br>4. Respirat","Exclusion criteria: 1. Children and pregnant women; <br>2. Serious cardiopulmonary diseases (chronic obstructive pulmonary disease, acute coronary syndrome, dilated cardiomyopathy, congenital heart disease, chronic pulmonary hypertension, etc.); <br>3. ","2019 novel coronavirus pneumonia (COVID-19)","Case series:N/A;","Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;","","","","Yes","0","          ",""
"ChiCTR2000030480","2020-03-09","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)                                                                ","","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50470","Recruiting","No","18.0","110.0","Both","2020-03-03","Interferon Therapy Group:164;Control group:164;","Interventional study","Parallel","4.0","China","Huilan Zhang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","huilanz_76@163.com","+86 15391532171","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged >=18 years;<br>2. Clinically diagnosed patients with COVID-19, including: on the basis of meeting the criteria for suspected cases, one of the following etiology evidence:<br>(1) real-time fluorescent RT-PCR detection of SARS","Exclusion criteria: 1. Any situation where the programme cannot be carried out safely;<br>2. Patients who have used interferon or remedesivir;<br>3. No clinical manifestations and chest imaging findings;<br>4. Known allergy or hypersensitivity to inter","Novel Coronavirus Pneumonia (COVID-19)","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","Incidence of side effects;","","","","Yes","0","          ",""
"ChiCTR2000030479","2020-03-09","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                             ","","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50450","Not Recruiting","No","18.0","75.0","Both","2020-02-26","Control group:50;Experimental group:50;","Interventional study","Parallel","0.0","China","Zhijun Fang","","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","fangzjnj@hotmail.com","+86 13372018676","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;<br>2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;<br>3) Inpatients aged 18 to 75 years male or female;<br>4) Vo","Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;<br>2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, inc","Novel Coronavirus Pneumonia (COVID-19)","Control group:Refer to the National Health Office Medical Letter (2020) 77 document ""Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)"" general treatment plan.;Experimental group:Refer to the National Health Office Medical L","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","","","","No","0","          ",""
"ChiCTR2000030892","2020-03-16","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study                                                                                       ","","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51118","Recruiting","No","18.0","80.0","Both","2020-03-06","Experimental group:20;Control group:20;","Interventional study","Parallel","0.0","China","Qun Luo","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","luoqunx@163.com","+86 13710658121","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University ","Inclusion criteria: 1. Patients aged from 18 to 80 years;<br>2. conformed to epidemic history;<br>3. fever and respiratory symptoms;<br>4. normal or decreased leukocyte count in peripheral blood; or decreased lymphocyte count;<br>5. conformed to imagi","Exclusion criteria: 1. people who are allergic to pifenidone capsules;<br>2. the researchers judged that the compliance of the subjects was not good;<br>3. those who cannot take drugs through gastrointestinal tract;<br>4. any significant clinical or la","Fibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumonia","Experimental group:Pirfenidone;Control group:Blank;","HRCT pulmonary fibrosis score;","","","","No","0","          ",""
"ChiCTR2000030883","2020-03-16","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)                                                                                             ","","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50960","Recruiting","No","10.0","75.0","Both","2020-02-18","Case series:100;","Observational study","Sequential","N/A","China","Yang Si-Jin","","182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China","lykyk3160823@126.com","+86 15228218357","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","Inclusion criteria: Based on the diagnostic criteria of provinces other than hubei province in the latest diagnosis and treatment program of novel coronavirus pneumonia issued by the national health commission, the light, common, severe and critical types","Exclusion criteria: (1) patients allergic to the prescription of traditional Chinese medicine;<br>(2) infants and young children unable to take traditional Chinese medicine decoction;<br>(3) patients with unconsciousness or loss of consciousness;<br>(4","Novel Coronavirus Pneumonia (COVID-19)","Case series:qingfei detoxification decoction (mixture);","temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;","","","","No","0","          ",""
"ChiCTR2000029308","2020-03-09","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection                                                                                                         ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-01-23","2020-01-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48684","Recruiting","No","18.0","","Both","2020-01-10","intervention group:80;Control group:80;","Interventional study","Parallel","N/A","China","Zhang Dingyu","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","1813886398@qq.com","13507117929.0","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Inclusion criteria: 1. Adult aged >=18years old;<br>2. Patients infected with new coronavirus confirmed by PCR<br>3. In the state of no oxygen at rest, the patient's SPO2<=94% or the oxygenation index is less than 300mmHg.","Exclusion criteria: 1. Any situation that makes the programme cannot proceed safely;<br>2. Known allergy or hypersensitivity reaction to lopinavir / ritonavir;<br>3. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more t","Novel Coronavirus Pneumonia (COVID-19)","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospital","","","","No","0","          ",""
"NCT04298814","2020-03-16","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","","Tongji Hospital","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04298814","Not recruiting","No","18 Years","90 Years","All","2020-03-07","120.0","Observational","","N/A","","","","","","","","<br>        Inclusion Criteria:<br><br>          -  Wuhan residents;<br><br>          -  novel coronavirus pneumonia was found to be characterized by fever and cough.<br>             Laboratory tests revealed leukocyte or lymphocyte decrease, chest ","","COVID-19;Endotracheal Intubation","Other: severe covid-19 pneumonia with ET","Success rate of intubation;Infection rate of Anesthesiologist","","","","Yes","0","          ",""
"ChiCTR2000030477","2020-03-09","oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study                                                                         ","","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50458","Not Recruiting","No","18.0","","Both","2020-03-04","Case series:19;","Interventional study","Single arm","0.0","China","Xuemei Li","","1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China","lixmpumch@126.com","+86 13911467356","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Inclusion criteria: 1. Written informed consent from patients or representative;<br>2. Aged over 18 years;<br>3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;<br>2019-nCoV diagnosis confirmed by the combination of ep","Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;<br>2. Comorbidities including lupus, vasculitis, APS et al.<br>3. Concurrent use of ","Novel Coronavirus Pneumonia (COVID-19)","Case series:oXiris membrane;","28 day mortality;","","","","Yes","0","          ",""
"ChiCTR2000030436","2020-03-09","Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)","Application of flash glucose monitoring to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19)                                                                                  ","","Shanghai Sixth People's Hospital","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50297","Not Recruiting","No","18.0","80.0","Both","2020-03-06","Case series:100;","Observational study","Single arm","N/A","China","ZHOU JIAN","","600 Yishan Road, Xuhui District, Shanghai, China ","zhoujian@sjtu.edu.cn","+86 18930172033","Shanghai Sixth People's Hospital","Inclusion criteria: 1. patient with novel coronavirus pneumonia (including nucleic acid positive case or clinically diagnosed case);<br>2. patients with type 2 diabetes;<br>3. Aged between 18-80 years old;<br>4. With effective flash glucose monitoring ","Exclusion criteria: 1.diabetic ketoacidosis, hyperosmolar hyperglycemic status, or severe recurrent hypoglycemia occurred within 3 months;<br>2.previous history of cardiovascular disease, malignant tumor, mental illness or severe liver and kidney dysfunc","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","time in range;","","","","Yes","0","          ",""
"ChiCTR2000030535","2020-03-09","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine                                                                                                                                               ","","Wuhan Red Cross Hospital","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49790","Recruiting","No","","","Both","2020-02-20","experimental group:50;control group:50;","Interventional study","Parallel","4.0","China","Xu Zhihua","","Mianyang Central Hospital of Sichuan province","1121733818@qq.com","+86 18508160990","Mianyang Central Hospital","Inclusion criteria: 1. Aged 18 to 75 years;<br>2. Real-time fluorescence RT-PCR detection of nucleic acid positive of novel coronavirus in respiratory tract specimens or blood preparation;<br>3. Sequencing of virus genes in respiratory tract specimens o","Exclusion criteria: (1) Combined with high blood pressure, diabetes, coronary heart disease and other underlying disease; <br>(2) Combined with malignant tumor or a medical history of malignant tumor; <br>(3) Pregnant or lactating women; <br>(4) Suffer","Novel Coronavirus Pneumonia (COVID-19)","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);","","","","No","0","          ",""
"ChiCTR2000030522","2020-03-09","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                    ","","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=44213","Recruiting","No","18.0","75.0","Both","2020-03-09","experimental group:50;control group:50;","Interventional study","Parallel","0.0","China","Chuantao Zhang","","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China ","1035788783@qq.com","+86 13880336152","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine ","Inclusion criteria: 1. Laboratory confirmed infection with 2019-nCoV;<br>2. Clinical classification is mild or common;<br>3. Lung involvement confirmed with chest imaging;<br>4. Hospitalised with: Fever: axilla temperature >= 36.7 degrees C, or Oral te","Exclusion criteria: 1. Patients with serious primary diseases such as severe mental and psychological disorders, heart and brain vessels diseases, liver and kidney diseases, endocrine diseases, hematopoietic system diseases and malignant tumors;<br>2. Pa","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Time to Clinical Recovery (TTCR);","","","","Yes","0","          ",""
"ChiCTR2000030898","2020-03-16","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)                                                                                                                                                     ","","The affiliated Hospital to Changchun University of Traditional Chinese Medicine","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50780","Recruiting","No","18.0","80.0","Both","2020-01-27","Population under risk:1000;","Observational study","Sequential","N/A","China","Wang Tan","","1478 Gongnong Road, Changchun, Jilin, China","Wangtan215@sina.com","+86 13756858523","Affiliated Hospital of Changchun University of Traditional Chinese Medicine","Inclusion criteria: Vulnerable and high risk groups such as health care workers and non health care workers in health care settings. 2019-ncov.","Exclusion criteria: 1. A pregnant or lactating woman; <br>2. With other major diseases, such as serious heart, lung, liver, kidney damage or psychiatric patients. Participants should not take part in the study under any of the above circumstances. The Re","Novel Coronavirus Pneumonia (COVID-19)","Population under risk:Chushifangyi prescription;","Confirmed 2019-ncov pneumonia;","","","","No","0","          ",""
"ChiCTR2000030866","2020-03-16","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-1                                                                                                                         ","","The First Hospital of Changsha","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50299","Recruiting","No","18.0","85.0","Both","2020-02-01","MSC group:30;","Observational study","Single arm","0.0","China","Xie yuanlin","","311 Yingpan Road, Kaifu District, Changsha, Hu'nan, China","1286779459@qq.com","+86 13975137399","The First Hospital of Changsha","Inclusion criteria: 1. Patients diagnosed as severe or critical COVID-19; or patients who have turned negative for viral nucleic acid detection but still have the following severe or critical manifestations:<br>According to the ""New Coronavirus Pneumonia","Exclusion criteria: (1) Past medical history of pulmonary embolism;<br>(2) Patients infected with human immunodeficiency virus (HIV);<br>(3) Patients with malignant tumors: Patients with cervical carcinoma in situ, skin non metastatic squamous or basal ","Novel Coronavirus Pneumonia (COVID-19)","MSC group:Intravenous infusion of MSC based on conventional treatments;","Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;","","","","No","0","          ",""
"ChiCTR2000030865","2020-03-16","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection                                                                                                                                                     ","","Tongji Hospital, Huazhong university of science and technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49933","Recruiting","No","","","Male","2020-02-01","Case series:200;","Observational study","Sequential","Retrospective study","China","Luo Xiaoping","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","xpluo@tjh.tjmu.edu.cn","+86 027-83662684","Tongji Hospital, Huazhong University of Science and Technology","Inclusion criteria: All patients who meet one or two of the followings will be included in this study(pregnant women and newborns delivered):<br>Epidemiological history: <br>1. travel or residence history of Wuhan or other areas with continuous transmis","Exclusion criteria: The family refused","COVID-19","Case series:Nil;","Maternal and neonatal morbidity;","","","","No","0","          ",""
"ChiCTR2000030858","2020-03-16","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital                                                ","","Hubei Cancer Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51097","Recruiting","No","18.0","82.0","Both","2020-02-06","Case series:483;","Observational study","Sequential","N/A","China","Tiejun Wang","","116 Zhuodaoquan Road South, Hongshan District, Wuhan, Hubei, China","tiejunwanghp@163.com","+86 13277914596","Department of Breast Surgery, Hubei Cancer Hospital","Inclusion criteria: The mild cases were defined as those with mild clinical symptoms and no abnormalities on imaging examination; critical cases were those that met any of the following conditions: <br>1) respiratory failure requiring mechanical ventilat","Exclusion criteria: All mild patients need to be isolated and treated in mobile cabin hospitals. After admission, patients were given antiviral and symptomatic treatment according to their condition and symptoms, and patients with fever were given antibio","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","Discharge rate;","","","","No","0","          ",""
"ChiCTR2000029958","2020-03-09","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department                            ","","Department of Anesthesiology, Zhongnan Hospital of Wuhan University","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49635","Not Recruiting","No","18.0","99.0","Both","2020-02-17","patient group:200;Health care team:60;","Observational study","Factorial","Retrospective study","China","Zongze Zhang","","169 Donghu Road, Wuhan, Hubei, China","zhangzz@whu.edu.cn","+86 13971687403","Zhongnan Hospital of Wuhan University","Inclusion criteria: 1. Confirmed and suspected patients undergoing new crown anesthesia;<br>2. Medical staff of anesthesiology department contacted with patients suspected of new crown in operating room;<br>3. Voluntary participation in the test and sig","Exclusion criteria: 1. General anesthesia surgery patients;<br>2. Medical staff with contact history outside the operating room.","Novel Coronavirus Pneumonia (COVID-19)","patient group:Under surgical and anesthesia;Health care team:Anesthesiologists for NCP patients;","CT image of lung;","","","","Yes","0","          ",""
"ChiCTR2000029757","2020-03-09","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                                 ","","China-Japan friendship hospital","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49081","Recruiting","No","18.0","-","Both","2020-02-14","Experimental group:100;Control group:100;","Interventional study","Parallel","0.0","China","Cao Bin","","Cherry Blossom Garden East Street, Chaoyang District, Beijing ","caobin_ben@163.com","13911318339.0","China-Japan friendship hospital","Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;<br>2.The age of the patient is 18 or more than18 years old;<br>3. COVID-19 patients diagnosed by PCR;<br>4. Nucleic acid posi","Exclusion criteria: 1.The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an un","novel coronavirus pneumonia (COVID-19)","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","the number of days between randomised grouping and clinical improvement;","","","","Yes","0","          ",""
"ChiCTR2000030503","2020-03-09","Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study                                                                                                     ","","The First Affiliated Hospital of Zhejiang University School of Medicine","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49632","Recruiting","No","18.0","","Both","2020-01-20","Experimental group:30;Control group:30;","Interventional study","Non randomized control","0.0","China","Xiaowei XU","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","xxw69@126.com","+86 13605708066","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Inclusion criteria: 1. aged >=18 years old;<br>2. laboratory conformed SARS-CoV-2 infection;<br>3. critically ill and require intensive care.","Exclusion criteria: 1. pregnancy;<br>2. blood purification treatment prior to admission;<br>3. patients had other indications for blood purification treatment including hyperkalemia, acute kidney failure, and so on;<br>4. allergic to dimethyl sulfoxide","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Mortality;","","","","No","0","          ",""
"ChiCTR2000030487","2020-03-09","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","","The First Affiliated Hospital of HeNan University of CM","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50507","Recruiting","No","18.0","","Both","2020-03-04","Azvudine Plus Symptomatic treatment:10;","Interventional study","Single arm","0.0","China","Li Suyun","","19 Renmin Road, Zhengzhou, He'nan, China","38797527@qq.com","13938415502.0","The First Affiliated Hospital of HeNan University of CM","Inclusion criteria: (1) aged >=18 years; <br>(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/low","Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;<br>(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;<br>(3) partic","Novel Coronavirus Pneumonia (COVID-19)","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health an","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;","","","","Yes","0","          ",""
"ChiCTR2000030864","2020-03-16","Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                    ","","Xiangyang 1st people's Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50662","Recruiting","No","","","Both","2020-02-01","Case series:50;","Interventional study","Non randomized control","N/A","China","Zhu Bo","","3 Yunxing Road, Fancheng District, Xiangyang, Hubei, China","274770142@qq.com","+86 13995789500","Xiangyang 1st People's Hospital","Inclusion criteria: 1. novel coronavirus pneumonia diagnostic criteria;<br>2. age unlimited, male and female unlimited.","Exclusion criteria: 1. not qualified for novel coronavirus pneumonia diagnostic criteria;<br>2. Pregnant or lactating women who are allergic to the drug;<br>3. Patients with severe primary diseases and psychosis, such as cardiovascular, liver, kidney an","Novel Coronavirus Pneumonia (COVID-19)","Case series:Western medicine plus Qingfei Paidu decoction;","2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;","","","","No","0","          ",""
"ChiCTR2000030859","2020-03-16","A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital","Analysis of influencing factors of death of COVID-19 patients in wuhan third hospital                                                                                                                                                                          ","","Wuhan Third Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51025","Not Recruiting","No","","","Both","2020-03-01","Group 1:700;Group 2:605;","Observational study","Factorial","N/A","Chian","Guoqin Sun","","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","707986890@qq.com","+86 18971163158","Wuhan Third Hospital","Inclusion criteria: 1) Comply with the diagnostic criteria for patients with new pneumonia virus in the Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(7th Edition);<br>(2) Complete clinical data of patients. ","Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections;<br>(2) Patients whose data could not be obtained for special reasons. ","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Traditional Chinese medicine and routine treatment of western medicine;Group 2:Routine treatment of western medicine;","Mortality rate;","","","","No","0","          ",""
"ChiCTR2000030856","2020-03-16","An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT","An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT                                                                                                                                                          ","","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51091","Recruiting","No","20.0","88.0","Both","2020-02-15","Target condition:600;Difficult condition:100","Diagnostic test","Sequential","0.0","China","Liming Xia","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Lmxia@tjh.tjmu.edu.cn","+86 13607176908","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: 1. COVID-19 patients with positive SARS-COV-2 nucleic acid RT-PCR test results;<br>2. Viral pneumonia manifestation on CT.","Exclusion criteria: CT negative results","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:RT-PCR test results;Index test:Artificial&#32;intelligence&#32;model;","sensitivity;SPE;","","","","No","0","          ",""
"ChiCTR2000030849","2020-03-16","Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies                                                                                                                                  ","","Zhengzhou People's Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51086","Not Recruiting","No","7.0","70.0","Both","2020-03-16","Case series:81;","Interventional study","Sequential","0.0","China","Yibin Hao","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","haoyibin0506@126.com","+86 15903715671","Zhengzhou people's hospital ","Inclusion criteria: 1. Above 7 years old, understand the purpose and significance of the research, and be able to cooperate with the research;<br>2. Meet the diagnostic criteria of the COVID-19;<br>3. Clear consciousness and stable vital signs;<br>4. V","Exclusion criteria: 1. Too young to understand the research or to cooperate with the research;<br>2. Non-neoplastic coronary pneumonia patients;<br>3. Impaired consciousness, affecting its understanding and expression;<br>4. Those who cannot cooperate ","Novel Coronavirus Pneumonia (COVID-19)","Case series:Psychological intervention;","SCL-90 scale;","","","","Yes","0","          ",""
"ChiCTR2000030857","2020-03-16","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)                                                                                                          ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51040","Recruiting","No","","","Both","2020-03-01","Case series:30;","Observational study","Sequential","Retrospective study","China","Shusheng Li","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Shushengli16@sina.com","+86 13971086498","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Critical patients with COVID-19 confirmed by etiology test;<br>2. airway intubation with mechanical ventilation is used;<br>3. voluntarily joined this study with informed consents.","Exclusion criteria: 1. Pregnant women;<br>2. Combined with severe basal diseases such as malignant tumor, cirrhosis and HIV;<br>3. Patients with lung tumor, interstitial fibrosis, alveolar proteinosis, and allergic alveolitis.","Novel Coronavirus Pneumonia (COVID-19)","Case series:The use of fiberoptic bronchoscopy;","cytology;proteomics;chest X-ray;Oxygenation index;","","","","No","0","          ",""
"ChiCTR2000030855","2020-03-16","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia                                                                                                              ","","Department of Critical Care Medicine, the Third Affiliated Hospital of Zunyi Medical University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51090","Not Recruiting","No","","","Male","2020-02-01","Case series:200;","Interventional study","Sequential","1.0","","Wen Jianli","","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","zywenjianli@163.com","+86 15186660001","The Third Affiliated Hospital of Zunyi Medical University","Inclusion criteria: 1. Aged >=18 years;<br>2. Endotracheal intubation patients with positive nucleic acid test of novel coronavirus;<br>3. Patients with off-line extubation.","Exclusion criteria: 1. Family members refuse to extubate;","Novel Coronavirus Pneumonia (COVID-19)","Case series:external diaphragmatic pacing;","Length of stay in ICU;Diaphragm movement;","","","","No","0","          ",""
"ChiCTR2000030833","2020-03-16","Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit","Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit                                                                                                                                                   ","","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51035","Not Recruiting","No","","","Male","2020-03-22","Target condition:400;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Ning Qin","","1095 Jiefang Avenue, Hankou, Wuhan, Hubei, China","qning@vip.sina.com","+86 027-83662391","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Patients with novel coronavirus pneumonia and suspending patients","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:PCR Nucleic acid detection;Index test:high-throughput&#32;novel&#32;coronavirus&#32;(2019-nCoV)&#32;screening&#32;detection&#32;kit;","RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000030831","2020-03-16","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia: a single center and descriptive study in Wuhan                                            ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51036","Not Recruiting","No","18.0","99.0","Both","2020-01-01","Case series:75;","Observational study","Sequential","Retrospective study","China","Ye Tu","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China ","whtuye@163.com","+86 18986152706","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ","Inclusion criteria: (1) patients who were diagnosed to NCP;<br>(2) patients who received with invasive mechanical ventilation","Exclusion criteria: (1) Aged <18 years;<br>(2) pneumonia patients whose novel coronavirus nucleic acid test were negative ;","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;","","","","No","0","          ",""
"NCT04292340","2020-03-16","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study","","Shanghai Public Health Clinical Center","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04292340","Recruiting","No","N/A","N/A","All","2020-02-01","15.0","Observational","","Phase 2/Phase 3","China"," ; ; ","Hongzhou Lu, Ph.D;Hongzhou Lu, Ph.D;Jun Chen","",";luhongzhou@fudan.edu.cn;",";+86-021-37990333;008602137990333","Shanghai Public Health Clinical Center;","<br>        Inclusion Criteria:<br><br>          -  The participants were diagnosed as COVID-19;<br><br>          -  Participants received anti-SARS-CoV-2 inactivated convalescent plasma<br><br>          -  Written the informed consent.<br><br>  ","","Coronavirus","","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, s","","","","Yes","0","          ",""
"NCT04293887","2020-03-16","Efficacy and Safety of IFN-a2 in the Treatment of Novel Coronavirus Patients","Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","","Tongji Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04293887","Not recruiting","No","18 Years","N/A","All","2020-03-01","328.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Early Phase 1",""," ","Jianping Zhao, Ph.D.","","Zhaojp88@126.com","13507138234.0","","<br>        Inclusion Criteria:<br><br>          1. Age = 18 years;<br><br>          2. Clinically diagnosed patients with new type of coronavirus pneumonia, including: in<br>             accordance with the criteria for suspected cases, have one of","","COVID-19;Recombinant Human Interferon a1","Drug: Recombinant human interferon a1","The incidence of side effects;The incidence of side effects;The incidence of side effects","","","","Yes","0","          ",""
"ChiCTR2000030902","2020-03-16","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors                                                                                         ","","Jingzhou Mental Health Center","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51130","Recruiting","No","16.0","65.0","Both","2020-02-10","Case series:1000;","Observational study","Sequential","N/A","China","Deng Xiaopeng","","47 Taqiao Road North, Shashi District, Jingzhou, Hubei, China","49637569@qq.com","+86 13872250922","Jingzhou Mental Health Center","Inclusion criteria: 1. including confirmed, suspected patients, isolated observers, ordinary residents and frontline staff;<br>2. residence in Jingzhou for more than 14 days during the outbreak;<br>3. Aged 16-65 years;<br>4. self-volunteered.","Exclusion criteria: To rule out anyone not living in Jingzhou during the outbreak.","Novel Coronavirus Pneumonia (COVID-19)","Case series:None;","mental health status and influence factors;","","","","No","0","          ",""
"ChiCTR2000030850","2020-03-16","Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic","Study for the physical and mental health status of medical workers under the situation of COVID-19                                                                                                                                                             ","","The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51056","Not Recruiting","No","18.0","??","Both","2020-03-15","Observation group:113;Control group:113;","Observational study","Factorial","N/A","China","Fengbin Liu","","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China ","liufb163@163.com","+86 020-36591782"," the First Affiliated Hospital, Guangzhou University of Chinese Medicine","Inclusion criteria: 1. Aged 18-65 years, gender without limitation;<br>2. Meical workers normal working during the period of COVID-19;<br>3. Auqired the informed consent and willing to be a volunteer.","Exclusion criteria: 1. Medical worker who is diagnosed with COVID-19,suspected to COVID-19 or segregated due to COVID-19;<br>2. Occupation is not medical wokers such as manager,secretary or support staff who is work in medical institution;<br>3. Medical","Somatopsychic illness; Novel Coronavirus Pneumonia (COVID-19)","Observation group:Medical workers in Hubei province;Control group:Non-Hubei medical staffNon-Hubei medical staff;","Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;","","","","Yes","0","          ",""
"ChiCTR2000030841","2020-03-16","Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients                                                                                                                                                                            ","","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51072","Recruiting","No","18.0","","Both","2020-02-17","Experimental group:5;Control group:5;","Interventional study","Non randomized control","0.0","China","Xiang Cheng","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","nathancx@hust.edu.cn","+86 15972061080","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Volunteers who have understood and signed the informed consent;<br>2. Aged >=18 years;<br>3. Patients diagnosed with acute severe 2019-nCoV pneumonia:<br>(1) Laboratory (RT-PCR) confirmed infection with 2019-nCoV.<br>(2) Lung in","Exclusion criteria: 1. Viral pneumonia with other viruses besides 2019-nCoV;<br>2. Patients are not suitable for immunoglobulin therapy;<br>3. Participation in other studies;<br>4. Other circumstances in which the investigator determined that the patie","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","Time to Clinical Improvement (TTCI);","","","","No","0","          ",""
"ChiCTR2000030485","2020-03-09","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A case records based retrospective Cohort study                                                                                            ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50459","Not Recruiting","No","14.0","90.0","Both","2020-03-03","Group 2:50;Group 1:40;","Observational study","Factorial","Retrospective study","China","Shusheng Li","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","shushengli16@sina.com","+86 13971086498","Eergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Inclusion criteria: 1. Meets 2019 novel coronavirus pneumonia diagnosis criteria;<br>2. Under non-invasive ventilation, finger oxygen saturation<90%.","Exclusion criteria: 1. Age <14 years;<br>2. Pregnant;<br>3. Patient is irritable during NIV treatment, and still cannot tolerate NIV after adequate health education and nursing guidance;<br>4. Intubation-mechanical ventilation without previous NIV trea","Novel Coronavirus Pneumonia (COVID-19)","Group 2:conservation mechanical ventilation group;Group 1:aggressive mechanical ventilation;","28-day mortality;ICU 14-day mortality;","","","","Yes","0","          ",""
"ChiCTR2000030472","2020-03-09","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","","Shenyang Sixth People's Hospita","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49753","Recruiting","No","18.0","75.0","Both","2020-02-25","Experimental group:10;Control group:10;","Interventional study","Non randomized control","N/A","China","Ye Gu","","85 Heping Street South, Heping District, Shenyang, Liaoning, China","sylykjk@163.com","+86 18502468189","Shenyang Sixth People's Hospital","Inclusion criteria: 1. Aged 18-75 years old;<br>2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 <93% in resting state; or arterial partial pressure of oxygen (PaO2) / concent","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;","","","","No","0","          ",""
"ChiCTR2000030816","2020-03-16","Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients","Nutritional risk assessment and outcome prediction of critically ill COVID-19 patients                                                                                                                                                                         ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51048","Not Recruiting","No","14.0","90.0","Both","2020-02-24","Case series:200;","Observational study","Sequential","Retrospective study","China","Yi Bian","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","bianyi2526@163.com","+86 15102710366","Eergency / Intensive Care Department of Tongji Hospital","Inclusion criteria: 1) Meets COVID-19 diagnosis criteria from WHO;<br>2) Critically ill COVID-19 patients who admiteed to ICUs;<br>3) length of stay in ICU >=24 hours","Exclusion criteria: 1) Aged <14 years; <br>2) Pregnant; <br>3) COVID-19 as an complication on other major diseases;<br>4) Insufficient medical information.","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","Mortality of ICU 28-day;","","","","No","0","          ",""
"ChiCTR2000030814","2020-03-16","A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route","Ocular dectection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: an observational study                                                                                                                                                     ","","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51042","Not Recruiting","No","10.0","88.0","Both","2020-02-20","Case series:100;","Observational study","Sequential","N/A","China","Junming Wang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","eyedrwjm@163.com","+86 13886169836","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","Inclusion criteria: (1) Subjects must understand the clinical trial requirements and potential risks, with voluntarily participation, and sign the informed consent;<br>(2) Fever and/or respiratory symptoms, normal or reduced total white blood cell count ","Exclusion criteria: (1) Infection with influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pneumonovirus, SARS coronavirus and other known viral pneumonia patients;<br>(2) Patients with mycoplasma pneu","Novel Coronavirus Pneumonia (COVID-19)","Case series:N/A;","Ocular  Symptoms;","","","","No","0","          ",""
"ChiCTR2000030901","2020-03-16","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong                                                                                                                        ","","The Chinese University of Hong Kong","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51064","Not Recruiting","No","0.0","100.0","Both","2020-03-09","Case series:100;","Observational study","Sequential","Retrospective study","China","Prof. Christopher CK Lai","","Department of Microbiology Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin , NT, Hong Kong SAR","chris.kclai@cuhk.edu.hk","+852 3505 3333","The Chinese University of Hong Kong","Inclusion criteria: All patients with laboratory confirmed diagnosis of COVID-19 and are listed in the Centre for Health Protection (CHP) database will be included in the study.","Exclusion criteria: Not applicable","Novel Coronavirus Pneumonia (COVID-19)","Case series:Not applicable;","Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;","","","","No","0","          ",""
"ChiCTR2000030854","2020-03-16","A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)","A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection                                                                                                                                                               ","","Li Lanjuan","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51083","Not Recruiting","No","","","Both","2020-01-22","The triple combination antiviral therapy:196;The dual combination antiviral therapy:41;","Observational study","Cohort study","N/A","China","Li Lanjuan","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","ljli@zju.edu.cn","+86 13906514210","The First Affiliated Hospital, College of Medicine,Zhejiang University","Inclusion criteria:  From January 22 to February 16, 2020,Patients diagnosed with new coronavirus infection in 15 medical institutions in Zhejiang Province.","Exclusion criteria: Patients with negative detection of new coronavirus nucleic acid","COVID-19","The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);","white blood cell;lymphocyte;creatinine;CRP;","","","","No","0","          ",""
"ChiCTR2000030839","2020-03-16","Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery","Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery                                                                                                                                        ","","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50904","Not Recruiting","No","12.0","85.0","Both","2020-03-01","Case series:100;","Screening","Sequential","0.0","China","Peng Sun","","1111 Xianxia Road, Changning District, Shangha","SP2082@shtrhospital.com","+86 18121225835","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","Inclusion criteria: Surgical admission patients requires emergency or scheduled surgery.","Exclusion criteria: The patients were diagnosed with Coronavirus Disease (COVID-19) before surgery.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Laboratory examination and pulmonary CT;","SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;","","","","No","0","          ",""
"ChiCTR2000030832","2020-03-16","Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)                                                                                                                                    ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51044","Not Recruiting","No","","","Both","2020-03-16","Group 1:200;Group 2:200;Group 3:200;Group 4:200;","Interventional study","Parallel","0.0","","Yuan Yang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China ","yuanyang70@hotmail.com","+86 13995561816","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Inclusion criteria: 1. Intervention group:<br>(1) Aged 18 to 50 years;<br>(2) Diagnosed as a depression or anxiety by Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the score of HAMD-17>17,or HAMA>7;<br>2. Non-intervention group:<br>(1","Exclusion criteria: (1) other psychiatric disorders;<br>(2) complicating with sever medical disorder on nervous, cardiovascular, respiratory system;<br>(3) taking antidepressants, psychoactive drugs, steroids, drugs that affect heart rate and blood pres","Novel Coronavirus Pneumonia (COVID-19)","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;","","","","Yes","0","          ",""
"ChiCTR2000030471","2020-03-09","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                ","","Maoming People's Hospital","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50421","Recruiting","No","18.0","75.0","Both","2020-03-02","Lipoic acid group:197;Blank control group:197;","Interventional study","Parallel","4.0","China","Chen Chunbo","","101 Weimin Road, Maoming, Guangdong, China","gghicu@163.com","+86 13922745788","Maoming People's Hospital","Inclusion criteria: (1) Patients aged from 18 to 75 years old;<br>(2) Mild patients with confirmed COVID-19 according to the diagnostic criteria of ""novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)"" issued by the National Heal","Exclusion criteria: (1) Female patients during pregnancy or lactation;<br>(2) Patients allergic to lipoic acid or similar drugs (B vitamins), previously intolerant to the recommended dose of lipoic acid;<br>(3) Patients who are taking part in clinical t","Novel Coronavirus Pneumonia (COVID-19)","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Progression rate from mild to critical/severe;","","","","Yes","0","          ",""
"ChiCTR2000030469","2020-03-09","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                   ","","Shanghai University of TCM","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50082","Recruiting","No","18.0","65.0","Both","2020-02-27","Control group:48;Experimental group:48;","Interventional study","Parallel","0.0","China","Xiuming Song","","528 Zhanghen Road, Pudong New Area District, Shanghai, China","Xiumingsong@sina.com","+86 13817525012","Shuguang Hospital Affiliated to Shanghai University of T.C.M.","Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;<br>2. Confirmed as a novel coronavirus pneumonia common and severe patients,","Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia;<br>2. Acute respiratory disease caused by non- novel coronavirus pneumonia;<br>3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency ","Novel Coronavirus Pneumonia (COVID-19)","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","fever clearance time;Effective rate of TCM symptoms;","","","","No","0","          ",""
"ChiCTR2000030853","2020-03-16","Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia                                                                                                                                                       ","","Department of critical care medicine, the third affiliated hospital of zunyi medical university","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51081","Not Recruiting","No","18.0","","Both","2020-02-01","Case series:200;","Interventional study","Sequential","0.0","","Wen Jianli","","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","zywenjianli@163.com","+86 15186660001","The Third Affiliated Hospital of Zunyi Medical University","Inclusion criteria: 1. Aged >=18 years old;<br>2. Symptoms of novel coronavirus infection;<br>3. Positive nucleic acid test of novel coronavirus.","Exclusion criteria: 1. Pregnancy;<br>2. Patients with advanced malignant tumor;<br>3. Suspected cases.","Novel Coronavirus Pneumonia (COVID-19)","Case series:dexmedetomidine;","CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;","","","","No","0","          ",""
"ChiCTR2000030852","2020-03-16","Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)","Factors associated with death patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                             ","","Beijing An Zhen Hospital, Capital Medical University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51077","Not Recruiting","No","18.0","100.0","Both","2020-01-27","Case series:150;","Observational study","Sequential","Retrospective study","China","Jiang Xie","","2 Anzhen Road, Chaoyang District, Beijing, China","frank782008@aliyun.com","+86 13161985564","Beijing Anzhen Hospital, Capital Medical University","Inclusion criteria: 1. positiveness of nucleic acid of COVID-19 in a in throat swab nucleic acid positive;<br>2. newly-onset pneumonia in a CT scan;<br>3. typical symptoms of pneumonia, i.e., fever, cough, dyspnea, etc.;<br>4. live in Wuhan in the past","Exclusion criteria: mild COVID-19 infection without intrapulmonary lesions","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Death;","","","","No","0","          ",""
"ChiCTR2000030807","2020-03-16","Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)","Screening and Identification of SARS-CoV-2 Infection and Progression in Cancer Patients Based on Bioinformatics Analysis                                                                                                                                       ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51019","Recruiting","No","23.0","94.0","Both","2020-02-15","non-cancer COVID-19 versus cancer with COVID-19:100;","Observational study","Factorial","Retrospective study","China","Zhihua Wang, Xianglin Yuan","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","zhwang_hust@hotmail.com","+86 13607195518","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Inclusion criteria: 1. tumor group:<br>(1) Aged >=18 years;<br>(2) Diagnosed as a malignant tumor or has a history of malignant tumors before enrollment;<br>(3) The diagnosis and treatment of new coronavirus pneumonia was issued in the seventh edition ","Exclusion criteria: (1) Those who do not meet the inclusion criteria of this study;<br>(2) Complicated with severe primary heart, liver, and kidney disease;<br>(3) Patients during perioperative period (within 7 days after operation);<br>(4) Immune dysf","Novel Coronavirus Pneumonia (COVID-19)","non-cancer COVID-19 versus cancer with COVID-19:none;","lynphocyte;cytokine;cancer history;order of severity;","","","","No","0","          ",""
"ChiCTR2000030805","2020-03-16","Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)","Quantitative CT characteristic estimate the severity of 2019-nCoV                                                                                                                                                                                              ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51026","Not Recruiting","No","","","Both","2020-02-15","Case series:200;","Observational study","Sequential","Retrospective study","","Liang Wang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","wang6@tjh.tjmu.edu.cn","+86 13971625289","Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology","Inclusion criteria: This study was a retrospective single-center study, which included patients suspected of novel coronavirus infection and underwent both chest CT imaging and laboratory virus nucleic acid test (RT-PCR assay with throat swab samples) fro","Exclusion criteria: There were no hospitalized patients, no CT patients.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Quantitative CT characteristic;","","","","No","0","          ",""
"ChiCTR2000030830","2020-03-16","Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning","Development and application of COVID-19 intelligent image classification system based on deep learning                                                                                                                                                         ","","Hwa Mei Hospital, University of Chinese Academy of Sciences","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51009","Recruiting","No","","","Both","2020-01-01","Case series:150;","Observational study","Sequential","N/A","China","Jingfeng Zhang","","Room 711, Building 4, 41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","jingfengzhang73@163.com","+86 15706855886","Hwa Mei Hospital, University of Chinese Academy of Sciences","Inclusion criteria: All patients hospitalized for novel coronavirus pneumonia in Hwa Mei Hospital, University of Chinese Academy Sciences from January 2020 were enrolled. The subjects were included the confirmed cases following the latest guideline of dia","Exclusion criteria: Confirmed cases who had the organ transplantation were excluded following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Abnormalities on chest CT;Exposure to source of transmission within past 14 days;","","","","No","0","          ",""
"ChiCTR2000030806","2020-03-16","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                ","","Wuhan Third Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51029","Recruiting","No","18.0","75.0","Both","2020-02-01","experimental group:20;","Observational study","Sequential","1.0","China","JIAN PENG","","216 Guanshan Avenue, Hongshan District, Wuhan, Hubei, China","137585260@qq.com","+86 13907105212","Wuhan third hospital","Inclusion criteria: The confirmed patients with common type of new coronavirus pneumonia were selected, and the diagnostic criteria were shown in [diagnosis and treatment scheme 5.0 for pneumonia caused by new coronavirus infection].","Exclusion criteria: 1. Aged > 75 years old and < 18 years old;<br>2. Patients who are contraindicated or allergic to this study drug (lung-clearing and detoxification decoction and ulinastatin for injection);<br>3. Patients with previous tumor, severe l","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Oral Chinese medicine ""qingfei detoxification soup"" + intravenous injection of ulinastatin 200000 U Bid.;","blood RT;ABG;blood clotting function;liver and kidney function;","","","","No","0","          ",""
"ChiCTR2000030468","2020-03-09","Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation","Key techniques of combination therapy of Novel Coronavirus Pneumonia (COVID-19) - Study on TCM symptoms and treatment law                                                                                                                                      ","","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50390","Recruiting","No","","","Both","2020-02-28","PRE-GROUP1:400;PRE-GROUP2:400;TRE-GROUP1:100;TRE-GROUP2:50;","Observational study","Non randomized control","N/A","China","Zhang Wei","","42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China","zhagnweijinan@126.com","+86 13505319899","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","Inclusion criteria: 1. Criteria for inclusion of confirmed patients:<br>(1) Comply with the diagnostic criteria of ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (COVID-19) (Trial Version 5)"";<br>(2) Above 2 years old;<br>2","Exclusion criteria: (1) Patients during pregnancy;<br>(2) Complicated liver, kidney, and metabolic diseases;<br>(3) Have other serious primary cardiovascular disease, kidney disease, liver disease, hematological changes, or serious diseases that affect ","Novel Coronavirus Pneumonia (COVID-19)","PRE-GROUP1:Taking Chinese medicine preventive decoction;PRE-GROUP2:General prevention methods;TRE-GROUP1:TCM syndrome differentiation treatment+ Western medicine treatment;TRE-GROUP2:Western medicine treatment;","disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;","","","","No","0","          ",""
"ChiCTR2000030453","2020-03-09","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)                                                                                                                                                        ","","The First Affiliated Hospital of Wenzhou Medical University","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50381","Not Recruiting","No","","","Both","2020-03-02","ACEIs/ARBs:100;","Observational study","Sequential","Retrospective study","China","Yanling Shi","","Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.Zhejiang, China","akidney_doctor@hotmail.com","+86 0577 55579261","The First Affiliated Hospital of Wenzhou Medical University","Inclusion criteria: confirmed cases of novel coronavirus(COVID-19) by real time fluorescent RT-PCR in Wenzhou City from January 2020","Exclusion criteria:  infection caused by other pathogens","Novel Coronavirus Pneumonia (COVID-19)","ACEIs/ARBs:NA;","ratio of severe cases;","","","","Yes","0","          ",""
"ChiCTR2000030838","2020-03-16","Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images","Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images                                                                                        ","","Zhongnan Hospital of Wuhan University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51071","Not Recruiting","No","18.0","80.0","Both","2020-01-20","Target condition:1000;Difficult condition:0","Diagnostic test","Sequential","N/A","China","Xu Haibo","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","xuhaibo1120@hotmail.com","+86 13545009416","Wuhan University Central South Hospital","Inclusion criteria: (1) Patients diagnosed with COVID-19 infection; the diagnostic criteria are as follows: SARS-COV-2 nucleic acid RT-PCR test results of respiratory specimens are positive;<br>(2) There are CT image examination data and manifestations o","Exclusion criteria: (1) CT result is negative;<br>(2) Incomplete clinical data.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:RT-PCR test results;Index test:Typing&#32;and&#32;prediction&#32;accuracy&#32;of&#32;artificial&#32;intelligence&#32;models;","Precision;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030836","2020-03-16","Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy                                                                                                                   ","","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51054","Not Recruiting","No","18.0","80.0","Both","2020-02-01","Group 2:150;Group 1:150;","Interventional study","Non randomized control","4.0","China","Bangjiang Fang","","725 Wanping Road South, Xuhui District, Shanghai, China","fangbji@163.com","+86 18917763257","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;<br>2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;<br>3. Aged 18 to 80 years;<br>4. Signed informed cons","Exclusion criteria: 1) Ordinary covid-19 pneumonia is not in conformity with the standard diagnostic criteria.            <br>2) Patients with allergy to traditional Chinese medicine and allergic constitution;           <br>3) Patients with malignant tu","Novel Coronavirus Pneumonia (COVID-19)","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;","","","","No","0","          ",""
"ChiCTR2000030798","2020-03-16","A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)","Clinical characteristics of COVID-19                                                                                                                                                                                                                           ","","Wuhan 3rd Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50994","Recruiting","No","30.0","85.0","Both","2020-02-10","Case series:100;","Observational study","Sequential","1.0","China","Wang Hua-bing","","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","273225540@qq.com","+86 15377628125","Wuhan 3rd Hospital","Inclusion criteria: 1. Confirmed case: any one of the epidemiological history, and in line with the two clinical manifestations, with one of the following etiological evidence:<br>(1) epidemiological history:<br>1) travel history or residence history of","Exclusion criteria: Missing clinical data.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","blood biochemistry;","","","","No","0","          ",""
"ChiCTR2000030796","2020-03-16","Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)","Clinical characteristics and treatment of COVID-19                                                                                                                                                                                                             ","","The Second Hospital of Hebei Medical University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50991","Recruiting","No","","","Both","2020-01-29","Case series:500;","Observational study","Sequential","Retrospective study","","Yuan Yadong","","215 Heping Road West, Shijiazhuang, Hebei, China","yuanyd1108@163.com","+86 15833119392","The Second Hospital of Hebei Medical University","Inclusion criteria: Patients who meet the diagnostic criteria for confirmed cases of pneumonia in the diagnosis and treatment program for novel coronavirus infection (trial seventh edition) issued by the national health commission on March 3, 2020","Exclusion criteria: Non-definitively diagnosed cases","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","mortality;effective rate;","","","","No","0","          ",""
"ChiCTR2000030804","2020-03-16","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial                                                                                                                                   ","","Maoming People's Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51018","Recruiting","No","18.0","75.0","Both","2020-02-01","Exocarpium Citri Grandis Group:64;Placebo Group:64;","Interventional study","Parallel","4.0","China","Hu Linhui","","101 Weimin Road, Maoming, Guangdong, China","hulinhui@live.cn","+86 13580013426","Maoming People's Hospital","Inclusion criteria: (1) aged between 18 and 75 years old;<br>(2) Common type patients with confirmed COVID-19 according to the diagnostic criteria of ""novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)"" issued by the National He","Exclusion criteria: (1) Female patients during pregnancy or lactation;<br>(2) Patients with allergy to Exocarpium Citri Grandis preparation, patients with intolerance to the recommended dose of Exocarpium Citri Grandis were previously applied;<br>(3) Pa","Novel Coronavirus Pneumonia (COVID-19)","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Cough Score;Expectoration score;","","","","No","0","          ",""
"ChiCTR2000030799","2020-03-16","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia                                                                                                                                                    ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50995","Not Recruiting","No","","","Both","2020-01-20","Target condition:1000;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","China","TAO WANG","","1095 Jiefang Avenue, Wuhan, Hubei, China","wt7636@126.com","+86 13971477320","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Patients who were confirmed diagnosis of COVID-19 pneumonia, according to the ""pneumonia diagnosis and treatment program for novel coronavirus infection (trial version seven)"", including clinical symptoms, pulmonary CT manifestation","Exclusion criteria: 1. Previous medication information was not recorded;<br>2. The patients' medical records  were incomplete after admission.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcome;Index test:artificial&#32;intelligence&#32;prediction&#32;model;","cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030835","2020-03-16","Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                               ","","the First Affiliated Hospital of Xinxiang Medical University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51050","Recruiting","No","16.0","75.0","Both","2020-02-14","High dose group:10;Low dose group:10;","Interventional study","Single arm","New Treatment Measure Clinical Study","China","Dou Qifeng","","88 Jiankang Road, Weihui, Xinxiang, He'nan, China","douqifeng@126.com","+86 13503735556","the First Affiliated Hospital of Xinxiang Medical University","Inclusion criteria: 1. Male or female patients aged 16-75 years;<br>2. Willing to sign informed consent;<br>3. novel coronavirus novel coronavirus is highly novel correlate with the novel coronavirus, based on the standard of suspected cases of new coro","Exclusion criteria: 1. Pregnant or lactating women;<br>2. Patients with malignant tumor, other serious systemic diseases and psychosis;<br>3. Patients who have recently or are participating in other clinical trials;<br>4. There was evidence of drug add","Novel Coronavirus Pneumonia (COVID-19)","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","","","","","No","0","          ",""
"ChiCTR2000030834","2020-03-16","Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area","Epidemiological Characteristics and Antibody Levels of COVID-19 Infection of Pediatric Medical Staff working in Quarantine Area                                                                                                                                ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51047","Not Recruiting","No","","","Both","2020-03-16","Case series:500;","Observational study","Sequential","N/A","China","Yan Hao, Xiaoping Luo","","1095 Jiefang Avenue, Qiaokou DIstrict, Wuhan, Hubei, China","haoyaner@163.com","+86 13971679960","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: This study intends to recruit all doctors, nurses, and care workers who have been in clinical work for more than half a month from January to March 2020 in pediatric fever clinic, pediatric buffer clinic, pediatric emergency department","Exclusion criteria: 1. Exclude medical staff who are not in clinical work due to sick leave;<br>2. Exclude medical staff who worked in the clinical setting for less than half a month recently.<br>3. Exclude if the medical staff and family members do not","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;","","","","Yes","0","          ",""
"ChiCTR2000030782","2020-03-16","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia                                                                                                                                                                             ","","Cangzhou People's Hospital","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50976","Recruiting","No","2.0","89.0","Both","2020-02-01","Case series:20;","Observational study","Case-Control study","N/A","","Lihui Wang","","13 North Qingchi Avenue, Xinhua District, Cangzhou, Hebei, China","849614995@qq.com","+86 13832102657","Cangzhou People's Hospital","Inclusion criteria: New Coronavirus Patients Meeting the Criteria for the Diagnosis and Treatment of New Coronavirus Infected Pneumonia (Trial Version 5)","Exclusion criteria: Pregnant woman","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","28-day prognosis;","","","","No","0","          ",""
"ChiCTR2000030773","2020-03-16","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","","Huashan Hospital Fudan Universtiy","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50934","Recruiting","No","18.0","80.0","Both","2020-02-12","Case series:20;","Interventional study","Cohort study","N/A","China","Jing Chen","","12 Wulumuqi Road Middle, Jin'an District, Shanghai, China","money_0921@163.com","+86 13816108686","Huashan Hospital Fudan University","Inclusion criteria: 1. Aged 18 to 80 years;<br>2. Diagnosed as COVID-19 pneumonia (according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee);<br>3. ad","Exclusion criteria: 1. Renal replacement therapy has been performed;<br>2. Relative / absolute contraindications of blood purification;<br>3. Pregnant women, participating in other clinical trials, etc.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Early initiation of blood purification;","death;Number of failure organs;Length of hospital stay;","","","","No","0","          ",""
"ChiCTR2000030797","2020-03-16","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia patients                                                                                                                                                                 ","","Shanghai Fifth People's Hospital, Fudan University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50988","Recruiting","No","18.0","80.0","Both","2020-03-07","Case series:100;","Observational study","Sequential","N/A","China","Yingjia Xu","","801 Heqing Road, Shanghai, China","xuyingjia@5thhospital.com","+86 18017321696","Shanghai Fifth People's Hospital, Fudan University","Inclusion criteria: 1. Aged 18 to 80 yrs;<br>2. Diagnosed as COVID-19 pneumonia(according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee) ","Exclusion criteria: 1. Patients with mental abnormality or unwilling to participate in this study;<br>2. Patients participating in other clinical trials.","Corona Virus Disease 2019(COVID-19)","Case series:Noninvasive hemodynamic monitoring;","all-cause death;fatal arrhythmias;","","","","No","0","          ",""
"ChiCTR2000030779","2020-03-16","A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                               ","","Shanghai Changzheng Hospital","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50973","Recruiting","No","","","Both","2020-03-16","Experimental group:50;Control group:50;","Interventional study","Parallel","4.0","China","Zhaofen Lin,Wansheng Chen,Weifen Xie","","415 Fengyang Road, Huangpu District, Shanghai, China","linzhaofen@sina.com","+86 13601605100, 13301833859, 13701682806","Shanghai Changzheng Hospital","Inclusion criteria: 1. Aged between 18 and 75 years;<br>2. In accordance with NCP criteria for severe and critical illness. Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive ","Exclusion criteria: 1. With contraindications of Ulinastatin Injection;<br>2. Pregnant or lactating women;<br>3. Patients taking other urinary trypsin inhibitors;<br>4. Not suitable to participate in the clinical trial by investigator's judgement.","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","blood gas;SOFA score;","","","","Yes","0","          ",""
"ChiCTR2000030819","2020-03-16","Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan","Retrospective analysis of digestive system symptoms in 600 cases of 2019-ncov pneumonia in Guanggu district, Wuhan                                                                                                                                             ","","Wuhan Third Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51039","Not Recruiting","No","1.0","100.0","Male","2020-03-01","Case series:600;","Observational study","Sequential","N/A","China","Xia Tian","","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","hcwy100@163.com","+86 13871480868","Wuhan Third Hospital","Inclusion criteria: Novel coronavirus pneumonia patients","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Liver function;","","","","No","0","          ",""
"ChiCTR2000030818","2020-03-16","A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)","The value of Lymphocyte subsets in Coronavirus Disease 2019                                                                                                                                                                                                    ","","Department of Critical Care Medicine, The First Affiliated Hospital, Henan Traditional Chinese Medicine University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51037","Not Recruiting","No","0.0","86.0","Both","2020-01-31","	 Case series:10;","Observational study","Sequential","N/A","China","Zhengrong Mao","","19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China","maozhengrong1971@163.com","+86 18695808321","The First Affiliated Hospital, He'nan Traditional Chinese Medicine University","Inclusion criteria: Acorrding to  Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Jan 11, 2020.","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","	 Case series:none;","ymphocyte subsets;","","","","No","0","          ",""
"ChiCTR2000030764","2020-03-16","Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Research for the influence of epidemic of  novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations                                                                                                     ","","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50852","Recruiting","No","18.0","","Both","2020-03-07","4 groups:2800;","Observational study","Factorial","Retrospective study","China","Xia Hong","","1 Xiyuan Playground, Haidian District, Beijing, China","970236538@qq.com","+86 13699207252","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Inclusion criteria: (1) Aged >18 years old; <br>(2) can complete the wechat questionnaire independently.","Exclusion criteria: People with severe mental disorders","Novel Coronavirus Pneumonia (COVID-19); psychosomatic medicine","4 groups:N/A;","PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian Version,PCL-C;","","","","No","0","          ",""
"ChiCTR2000030762","2020-03-16","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''                                                                                                            ","","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50950","Not Recruiting","No","1.0","99.0","Both","2019-12-01","Case series:100;","Epidemilogical research","Single arm","Retrospective study","China","GuoLin Song","","32 Feishan Street, Guiyang, Guizhou, China","ant000999@126.com","+86 13985004689","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Inclusion criteria: Common and severe new coronavirus pneumonia","Exclusion criteria: Mild and critical new coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical characteristics according to TCM;","","","","No","0","          ",""
"ChiCTR2000030763","2020-03-16","A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Analysis of Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)                                                                                                                            ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50921","Recruiting","No","14.0","90.0","Both","2020-02-01","case series:100;","Observational study","Sequential","Retrospective study","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest Hospital","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;<br>2. ARDS patients according to the Berlin definition.","Exclusion criteria: 1. Age<14 years;<br>2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Novel Coronavirus Pneumonia (COVID-19)","case series:no;","Pulmonary function;Cardiac function;neural function;","","","","No","0","          ",""
"ChiCTR2000030761","2020-03-16","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study                                                                 ","","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50956","Not Recruiting","No","16.0","","Both","2020-05-31","Case series:20;","Interventional study","Single arm","N/A","China","Qin Wang","","1630 Dongfang Road, Pudong District, Shanghai, China","qinwang_1975@126.com","+86 13621964604","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","Inclusion criteria: 1. Patients who agree to join the study and signed the informed consent;<br>2. Aged >16 years old;<br>3. Patients with CRP more than twice the upper limit of laboratory test;<br>4. The severe or critial patients with COVID-19 accord","Exclusion criteria: 1. Patients who are unable to establish proper vascular access;<br>2. Patients with hemodynamic instability;<br>3. With severe coagulation dysfunction;<br>4. With active bleeding, especially intracranial hemorrhage;<br>5. Pregnant ","Novel Coronavirus Pneumonia (COVID-19)","Case series:CRRT;","CRP;IL-6;TNF-alpha;IL-8;","","","","Yes","0","          ",""
"ChiCTR2000030803","2020-03-16","Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)","Clinical characteristics of severe or critically ill patients infected with 2019-nCoV                                                                                                                                                                          ","","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51007","Recruiting","No","18.0","","Both","2020-01-31","severe patients:400;","Observational study","Sequential","Retrospective study","","Xin Li","","1277 Jiefang Avenue, Wuhan, Hubei, China","314440820@qq.com","+86 13797062903","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: The patients who had been confirmed with SARS-CoV-2 infection by a nucleic acid-positive test and identified as severe or critical according to the diagnosis and treatment protocol for novel coronavirus pneumonia , were enrolled in thi","Exclusion criteria: Patients who are younger than 18 years , who have severe liver or kidney dysfunction,or patients with other condition evaluated by doctors were excluded from this study.","Novel Coronavirus Pneumonia (COVID-19)","severe patients:none;","age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate transaminase;creatinine;glucose;lipids;procalcitonin;C-reactive protein;coagulation function;nutritional risk screening;body wei","","","","No","0","          ",""
"ChiCTR2000030802","2020-03-16","A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)","A retrospective study of clinical drug therapy in patients with COVID-19                                                                                                                                                                                       ","","Tongji Hospital, Tongji medical college of HUST","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51004","Not Recruiting","No","","","Both","2020-01-27","Case series:2000;","Observational study","Case study","Retrospective study","China","LIU DONG","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","ld_2069@163.com","+86 13507183749","Tongji Hospital, Tongji Medical College of HUST","Inclusion criteria: 1. Those who meet the diagnosis of COVID-19;<br>2. In-patients admitted in designated hospitals.","Exclusion criteria: 1. Incomplete medical records, especially medication information,which may affect the evaluation<br>2. Those which the researchers deemed inappropriate","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","time  and rate of cure; proportion and time of patients who progressed to severe disease;","","","","No","0","          ",""
"ChiCTR2000030760","2020-03-16","A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","Clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China                                                                                                                                                            ","","Zhejiang Hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50955","Not Recruiting","No","18.0","74.0","Both","2020-03-13","two groups:74;","Observational study","Case-Control study","Retrospective study","China","Hong Wang","","1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, China","hongwang71@yahoo.com","+86 0571 87377780","Zhejiang Hospital","Inclusion criteria: According to the sixth edition of the Chinese New Coronary Virus Pneumonia Diagnosis and Treatment Guidelines, patients with suspected novel coronavirus pneumonia were included in the study.","Exclusion criteria: Not eligible for novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","two groups:no intervention;","the clinical, laboratory and the radiologic characteristics;","","","","Yes","0","          ",""
"ChiCTR2000030755","2020-03-16","A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area","Characteristics, prognosis of  ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area: a dual-center, retrospective, cohort study                                                                                                           ","","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50945","Not Recruiting","No","65.0","90.0","Both","2020-03-15","Case series:400;","Observational study","Sequential","Retrospective study","China","Cuntai Zhang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","ctzhang0425@163.com","+86 15927668408","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. confirmed with COVID-19;<br>2 olderer than 65 years;<br>3. meet the critically ill criteria according to Chinese management guideline for COVID-19 (version 7).","Exclusion criteria: 1. declared clinical death or discharged after admission within 24 hour;<br>2. important data missing.","Novel coronavirus pneumonia (COVID-19)","Case series:no;","Critical illness ratio;","","","","Yes","0","          ",""
"ChiCTR2000030754","2020-03-16","Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)","Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19                                                                                                                                                                               ","","The Third Affiliated Hospital of Sun Yat-sen University","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50824","Not Recruiting","No","18.0","70.0","Both","2020-03-11","Target condition:30;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","China","Zhanlian Huang","","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","zhanlianh@163.com","+86 13580584031","The Third Affiliated Hospital of Sun Yat-sen University","Inclusion criteria: patients with positive SARS-CoV-2 IgM antibody ","Exclusion criteria: recently diagnosed as a confirmed COVID-19 case ","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;","false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030752","2020-03-16","A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","Analysis of risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                     ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50925","Recruiting","No","14.0","90.0","Both","2020-02-01","case series:500;","Observational study","Sequential","Retrospective study","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest hospital","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test","Exclusion criteria: no","Novel Coronavirus Pneumonia (COVID-19)","case series:Nil;","Outcome;","","","","No","0","          ",""
"ChiCTR2000030801","2020-03-16","Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study","Analysis of risk factors affecting prognosis of elderly patients infected with COVID-19 pneumonia: a single-center retrospective observational study                                                                                                           ","","The Third Hospital of Wuhan","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50998","Recruiting","No","65.0","100.0","Both","2020-01-23","discharge group:100;","Observational study","Case study","1.0","China","Peng Jian","","241 Peng-Liu-Yang Road, Wuchang, Wuhan, Hubei, China","541163409@qq.com","+86 18627151212","The Third Hospital of Wuhan","Inclusion criteria: Aged >=65 years patient with novel coronavirus pneumonia COVID-19","Exclusion criteria: 1. Transfers to Huoshen shan or Leishen shan hospital;<br>2. Patient with only one laboratory test.","Novel Coronavirus Pneumonia (COVID-19)","discharge group:no;","discharg time;","","","","No","0","          ",""
"ChiCTR2000030800","2020-03-16","Cancelled by the investigator                Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value","Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value                                                                                                             ","","The Third Affiliated Hospital of Zunyi Medical University","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50997","Not Recruiting","No","0.0","86.0","Both","2020-02-01","Target condition:22;Difficult condition:57","Diagnostic test","Sequential","0.0","China","Wu Kaifeng","","98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China","kiphoonwu@126.com","+86 13788989286","The Third Affiliated Hospital of Zunyi Medical University","Inclusion criteria: Refer to the national health commission document ""diagnosis and treatment plan of new coronavirus pneumonia (trial seven edition)"".","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa&#32;analysis&#32;of&#32;validation&#32;factors,&#32;inflammatory&#32;factors,&#32;adhesion&#32;factors;","","","","","No","0","          ",""
"ChiCTR2000030753","2020-03-16","A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                     ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50901","","No","14.0","90.0","Both","2020-02-01","case series:100;","Observational study","Sequential","Retrospective study","China","Fenglin Liu","","12 Lieshishan Road East, Licheng District, Jinan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest hospital","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;<br>2. ARDS patients according to the Berlin definition;<br>3. Patients in ICU met the VAP criteria and were not associated with other site infection.","Exclusion criteria: 1. With other parts of the infection occurred within 7 days after discontinuation of antibiotic therapy, including urinary tract infections, bloodstream infections, biliary tract infections, central nervous system infections, and so on","Novel Coronavirus Pneumonia (COVID-19)","case series:no;","ICU hospitalization days;The recurrence rate of infection;","","","","No","0","          ",""
"ChiCTR2000030744","2020-03-16","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)                                                                                             ","","Shandong Provincial Chest Hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50910","Recruiting","No","14.0","90.0","Both","2020-02-01","ECMO group:10;the conventional treatment group:20;","Interventional study","Non randomized control","Retrospective study","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest Hospital","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;<br>2. Severe ARDS patients according to the Berlin definition.","Exclusion criteria: 1. Aged<14 years;<br>2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Novel Coronavirus Pneumonia (COVID-19)","ECMO group:ECMO therapy;the conventional treatment group:no;","Inpatient mortality;ICU hospital stay;","","","","No","0","          ",""
"ChiCTR2000030747","2020-03-16","A prospective cohort  study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)","A prospective cohort  study on recovering patients with novel coronavirus pneumonia (COVID-19) by comprehensive treatment of Chinese medicine                                                                                                                  ","","Hubei Provincial Hospital of TCM","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50000","Recruiting","No","","","Both","2020-02-22","Control group :750;Comprehensive treatment group:750;","Observational study","Non randomized control","0.0","China","Li Xiaodong","","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","lixiaodong555@126.com","+86 13908658127","Hubei Provincial Hospital of TCM","Inclusion criteria: (1) Corresponding to diagnosis standards of convalescence of COVID-19 mentioned above;<br>(2) Imaging manifestations Fibrous cable-like shadow (patchy) ground glass changes in the lungs,honeycomb sign,reticular changes, increased bron","Exclusion criteria: 1. With other serious primary pulmonary diseases (such as active pulmonary tuberculosis, pneumothorax, pleural effusion, pulmonary embolism and neuromuscular diseases affecting respiratory and motor function);<br>2. Severe primary dis","Novel coronavirus pneumonia (COVID-19)","Control group :Health education and   symptomatic treatment;Comprehensive treatment group:Health education+Comprehensive TCM treatment;","CT Scan-Chest;","","","","No","0","          ",""
"ChiCTR2000030722","2020-03-16","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                         ","","Shanghai First People's Hospital","2020-03-12","2020-03-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50338","Not Recruiting","No","18.0","","Both","2020-03-09","Case series:30;","Observational study","Sequential","N/A","China","Zhi Zhang","","100 Haining Road, Hongkou District, Shanghai, China","16683890@qq.com","+86 13621759762","Shanghai First People's Hospital","Inclusion criteria: 1. over 18 years old;<br>2. Patients diagnosed with Covid-19 pneumonia (those who meet the clinical diagnosis above the common type or have a positive nucleic acid test);<br>3. Have 64-row high-resolution CT examination of the chest ","Exclusion criteria: 1. Investigator believes that subjects should not be included (patients are severely uncooperative);<br>2. Not suitable for inclusion in subjects (clinically considered fully healthy patients or light);<br>3. Patients who cannot ausc","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","ascultation;","","","","No","0","          ",""
"ChiCTR2000030784","2020-03-16","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi                                                                                                                                                   ","","The People's Hospital of Guangxi Zhuang Autonomous Region","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50307","Recruiting","No","","","Both","2020-01-17","Case series:150;","Observational study","Sequential","N/A","China","Guo Zhang","","6 Taoyuan Road, Nanning, Guangxi Zhuang Autonomous Region, China","zhangguogx@hotmail.com","+86 13978839646","The People's Hospital of Guangxi Zhuang Autonomous Region","Inclusion criteria: Inclusion criteria Patients confirmed to be infected with 2019-nCoV. ","Exclusion criteria: 1. Patients who refused to participate in the project;<br>2. Patients developed symptoms caused by other pathogens rather than the 2019-nCoV, and there was no evidence show that patients were infected with 2019-nCoV. ","Novel Coronavirus Pneumonia (COVID-19)","Case series:No;","Epidemiological characteristics;clinical features;Treatment outcome;","","","","No","0","          ",""
"ChiCTR2000030768","2020-03-16","Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)","Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)                                                                                                                                   ","","Zhongnan Hospital of Wuhan University","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50968","Recruiting","No","","","Both","2020-02-01","Case series:450;","Epidemilogical research","Sequential","N/A","China","Xiong Chen","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","zn_chenxiong@126.com","+86 13995599373","Zhongnan Hospital of Wuhan University","Inclusion criteria: otolaryngology healthcare workers in Hubei Province","Exclusion criteria: People with anxiety or depression prior to the COVID-19 outbreak.","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","Case series:no;","anxiety;","","","","No","0","          ",""
"ChiCTR2000030739","2020-03-16","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS                                                                                         ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50896","Recruiting","No","14.0","90.0","Both","2020-02-01","case series:100;","Observational study","Case study","Retrospective study","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest hospital","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatme","Exclusion criteria: no","Novel Coronavirus Pneumonia (COVID-19)","case series:no;","Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;","","","","No","0","          ",""
"ChiCTR2000030721","2020-03-16","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)                                                                            ","","Affiliated Hospital of Guangdong Medical University","2020-03-12","2020-03-12","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50759","Not Recruiting","No","","","Both","2020-03-16","Target condition:50;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Huanqin Han","","57 South Renmin Road, Zhanjiang, Guangdong, China","huanqinhan@126.com","+86 13828291023","Affiliated Hospital of Guangdong Medical University","Inclusion criteria: 1. Aged 15-79 years;<br>2. Patients with COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;","Exclusion criteria: 1. The patient has a history of alcohol or narcotic drug abuse, or a history of mental illness (such as schizophrenia, obsessive-compulsive disorder, depression), antagonistic personality, bad motivation, doubt, or other emotional or i","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.&#32;throat&#32;swab<br>2.&#32;induced&#32;sputum;","detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;","","","","Yes","0","          ",""
"ChiCTR2000030312","2020-03-09","Cancelled, due to modify the protocol                                          A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                                     ","","First people's hospital of Jiangxi district,Wuhan","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50258","Not Recruiting","No","18.0","70.0","Both","2020-02-29","Case series:24;","Interventional study","Single arm","N/A","China","Bende Liu","","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","liubende99@outlook.com","+86 13907191851","First People's Hospital of Jiangxi District","Inclusion criteria: 1. Aged 18 to 70 years old;<br>2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);<br>3. Confirmed cas","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:<br>1) Respiratory failure occurs and requires mechanical ventilation;<br>2) Shock occurs;<br>3) Combined failure of ","Novel Coronavirus Pneumonia (COVID-19)","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","","","","Yes","0","          ",""
"ChiCTR2000030304","2020-03-09","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)                                                                                                                                                       ","","The Third Affiliated Hospital of Sun Yat-sen University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49653","Not Recruiting","No","20.0","55.0","Both","2020-03-10","Case series:300;","Observational study","Sequential","0.0","China","Pang Yong-li","","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","pangi88@126.com","+86 15626235237","The Third Affiliated Hospital of Sun Yat-sen University","Inclusion criteria: (1) registered nurse;<br>(2) to combat the new coronavirus pneumonia of the first line of nurses (infection department, fever clinic, emergency);<br>(3) volunteer to participate in this study.","Exclusion criteria: suspected or diagnosed isolation of nurses","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Mental status;Social support;","","","","Yes","0","          ",""
"ChiCTR2000030751","2020-03-16","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                ","","Affiliated Hospital of Inner Mongolia University for the Nationalities","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50941","Not Recruiting","No","18.0","70.0","Both","2020-01-25","Case series:60;","Interventional study","Sequential","N/A","China","Burenbatu","","1742 Huolinhe Street, Keerqin District, Tongliao, Inner Mongolia Autonomous Region, China","nmbrbt8989@163.com","+86 18804758989","Affilated Hospital of Inner Mongolia University for the Nationalities","Inclusion criteria: (1) novel coronavirus pneumonia novel coronavirus pneumonia is diagnosed according to the new pneumonia diagnosis and treatment plan (trial version fifth);<br>(2) According to the diagnostic standard of ""lung invasion"" in Mongolian me","Exclusion criteria: (1) Other viral pneumonia (influenza virus parainfluenza virus adenovirus respiratory syncytial virus rhinovirus human metapneumovirus SARS Coronavirus) was excluded;<br>(2) Serious mental illness or history of depression;<br>(3) Sus","Novel Coronavirus Pneumonia (COVID-19)","Case series:Traditional Mongolian Medicine;","nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;","","","","No","0","          ",""
"ChiCTR2000030750","2020-03-16","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia                                                                                                  ","","Shenzhen Third People's Hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50928","Not Recruiting","No","25.0","65.0","Both","2020-03-01","common type :30;Latent period group:30;Normal control group:30;Blank vaccine control group:30;","Interventional study","Parallel","43862.0","China","Zhenlin Zhao","","Floor 10, Building 10, Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi street, Pingshan District, Shenzhen, Guangdong, China","zhaozl2006@163.com","+86 13828895409","Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine","Inclusion criteria: 1. Confirmed cases: positive nucleic acid test;<br>2. Aged 25-65 years old;<br>3. Asexual difference;<br>4. Clinical stage (light, common type);<br>5. Immunology standard: peripheral blood lymphocyte was higher than the lower limit","Exclusion criteria: 1. There were symptoms but negative nucleic acid test;<br>2. Patients with malignant tumor;<br>3. Pregnant women;<br>4. HIV positive;<br>5. Critical stage (ARDS with multiple organ failure);<br>6. The peripheral blood lymphocyte w","Novel Coronavirus Pneumonia (COVID-19)","common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;","","","","No","0","          ",""
"ChiCTR2000030719","2020-03-16","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan                                                                                    ","","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50867","Recruiting","No","","","Both","2020-03-01","Integrated traditional Chinese and western medicine group:771;Western medicine group:300;","Observational study","Cohort study","Retrospective study","China","Wei Li","","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China ","784404524@qq.com","+86 18995598097","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Inclusion criteria: (1) Comply with the diagnostic criteria for patients with new pneumonia virus in the The Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(Sixth Edition); <br>(2) Complete clinical data of patients.","Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections; <br>(2) Patients whose data could not be obtained for special reasons.","Novel Coronavirus Pneumonia (COVID-19)","Integrated traditional Chinese and western medicine group:Traditional Chinese medicine and routine treatment of western medicine;Western medicine group:Routine treatment of western medicine;","Mortality rate;Common-severe conversion rate;Length of hospital stay.;","","","","No","0","          ",""
"ChiCTR2000030703","2020-03-16","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)                                             ","","Xiangya Hospital of Central South University","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50251","Recruiting","No","18.0","75.0","Both","2020-03-10","experimental group:20;control group:20;","Interventional study","Parallel","0.0","China","Pinhua Pan, Yehong Kuang","","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","pinhuapan668@126.com","+86 13574171102","Xiangya Hospital of Central South University","Inclusion criteria: 1. Aged 18 to 75 years old;<br>2. The diagnosis of new-type coronavirus pneumonia was confirmed by RT-PCR or gene sequencing according to the ""Diagnosis and Treatment Scheme for Pneumonia of New Coronavirus Infection (Trial Version 6 ","Exclusion criteria: 1. Critical new pneumonia infection that meets one of the following conditions: respiratory failure occurs and requires mechanical ventilation; shock; combined organ failure requires ICU monitoring and treatment<br>2. Known allergies ","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Lung CT;","","","","Yes","0","          ",""
"ChiCTR2000030720","2020-03-16","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management                                                                                                 ","","Hubei Provincial Hospital of TCM","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50793","Recruiting","No","18.0","65.0","Both","2020-03-01","Group 2:60;Group 1:60;","Interventional study","Parallel","0.0","China","Xiaodong Li","","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","lixiaodong555@126.com","+86 13908658127","Hubei Provincial Hospital of TCM","Inclusion criteria: 1. Conforming to the Chinese and Western Medicine Diagnostic Standards of patients with novel coronavirus pneumonia (COVID-19) in recovery period;<br>2. Aged between 18 and 65 years old;<br>3. Signing the generalized informed consent","Exclusion criteria: 1. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affect participation in the trial or may affect the outcome of the study by the judgment of the r","Novel Coronavirus Pneumonia (COVID-19)","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","Medical imaging improvement rate in patients during recovery period;","","","","No","0","          ",""
"ChiCTR2000030702","2020-03-16","Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial                                                                                                                                                            ","","China-Japan friendship hospital","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50537","Recruiting","No","18.0","-","Both","2020-02-15","eperimental group:25;control group:25;","Interventional study","Parallel","0.0","China","Cao Bin","","2 Yinghua Street East, Chaoyang District, Beijing, China","caobin_ben@163.com","+86 13911318339","China-Japan Friendship Hospital","Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;<br>2. patient aged >=18 years old;<br>3. COVID-19 patients diagnosed by PCR;<br>4. Nucleic acid positive within 72 hours befo","Exclusion criteria: 1. The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an u","Novel Coronavirus Pneumonia (COVID-19)","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","Time to clinical recovery after randomization;","","","","No","0","          ",""
"ChiCTR2000029550","2020-03-09","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)                                                             ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48775","Recruiting","No","","","Both","2020-01-29","Experimental group 1 (mild):150;Experimental group 1 (moderate):150;","Interventional study","Factorial","N/A","China","Xie Chunguang","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","xcg718@aliyun.com","+86 18980880132","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: 1. Conform to the western medicine influenza diagnostic criteria<br>2. Conform to the diagnostic criteria of TCM wind-heat clip dampness syndrome<br>3. Over 18 years old","Exclusion criteria: No","influenza","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;","","","","No","0","          ",""
"ChiCTR2000029549","2020-03-09","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                              ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49014","Recruiting","No","","","Both","2020-02-03","Experimental group:200;Control group:200;","Interventional study","Parallel","N/A","China","Xie Chunguang","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","xcg718@aliyun.com","+86 18980880132","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: Patients with suspected and confirmed diagnosis of 2019-nCoV Pneumonia Version 4.0 (published at 2020.01.27) of the National Health Commission","Exclusion criteria: Exclude patients with severe and critical 2019-nCoV pneumonia","novel coronavirus pneumonia (COVID-19)","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;","","","","No","0","          ",""
"ChiCTR2000030718","2020-03-16","Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection                                                                                                                                                                                ","","Zhongnan Hospital of Wuhan University","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50843","Recruiting","No","18.0","","Both","2020-02-12","Experimental group:40;Control group:40;","Interventional study","Parallel","4.0","China","Zhao Yan","","169 Donghu Road, Wuhan, Hubei, China","doctoryanzhao@whu.edu.cn","+86 13995577963","Zhongnan Hospital of Wuhan University","Inclusion criteria: 1. Male and female, older than 18 years; <br>2. Patients with confirmed COVID19;<br>3. Need to continue the antivirus therapy;<br>4. Agree to sign the informed consent;<br>5. Able to ingest, absorb and tolerate oral medication;<br","Exclusion criteria: 1. Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;<br>2. Pregnant and lactating women;<br>3. The subjects participated other clinical trials within 30 ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:chloroquine phosphate ;Control group:none;","Time to Clinical Recovery;","","","","No","0","          ",""
"ChiCTR2000030717","2020-03-16","A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients","Risk assessment and treatment timing of invasive fungal infection in critically ill covid-19 patients: medical records based study                                                                                                                             ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50860","Not Recruiting","No","14.0","90.0","Both","2020-04-01","Exposed group:130;Control group:130;","Observational study","Factorial","Retrospective study","China","Minghao Fang","","1095 Jiefang Road, Wuhan, Hubei, China","fangmh@tjh.tjmu.edu.cn","+86 15071157405","Department of Emergency, Tongji Hospital","Inclusion criteria: 1. confirmed critically ill covid-19;<br>2. grouping criteria: meet the clinical risk factor combination criteria for invasive candidiasis in critically ill patients proposed by ostrosky-zeichner et al in 2009:<br>(1) the length of s","Exclusion criteria: 1. If the patient received any antifungal treatment (excluding fluconazole or up to 7 days of selective digestion purification therapy) within 14 days prior to randomization, or if there was evidence of IFI; <br>2. aged < 14 years;<b","Novel Coronavirus Pneumonia (COVID-19)","Exposed group:Prophylactic antifungal therapy;Control group:Diagnostic antifungal therapy;","14-days mortality;28-days mortality;","","","","Yes","0","          ",""
"ChiCTR2000030697","2020-03-16","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals                                                 ","","Ningbo First Hospital, Ningbo Hospital of Zhejiang University","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50781","Not Recruiting","No","18.0","96.0","Both","2020-03-10","Case series:1500;","Observational study","Non randomized control","Retrospective study","China","Zhongze Lou","","59 Liuting Street, Haishu, Ningbo, Zhejiang, China ","lorenzo_87@163.com","+86 0574-87085111","Ningbo First Hospital, Ningbo Hospital of Zhejiang University ","Inclusion criteria: 1. Medical staff of designated hospitals for new crown pneumonia in Ningbo area;<br>2. Patients with new-coronary pneumonia infection, suspected cases, patients in fever observation ward, forced isolation and home isolation in Ningbo ","Exclusion criteria: 1. Those who have not completed effective psychological consultation and assessment;<br>2. Researchers who are unwilling to participate in this survey;<br>3. The investigator is unwilling to continue during the evaluation process.","Novel Coronavirus Pneumonia (COVID-19)N; psychosomatic medicine","Case series:NA;","SDS;SAS;PSQI;","","","","Yes","0","          ",""
"ChiCTR2000030686","2020-03-16","The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","The effects of  prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak                                                                                            ","","Peking University Third Hospital","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50714","Recruiting","No","18.0","","Both","2020-03-03","tumor patients group:300;","Observational study","Sequential","N/A","China","Baoshan Cao","","49 North Garden Road, Haidian District, Beijing, China","caobaoshan0711@aliyun.com","+86 15611963362","Peking University Third Hospital","Inclusion criteria: 1. patients diagnosed as malignant tumor by pathology or cytology inpatient or outpatient in general hospital during the outbreak of 2019-nCOV;<br>2. aged 18 or above;<br>3. informed consent and ability to cooperate with research. ","Exclusion criteria: anyone who is  reluctant or unable to answer the questionnaire ","malignant  tumor","tumor patients group:no;","impact on the treatment of tumor patients;","","","","No","0","          ",""
"ChiCTR2000030687","2020-03-16","Novel coronavirus pneumonia (COVID-19) associated kidney injury in children","COVID-19 infection associated kidney injury in children                                                                                                                                                                                                        ","","Department of Nephrology, Wuhan children's Hospital","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50572","Not Recruiting","No","0.0","18.0","Both","2020-02-01","Infection without renal injury group:30;Infection with proteinuria group:30;Infection with hematuria group:30;Infection with impaired renal function group:30;","Basic Science","Factorial","0.0","China","Wang Xiaowen","","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","b5477@163.com","+86 15907190882","Department of Nephrology, Wuhan Children's Hospital","Inclusion criteria: 1. COVID-19 infection;<br>2. Children with kidney injury: Hematuria, Proteinuria, renal dysfunction.","Exclusion criteria: 1. Exclusion of COVID-19 infection in children;<br>2. Dead children;<br>3. Sign to reject this project.","Novel Coronavirus Pneumonia (COVID-19); Kidney disease in children","Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;","temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine ","","","","No","0","          ",""
"ChiCTR2000030545","2020-03-16","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                          ","","Hubei Hospital of Traditional Chinese Medicine","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50126","Recruiting","No","18.0","75.0","Both","2020-02-04","Control group:100;Experimental group 1:100;Experimental group 2:100;","Interventional study","Parallel","4.0","China?","Yang Yi","","4 Garden Hill, Wuchang District, Wuhan, Hubei, China ","153267742@qq.com","+86 18971163518","Hubei Hospital of Traditional Chinese Medicine","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;<br>2. Aged 18 to 65 years;<br>3. The time interval between symptom onset and randomization was within 7 days (the onset of symp","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal r","Novel Coronavirus Pneumonia (COVID-19)","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients ","Recovery time;Pneumonia psi score;","","","","No","0","          ",""
"ChiCTR2000030716","2020-03-16","Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients","Shedding of SARS-CoV-2 in human semen and reproductive health evaluation of ever infected males                                                                                                                                                                ","","Tongji Medical College, HUST","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50850","Recruiting","No","22.0","55.0","Male","2020-03-05","in hospital:50;Recovered:100;","Observational study","Sequential","N/A","China","HONGGANG LI","","13 Hangkong Road, Qiaokou District, Wuhan, Hubei, China","lhgyx@hotmail.com","+86 13871402927","Huazhong University of Science and Technology","Inclusion criteria: Men with diagnosed COVID-19, aged 22-55 years old. 50 inpatients and 100 males after recovery. ","Exclusion criteria: Severe patients","Novel Coronavirus Pneumonia (COVID-19)","in hospital:Virus detection in semen;Recovered:Hormones and sperm quality;","SARS-CoV-2 virus;sex hormones;sperm quality;","","","","No","0","          ",""
"ChiCTR2000030701","2020-03-16","A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                   ","","The Third People's Hospital of Shenzhen","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50795","Not Recruiting","No","18.0","","Both","2020-03-10","experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Cai Qingxian","","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","41180423@qq.com","+86 13760857996","The Third People's Hospital of Shenzhen","Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;<br>2. Adult aged >=18years old, male or female;<br>3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnost","Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;<br>2. Low body weight pati","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Time to Virus Eradication;","","","","Yes","0","          ",""
"ChiCTR2000029479","2020-03-09","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population                                                                                                              ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48773","Recruiting","No","","","Both","2020-01-30","Experimental group:10000;blank cntrol group:10000;","Interventional study","Cluster randomization","N/A","China","Tang Jianyuan","","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","tangjianyuan163@163.com","+86 13910768464","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: 1. No physical discomfort;<br>2. Aged 16 years old and above;<br>3. Take the medicine recommended by this research voluntarily.","Exclusion criteria: If one of the following situations occurs, it is not recommended to take the traditional Chinese medicine preparation recommended by this plan:<br>(1) Has fever, cough, fatigue, stuffy nose, runny nose, dry throat, thirst, poor stool ","novel coronavirus pneumonia (COVID-19)","Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","Inccidence of 2019-nCoV pneumonia;","","","","No","0","          ",""
"NCT04252274","2020-03-16","Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV","Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV","DACO-nCoV","Shanghai Public Health Clinical Center","2020-01-29","2020-01-29","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04252274","Recruiting","No","N/A","N/A","All","2020-01-30","30.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","China"," ","Hongzhou Lu, Ph.D","","luhongzhou@fudan.edu.cn","-37990268.0","","<br>        Inclusion Criteria:<br><br>          -  The participants were diagnosed as pneumonia caused by 2019-nCoV, according to the<br>             notice on printing and distributing the diagnosis and treatment plan of pneumonia with<br>         ","","Pneumonia, Pneumocystis;Coronavirus","Drug: Darunavir and Cobicistat","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7","","","","Yes","0","          ",""
"ChiCTR2000030466","2020-03-16","Cancelled due to lack of patients                                       Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                      ","","Yongchuan Hospital,Chongqing Medical University","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50387","","No","18.0","55.0","Both","2020-02-26","Case series:50;","Observational study","Sequential","N/A","China","Song Ying","","439 Xuanhua Road, Yongchuan District, Chongqing, China","164738059@qq.com","+86 13668077090","Yongchuan Hospital, Chongqing Medical University","Inclusion criteria: All patients meet the diagnostic criteria for neo-coronary pneumonia (New Coronavirus Infected Pneumonia Diagnosis and Treatment Program, Fifth Edition)","Exclusion criteria: People with a history of mental illness or a genetic history of familial psychosis, people with previous mental disorders, sequelae of traumatic brain injury, patients with drug and alcohol abuse, or people with other mental illnesses.","Mental health; Novel Coronavirus Pneumonia (COVID-19)","Case series:Psychological counseling;","Comprehensive psychological assessment;Mental toughness;Solution;","","","","No","0","          ",""
"ChiCTR2000030388","2020-03-16","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)                                                                                                                                        ","","Jingzhou First People's Hospital","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50306","Recruiting","No","18.0","80.0","Both","2020-02-18","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","China","xiao wei","","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","99xw@sina.com","+86 071 68494565","Jingzhou First People's Hospital","Inclusion criteria: 1. The patient signs the written informed consent;<br>2. Aged 18-80 years;<br>3. the novel coronavirus novel coronavirus infection diagnostic criteria for pneumonia, namely, the new coronavirus pneumonia diagnosis and treatment plan ","Exclusion criteria: 1. Those who are allergic to Xuebijing injection and its components;<br>2. Pregnant or lactating women;<br>3. Serious basic diseases affecting survival, including: malignant tumor, hematopathy, HIV, etc;<br>4. Expected death within ","Novel coronavirus pneumonia (COVID-19)","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;","","","","No","0","          ",""
"ChiCTR2000030679","2020-03-16","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children                                                                                                                                                                                     ","","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50730","Recruiting","No","0.0","18.0","Both","2020-01-28","case series:500;","Observational study","Sequential","N/A","China","Liu Zhisheng","","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","liuzsc@126.com","+86 027-82433145","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology","Inclusion criteria: 1. Children aged 0-18 years and met the guideline for the diagnosis and treatment of COVID-19;<br>2. Agreed to participant in the study;<br>3. Can cooperate with the later on follow-up.","Exclusion criteria: no exclusion criteria ","Novel Coronavirus (COVID-19) Infected Diseases","case series:N/A;","Clinical characteristics;Clinical outcomes;","","","","No","0","          ",""
"ChiCTR2000030606","2020-03-16","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)                                                                                                                  ","","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50713","Not Recruiting","No","18.0","ND","Both","2020-03-09","Chinese medicine treatment cohort:40;Integrated Chinese and western medicine treatment cohort:40;Western medicine treatment cohort:40;","Observational study","Factorial","Retrospective study","China","Miao Qing","","1 Xiyuan Playground, Haidian District, Beijing, China","miaoqing55@sina.com","+86 13910812309","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine ","Inclusion criteria: 1. Compliance with NCP diagnostic criteria; <br>2. Aged >=18 years. ","Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease; <br>2. A case of a pregnant or lactating woman; <br>3. Incomplete case. ","novel coronavirus pneumonia","Chinese medicine treatment cohort:traditional Chinese medicine;Integrated Chinese and western medicine treatment cohort:Chinese medicine and western medicine;Western medicine treatment cohort:western medicine;","Imaging;","","","","Yes","0","          ",""
"ChiCTR2000030700","2020-03-16","Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)                                                                 ","","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50786","Not Recruiting","No","18.0","","Both","2020-03-09","experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Zhang Yu","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","whxhzy@163.com","+86 13971292838","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;<br>2. Adults aged >=18years old, male or female;<br>3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnos","Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;<br>2. With bleeding or ble","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Time to Virus Eradication;","","","","No","0","          ",""
"ChiCTR2000030683","2020-03-16","The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study","The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study                                                                                                                  ","","The Sixth Affiliated Hospital of Sun Yat-sen University","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50633","Not Recruiting","No","60.0","110.0","Both","2020-03-09","Target condition:234;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","China","Chen Lei","","26 Yuancun Erheng Road, Tianhe District, Guangzhou, Guangdong, China","chenlei0nan@163.com","+86 13570236595","The Sixth Affiliated Hospital of Sun Yat-sen University","Inclusion criteria: 1. From January 1, 2020 to March 31, 2020, the elderly patients who aged 60 or over were clinically diagnosed as new coronavirus pneumonia by the Guangdong medical team of Hankou hospital, Wuhan city, Hubei province;<br>2. From Januar","Exclusion criteria: 1. Pneumonia caused by other etiology; <br>2. Patients with incomplete data.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcomes;Index test:MEWS&#32;and&#32;other&#32;scores;","In-hospital mortality;ACC, SEN, SPE, ROC;","","","","Yes","0","          ",""
"ChiCTR2000030597","2020-03-16","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)                                                                                                                                        ","","China Academy of Chinese Medical Science","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50702","Not Recruiting","No","18.0","ND","Both","2020-03-09","Case series:150;","Observational study","Sequential","Retrospective study","China","Miao Qing","","1 Xiyuan Playground, Haidian District, Beijing, China","miaoqing55@sina.com","+86 13910812309","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Inclusion criteria: 1. Compliance with NCP diagnostic criteria;<br>2. Aged >=18 years.","Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease;<br>2. A case of a pregnant or lactating woman;<br>3. Incomplete case.","Novel Coronavirus Pneumonia (COVID-19)","Case series:N/A;","Disease Severity;Imaging;Syndrome Features of TCM;","","","","Yes","0","          ",""
"ChiCTR2000030528","2020-03-16","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                      ","","The Second Clinical College of Guangzhou University of Chinese Medicine","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50641","Not Recruiting","No","18.0","","Male","2020-03-06","Group 1:30;Group 2:30;","Observational study","Non randomized control","N/A","China","Meizhen Lin","","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","lmzmay@163.com","+86 18922108136","The Second Clinical College of Guangzhou University of Chinese Medicine","Inclusion criteria: Refer to the National Health and Health Commission's ""Diagnosis and Treatment Plan for New Coronavirus Infected Pneumonia (Trial Version 5)"" (hereinafter referred to as ""Diagnosis and Treatment Plan"") to confirm the diagnosis of adult ","Exclusion criteria: Participants in other clinical trials within 4 weeks before the start of this study","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Baduanjin;Group 2:Auricular acupressure;","GAD-7;","","","","Yes","0","          ",""
"ChiCTR2000030114","2020-03-16","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)                                                                                                                                        ","","Peking University People's Hospital","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49987","Not Recruiting","No","18.0","","Both","2020-02-24","Target condition:150;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Zhu Fengxue","","11 Xizhimen Street South, Xicheng District, Beijing, China","fxzhu72@163.com","+86 13911005275","Peking University People's Hospital","Inclusion criteria: Patients with severe cases of newly diagnosed novel coronavirus pneumonia, aged over 18 years old, meeting the diagnostic criteria for confirmed cases and patients with severe and critical types in the sixth edition of the diagnosis an","Exclusion criteria: Patients with severe hemodynamic instability, unfavorable to change body position; Patients with severe deformity of the thorax or massive subcutaneous emphysema that cannot be examined by lung ultrasound; Patients who did not check al","novel coronavirus pneumonia","Gold Standard:Chest CT examination;Index test:Lung&#32;ultrasound&#32;examination;","Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);","","","","Yes","0","          ",""
"ChiCTR2000030082","2020-03-16","Cancelled by the investigator             Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)                                                                                                         ","","The First Affiliated Hospital of Nanchang University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49915","","No","18.0","80.0","Both","2020-02-23","experimental group:20;control group:20;","Interventional study","Parallel","4.0","China","Hong tao","","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","ht2000@vip.sina.com","+86 13803535961","The First Affiliated Hospital of Nanchang University","Inclusion criteria: Patients with mild/common novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form","Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.","novel coronavirus pneumonia (COVID-19)","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;","","","","Yes","0","          ",""
"ChiCTR2000030681","2020-03-16","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room                                             ","","Liaocheng People's Hospital","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50763","Not Recruiting","No","2.0","65.0","Both","2020-03-16","Group A:60;Group B:60;Group C:60;Group D:60;","Interventional study","Parallel","0.0","China","Zunyuan Liu","","67 Dongchang Road West, Liaocheng, Shandong, China","ly29.love@163.com","+86 18263511977","Liaocheng People's Hospital","Inclusion criteria: Aged 2-65 years, with a BMI of 18-28, who underwent otolaryngological surgery. The patients were ASA grade I-III.","Exclusion criteria: Patients with difficult airways;Patients who need to remain tracheal intubation to return to the ward after surgery;After signing the informed consent, those who were conscious and awake during the perioperative period refused to conti","Novel Coronavirus Pneumonia (COVID-19)","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of ""circulatory induced respiration"" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common ","cough;agitation;","","","","Yes","0","          ",""
"ChiCTR2000030619","2020-03-16","A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Analysis of the characteristics of traditional Chinese medicine combined with western medicine and its correlation mechanism based on real-world patients with  novel coronavirus pneumonia (COVID-19)                                                         ","","The First Affiliated Hospital of Bengbu Medical College","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50656","Not Recruiting","No","","","Both","2020-02-01","Case series:160;","Observational study","Sequential","Retrospective study","China","Qingping Shi","","287 Changhuai Road, Longzihu District, Bengbu, Anhui, China","sir_shi@126.com","+86 13855288331","The First Affiliated Hospital of Bengbu Medical College","Inclusion criteria: Patients were diagnosed with a new type of coronavirus pneumonia when they were discharged or admitted to the hospital. The diagnostic criteria were based on the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial) (First to ","Exclusion criteria: (1) Those who were not treated with drugs during hospitalization;<br>(2) Patients with active tuberculosis;<br>(3) Organ transplant patients;<br>(4) Patients with mental disorders.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","treatment effect;","","","","No","0","          ",""
"ChiCTR2000030509","2020-03-16","Cancelled by the investigator           Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                          ","","The First Hospital of Harbin Medical University","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49956","Not Recruiting","No","18.0","80.0","Both","2020-03-13","experimental group:20;control group:20;","Interventional study","Parallel","0.0","China","Kaijiang Yu","","23 Youzheng Street, Harbin, Heilongjiang, China","drkaijiang@163.com","+86 0451-53602290","The First Hospital of Harbin Medical University","Inclusion criteria: 1. Male or female aged 18-80 years old;<br>2. Patients with confirmed novel coronavirus-infected pneumonia;<br>3. Diagnosed as moderate cases of COVID-19 with fever and respiratory symptoms and image showing pneumonia;<br>4. Volunta","Exclusion criteria: 1. Sever cases with shock, acute respiratory distress syndrome;<br>2. Multiple organ failure;<br>3. Pregnant or lactating women;<br>4. Cases with malignant disease, autoimmune disease or sever diseases of immune immune system, such ","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","Time and rate of novel coronavirus become negative.;","","","","Yes","0","          ",""
"ChiCTR2000030476","2020-03-16","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)                                                                                                                                                   ","","Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50455","Recruiting","No","14.0","70.0","Both","2020-03-03","1:100;2:100;","Interventional study","Parallel","0.0","China","Jia Lijun","","725 Wanping Road South, Xuhui District, Shanghai, China","ljjia@shutcm.edu.cn","+86 13585779708","Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","Inclusion criteria: (1) diagnosed as a mild and common type of the new coronavirus pneumonia, meeting the diagnostic criteria of the new coronavirus pneumonia diagnosis plan (trial version 6), both male and female;<br>(2) aged 14 to 70 years old;<br>(3)","Exclusion criteria: (1) patients with severe heart, liver, kidney and other complications or other serious primary disease or mental illness;<br>(2) patients whose survival time is not expected to exceed 48 hours from screening;<br>(3) endotracheal intu","Novel Coronavirus Pneumonia (COVID-19)","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;","","","","Yes","0","          ",""
"ChiCTR2000029984","2020-03-16","Cancelled by the investigator              Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)                                                                                                                  ","","Guangzhou reborn health management consultation co., LTD","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49712","Not Recruiting","No","","","Both","2020-03-01","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","","Wei Wei","","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China ","wwei@chinacord.org","+86 13729856651","Guangzhou reborn health management consultation co., LTD","Inclusion criteria: 1. Patients with confirmed novel coronavirus-infected pneumonia; <br>2. Voluntarily sign written informed consent.  ","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","novel coronavirus pneumonia (COVID-19)","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);","","","","Yes","0","          ",""
"ChiCTR2000029957","2020-03-16","Cancelled by the investigator                         An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)                                                                                                                     ","","The Second Affiliated Hospital Of Xi'an Jiaotong University","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49633","Not Recruiting","No","18.0","","Both","2020-02-24","Case series:66;","Observational study","Sequential","N/A","China","Gao Dengfeng","","157 Xiwu Road, Xi'an, Shaanxi, China","gaomedic@163.com","+86 15091544672","The Second Affiliated Hospital of Xi'an Jiaotong University","Inclusion criteria: 1. Aged>=18 years old;<br>2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;<br>3. Being treated in the ICU.","Exclusion criteria: 1. Allergic to vitamin C;<br>2. Cardiogenic dyspnea;<br>3. Life expectancy<24h;<br>4. Pregnant and/or lactating female;<br>5. There is a state of tracheotomy or home oxygen therapy in the past;<br>6. Previously complicated with in","novel coronavirus pneumonia (COVID-19)","Case series:high-dose Vitamin C+Standard treatment;","Ventilation-free days;mortality;","","","","Yes","0","          ",""
"ChiCTR2000030483","2020-03-16","Cancelled by the investigator         A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)                                                                                                ","","The first affiliated hospital of guangzhou university of Chinese medicine","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50495","Not Recruiting","No","","","Both","2020-03-01","treatment group :16;","Interventional study","Parallel","1.0","China","He jing","","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","sakeonel@126.com","+86 13760661654","The First Affiliated Hospital of Guangzhou University of Chinese Medicine","Inclusion criteria: (1) age: 18-75 years old (including threshold), regardless of gender;<br>(2) compliance with the pneumonia diagnosis and treatment protocol for novel coronavirus infection - the diagnostic criteria for the trial version 6 (the latest ","Exclusion criteria: (1) asthma requiring daily treatment, any other chronic respiratory disease<br>(2) patients with severe mental illness and severe neurosis.?<br>(3) the risk stratification of exercise rehabilitation was assessed as high-risk patients","novel common type of coronavirus pneumonia","treatment group :Ba duanjin;","","","","","No","0","          ",""
"ChiCTR2000030478","2020-03-16","Cancelled by the investigator                                    Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                              ","","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","2020-03-03","2020-03-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50460","Not Recruiting","No","18.0","75.0","Both","2020-02-26","Positive drug control group:60;Compound Yuxingcao Mixture Group:60;","Interventional study","Parallel","0.0","China","Haibin Ni","","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","nhb_2002@126.com","+86 15312019183","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;<br>2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;<br>3) Inpatients aged 18 to 75 years male or female;<br>4) Vo","Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;<br>2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, inc","Novel Coronavirus Pneumonia (COVID-19)","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document ""Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)"" general treatment plan. Based on the general treatment plan of Western med","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","","","","No","0","          ",""
"ChiCTR2000030417","2020-03-16","Cancelled by the investigator                               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                              ","","Harbin infectious diseases hospital","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50279","","No","18.0","65.0","Both","2020-03-01","Experimental group:15;control group:15;","Interventional study","Parallel","0.0","China","Jing Xu","","Room 319, life medicine venture building, Limin biomedical R & D center, East Shenyang Street and South Zhuhai Road, Harbin, Heilongjiang, China","18604501911@163.com","+86 18604501911","Harbin Peiyou Jiandi Biotechnology Co., Ltd","Inclusion criteria: 1. Aged 18 to 65 years old, both male and female;<br>2. The eligible subjects (male and female) with fertility must agree to take effective contraceptive measures from the beginning of self-sufficiency with their partners to 6 months ","Exclusion criteria: 1. Patients with allergic history to 4-aminoquinoline (such as chloroquine, hydroxychloroquine, piperaquine, aminophenquine, etc.) and similar drugs (such as primaquine, etc.) were identified;<br>2. Patients with blood system diseases","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sam","","","","Yes","0","          ",""
"ChiCTR2000030381","2020-03-16","Cancelled by investigator           A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                         ","","First people's hospital of Jiangxi district,Wuhan","2020-02-29","2020-02-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50290","Not Recruiting","No","18.0","70.0","Both","2020-02-29","Experimental group:20;Control group:20;","Interventional study","Parallel","N/A","China","Bende Liu","","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","liubende99@outlook.com","+86 13907191851","First people's hospital of Jiangxi district, Wuhan","Inclusion criteria: 1. Aged 18 to 70 years old;<br>2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);<br>3. Confirmed cas","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:<br>1) Respiratory failure occurs and requires mechanical ventilation;<br>2) Shock occurs;<br>3) Combined failure of ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","","","","Yes","0","          ",""
"ChiCTR2000030896","2020-03-16","Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                     ","","Zhengzhou People's Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51028","Recruiting","No","18.0","75.0","Both","2020-02-06","Case series:24;","Interventional study","Single arm","0.0","China","Wang Dazhong","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","13803818341@163.com","+86 13803818341","Zhengzhou People's Hospital","Inclusion criteria: 1. Pneumonitis patients infected with new coronavirus;<br>2. Meet the standard of TCM syndrome differentiation;<br>3. Sign the informed consent.","Exclusion criteria: 1. Complicated active tuberculosis, malignant arrhythmia, acute myocardial infarction, stroke, etc.<br>2. pregnant and lactating women;<br>3. Combining severe cognitive and mental disorders;<br>4. Clinical researchers who are partic","Novel Coronavirus Pneumonia (COVID-19)","Case series:traditional Chinese medicine and Western medicine treatment;","Improvement of symptoms;","","","","No","0","          ",""
"ChiCTR2000030895","2020-03-16","Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period","Retrospective and Prospective Study on Nosocomial infection in Stomatology Department under the Background of COVID-19                                                                                                                                         ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51034","Not Recruiting","No","","","Male","2020-03-14","Case series:1000;","Observational study","Sequential","1.0","China","Jingzhi Ma","","1095 Jiefang Avenue, Wuhan, Hubei, China ","majingzhi2002@163.com","+86 13871257728","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Patients of stomatology department in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 4 to January 23, 2020.<br>1. The visiting data of patients could be backtracked;<br>2. The pati","Exclusion criteria: 1. The patients refused to cooperate in investigation;<br>2. The patients were out of contact;<br>3. The patients was unable to receive the investigation or could not understand the content of investigation;<br>4. The patients was u","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","nosocomial infection ratio of SARS-Cov-2;","","","","No","0","          ",""
"ChiCTR2000030135","2020-03-16","Cancelled by the investigator                  A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients                                                                                                                  ","","The Second Affiliated Hospital Of Xi'an Jiaotong University","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50002","Not Recruiting","No","18.0","","Both","2020-02-25","Experimental group:26;Control group:13;","Interventional study","Parallel","N/A","China","Gao Dengfeng","","157 Xiwu Road, Xi'an, Shaanxi, China ","gaomedic@163.com","+86 15091544672","The Second Affiliated Hospital of Xi'an Jiaotong University","Inclusion criteria: 1. Aged>=18 years old;<br>2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;<br>3. Being treated in the ICU. ","Exclusion criteria: 1. Allergic to vitamin C; <br>2. Cardiogenic dyspnea; <br>3. Life expectancy<24h; <br>4. Pregnant and/or lactating female; <br>5. There is a state of tracheotomy or home oxygen therapy in the past; <br>6. Previously complicated wi","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","Ventilation-free days;mortality;","","","","Yes","0","          ",""
"ChiCTR2000030085","2020-03-16","Cancelled by the investigator               Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients                                                                                                                            ","","Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49948","","No","12.0","","Both","2020-02-22","Target condition:400;Difficult condition:100","Diagnostic test","Factorial","0.0","China","Zairong Wei","","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","188116999@qq.com","+86 15208660008","Affiliated Hospital of Zunyi Medical University","Inclusion criteria: 1. Common inpatient, volunteer and fever patient;<br>2. Patients who are older than 12 years, gender unlimited;<br>3. Consenting or the guardian of a minor is willing to participate in this trial and will sign the informed consent.","Exclusion criteria: With acute cardio-cerebrovascular liver and kidney function damage, or combined with other important organ injury;","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG&#32;detection&#32;method&#32;of&#32;COVID-19;","Positive/Negtive;False positive of rate  ;","","","","Yes","0","          ",""
"ChiCTR2000030055","2020-03-16","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                ","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-22","2020-02-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49864","Recruiting","No","18.0","70.0","Both","2020-02-10","Routine treatment group:230;Dipyridamole treatment group:230;","Prognosis study","Parallel","4.0","China","Qingling Zhang","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","zqling68@hotmail.com","+86 13609068871","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: Suspected cases of neo-coronary pneumonia (outside Hubei province), clinically diagnosed cases (in Hubei province), and light / general confirmed cases, severe/critical confirmed cases, aged 18-70 years, each center enrolls cases in a ","Exclusion criteria: 1. Patients with presence, coagulopathy or hypotension;<br>2. Pregnant and lactating women;<br>3. People with allergies or allergies to Xuebijing Injection and its components;<br>4. Severe basic diseases that affect survival, includ","2019-nCoV pneumonia","Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;","Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;","","","","No","0","          ",""
"ChiCTR2000030031","2020-03-16","Cancelled by the investigator                              A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus p","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)                                        ","","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49806","","No","18.0","65.0","Both","2020-02-20","Phosphoric chloroquine:80;Placebo:40;","Interventional study","Parallel","4.0","China","Ying Deng","","22 Second Shuguang Road, Qingcheng District, Qingyuan, Guangdong, China","surewin001@126.com","+86 13500296796","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","Inclusion criteria: 1. Meet the requirements of the ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)"";<br>2. Aged 18 to 65 years male or female; <br>3. The interval from the onset of symptoms to enrollment","Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;<br>2. With pneumonia infected by other virus;<br>3. With one of following abnormal","Novel Coronavirus Pneumonia (COVID-19)","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy re","Time of conversion to be negative of novel coronavirus nucleic acid;","","","","No","0","          ",""
"ChiCTR2000029817","2020-03-16","Cancelled by the investigator                    Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                         ","","Guangzhou reborn health management consultation co., LTD","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49384","Not Recruiting","No","18.0","","Both","2020-02-20","High dose group:20;Conventional dose group:20;Preventive dose group:20;","Interventional study","Parallel","0.0","","Chao Xu","","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China ","164972769@qq.com","+86 15018720816","Guangzhou reborn health management consultation co., LTD","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Voluntarily sign written informed consent.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","novel coronavirus pneumonia (NCP)","High dose group:High-dose NK cells (>5x10^9)and mesenchymal stem cells(>5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (>3x10^9)and mesenchymal stem cells(>3x10^9),Intravenous ","Time to disease recovery;","","","","Yes","0","          ",""
"ChiCTR2000029812","2020-03-16","Cancelled by the investigator               Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)                                                                                                                                          ","","Guangzhou reborn health management consultation co., LTD","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49374","Not Recruiting","No","18.0","","Both","2020-02-20","Experimental group:30;Control group:30;","Interventional study","Parallel","0.0","","Chao Xu","","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","164972769@qq.com","+86 15018720816","Guangzhou reborn health management consultation co., LTD ","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Voluntarily sign written informed consent.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","Time to disease recovery;","","","","Yes","0","          ",""
"ChiCTR2000030894","2020-03-16","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial                                                                                                                 ","","Peking University First Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51126","Recruiting","No","18.0","65.0","Both","2020-03-01","Group 1:90;Group 2:30;Group 3:30;","Interventional study","Parallel","4.0","China","Guiqiang Wang","","8 Xishiku Street, Xicheng District, Beijing, China","john131212@126.com","+86 13911405123","Peking University First Hospital","Inclusion criteria: 1. Male and female aged 18-65 years;<br>2. Clinically diagnosed with Corona Virus Disease 2019;<br>3. Increased interleukin-6;<br>4. Sign the informed consent;<br>5. Subjects who can take medicine orally;<br>6. Agree to collect cl","Exclusion criteria: 1. Cases of severe vomiting that make it difficult to take the drug orally;<br>2. Allergic to Favipiravir or tocilizumab;<br>3. Pregnant and lactating women;<br>4. Subjects received specific antiviral drugs such as lopinavir / riton","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","Clinical cure rate;","","","","No","0","          ",""
"ChiCTR2000030893","2020-03-16","Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field","Study of effects of crisis intervention on medical staff based on positive psychology                                                                                                                                                                          ","","Zhengzhou People's Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51073","Not Recruiting","No","18.0","70.0","Both","2020-03-19","Observation group:50;","Observational study","Single arm","N/A","China","Wang He","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","WH9400@163.com","+86 15937129400","Zhengzhou People's Hospital","Inclusion criteria: Positive Screening for the SCL-90; Voluntary participation in this research","Exclusion criteria: no","psychological well-being; Novel Coronavirus Pneumonia (COVID-19)","Observation group:Positive Psychological Guidance Group Counseling;","Symptom Checklist 90;","","","","Yes","0","          ",""
"ChiCTR2000030005","2020-03-16","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test                                                                                                                 ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49669","Not Recruiting","No","18.0","85.0","Both","2020-02-21","Target condition:200;Difficult condition:0","Diagnostic test","Sequential","N/A","China","Jingzhi Ma","","1095 Jiefang Avenue, Wuhan, Hubei, China","majingzhi2002@163.com","+86 13871257728","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.<br>1. Aged between 18-85 years old;<br>2. Patients with newly diagnosed and suspected COVID-19;<br>3.","Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;<br>2. Those with severe nasal diseases affecting the sampling;<br>3. Inability to understand or follow research protocols for severe mental illness;<br>4. Invasive ve","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologo","detection of SARS-Cov-2 nucleic acid;SEN, ACC;","","","","Yes","0","          ",""
"ChiCTR2000029592","2020-03-16","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff                                                                                                                       ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49069","Not Recruiting","No","18.0","65.0","Both","2020-02-07","Two cohorts:1000;","Observational study","Factorial","4.0","China","Xin Zheng","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","xin11@hotmail.com","+86 027 85726732","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: High-risk population including medical staff on duty during the outbreak of 2019-nCoV pneumonia.","Exclusion criteria: 1. People with high-risk exposure who are unwilling to participate in this survey;<br>2. People with high-risk exposure who want to withdraw from the research during the study.","novel coronavirus pneumonia (COVID-19)","Two cohorts:Arbidol cohort versus without Arbidol cohort;","2019-nCoV RNA;2019-nCoV antibody;Chest CT;","","","","Yes","0","          ",""
"ChiCTR2000029818","2020-03-16","Cancelled by the investigator            Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                ","","Guangzhou reborn health management consultation co., LTD","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49382","Not Recruiting","No","18.0","","Both","2020-02-20","Experimental group :30;Control group:30;","Interventional study","Parallel","0.0","","Chao Xu","","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China ","164972769@qq.com","+86 15018720816","Guangzhou reborn health management consultation co., LTD ","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Voluntarily sign written informed consent.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","novel coronavirus pneumonia (NCP)","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Time to disease recovery;","","","","Yes","0","          ",""
"ChiCTR2000029816","2020-03-16","Cancelled by the investigator                      Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                          ","","Guangzhou reborn health management consultation co., LTD","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49389","Not Recruiting","No","18.0","","Both","2020-02-20","Experimental group:30;Control group :30;","Interventional study","Parallel","0.0","","Chao Xu","","85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China","164972769@qq.com","+86 15018720816","Guangzhou reborn health management consultation co., LTD ","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;<br>2. Voluntarily sign written informed consent.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;<br>2. Pregnant or lactating women;<br>3. In the opinion of the investigator, previous or present illnesses may affect patients' pa","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","Time to disease recovery;","","","","Yes","0","          ",""
"NCT04302519","2020-03-23","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","","CAR-T (Shanghai) Biotechnology Co., Ltd.","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04302519","Not recruiting","No","18 Years","75 Years","All","2020-03-05","24.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Early Phase 1",""," ; ","Liwei cheng, doctor;Xiaoyang Zhou, doctor","",";xiaoyangzh@hotmail.com",";18986033792","Research office of wuhan renmin university;","<br>        Inclusion Criteria:<br><br>          -  1. Age = 18, age = 75, gender unlimited;<br><br>          -  2. novel coronavirus diagnosed severe pneumonia and confirmed no effective treatment<br>             plan. (severe patients meet any of ","","COVID-19","Biological: Dental pulp mesenchymal stem cells","Disppear time of ground-glass shadow in the lungs","","","","Yes","0","          ",""
"ChiCTR2000031163","2020-03-23","The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)","The correlation between Vitamin D deficient and severe status of novel coronavirus pneumonia (COVID-19) patients                                                                                                                                               ","","The People's Hospital of GuangXi Zhuang Autonomous Region","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51390","Not Recruiting","No","0.1","85.0","Male","2020-02-16","Case series:80;","Observational study","Sequential","N/A","China","Kun Ye","","6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China","yezi5729@163.com","+86 18978817899","The People's Hospital of GuangXi Zhuang Autonomous Region","Inclusion criteria: Patinets diagnosed with COVID-19 according to Diagnosis and treatment of novel coronavirus pneumonia (trial version sixth)","Exclusion criteria: 25(OH)D level not available","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","25(OH)D;","","","","No","0","          ",""
"NCT04307693","2020-03-23","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","","Asan Medical Center","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04307693","Recruiting","No","16 Years","99 Years","All","2020-03-11","150.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Korea, Republic of"," ","Sung-Han Kim, MD.PhD","","shkimmd@amc.seoul.kr","82-2-3010-3114","","<br>        Inclusion Criteria:<br><br>          -  confirmed mild COVID-19 (NEWS scoring system 0-4)<br><br>        Exclusion Criteria:<br><br>          -  unable to take oral medication<br><br>          -  pregnancy or breast feeding<br><br> ","","COVID-19","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate","Viral load","","","","Yes","0","          ",""
"ChiCTR2000031104","2020-03-23","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                 ","","The Fifth Affiliated Hospital of Sun Yat-Sen University","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51185","Recruiting","No","0.0","90.0","Both","2020-02-05","Diagnosed Group:98;Suspending Group:102;","Observational study","Sequential","N/A","China","Pengfei Pang","","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","pangpf@mail.sysu.edu.cn","+86 18902536585","The Fifth Affiliated Hospital of Sun Yat-Sen University ","Inclusion criteria: (1) Fever patients;<br>(2) peoples who need to screen the novel coronavirus;<br>(3) patients for possible infection with novel coronavirus through High throughput sequencing of pathogens;<br>(4) Age and gender are not limited;<br>(","Exclusion criteria: (1) limited sample size;                                                                          <br>(2) Lack of sample information;<br>(3) unable or failure to detect due to human error;<br>(4) Abnormal results or failure in detec","Novel Coronavirus Pneumonia (COVID-19)","Diagnosed Group:Nil;Suspending Group:Nil;","Metagenomics Sequencing;","","","","No","0","          ",""
"ChiCTR2000029770","2020-03-16","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                      ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49412","Recruiting","No","","","Both","2020-02-13","Case series:500;","Observational study","Sequential","N/A","China","Jin Yang","","1277 Jiefang Avenue, Wuhan, Hubei, China","whuhjy@sina.com","+86 13554361146","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)""","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial.","novel coronavirus pneumonia (COVID-19)","Case series:NA;","Patients general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;B","","","","Yes","0","          ",""
"NCT04285801","2020-03-23","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","","Chinese University of Hong Kong","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04285801","Not recruiting","No","18 Years","N/A","All","2020-02-14","8.0","Observational","","N/A","Hong Kong","","","","","","","<br>        Inclusion Criteria:<br><br>          -  admission to ICU<br><br>          -  adult (=18 years old)<br><br>          -  confirmed case of 2019-nCov infection by 2019-nCov RNA by reverse transcription<br>             polymerase chain rea","","COVID-19","","28 day mortality","","","","Yes","0","          ",""
"NCT04299724","2020-03-23","Safety and Immunity of Covid-19 aAPC Vaccine","Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","","Shenzhen Geno-Immune Medical Institute","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04299724","Recruiting","No","6 Months","80 Years","All","2020-02-15","100.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1","China"," ; ; ","Lung-Ji Chang;Lung-Ji Chang;Lung-Ji Chang","",";c@szgimi.org;c@szgimi.org",";+86(755)8672 5195;86-755-86725195","Shenzhen Geno-Immune Medical Institute;","<br>        Inclusion Criteria:<br><br>          -  Healthy and Covid-19-positive volunteers<br><br>          -  The interval between the onset of symptoms and randomized is within 7 days in Covid-19<br>             patients. The onset of symptoms i","","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events;Frequency of serious vaccine events;Proportion of subjects with positive T cell response","","","","Yes","0","          ",""
"ChiCTR2000031140","2020-03-23","Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV","Study on the impact on fetus and neonates of vertical transmission of 2019-nCoV                                                                                                                                                                                ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50605","Recruiting","No","20.0","50.0","Female","2020-02-01","Case series:300;","Observational study","Sequential","0.0","China","CHEN Hui","","58 Shenlong Avenue, Wuhan, Hubei, China","chenhhust@126.com","+86 13437171877","Union Hospital West Campus, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Pregnant women confirmed with COVID-19 and admitted in our department from February,2020 to August, 2020","Exclusion criteria: none","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","Neonatal outcome;","","","","No","0","          ",""
"ChiCTR2000031138","2020-03-23","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                 ","","The third xiangya hospital of Central South University","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51416","Recruiting","No","","","Both","2020-02-26","Pirfenidone group:20;Support treatment group:20;","Interventional study","Parallel","0.0","China","Meng Jie","","138 Tong-Zi-Po Road, Yuelu District, Changsha, Hu'nan, China","mengjie@csu.edu.cn","+86 13607492399","The Third Xiangya Hospital of Central South University","Inclusion criteria: (1) Patients aged 18-80 years;<br>(2) Clear diagnosis of patients with severe COVID-19;<br>(3) Voluntarily join the trial and sign the informed consent.","Exclusion criteria: (1) Those who are allergic to pirfenidone;<br>(2) The investigator judges that the subject's compliance is poor.<br>(3) Patients with severe liver disease;<br>(4) pregnant and lactating patients;<br>(5) Those who have severe kidney","Severe COVID-19","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","HRCT score;","","","","No","0","          ",""
"ChiCTR2000031088","2020-03-23","A prognosis study of novel coronavirus pneumonia (COVID-19)","The Cohotr of COVID-19                                                                                                                                                                                                                                         ","","Xiangyang 1st People's Hospital","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51132","Recruiting","No","0.0","100.0","Both","2020-02-09","COVID-19  patients:314;","Observational study","Cohort study","Retrospective study","China","Pei Bin","","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","xyxzyxzx@163.com","+86 18995678520","Xiangyang 1st People's Hospital","Inclusion criteria: We recruited patients with positive real-time RT-PCR results who were admitted to Xiangyang No.1 Peoples Hospital before February 9th, 2020.","Exclusion criteria: no","Novel coronavirus pneumonia (COVID-19)","COVID-19  patients:no;","demographic information;exposure history;clinical  symptoms;Laboratory examination;radiological  findings;treatment;disease progression;","","","","No","0","          ",""
"ChiCTR2000031023","2020-03-23","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period                                                                                                        ","","Hu'nan Cancer Hospital","2020-03-21","2020-03-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50984","Recruiting","No","","","Both","2020-03-16","Group 2:160;Group 1:160;","Interventional study","Historical control","N/A","China","Yang Jinfeng","","283 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","315977705@qq.com","+86 13875985950","Hu'nan Cancer Hospital","Inclusion criteria: (1) aged 18-60 years;<br>(2) BMI in the normal range (1+/-20%);<br>(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;<br>(4) ASA grade I-II;<br>(5) no ","Exclusion criteria: (1) had participated in other clinical trials within 4 weeks before the start of this study;<br>(2) used albumin and immunoenhancer drugs within 15 days before operation;<br>(3) had a history of coronavirus infection, direct or indir","cancer","Group 2:thymosin;Group 1:BaZhen soup;","postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;","","","","No","0","          ",""
"NCT04302688","2020-03-23","Accurate Classification System for Patients With COVID-19 Pneumonitis","Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram","","Renmin Hospital of Wuhan University","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04302688","Not recruiting","No","N/A","N/A","All","2019-12-10","669.0","Observational","","N/A","China"," ","Qiong Gong, MD.","","","","Renmin Hospital of Wuhan University","<br>        Inclusion Criteria:<br><br>          -  Patients with novel coronavirus pneumonia should be examined and diagnosed by CT and<br>             swab test of viral nucleic acid.<br><br>        Exclusion Criteria:<br><br>          -  Patien","","Pneumonitis","","survival status","","","","No","0","          ",""
"ChiCTR2000031150","2020-03-23","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","Application of radiology in the prevention and control system of emergency respiratory infectious diseases                                                                                                                                                     ","","Hwa Mei Hospital, University of Chinese Academy of Sciences","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51021","Recruiting","No","","","Both","2020-04-01","Case series:150;","Health services reaserch","Sequential","N/A","China","Jie Lin","","41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","linjie1992@zju.edu.cn","+86 15258871484","Hwa Mei Hospital, University of Chinese Academy of Sciences","Inclusion criteria: All patients hospitalized for novel coronavirus pneumonia in Hwa Mei Hospital, University of Chinese Academy Sciences from January 2020 were enrolled. The subjects were included the confirmed cases following the latest guideline of dia","Exclusion criteria: Confirmed cases who had an organ transplantation were excluded, following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Abnormalities on chest CT;","","","","Yes","0","          ",""
"ChiCTR2000031090","2020-03-23","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                       ","","Ningbo Kangning Hospital","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51148","Not Recruiting","No","18.0","65.0","Both","2020-03-23","Group 1:30;Group 2:30;","Interventional study","Parallel","N/A","China","Haihang Yu","","Zhuangyu Road South, Zhenhai District, Ningbo, China","yuhaihang0414@sina.com","8613605880185.0","Ningbo Kangning Hospital","Inclusion criteria: Positive result in nucleic acid test, medical diagnosis is Corona Virus Disease 2019","Exclusion criteria: 1. Other major mental disorders;<br>2. Weakness affects participation in the experiment;<br>3. Communication barriers;<br>4. Already participated in regular cognitive training;<br>5. Take psychotropic or other drugs that are known ","Novel Coronavirus Pneumonia (COVID-19)","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;","","","","Yes","0","          ",""
"ChiCTR2000030996","2020-03-23","Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial.","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.                                                                                                                                      ","","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51349","Recruiting","No","33.0","75.0","Both","2020-03-18","Experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Jing Li","","1 Xiyuan Playground, Haidian District, Beijing","xyyylijing@sina.com","+86 15901203883","Nursing Department of Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Inclusion criteria: (1) Patients with mild, common, and severe neocoronary pneumonia; <br>(2) Those who meet the diagnostic criteria for insomnia with traditional Chinese medicine; <br>(3) Those who meet the diagnostic criteria for insomnia with western","Exclusion criteria: (1) Patients who are unwilling to cooperate during the treatment; <br>(2) Patients with neocoronary pneumonia converted to critically ill during the treatment; <br>(3) Patients with mental illness who have severe primary diseases suc","novel coronavirus pneumonia (COVID-19)","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","insomnia;anxiety;depression;comfort;","","","","No","0","          ",""
"ChiCTR2000031014","2020-03-23","A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus Pneumonia (COVID-19) Convalescent Patients","Detection of SARS-COV-2 RNA Level in Blood and Excrement of Patients Infected with 2019-nCOV in Recovery Period                                                                                                                                                ","","HwaMei Hospital, University of Chinese Academy of Sciences","2020-03-21","2020-03-21","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51348","Not Recruiting","No","","","Both","2020-03-19","SARS-COV-2 RNA Positive group:50;SARS-COV-2 RNA Negative group:50;","Observational study","Factorial","Retrospective study","China","Rengbin Ji","","41 Xibei Street, Ningbo, Zhejiang, China  ","rengbinji@163.com","+86 13989370664","HwaMei Hospital, University of Chinese Academy of Sciences","Inclusion criteria: 1. Aged >14years old;<br>2. The diagnosis conforms to the ""Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus""","Exclusion criteria: No","2019-nCOV Disease","SARS-COV-2 RNA Positive group:None;SARS-COV-2 RNA Negative group:None;","Serum SARS-COV-2 RNA;Swallow swab SARS-COV-2 RNA;feces SARS-COV-2 RNA;Sputum SARS-COV-2 RNA;Urine SARS-COV-2 RNA;","","","","No","0","          ",""
"ChiCTR2000030947","2020-03-23","A medical records based study for clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19)","Clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia                                                                                                           ","","Beijing Chaoyang Hospital, Capital Medical University","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51267","Recruiting","No","38.0","70.0","Male","2020-02-11","Case series:34;","Observational study","Cohort study","N/A","China","Zhaohui Tong","","8 Worker Stadium Road South, Chaoyang District, Beijing, China","tongzhaohuicy@sina.com","+86 13910930309","Beijing Chaoyang Hospital","Inclusion criteria: 1. patients who meet the requirements of the ""diagnosis and treatment plan for pneumonia caused by novel coronavirus infection (the fourth edition)"" issued by the general office of the national health commission;<br>2. patients with s","Exclusion criteria: 1. aged >75 years old.<br>2. after cardiopulmonary resuscitation;<br>3. accompanied by other severe organ dysfunction (including severe liver and kidney dysfunction, massive upper gastrointestinal bleeding, DIC, etc.).","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","hospital mortality;","","","","No","0","          ",""
"ChiCTR2000031139","2020-03-23","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)                                                                                                    ","","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51404","Recruiting","No","18.0","80.0","Both","2020-03-20","Case series:20;","Interventional study","Sequential","0.0","China","Zhang Dingyu","","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China ","1813886398@qq.com","+86 13507117929","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) ","Inclusion criteria: 1. Aged 18 to 80 years old;<br>2. Patients diagnosed with novel coronavirus pneumonia (COVID-19);<br>3. Patients >=21 days since the first symptoms ;<br>4. The diagnosis of pulmonary fibrosis is based on the chest CT (such as fibrot","Exclusion criteria: 1. Patients who are using invasive mechanical ventilation for respiratory support;<br>2. Patients with recent hemodynamic instability requiring maintenance of vasoactive drugs and determined by the investigator to be unsuitable to par","Novel Coronavirus Pneumonia (COVID-19)","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion i","Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;","","","","No","0","          ",""
"ChiCTR2000031089","2020-03-23","A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules                                                                                                                                                                 ","","Guangzhou Eighth People's Hospital","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51136","Not Recruiting","No","18.0","80.0","Both","2020-03-13","experimental group:150;control group:150;","Interventional study","Non randomized control","N/A","China","Luping Lin","","627 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong, China","13533550083@163.com","+86 13533550083","Guangzhou Eighth People's Hospital","Inclusion criteria: 1. Patients who have been diagnosed as COVID-19 according to The Diagnosis and Treatment Plan for 2019-nCoV(The Fifth Trial Edition);<br>2. aged between 18 to 80 years old, male or female;<br>3. the subjects participating the clinica","Exclusion criteria: 1. Patients who are difficult to be administered orally or by nasal feeding, those who are allergic to the test drug and those who are intolerant to the drug;<br>2. The compliance of medication cannot be guaranteed during the treatmen","COVID-19","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","syndrome;nucleic acid of nCoV-19;","","","","No","0","          ",""
"ChiCTR2000030986","2020-03-23","Correlation of T lymphocytes level and clinical severity in novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study","association of T lymphocytes level and clinical severity in patients of NCP: a single-center retrospective data                                                                                                                                                ","","Shenzhen Third People's Hospital","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51316","Recruiting","No","","","Both","2020-03-20","Critical group/ Ordinary group:200;","Observational study","Factorial","Retrospective study","China","GAO Hong","","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","13603035264@139.com","+86 13603035264","Shenzhen Third People's Hospital","Inclusion criteria: 1. Patients diagnosed with COVID-19;<br>2. Aged older than 18 years.","Exclusion criteria: Undetected T lymphocyte count within 48 hours of admission","Novel Coronavirus Pneumonia (COVID-19)","Critical group/ Ordinary group:no;","T lymphocyte count;","","","","Yes","0","          ",""
"ChiCTR2000030961","2020-03-23","A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan","The Retrospective Study about Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia in WuHan                                                                                                                         ","","Changzheng Hospital, Naval Military Medical University, Shanghai","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51291","Recruiting","No","","","Both","2020-01-01","Case series:2000;","Observational study","Sequential","Retrospective study","","Tang Hao","","415 Fengyang Road, Huangpu District, Shanghai, China","tanghao_0921@126.com","+86 13816033045","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University","Inclusion criteria: (1) Patients with novel coronavirus pneumonia in Wuhan Hankou Hospital<br>(2) Patients with novel coronavirus pneumonia in Wuhan Huoshenshan Hospital<br>(3) Patients meet the clinical suspicion and diagnosis of new type of coronaviru","Exclusion criteria: Patients with inadequate clinical information","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical Characteristics, Treatments and Prognosis;","","","","No","0","          ",""
"ChiCTR2000030946","2020-03-23","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19)","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia                                                                                                                                         ","","The First Affiliated Hospital of Guangzhou Medical University","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51265","Recruiting","No","18.0","80.0","Both","2020-02-10","1:80;2:40;","Interventional study","Non randomized control","4.0","China","Chunli Liu","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","chunli@gird.cn","+86 13560158649","The First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: 1. Patients diagnosed with new coronavirus pneumonia and in need of hospitalization: they meet the diagnostic criteria of the diagnosis and treatment program for new coronavirus pneumonia (trial fifth edition) issued by the national he","Exclusion criteria: 1. Pregnant women or lactating women;<br>2. Severe liver function damage (child-pugh grade C);<br>3. Severe renal impairment (Ccr<=15ml/min);<br>4. Have any coexisting medical conditions or diseases that the investigator determines ","Novel Coronavirus Pneumonia (COVID-19)","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","The biochemical indicators;","","","","No","0","          ",""
"ChiCTR2000030933","2020-03-23","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques                                                                                          ","","The First Affiliated Hospital of Nanchang University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51184","Not Recruiting","No","18.0","75.0","Both","2020-03-31","Group 1:36;Group 2:36;Group 3:36;","Interventional study","Parallel","0.0","China","Feng Zhen","","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","fengzhenly@sina.com","+86 13970038111","The First Affiliated Hospital of Nanchang University","Inclusion criteria: 1. Patients diagnosed with COVID-19 [in accordance with the diagnostic criteria of the Notice on Printing and Distributing COVID-19 Diagnosis and Treatment Plan (Trial Implementation Version 6th) issued by the National Health and Medic","Exclusion criteria: 1. Patients diagnosed with the critical type of COVID-19 [in accordance with the diagnostic criteria of the Notice on Printing and Distributing COVID-19 Diagnosis and Treatment Plan (Trial Implementation Version 6th) issued by the Nati","Novel Coronavirus Pneumonia (COVID-19)","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","Maximal inspiratory pressure;Respiratory muscle evaluation;","","","","Yes","0","          ",""
"ChiCTR2000030932","2020-03-23","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                 ","","Anqing Municipal Hospital","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51230","Recruiting","No","16.0","90.0","Both","2020-02-01","COVID-19 patients:100;","Observational study","Sequential","Retrospective study","China","Changqing Hu","","352 Renmin Road, Yingjiang District, Anqing, Anhui, China","13966906638@139.com","+86 13966906638","Department of Infectious Diseases, Anqing Municipal Hospital","Inclusion criteria: Patients with COVID-19 confirmed by CDC","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 patients:Nil;","Length of hospital stay;","","","","No","0","          ",""
"ChiCTR2000030931","2020-03-23","A Medical Records Based Study for Clinical Characteristic and Outcomes of Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)","Clinical Characteristic and Outcomes of Hospitalized Patients With Coronavirus Disease 2019                                                                                                                                                                    ","","HuiZhou Municipal Central Hospital","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51212","Not Recruiting","No","","","Both","2020-03-23","COVID-19 patients:60;","Observational study","Sequential","Retrospective study","China","Huang Hui","","41 Erling Road, Huizhou, Guangdong, China","393406816@qq.com","+86 13825498648","HuiZhou Municipal Central Hospital","Inclusion criteria: Hospitalized patients with COVID19","Exclusion criteria: Suspected patients with COVID19, not confirmed by the laboratory","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 patients:Retrospective analysis;","Time to negative conversion of severe acute respiratory syndrome coronavirus 2;","","","","Yes","0","          ",""
"ChiCTR2000030993","2020-03-23","A medical records based study for the value of Upper Respiratory Tract Virus Detection in the assessment of rehabilitation of novel coronavirus pneumonia (COVID-19) patient","Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients                                                                                                                               ","","Renmin Hospital of Wuhan University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51342","Not Recruiting","No","18.0","100.0","Both","2020-03-12","Target condition:300;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","China","Binru Wang","","241 Pengliuyang Road, Wuchang District, Wuhan, Hubei, China ","wanbr2000@sina.com","+86 13554260702","Wuhan Third Hospital","Inclusion criteria: Meet the criteria for confirmed cases in the ""Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7)"" issued by the National Health and Health Committee of the People's Republic of China:<br>1. clinical manifestations:","Exclusion criteria: (1) Patients with severe mental illness who could not cooperate with treatment; <br>(2) Maternal patients; <br>(3) Pediatric patients; <br>(4) Suicide death cases; <br>(5) Transferred to hospital halfway and failed to obtain final ","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Other parts samples or other methods for virus detection;Index test:Upper&#32;Respiratory&#32;Tract&#32;Virus&#32;Detection;","PT-PCR test;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030987","2020-03-23","A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                            ","","Beijing Chao-yang Hospital, Capital Medical University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51329","Recruiting","No","18.0","75.0","Male","2020-03-05","Experimental group 1:50;Experimental group 2:50;Control group:50;","Interventional study","Parallel","43892.0","China","Zhaohui Tong","","8 Worker Stadium Road South, Chaoyang District, Beijing, China","tongzhaohuicy@sina.com","+86 13910930309","Beijing Chao-yang Hospital, Capital Medical University","Inclusion criteria: 1. Male and female aged 18-75 years old;<br>2. Patients previously diagnosed with COVID-2019: the course of illness is no more than 14 days;If the course of disease was more than 14 days, patients meeting one of the following conditio","Exclusion criteria: 1. Cases of severe vomiting or difficulty in ingesting medication;<br>2. Pregnant and lactating women;<br>3. Lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody were received 3 days before enrollment;<br>4. Cases of r","Novel Coronavirus Pneumonia (COVID-19)","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","improvement or recovery of respiratory symptoms;viral nucleic acid shedding;","","","","No","0","          ",""
"ChiCTR2000030952","2020-03-23","Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19) patients","Myocardial injury and arrythmias in the COVID-19 patients                                                                                                                                                                                                      ","","The Fifth Hospital Affiliated to Sun Yat-sen University","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51278","Recruiting","No","15.0","80.0","Both","2020-01-18","Case series:93;","Observational study","Sequential","Retrospective study","China","Chen Jian","","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","chenjn@mail.sysu.edu.cn","+86 13926931713","The Fifth Hospital Affiliated to Sun Yat-sen University","Inclusion criteria: 1. Diagnosed COVID-19 patients;<br>2. Suspending COVID-19 patients.","Exclusion criteria: Age <14 years old","Novel Coronavirus Pneumonia (COVID-19); myocardial injury, arrythmias","Case series:Nil;","Clinical characteristics and risk factors;","","","","No","0","          ",""
"ChiCTR2000030950","2020-03-23","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design                                                                                                                                         ","","West China Hospital of Sichuan University","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51272","Recruiting","No","","","Both","2020-02-10","the patients of 2019 new coronavirus pneumonia:50;","Basic Science","Sequential","0.0","China","Liujie","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","liudr@outlook.com","+86 18980606533","West China Hospital of Sichuan University","Inclusion criteria: Patients diagnosed with new coronavirus pneumonia","Exclusion criteria: None","Novel Coronavirus Pneumonia (COVID-19)","the patients of 2019 new coronavirus pneumonia:None;","Nucleic acid;","","","","No","0","          ",""
"ChiCTR2000030863","2020-03-16","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19)9: An Multicenter Cohort Study                                                                                                                                                ","","Jinling Hospital, Medical School of Nanjing University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50767","Recruiting","No","","","Both","2020-01-22","Case series:5000;","Observational study","Sequential","Retrospective study","China","Lu Guangming","","305 East Zhongshan Road, Nanjing, Jiangsu, China","cjr.luguangming@vip.163.com","+86 13951608346","Jinling Hospital, Medical School of Nanjing University","Inclusion criteria: 1. Suspected COVID-19 patients with chest CT scannings(including follow-up scanning);<br>2. Patients confirmed with etiological detection and clinical following data.","Exclusion criteria: 1. CT imaging data with poor quality;<br>2. Incomplete etiological or clinical data.","Novel Coronavirus Pneumonia (COVID-19)","Case series:None;","chest CT images;","","","","No","0","          ",""
"ChiCTR2000030862","2020-03-16","Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study","Correlation analysis of blood eosinophil cell levels and clinical novel coronavirus pneumonia type: a single-center, retrospective study                                                                                                                       ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51107","Not Recruiting","No","0.0","99.0","Both","2020-01-24","Ordinary COVID-19 patients:100;Heavy COVID-19 patients:50;","Observational study","Sequential","Retrospective study","China","Feng Gao","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China ","13971587381@163.com","+86 13971587381","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: COVID-19 nucleic acid testing positive non-critically ill hospitalized patients.","Exclusion criteria: (1) before the application or hospital admission corticosteroids; <br>(2) malignancies;<br>(3) the presence of severely impaired immune function, immunodeficiency diseases; <br>(4) 7 days before admission row major surgery or severe","Novel Coronavirus Pneumonia (COVID-19)","Ordinary COVID-19 patients:Nil;Heavy COVID-19 patients:Nil;","Laboratory inspection index;Oxygen therapy case;Film degree exam;","","","","No","0","          ",""
"ChiCTR2000030985","2020-03-23","Psychological Responses of Medical Staff during the Metaphase of novel coronavirus pneumonia (COVID-19) Outbreak in Hubei, China","Psychological Responses of Medical Staff during the Metaphase of Coronavirus Disease 2019 Outbreak in Hubei, China                                                                                                                                             ","","Renmin Hospital of Wuhan University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51311","Not Recruiting","No","18.0","65.0","Both","2020-03-04","cross-sectional study:1300;","Observational study","Sequential","N/A","China","Zhongyuan Xia","","238 Jiefang Road/99 Zhangzhidong Raod, Wuchang, Wuhan, Hubei, China  ","wenqin-1987@163.com","+86 13808628586","Renmin Hospital of Wuhan University","Inclusion criteria: (1) Medical staff in Hubei province;<br>(2) People aged between 18 and 65 years old;<br>(3) People have electronic social software such as WeChat, QQ and Email. ","Exclusion criteria:  a history of neurologic and psychiatric deficits","sleep disorders","cross-sectional study:Nil;","Pittsburgh sleep quality index;hospital anxiety and depression scale;","","","","No","0","          ",""
"ChiCTR2000030951","2020-03-23","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study                                                                                                                 ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51283","Not Recruiting","No","0.0","99.0","Both","2020-03-20","Target condition:2500;Difficult condition:500","Diagnostic test","Sequential","Retrospective study","China","Wei Wang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China ","wwang@vip.126.com","+86 13871143176","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: (1) The patients with covid-19 were diagnosed;<br>(2) CT was positive for the first time.                  ","Exclusion criteria: (1) Reexamine CT;<br>(2) The CT image can not be analyzed caused by respiratory movement ;<br>(3) Patients with pleural effusion or atelectasis.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:RT-PCR test;Index test:artificial&#32;intelligence&#32;triage&#32;system;","CT image;sensitivity;Specificity;Time efficiency;","","","","Yes","0","          ",""
"ChiCTR2000030771","2020-03-23","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies                                                                                                                                    ","","The Second Xiangya Hospital of CSU","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50961","Not Recruiting","No","0.0","100.0","Both","2020-03-01","Target condition:30;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Qianjin Lu","","139 Renmin Middle Road, Furong District, Changsha, Hu'nan, China","qianlu5860@gmail.com","+86 731-85295860","The 2nd Xiangya Hospital of CSU","Inclusion criteria: 1. Patients with COVID-19 infection that meet the diagnostic criteria of ""the 5th edition Pneumonitis diagnosis and treatment guideline for COVID-19 infection of China"";<br>2. Age- and sex-matched normal people and patients with influ","Exclusion criteria: 1. Patients who are using warfarin or with bleeding disorders or bleeding tendencies;<br>2. Those who refuse to sign the informed consent;","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcome;Index test:Based&#32;on&#32;proteomics,&#32;genomics,&#32;and&#32;epigenomics&#32;to&#32;detect&#32;molecular&#32;markers&#32;in&#32;peripheral&#32;blood&#32;of&#32;patients&#32;with&#32;mild&#32;and&#32;severe&#32;COVID-19&","RNA;DNA;","","","","No","0","          ",""
"ChiCTR2000030765","2020-03-23","Cancelled by the investigator                 Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''                                                                                                                                                  ","","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50964","Not Recruiting","No","1.0","99.0","Both","2019-12-01","","Epidemilogical research","Sequential","Retrospective study","China","GuoLin  Song","","32 Feishan Street, Guiyang, Guizhou, China","ant000999@126.com","+86 13985004689","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Inclusion criteria: Common and severe new coronavirus pneumonia","Exclusion criteria: Mild and critical new coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","","prognosis;","","","","No","0","          ",""
"ChiCTR2000030943","2020-03-23","Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A Prospective Study","Venous Thrombosis Risk of 2019-nCoV Pneumonia(COVID-19) Patients: A Prospective Study                                                                                                                                                                          ","","Shandong Provincial Hospital","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50898","Not Recruiting","No","","","Both","2020-03-31","Case series:200;","Observational study","Sequential","0.0","China","Jiang Shujuan","","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China","docjiangshujuan@163.com","+86 15168887199","Shandong Provincial Hospital","Inclusion criteria: 1. Patients who were diagnosed with novel coronavirus pneumonia by the nucleic acid test;<br>2. Patients who agreed to enrollment. ","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Venous Thrombosis;","","","","Yes","0","          ",""
"ChiCTR2000030934","2020-03-23","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of Novel Coronavirus (2019-COV)","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of  Coronavirus SARS-CoV-2                                                                                                                                                             ","","The Fifth Affiliated Hospital of Sun Yat-sen University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51160","Recruiting","No","","","Both","2020-03-01","Case series:90;","Observational study","Sequential","Retrospective study","China","Tian Lin","","52 Meihua Road, Xiangzhou District, Zhuhai, Guangdong, China","tianlin@mail.sysu.edu.cn","+86 0756 2528222","The Fifth Affiliated Hospital of Sun Yat-sen University","Inclusion criteria: 1. novel coronavirus pneumonia confirmed patients, and clinical classification is common, heavy or severe;<br>2. Willing to participate in rapid immunoassay research.","Exclusion criteria: Exclusion criteria (subjects cannot enter the study if they meet any of the following conditions):<br>(1) There was no rapid immunoassay;<br>(2) Subjects who could not cooperate with information collection were excluded.","Novel coronavirus pneumonia (COVID-19)","Case series:Nil;","Immune response multiomics;","","","","No","0","          ",""
"ChiCTR2000030861","2020-03-16","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling                                                                                                                                                 ","","The First Affiliated Hospital of the Guangzhou Medical University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51103","Recruiting","No","18.0","85.0","Both","2019-02-27","Case series:90;","Health services reaserch","Sequential","0.0","","Shiyue Li","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","lishiyue@188.com","+86 13902233925","The First Affiliated Hospital of the Guangzhou Medical University","Inclusion criteria: Stage I and ii healthy subjects<br>Stage 3:<br>1. Clinical manifestations:<br>(1) Fever;<br>(2) normal or decreased white blood cells;<br>(3) CT pulmonary exudation; Or a suspected patient with an epidemiological history;<br>2. I","Exclusion criteria: Stage 1 and stage 2: subjects who cannot cooperate; Patients with fever, cough and expectoration in recent 2 weeks; Patients with underlying diseases.<br>Stage 3:<br>1. Patients who cannot cooperate with the throat swab examination;","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","CT;","","","","No","0","          ",""
"ChiCTR2000030860","2020-03-16","A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients","Investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid                                                                                                                                                                                    ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51102","Recruiting","No","18.0","85.0","Male","2020-03-16","Case series:100;","Observational study","Sequential","0.0","China","Zhang Sheng","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","aloof3737@126.com","+86 18971201115","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Patients with confirmed COVID-19","Exclusion criteria: N/A","Novel Coronavirus Pneumonia (COVID-19)","Case series:N/A;","RT-PCR test for SARS-CoV-2;","","","","Yes","0","          ",""
"ChiCTR2000030944","2020-03-23","Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia                                                                                                                ","","The Second Affiliated Hospital of Nanchang University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50199","Not Recruiting","No","4.0","80.0","Both","2020-09-01","Experimental group:10;Control group:10;","Interventional study","Parallel","1.0","China","Ye Xiaoqun","","1 Minde Road, Donghu District, Nanchang, Jiangxi, China","511201663@qq.com","+86 0791 86300047","The Second Affiliated Hospital of Nanchang University","Inclusion criteria: 1. Patients are eligible for inclusion if they meet all of the following criteria within 5-7 days after the first admission to the ICU.<br>2. The patients met the diagnostic criteria of 2019-nCoV pneumonia (new coronavirus infection) ","Exclusion criteria: 1. sNCP caused by other non-viral infections (such as trauma);<br>2. WHO grade III or IV pulmonary hypertension;<br>3. Malignant tumor in lung and other systems;<br>4. Lactating women or screening women with positive blood pregnancy","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;","","","","Yes","0","          ",""
"ChiCTR2000030942","2020-03-23","Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP","Combined diagnostic value of novel coronavirus infection detected by NLR and CRP                                                                                                                                                                               ","","Shanghai Kongjiang Hospital","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50981","Not Recruiting","No","20.0","90.0","Both","2020-01-20","Case series:191;","Observational study","Sequential","Retrospective study","China","MINGLI LIU","","480 Shuangyang Road, Yangpu District, Shanghai, China","395956184@qq.com","+86 13761153836","Shanghai Kongjiang Hospital","Inclusion criteria: A novel coronavirus infection was treated in 191 hospitals in Wuhan Third Hospital from January 21, 2020 to February 20, 2020. Among them, 83 cases were common group, 20 cases were severe group, 43 cases were critical group, 45 cases w","Exclusion criteria: Undiagnosed NCP patients","Novel Coronavirus Pneumonia (COVID-19)","Case series:no;","Blood routine test;","","","","No","0","          ",""
"ChiCTR2000029658","2020-03-23","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial                                                                                       ","","Central Theater General Hospital of PLA","2020-02-09","2020-02-09","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49074","","No","18.0","80.0","Both","2020-02-10","experimental group:30;control group:30;","Interventional study","Parallel","N/A","China","Li Bixi","","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","bxlee@sohu.com","+86 13397192089","Central Theater General Hospital of PLA","Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years);<br>2. Were identified as laboratory-confirmed 2019-nCoV infection;<br>3. Those who need intubation in ICU, and with no severe hypoxemia.","Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia;<br>2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle;<br>3. Those patients has intubated","novel coronavirus pneumonia (COVID-19)","experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","the lowest SpO2 during intubation;","","","","Yes","0","          ",""
"ChiCTR2000029573","2020-03-23","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection                        ","","The First Affiliated Hospital of Medical College of Zhejiang University","2020-02-05","2020-02-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49065","Recruiting","No","","","Both","2020-02-06","Mild Type Group A:80;Mild Type Group B:80;Common and Heavy Type Group C:160;Common and Heavy Type Group C:160;","Interventional study","Parallel","4.0","China","Li Lanjuan","","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","ljli@zju.edu.cn","+86 13906514210","The First Affiliated Hospital of Medical College of Zhejiang University","Inclusion criteria: o be enrolled, all the following criteria must be met:<br>1) the confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent;<br>2) Aged 18-65 years, gender not limited;<br>3) the time int","Exclusion criteria: You cannot be enrolled if you meet any of the following criteria:<br>1) any situation that cannot allow the program to proceed safely;<br>2) allergic constitution, allergic to more than one kind of food or medicine;<br>3) patients w","novel coronavirus pneumonia","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy T","The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;","","","","Yes","0","          ",""
"ChiCTR2000030812","2020-03-16","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients                                                                                        ","","Shanghai Ninth People's Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50947","Recruiting","No","18.0","100.0","Both","2020-01-31","Case series:50;","Observational study","Cohort study","N/A","China","Xu Jie","","280 Mohe Road, Baoshan District, Shanghai, China","dr.xu@aliyun.com","+86 13501722091","Shanghai Ninth People's Hospital","Inclusion criteria: 1. Aged >=18 years Chinese people;<br>2. Clinical diagnosis of 2019 - nCoV suspected cases: clinical diagnosis of 2019 - nCoV suspected cases: according to the national health committee office of the general office of the state admini","Exclusion criteria: Unsigned or unwilling to sign informed consent","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","Single cell sequencing;","","","","No","0","          ",""
"ChiCTR2000030810","2020-03-16","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine                                                       ","","Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50986","Recruiting","No","18.0","","Both","2020-02-23","Experimental group:50;control group:50;","Interventional study","Cross-sectional","1.0","China","Li Xugui","","279 Luoyu Road, Hongshan District, Wuhan, Hubei, China","spine672@163.com","+86 13807172756","Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine","Inclusion criteria: (1) mild / general patients who meet the diagnostic criteria of the Protocol;<br>(2) Aged >=18 years;<br>(3) Obtain patients' informed consent.","Exclusion criteria: (1) Patients who cannot guarantee medication compliance during treatment, and patients who have difficulty in oral administration;<br>(2) Patients more than 7 days after diagnosis;<br>(3) Patients with severe primary respiratory dise","COVID-19","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;","","","","No","0","          ",""
"ChiCTR2000030929","2020-03-23","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                        ","","Renmin Hospital of Wuhan University","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50696","Not Recruiting","No","18.0","70.0","Both","2020-03-17","Experimental group:30;Control group:30;","Interventional study","Parallel","N/A","China","Binghong Zhang","","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","zbhong6288@163.com","+86 13886009855","Renmin Hospital of Wuhan University","Inclusion criteria: 1. Aged 18 to 70 years old, inpatients, male or female;<br>2. Patients with severe COVID-19: confirmed cases shall be in compliance with guideline of ""Diagnosis and Treatment Plan for COVID-19 (Version 7)"" or updated versions.Confirme","Exclusion criteria: The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:<br>1) Respiratory failure occurs and requires mechanical ventilation;<br>2) Shock occurs;<br>3) Combined failure of oth","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","","","","Yes","0","          ",""
"ChiCTR2000030920","2020-03-23","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.                                               ","","HwaMei Hospital, University of Chinese Academy of Sciences","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50476","Recruiting","No","","","Both","2020-02-20","Tricholoma matsutake group:25;Cannabis sativa capsule group:25;Dendrobium candidum group:25;Routine treatment group:25;","Interventional study","Parallel","N/A","China","Ting Cai","","41 Xibei Street, Ningbo, Zhejiang, China ","caiting@ucas.ac.cn","+86 13738498188","HwaMei Hospital, University of Chinese Academy of Sciences ","Inclusion criteria: 1. Aged >=18 years old;<br>2. The person, who is diagnosed as COVID-19 according to the 'Diagnosis and treatment of novel coronavirus pneumonia (trial edition 5)', is treated with de-isolation and meets hospital discharge criteria:<b","Exclusion criteria: 1. Gestational female patients;<br>2. Patients with allergic constitution, specifically with a history of allergies to these three intervention drugs;<br>3. Patients with other malignant diseases such as malignant tumours, chronic li","Novel Coronavirus Pneumonia (COVID-19)","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));","","","","No","0","          ",""
"ChiCTR2000030919","2020-03-23","An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","An observational study of cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)                                                                                                          ","","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51149","Not Recruiting","No","18.0","-","Both","2020-03-20","observational:80;","Observational study","Single arm","N/A","China","Zhang Lina","","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","zln7095@163.com","+86 15874875763","Intensive Care Unit, XiangYa Hospital, Central South University","Inclusion criteria: 1) > 18 years of age;<br>2) identify the patients infected with the new coronavirus pneumonia;<br>3) the patient completes CT examination;<br>4) sign the informed consent.","Exclusion criteria: 1. those who cannot complete cardiopulmonary ultrasound according to the a-ccue process;<br>2. the patient or his guardian requests to withdraw from the researcher;","Novel Coronavirus Pneumonia (COVID-19)","observational:Ultrasonic monitoring;","auto B line method;Semi-automatic manual measurement of line B;CT image score;NEWS score;hospital time;ICU time;Critical time;Hospital costs;mechanical ventilation time;prognosis of the patient;","","","","Yes","0","          ",""
"ChiCTR2000030539","2020-03-23","Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)                                                                                                             ","","Guangzhou Eighth People's Hospital","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50660","Not Recruiting","No","18.0","85.0","Both","2020-03-06","control group:20;Experimental group (mild and normal type in patients with new coronavirus pneumonia):20;","Interventional study","Case-Control study","0.0","China","Fan Zhong","","8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","gz8hzf@126.com","+86 18122317900","Guangzhou Eighth People's Hospital","Inclusion criteria: 1. Pharyngeal swabs are used to detect the positive nucleic acid of the novel coronavirus, or the virus gene sequencing is highly homologous with the known novel coronavirus;<br>2. Ages between 18 to 85 years male or female;<br>3. Su","Exclusion criteria: 1. Patients with mental illness who cannot cooperate with the sampling;<br>2. Patients judged by the researchers as unsuitable for the study.","Novel Coronavirus Pneumonia (COVID-19)","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","novel coronavirus nucleic acid;","","","","Yes","0","          ",""
"ChiCTR2000030809","2020-03-16","A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients","Clinical outcomes and follow-up study of COVID-19 patients                                                                                                                                                                                                     ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51015","Recruiting","No","13.0","90.0","Both","2020-02-22","Case series:1000;","Observational study","Sequential","N/A","China","Xu Shuyun","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China ","sxu@hust.edu.cn","+86 13517248539","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: According to the clinical diagnostic criteria of the fifth edition ""diagnosis and treatment of pneumonia with novel coronavirus infection"", COVID 19 pneumonia was clinically diagnosed.","Exclusion criteria: 1. Discharge cases that cannot be contacted by WeChat or telephone;<br>2. Discharge cases with language and other barriers, inability to communicate effectively, or failure to receive follow-up for various reasons.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical outcomes after discharge;","","","","No","0","          ",""
"ChiCTR2000030795","2020-03-16","A multicenter retrospective study of rheumatic  patients with novel coronavirus pneumonia (COVID-19)","A multicenter retrospective study of rheumatic  patients with COVID-19                                                                                                                                                                                         ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50982","Not Recruiting","No","12.0","","Both","2020-03-20","Case series:90;","Observational study","Factorial","Retrospective study","China","Lingli Dong","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","tjhdongll@163.com","+86 18672912727","Tongji Hospital","Inclusion criteria: Patients must meet all of the following inclusion criteria before they can join this study: <br>1. Patients admitted to hospital from December 2019 to March 2020;<br>2. Patients identified as any rheumatic disease according to the la","Exclusion criteria: Patients who meet any of the following criteria are not eligible for this study: <br>1. The clinical data are insufficient and the required clinical data cannot be collected;<br>2. The age of the patient is below 12 years old.","Rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical features;","","","","Yes","0","          ",""
"ChiCTR2000029496","2020-03-23","A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)                                   ","","The First Hospital of Changsha; The Second Xiangya Hospital of Central South University","2020-02-03","2020-02-03","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=48809","Recruiting","No","18.0","70.0","Both","2020-01-29","Intervention A:30;intervention B:30;intervention C:30;","Interventional study","Parallel","4.0","China","Gong Guozhong","","139 Renmin Road, Furong District, Changsha, Hu'nan, China","gongguozhong@csu.edu.cn","+86 13873104819","The Second Xiangya Hospital of Cental South University","Inclusion criteria: (1) aged 18 to 70 years;<br>(2) Light and heavy patients with new coronavirus infection confirmed by etiology.","Exclusion criteria: (1) any situation in which the program cannot proceed safely;<br>(2) allergic constitution;<br>(3) serious basic diseases affecting survival, including uncontrolled malignant tumors with multiple metastases that cannot be resected, b","Novel Coronavirus Pneumonia (COVID-19)","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / riton","novel coronavirus nucleic acid clearance rate;","","","","No","0","          ",""
"IRCT20100228003449N27","2020-03-24","Interferon  in treatment  of COVID-19","Evaluating efficacy and safety of interferone -1b (IFN -1b) in the treatment of COVID-19                                                                                                                                                                   ","","Tehran University of Medical Sciences","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46545","Recruiting","No","18 years","65 years","Both","2020-03-15","30.0","interventional","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria of the study will be recruited in the intervention or the control group according th","43892.0","Iran (Islamic Republic of)","Hossein Khalili","","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","khalilih@tums.ac.ir","+98 21 6695 4715","Tehran University of Medical Sciences","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination.","Exclusion criteria: History of drug allergy<br>Pregnancy and lactation <br>Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease, baseline liver failure","COVID-19 pneumonia.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + oseltamivir +lopinavir/ritonavir), patients will receive interferon , sub-type 1b with dose of 250 mcg subcutaneously every other day","Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.","","","","No","0","          ",""
"ChiCTR2000029955","2020-03-23","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging                                                                                                                                                   ","","West China Second University Hospital, Sichuan University","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49531","Not Recruiting","No","","","Both","2020-03-01","Target condition:80;Difficult condition:20","Diagnostic test","Sequential","0.0","China","Ying-kun Guo","","20 South Renmin Road, Chengdu, Sichuan, China","gykpanda@163.com","+86 18180609256","West China Second University Hospital, Sichuan University","Inclusion criteria: 1. novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV and the Chinese medicine authority;<br>2. No contraindications for MR examination;<br>3. understand the potential risks / be","Exclusion criteria: 1. Patients with congenital heart disease, primary and other secondary cardiomyopathy, severe arrhythmia, frequent atrial fibrillation, and serious image quality artifacts;<br>2. Contraindications of MRI: there are ferromagnetic metal","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First&#32;pass&#32;perfusion&#32;imaging&#32;parameters&#32;(slope,&#32;tip,&#32;PT","First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;","","","","Yes","0","          ",""
"ChiCTR2000029830","2020-03-23","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak                                                                               ","","The Fifth Affiliated Hospital of Sun Yat-Sen University","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49511","Not Recruiting","No","","","Both","2020-02-14","tumor patients group:200;non tumor patients group:200;","Observational study","Factorial","0.0","China","Hongmei Tao","","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","13926946929@163.com","+86 13926946929","The Fifth Affiliated Hospital of Sun Yat-Sen University","Inclusion criteria: 1. Patients diagnosed as malignant tumor by pathology are admitted to tertiary general hospital, which is a designated hospital for admission to COVID-19;<br>2. Stay in hospital for 3 days or more;<br>3. Aged 18 or above;<br>4. Info","Exclusion criteria: 1. Confirmed or suspected novel coronavirus pneumonia infection;<br>2. KPS > 30 points.","malignant tumor; Novel Coronavirus Pneumonia (COVID-19)","tumor patients group:N/A;non tumor patients group:N/A;","psychological states;","","","","No","0","          ",""
"ChiCTR2000030095","2020-03-23","A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","Optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia                                                                                     ","","The First Affiliated Hospital of Nanchang University","2020-02-23","2020-02-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49845","Recruiting","No","","","Both","2020-02-23","Case series:94;","Observational study","Sequential","0.0","China","Wei Zhang","","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","zhangweiliuxin@163.com","+86 13707089183","The First Affiliated Hospital of Nanchang University","Inclusion criteria: Viral nucleic acid test positive","Exclusion criteria: Viral nucleic acid test negative","2019 - nCoV pneumonia","Case series:Nil;","detection of virus nucleic acid;","","","","Yes","0","          ",""
"ChiCTR2000029868","2020-03-23","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial                                                                                                                                     ","","Ruijin Hospital, Shanghai Jiaotong University School of Medicine","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49524","Not Recruiting","No","18.0","","Both","2020-02-11","Experimental group:180;Control group:180;","Interventional study","Parallel","4.0","China","Guochao Shi","","197 Second Ruijin Road, Huangpu District, Shanghai, China","shi_guochao2010@qq.com","+86 13918462035","Ruijin Hospital, Shanghai Jiaotong University School of Medicine","Inclusion criteria: 1. Aged 18 years old and above;<br>2. Meet the novel coronavirus pneumonia (COVID-19) diagnostic criteria. The upper and lower respiratory tract RT-PCR confirmed that 2019-nCoV nucleic acid positive, chest CT imaging examination could","Exclusion criteria: 1. Aged less than 18 years old;<br>2. Other serious medical diseases such as malignant tumor, heart, liver and kidney disease, uncontrollable metabolic disease, etc;<br>3. Not suitable for gastrointestinal administration;<br>4. Preg","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","Viral nucleic acid test;","","","","No","0","          ",""
"ChiCTR2000030778","2020-03-16","A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital","Epidemiologic and Clinical features of COVID-19 in Ningbo                                                                                                                                                                                                      ","","Ningbo First Hospital","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50987","Not Recruiting","No","","","Both","2020-01-20","Case series:40;","Observational study","Sequential","Retrospective study","China","Qian Guoqing","","59 Liuting  Street, Ningbo, Zhejiang, China","guoqing.qian@foxmail.com","+86 15888193663","Ningbo First Hospital","Inclusion criteria: All confirmed COVID-19 followed  by  the guidance of NHC.","Exclusion criteria: None.","COVID-19","Case series:No;","Epidemiological features;","","","","No","0","          ",""
"ChiCTR2000030759","2020-03-16","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","","The First Affiliated Hospital of Wenzhou Medical University","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49284","Not Recruiting","No","","","Both","2020-02-15","control group:14;experimental group:56;","Interventional study","Parallel","0.0","China","Jing-Guo Cheng","","Wenzhou Medical University, Chashan Higher Education Park, Wenzhou, Zhejiang, China","wzwsjcjg@126.com","+86 13857797188","WenZhou Medical University ","Inclusion criteria: (1) Patients with Novel coronavirus pneumonia diagnosed according to <diagnosis and treatment scheme for pneumonia of new coronavirus infection (trial version 5)>;<br>(2) Inpatients aged >18 years old;<br>(3) Patients Know the inform","Exclusion criteria: (1) Death is expected within 48 hours;<br>(2) Basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation , congenital heart disease, gastroesophageal reflux disease","Novel Coronavirus Pneumonia (COVID-19)","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;","","","","No","0","          ",""
"IRCT20200316046792N1","2020-03-24","Effect of herbal syrup and solution in treatment of COVID-19","Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial                                                                                   ","","Iran University of Medical Sciences","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46554","Recruiting","No","18 years","65 years","Both","2020-03-16","150.0","interventional","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using compu","43892.0","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Amir Hossein Jamshidi","","No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran","jamshidi.ah@iums.ac.ir","+98 21 5563 9666","Iran University of Medical Sciences","Inclusion criteria: Laboratory-confirmed COVID-19 cases (2019-nCoV Real-Time RT-PCR ), regardless of the clinical manifestations and history of close contact<br>Both the men and women, aged between 18 to 65 years old<br>Signing informed written consent<br","Exclusion criteria: 5 days or more after the onset of illness<br>Pregnancy<br>Breastfeeding<br>History of drug allergy<br>Complicated cases with bacterial infection<br>Patients in recovery phase<br>Critical and severe cases such as ARDS<br>Clinical eviden","COVID-19. <br>COVID-19;U07.1","Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee. Intervention 2:","Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Cli","","","","No","0","          ",""
"IRCT20151227025726N12","2020-03-24","Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)","Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)                                                                                                                 ","","Shahid Beheshti University of Medical Sciences","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46561","Recruiting","No","18 years","no limit","Both","2020-03-03","20.0","interventional","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","3.0","Iran (Islamic Republic of)","Farzaneh Dastan","","Dr. Masih Daneshvari Hospital, Daar-Abad, Niavaran","f_dastan@sbmu.ac.ir","+98 21 2610 9490","Shahid Beheshti University of Medical Sciences","Inclusion criteria: Laboratory confirmed COVID-19  with RT-PCR<br>Respiratory rate > 30/min<br>Oxygen saturation < 90%<br>PaO2/FiO2 < 300mmHg","Exclusion criteria: Chronic kidney Disease<br>Pregnancy or breastfeeding<br>Drug allergy history<br>Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes<br>Chronic liver disease<br>Acute kidney injury","COVID-19 pneumonia. <br>Coronavirus infection, unspecified;B34.2","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 da","Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.","","","","No","0","          ",""
"EUCTR2020-000890-25-FR","2020-03-23","Hydroxychloroquine as a treatment for coronavirus disease COVID-19","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine                                                                                                                                                             ","","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-05","25.0","Interventional clinical trial of medicinal product","Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
","France","IHU Mditerrane Infection","","19-21 Boulevard Jean Moulin","line.meddeb@ap-hm.fr","00334 13 73 23 47","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","Inclusion criteria: <br>- Women and men with documented respiratory infection with Coronavirus SARS CoV 2<br>- Teenager girls and boys aged more than 12 years old<br>- Persons who have given their free and informed consent and have signed the written fo","Exclusion criteria: <br>- Pregnant woman <br>-Child less than 12 years-old <br>-Known hypersensitivity to chloroquine or hydroxy chloroquine.<br>-Feeding<br>-Retinopathy<br>-Known deficit in G6PD<br>-Refusal to participate in the study<br>-Patient ","Patients with documented respiratory infection with coronavirus SARS COV 2;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Plaquenil 200 mg, comprim pellicul<br>Pharmaceutical Form: Coated tablet<br><br>","Main Objective: To shorten the period of virus carrying and thus contagion;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respiratory rate, and average length of hospital stay and mortality.;","","","","No","0","          ",""
"DRKS00021134","2020-03-23","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection - SC2                                                                                                                               ","","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","German Clinical Trials Register","http://www.drks.de/DRKS00021134","Not Recruiting","No","18 Years","no maximum age","Both, male and female","2020-03-20","60.0","observational","Allocation: Non-randomized controlled trial;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Prognosis;","N/A","Germany","Sven","Laudi","Liebigstrasse 20","anaesthesie@medizin.uni-leipzig.de","+49 341 97 17700","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","Inclusion criteria: see study arms","Exclusion criteria: minor",";J12.8 - Other viral pneumonia","Intervention 1: no or mild symptoms of common cold, SARS-CoV-2 negative Intervention 2: mild COVID-19 Intervention 3: severe COVID-19 Intervention 4: severe viral pneumonia, SARS-CoV-2 negative","genetic and epigenetic risk profiles","","","","Yes","0","          ",""
"EUCTR2020-000936-23-FR","2020-03-23","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults                                                                                                                                           ","","INSERM","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-09","3300.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 4
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
","France","Christelle DELMAS","","8 rue de la Croix Jarry","rqrc.siege@inserm.fr","33182533368.0","INSERM","Inclusion criteria: <br>1.	1.	Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.<br>2.	Understands and agrees to comply with planned study procedures.<br>3.	Agrees to the collect","Exclusion criteria: <br>1.	ALT/AST > 5 times the upper limit of normal.<br>2.	Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)<br>3.	Pregnancy or breast feeding.<br>4.	Anticipated transfer to another hospital which is not a ","COVID-19 

- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization.
- Illness of any duration, and at least one of the following:
Clinical as","<br>Trade Name: MYLAN<br>Product Name: lopinavir/ritonavir<br>Pharmaceutical Form: <br>INN or Proposed INN: LOPINAVIR<br>CAS Number: 192725-17-0<br>INN or Proposed INN: RITONAVIR<br>CAS Number: 155213-67-5<br><br>Trade Name: REBIF<br>Pharmaceutical Form: ","Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.<br>	The primary endpoint is subject clinica","","","","Yes","0","          ",""
"IRCT20100228003449N28","2020-03-24","Interferon in treatment of COVID-19","Evaluating efficacy and safety of interferone -1a in the treatment COVID-19 infection                                                                                                                                                                        ","","Tehran University of Medical Sciences","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46538","Recruiting","No","18 years","75 years","Both","2020-03-15","30.0","interventional","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 3 patients wil","43892.0","Iran (Islamic Republic of)","Hossein Khalili","","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","khalilih@tums.ac.ir","98216654715.0","Tehran University of Medical Sciences","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 infection who are candid forhospitalized and starting triple-drug combination","Exclusion criteria: History of drug allergy<br>Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease<br>Pregnancy and lactation<br>Baseline liver failure","COVID-19 pneumonia.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + Oseltamivir +Lopinavir/ritonavir), patients will receive interferon B, sub type 1a (CinnaGen Company) with dose of 44 mcg subcutaneousl","Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.","","","","No","0","          ",""
"IRCT20100228003449N29","2020-03-24","?Effect of sofosbuvir/ ledipasvir on COVID-19","Evaluating efficacy and safety of sofosbuvir/ ledipasvir in  treatment of COVID-19                                                                                                                                                                             ","","Tehran University of Medical Sciences","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46567","Recruiting","No","18 years","75 years","Both","2020-03-18","50.0","interventional","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 5 patients wil","43892.0","Iran (Islamic Republic of)","Hossein Khalili","","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","khalilih@tums.ac.ir","+98 21 6695 4715","Tehran University of Medical Sciences","Inclusion criteria: Patients with highly suspected diagnosis of COVID-19<br>Patients with confirmed diagnosis of  COVID-19<br>Patients who are candid for hospitalization<br>Patients  who are candid for starting triple-drug combination","Exclusion criteria: History of drug allergy<br>Pregnancy<br>Lactation","COVID-19 pneumonia.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg single dose + Cap oseltamivir 75 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 day","Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timep","","","","No","0","          ",""
"TCTR20200321001","2020-03-25","ED Response against Covid-19 pandemic","Response adjustment of emergency deparytment against Covid-19 pandemic: experience of 5-French academic hospitals.                                                                                                                                             ","","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","TCTR","http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5975","Not Recruiting","No","18 Years","95 Years","Both","2020-03-20","5000.0","Observational","N/A","N/A","France;France","Enrique","Casalino","46 rue Henri Huchard Paris 75018","enrique.casalino@aphp.fr","33140257761.0","APHP","Inclusion criteria: Patients suspected of Covid-19 (fever + cough) presenting: <br>qSOFA >=1 (respiratory rate ? 22, systolic blood pressure ? 100 mmHg, or altered mental status)","Exclusion criteria: None","Covid-19 cases management during epidemic phase <br>Covid-19; Emergency; Quality; ;Covid-19; Emergency; Quality; ","Patients suspected of Covid-19 infection with severity criteria","ED time interval [Timeframe hospital exit Time between ED arrival and hospital admission]			","","2020-04-30","","Yes","0","          ",""
"ChiCTR2000030758","2020-03-16","A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","Sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                            ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50590","Not Recruiting","No","14.0","90.0","Both","2020-03-10","NIV group:150;MV group:50;","Observational study","Factorial","Retrospective study","China","Zhigang He","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1097685807@qq.com","+86 18827001384","Eergency / Intensive Care Department of Tongji Hospital","Inclusion criteria: 1) The diagnosis meets the diagnostic criteria for new coronavirus pneumonia;<br>2) Patients receiving NIV or MV treatment.","Exclusion criteria: 1) Age < 14 years;<br>2) Pregnant women;<br>3) Incomplete information of necessary clinical data.","Novel coronavirus pneumonia (COVID-19)","NIV group:no;MV group:no;","Dose of analgesic and sedative drugs;28-day mortality rate;","","","","No","0","          ",""
"ChiCTR2000030757","2020-03-16","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers                                                                                    ","","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science & Technology Medical Center","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50648","Not Recruiting","No","","","Both","2020-03-13","Case series:100;","Observational study","Sequential","N/A","China","Zhang Yue","","1120 Lianhua Road, Futian District, Shenzhen, Guangdong, China","zyzy1933@163.com","+86 18823361933","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science & Technology Medical Center","Inclusion criteria: (1) Currently participating in or responsible for an investigator-initiated clinical trial;<br>(2) Voluntarily participate in this study.","Exclusion criteria: none","novel coronavirus pneumonia (COVID-19); mental health status","Case series:Nil;","Psychological assessment;","","","","Yes","0","          ",""
"IRCT20100228003449N30","2020-03-24","Combination therapy in COVID 19","Evaluating efficacy and safety of Hydroxychloroquine + Oseltamivir + Lopinavir or Atazanavir/ritonavir combination  in patients with COVID-19                                                                                                                  ","","Tehran University of Medical Sciences","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46536","Recruiting","No","no limit","no limit","Both","2020-03-15","50.0","interventional","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","43892.0","Iran (Islamic Republic of)","Hossein Khalili","","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","khalilih@tums.ac.ir","+98 21 6695 4715","Tehran University of Medical Sciences","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination","Exclusion criteria: History of drug allergy<br>Pregnancy","COVID-19 pneumonia.","Intervention group: Patients in this group will receive triple-drug regimen including hydroxychloroquine 200 mg two tablets singe dose + cap oseltamivir 75 mg twice daily + lopinavir/ritonavir 200/50 mg two tablets twice daily or atazanavir/ritonavir 300/","Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepo","","","","No","0","          ",""
"JPRN-jRCTs031190227","2020-03-23","Triple combination therapy in patients infected with COVID-19","A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.                                                           ","","Tokue Yutaka","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","JPRN","https://jrct.niph.go.jp/latest-detail/jRCTs031190227","Not Recruiting","No",">= 20age old","Not applicable","Both","2020-02-27","50.0","Interventional","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","2.0","Japan","Tetsuya","Nakamura","3-39-15 Showa-mchi, Maebashi-shi,Gunma","nakamurt@gunma-u.ac.jp","-8906.0","Gunma University Hospital","Inclusion criteria: positive result for COVID-19 detection test<br>fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan<br>hospital admission","Exclusion criteria: past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir<br>pregnancy","patients infected with COVID-19 <br>Coronavirus","oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","","","","Yes","0","          ",""
"IRCT20160625028622N1","2020-03-24","The effect of Noscapine  on clinical and pulmonary manifestations of COVID-19 patients","The effect of  NOSCOVID on pulmonary & other clinical manifestations of COVID-19 patients                                                                                                                                                                      ","","Qazvin University of Medical Sciences","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46576","Recruiting","No","2 years","no limit","Both","2020-03-19","125.0","interventional","Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study  patients,  nurse , supervisor and researcher don't know which group of patients will use  the medici","2.0","Iran (Islamic Republic of)","Dr Ehsan Aali","","Bahonar","en.aali@gmail.com","+98 28 3333 6001","Qazvin University of Medical Sciences","Inclusion criteria: Positive PCR test for Coronavirus (SARS-COV2)<br>CT Scan finding","Exclusion criteria: Patient who use warfarin<br>Patient who ACEI (captopril. enalapril,...  )","Novel Cronavirus Disease (COVID-19). <br>?????? ?????? ?????;COVID-19","Intervention 1: Intervention group: Treatment group which received Noscapine   mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.","Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.","","","","No","0","          ",""
"JPRN-jRCTs031190226","2020-03-23","Favipiravir in patients infected with COVID-19","A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.                                                                                                                                   ","","Tokue Yutaka","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","JPRN","https://jrct.niph.go.jp/latest-detail/jRCTs031190226","Recruiting","No",">= 20age old","Not applicable","Both","2020-02-27","50.0","Interventional","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","2.0","Japan","Tetsuya","Nakamura","3-39-15 Showa-mchi, Maebashi-shi, Gunma","nakamurt@gunma-u.ac.jp","-8906.0","Gunma Universty Hospital","Inclusion criteria: positive result for COVID-19 detection test<br>fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan<br>hospital admission","Exclusion criteria: pregnancy<br>lactation","patients infected with COVID-19 <br>Coronavirus","oral administration of favipiravir","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","","","","Yes","0","          ",""
"ChiCTR2000030756","2020-03-16","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                 ","","Shenzhen Hospital of Southern Medical University","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50705","Recruiting","No","20.0","80.0","Male","2020-02-20","Case series:60;","Observational study","Sequential","0.0","China","Qingyou Zheng","","1333 Xinhu Road, Bao'an District, Shenzhen, Guangdong, China","zhengqingyou@163.com","+86 18601085226","Shenzhen Hospital of Southern Medical University","Inclusion criteria: we collected 30 mild and common type patients who have positive SARS-CoV-2 of throat swab and 30 suspected patients who have negative nucleic acid but have some symptoms (fever, cough, etc) as controls ","Exclusion criteria: severe patients and juveniles","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","SARS-CoV-2;","","","","No","0","          ",""
"ChiCTR2000030742","2020-03-16","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19): a dual-center, retrospective, cohort study                                                                                    ","","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50857","Not Recruiting","No","18.0","90.0","Both","2020-03-15","Case series:200;","Observational study","Sequential","Retrospective study","China","Hongyu Gao","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","hygao@tjh.tjmu.edu.cn","+86 13886188018","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. confirmed with COVID-19;<br>2. ICU admission;<br>3. meet the critically ill criteria  according to Chinese management guideline for COVID-19 (version 7)","Exclusion criteria: 1. younger than 18 years old;<br>2. do not fulfill the criteria of critical cases;<br>3. declared clinical death or discharged after ICU admission within 24 hour;<br>4. important data missing.","Novel coronavirus pneumonia (COVID-19)","Case series:no;","in-ICU mortality;","","","","Yes","0","          ",""
"NCT04061382","2020-03-30","Sero-epidemiological Survey of England in 2019/2020","Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020","STORY","University of Oxford","2019-07-30","2019-07-30","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04061382","Recruiting","No","N/A","24 Years","All","2019-10-15","2300.0","Observational","","Phase 2","United Kingdom"," ; ; ","Matthew Snape, Professor;Iason Vichos;Iason Vichos","",";info@ovg.ox.ac.uk;info@ovg.ox.ac.uk",";01865611400;01865 611 400","University of Oxford;","<br>        Inclusion Criteria:<br><br>          -  Parents/legal guardians or adult participant* is willing and able to give informed<br>             consent for participation in the study.<br><br>          -  Male or Female, aged 0 - 24 years incl","","Serogroup C Meningococcal Meningitis;Diphtheria;COVID-19","Procedure: venepuncture","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds","","","","Yes","0","          ",""
"NCT04251767","2020-03-30","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study","","The Second Hospital of Nanjing Medical University","2020-01-30","2020-01-30","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04251767","Not recruiting","No","14 Years","70 Years","All","2020-02-05","0.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","N/A","China"," ","Faming Zhang, MD; PHD","","","","The Second Hospital of Nanjing Medical University","<br>        Inclusion Criteria:<br><br>          1. 14-70 years old<br><br>          2. 2019 novel coronavirus pneumonia (severe type)<br><br>          3. Subjects voluntarily participate in the clinical trial and sign the informed consent<br><br","","COVID-19 Complicated With Refractory Intestinal Infections","Other: washed microbiota transplantation;Other: placebo","Number of participants with improvement from severe type to common type","","","","Yes","0","          ",""
"NCT04254874","2020-03-30","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","","Tongji Hospital","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04254874","Recruiting","No","18 Years","N/A","All","2020-02-01","100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 4","China"," ; ","Qing Ning, Professor;Qin Ning, professor","","qning@vip.sina.com;qning@vip.sina.com","+8613971521450;","","<br>        Inclusion Criteria:<br><br>        1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation<br>        of viral pneumonia.<br><br>        Exclusion Criteria:<br><br>          1. Patients who meet any ","","2019-nCoV","Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization","Rate of disease remission;Time for lung recovery","","","","Yes","0","          ",""
"NCT04255017","2020-03-30","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","","Tongji Hospital","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04255017","Recruiting","No","18 Years","N/A","All","2020-02-01","400.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 4","China"," ; ","Qing Ning, Professor;Qin Ning, professor","","qning@vip.sina.com;qning@vip.sina.com","+8613971521450;","","<br>        Inclusion Criteria:<br><br>          1. 2019-nCoV nucleic acid test was positive.<br><br>          2. CT of the lung conformed to the manifestation of viral pneumonia.<br><br>        Exclusion Criteria:<br><br>          1. Patients wh","","2019-nCoV","Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir","Rate of disease remission;Time for lung recovery","","","","Yes","0","          ",""
"JPRN-UMIN000039686","2020-03-23","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease - ECMOCARD Study                                                                                                                                                      ","","Critical Care Research Group
The Prince Charles Hospital","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","JPRN","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045268","Recruiting","No","1years-old","100years-old","Male and Female","2020-02-01","500.0","Observational","Not selected Not selected","Not applicable","Japan,Asia(except Japan),Australia,Europe","Keibun","Liu","Takebayashi 911-1, Utsunomiya-shi, Tochigi","keiliu0406@gmail.com","028-626-5500","Saiseikai Utsunomiya Hospital Department of emergency medicine and intensive care unit","Inclusion criteria: ","Exclusion criteria: 1.	Patients treated with mechanical ventilation for other concomitant causes<br>2.	Patients treated with ECMO for other concomitant causes","COVID-19","","1.	Date of ECMO discontinuation<br>2.	Date of invasive mechanical ventilation discontinuation<br>3.	Date of ICU Discharge<br>4.	Date of Hospital Discharge<br>5.	Mortality at 28 days<br>6.	Main cause of death","","2021-08-31","","No","0","          ",""
"NCT04276896","2020-03-30","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","","Shenzhen Geno-Immune Medical Institute","2020-02-17","2020-02-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04276896","Recruiting","No","6 Months","80 Years","All","2020-03-24","100.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1/Phase 2","China"," ; ; ","Lung-Ji Chang, PhD;Lung-Ji Chang, PhD;Lung-Ji Chang, PhD","",";c@szgimi.org;c@szgimi.org",";+86(755)8672 5195;86-755-86725195","Shenzhen Geno-Immune Medical Institute;","<br>        Inclusion Criteria:<br><br>          -  Laboratory (RT-PCR) confirmed Covid-19 infection in throat swab and/or sputum and/or<br>             lower respiratory tract samples;<br><br>          -  The interval between the onset of symptoms ","","Pathogen Infection Covid-19 Infection","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Clinical improvement based on the 7-point scale;Lower Murray lung injury score","","","","Yes","0","          ",""
"JPRN-jRCTs041190120","2020-03-23","Favipiravir for SARS-CoV-infected patients","Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction                                                                                           ","","Doi Yohei","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","JPRN","https://jrct.niph.go.jp/latest-detail/jRCTs041190120","Recruiting","No",">= 16age old","Not applicable","Both","2020-03-02","86.0","Interventional","randomized controlled trial, open(masking not used), no treatment control, parallel assignment, treatment purpose","2.0","Japan","Masashi","Kondo","1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi 470-1192, Japan","mkond@fujita-hu.ac.jp","-9981.0","Fujita Health University Hospital","Inclusion criteria: (1) Age 16 or greater at the time of consent<br>(2) Sex;  male or female<br>(3) Outpatient or inpatient: inpatient <br>(4) Meets all of 1), 2), 3) below<br> 1)Has at least one RT-PCR test positive for SARS-CoV2 from pharyngeal or nasop","Exclusion criteria: (1) 7 days or more since the onset of COVID-19, as diagnosed by fever, pneumonia or other relevant findings<br>(2) Performance status of 2 or greater<br>(3) Advanced liver function abnormalities classified as grade C by the Child-Pugh ","COVID-19 infection <br>COVID-19 infection","Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2<br>Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice","Proportion of subjects with clearance of SARS-CoV2 in nasopharyngeal swab on Day 6","","","","Yes","0","          ",""
"JPRN-UMIN000039873","2020-03-23","COVID-19 Registry","COVID-19 Registry - COVID-19 Registry                                                                                                                                                                                                                          ","","National Center for Global Health and Medicine","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","JPRN","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045453","Recruiting","No","Not applicable","Not applicable","Male and Female","2020-03-19","9999.0","Observational","Not selected Not selected","Not applicable","Japan","Junko","Terada","1-21-1, Toyama, Shinjuku-ku, Japan","registry.covid@hosp.ncgm.go.jp","332027181.0","National Center for Global Health and Medicine Center for Clinical Sciences","Inclusion criteria: ","Exclusion criteria: Those who refused to participate in the study by opt-out","COVID-19","","none","","2021-01-31","","Yes","0","          ",""
"NCT04261270","2020-03-30","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","","Tongji Hospital","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04261270","Recruiting","No","18 Years","55 Years","All","2020-02-01","60.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 3","China"," ; ","Qing Ning, Professor;Qin Ning, professor","","qning@vip.sina.com;qning@vip.sina.com","+8613971521450;","","<br>        Inclusion Criteria:<br><br>          1. Age:18~55 years old, unlimited gender.<br><br>          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV and accompanied with clinical<br>             manifestations.<br><br>          3.","","2019-nCoV Pneumonia","Drug: ASC09F+Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: Oseltamivir","Rate of comprehensive adverse outcome","","","","Yes","0","          ",""
"NCT04261517","2020-03-30","Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )","Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )","","Shanghai Public Health Clinical Center","2020-02-06","2020-02-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04261517","Not recruiting","No","18 Years","N/A","All","2020-02-06","30.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  The participants were diagnosed as pneumonia caused by 2019-nCoV, according to the<br>             notice on printing and distributing the diagnosis and treatment plan of pneumonia with<br>         ","","Pneumonia, Pneumocystis;Coronavirus","Drug: Hydroxychloroquine","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The virological clearance rate of throat swabs, s","","","","Yes","0","          ",""
"NCT04264858","2020-03-30","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","","Wuhan Union Hospital, China","2020-02-08","2020-02-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04264858","Not recruiting","No","18 Years","N/A","All","2020-03-17","10.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          1. Volunteers who have understood and signed the informed consent;<br><br>          2. Age =18 years, gender unlimited;<br><br>          3. Patients diagnosed with acute severe 2019-nCoV pneumonia:<","","2019-nCoV;Immunoglobulin of Cured Patients","Drug: Immunoglobulin of cured patients;Drug: ?-Globulin","Time to Clinical Improvement (TTCI)","","","","Yes","0","          ",""
"NCT04278963","2020-03-30","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","","China Academy of Chinese Medical Sciences","2020-02-19","2020-02-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04278963","Not recruiting","No","18 Years","N/A","All","2020-02-27","300.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). ","Phase 2/Phase 3","China"," ; ; ","Wei Zhang;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.","",";;",";;","Jingzhou Hospital of Traditional Chinese Medicine;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine","<br>        Inclusion Criteria:<br><br>          1. Age =18 years at time of signing Informed Consent Form.<br><br>          2. Laboratory (RT-PCR) confirmed infection with CoVID-19.<br><br>          3. Hospitalised with Fever(=36.7? -axilla or ora","","CoVID-19;Chinese Medicine","Drug: YinHu QingWen Decoction;Drug: YinHu QingWen Decoction(low dose);Other: Chinese medicine treatment;Other: standard western medicine treatment","Mean clinical recovery time (hours)","","","","Yes","0","          ",""
"TCTR20200324001","2020-03-25","Covid-19 preparedness among Emergency Departments: a cross-sectional study in France.","Preparedness and Responsiveness among Emergency Department against Covid-19 during a rapid growth epidemic phase.                                                                                                                                              ","","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","2020-03-21","2020-03-21","2020-01-04 15:51:14 ","TCTR","http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5976","Not Recruiting","No","30 Years","70 Years","Both","2020-03-24","650.0","Observational","N/A","N/A","France","Enrique","Casalino","46 rue Henri Huchard Paris 75018","enrique.casalino@aphp.fr","33140257761.0","Assistance Publique Hopitaux de Paris","Inclusion criteria: Head of french Emergency Department","Exclusion criteria: Only one response per hospital or ED","Preparedness and responsiveness of french Hospital and ED by electronic survey.
Head of Emergency Department will be questionned. <br>Covid-19, Preparedness, Responsiveness, Emergency, Quality, Organization, Formation, Resources, Management, Interoperabi","Head of departmenet or nurse supervisor of all emergency departments in France","Prepredness measurement [Timeframe at response date electronic survey with electronic questionnaire]			","","2020-04-30","","Yes","0","          ",""
"NCT04272710","2020-03-30","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China","","Chongqing Medical University","2020-02-12","2020-02-12","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04272710","Not recruiting","No","18 Years","100 Years","All","2020-01-25","0.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  Adult aged >=18years old;<br><br>          -  Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed<br>             2019-nCoV infection; CT of the lung conformed to","","2019-nCoV","","Occupancy rate in the intensive care unit (ICU);Mechanical Ventilation;Death","","","","Yes","0","          ",""
"NCT04283461","2020-03-30","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection","Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","","National Institute of Allergy and Infectious Diseases (NIAID)","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04283461","Recruiting","No","18 Years","55 Years","All","2020-03-03","45.0","Interventional","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 1","United States"," ","20-0003 Central Contact","","KPWA.vaccine@kp.org","12062872061.0","","<br>        Inclusion Criteria:<br><br>        A subject must meet all of the following criteria to be eligible to participate in this<br>        study:<br><br>          1. Provides written informed consent prior to initiation of any study procedure","","Corona Virus Infection","Biological: mRNA-1273","Frequency of solicited local reactogenicity adverse events (AEs);Frequency of any medically-attended adverse events (MAAEs);Frequency of any new-onset chronic medical conditions (NOCMCs);Frequency of any serious adverse events (SAEs);Frequency of any unso","","","","Yes","0","          ",""
"NCT04288102","2020-03-30","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)","","Beijing 302 Hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04288102","Recruiting","No","18 Years","75 Years","All","2020-03-05","90.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 1/Phase 2","China"," ; ","Fu-Sheng Wang, MD, PhD;Lei Shi, MD,PhD","",";shilei302@126.com",";86-10-66933333","The fifth medical center of PLA general hospital;","<br>        Inclusion Criteria:<br><br>          1. Male or female, aged at 18 years (including) -75 years old<br><br>          2. Laboratory confirmation of SARS-CoV-2 infection by reverse-transcription polymerase<br>             chain reaction (RT","","Corona Virus Disease 2019(COVID-19)","Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","Size of lesion area and severity of pulmonary fibrosis by chest CT","","","","Yes","0","          ",""
"NCT04290871","2020-03-30","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.","NOSARSCOVID","Xijing Hospital","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04290871","Not recruiting","No","18 Years","N/A","All","2020-03-23","0.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). ","Phase 2",""," ; ","Chong Lei, MD, PhD;Lorenzo Berra, MD","",";",";","Fourth Military Medical University;Massachusetts General Hospital","<br>        Inclusion Criteria:<br><br>          1. Age =18 years<br><br>          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV<br><br>          3. PaO2/FiO2 < 300 or SpO2 below 93% breathing ambient air<br><br>        Exclusion Crit","","Coronavirus;SARS (Severe Acute Respiratory Syndrome)","Drug: Nitric Oxide Gas","SARS-free patients at 14 days","","","","Yes","0","          ",""
"ChiCTR2000030741","2020-03-16","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)                                                                                                          ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50907","Recruiting","No","14.0","90.0","Both","2020-02-01","transnasal high-flow oxygen therapy:50;noninvasive mechanical ventilation:30;invasive mechanical ventilation:20;","Observational study","Sequential","0.0","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest Hospital","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;<br>2. aged 14 years or more;<br>3. diagnosis of  ARDS according to Berlin definition.","Exclusion criteria: 1. Hemodynamic instability: Cardiac pacemaker inserted in the last 2 days or life-threatening arrhythmias or circulatory disorders (use of large doses of vasoactive drugs);<br>2. Intracranial pressure >30 mm Hg or cerebral perfusion p","Novel Coronavirus Pneumonia (COVID-19)","transnasal high-flow oxygen therapy:prone position ventilation;noninvasive mechanical ventilation:prone position ventilation ;invasive mechanical ventilation:prone position ventilation;","PaO2;PaCO2;","","","","No","0","          ",""
"ChiCTR2000030740","2020-03-16","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                     ","","Shandong Provincial Chest hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50900","Recruiting","No","14.0","90.0","Both","2020-02-01","case series:100;","Observational study","Sequential","Retrospective study","China","Fenglin Liu","","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","xkyylfl@163.com","+86 13953116564","Shandong Provincial Chest Hospital","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;<br>2. ARDS patients are defined According to the Berlin definition.","Exclusion criteria: 1. Aged<14 years; <br>2. Pneumothorax; <br>3. Severe asthma or COPD.","Novel Coronavirus Pneumonia (COVID-19)","case series:no;","mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;","","","","No","0","          ",""
"ChiCTR2000030708","2020-03-16","Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China","Cross sectional study of dialysis treatment and mental status under the outbreak of COVID-2019 in China                                                                                                                                                        ","","West China Hospital, Sichuan University","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50083","Recruiting","No","24.0","89.0","Both","2020-03-10","Case series:1000;","Observational study","Sequential","N/A","China","Hui Zhong","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","zhonghui39@126.com","+86 18980601215","West China Hospital, Sichuan University","Inclusion criteria: Hemodialysis and peritoneal dialysis patients","Exclusion criteria: 1. Patients who are not willing to fill in the scale;<br>2. Patients without the ability to fill in the scale  autonomously.","End-stage renal disease; Novel Coronavirus Pneumonia (COVID-19)","Case series:filling in the  scale;","Levels of anxiety, stress and depression;","","","","No","0","          ",""
"ChiCTR2000030707","2020-03-16","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau                                                                                                                                                                               ","","Ganzi Hospital of West China Hospital, Sichuan University","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50160","Not Recruiting","No","","","Both","2020-03-20","Case series:78;","Observational study","Sequential","Retrospective study","China","Lijia Demi","","94 West Street, Kangding, Ganzi Prefecture, Sichuan, China","27216302@qq.com","+86 17723451376","Ganzi Hospital of West China Hospital, Sichuan University","Inclusion criteria: Patients diagnosed with NCIP in Tibetan Plateau were included in the study","Exclusion criteria: Patients in non plateau areas","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Blood oxygen saturation;","","","","Yes","0","          ",""
"NCT04291729","2020-03-30","Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection","An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus(2019-nCoV) Infection","","The Ninth Hospital of Nanchang","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04291729","Not recruiting","No","18 Years","75 Years","All","2020-02-17","11.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","China"," ","Yahong Chen, MD","","","","Ascletis Pharmaceuticals Co., Ltd.","<br>        Inclusion Criteria:<br><br>          -  Aged 18-75 years old;<br><br>          -  Pneumonia patients with new coronavirus infection were confirmed to be positive by<br>             RT-PCR and clinical manifestations. The diagnosis standa","","2019-nCoV Pneumonia","Drug: Ganovo+ritonavir+/-Interferon nebulization","Rate of composite adverse outcomes","","","","Yes","0","          ",""
"NCT04292730","2020-03-30","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","","Gilead Sciences","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04292730","Recruiting","Yes","18 Years","N/A","All","2020-03-15","600.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","United States;Hong Kong;Italy;Korea, Republic of;Singapore;Spain;Taiwan;Hong Kong;Italy;Korea, Republic of;Singapore;Spain;Taiwan;United States"," ; ","Gilead Study Director;Gilead Clinical Study Information Center","",";GileadClinicalTrials@gilead.com",";1-833-445-3230 (GILEAD-0)","Gilead Sciences;","<br>        Key Inclusion Criteria:<br><br>          -  Willing and able to provide written informed consent prior to performing study<br>             procedures<br><br>          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infectio","","COVID-19","Drug: Remdesivir;Drug: Standard of Care","Proportion of Participants Discharged by Day 14","","","","Yes","True ","parent    ",""
"NCT04292899","2020-03-30","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19","","Gilead Sciences","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04292899","Recruiting","Yes","18 Years","N/A","All","2020-03-06","400.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","United States;Hong Kong;Italy;Korea, Republic of;Singapore;Spain;Taiwan;Hong Kong;Italy;Korea, Republic of;Singapore;Spain;Taiwan;United States"," ; ","Gilead Study Director;Gilead Clinical Study Information Center","",";GileadClinicalTrials@gilead.com",";1-833-445-3230 (GILEAD-0)","Gilead Sciences;","<br>        Key Inclusion Criteria:<br><br>          -  Willing and able to provide written informed consent prior to performing study<br>             procedures<br><br>          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infectio","","COVID-19","Drug: Remdesivir;Drug: Standard of Care","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14","","","","Yes","True ","parent    ",""
"NCT04292964","2020-03-30","Prognostic Factors of Patients With COVID-19","Prognostic Factors of Patients With COVID-19","","Chongqing Medical University","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04292964","Not recruiting","No","18 Years","N/A","All","2020-03-01","201.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  Adult aged >=18years old;<br><br>          -  Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed<br>             SARS-Cov-2 infection; CT of the lung conformed to","","SARS-CoV-2;Outcome, Fatal","","all-cause mortality","","","","Yes","0","          ",""
"NCT04304053","2020-03-30","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","HCQ4COV19","Fundacio Lluita Contra la SIDA","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04304053","Recruiting","No","18 Years","N/A","All","2020-03-18","3040.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 3","Spain"," ","oriol Mitja, PhD","","oriolmitja@hotmail.com","0034 934651072","","<br>        Inclusion Criteria for a case:<br><br>          1. Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute<br>             respiratory infection symptoms or acute cough alone and positive PCR)<br><br>        ","","COVID-19","Drug: Antiviral treatment and prophylaxis;Other: Standard Public Health measures","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases","","","","Yes","0","          ",""
"NCT04305106","2020-03-30","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial","BEST-RCT","Qilu Hospital of Shandong University","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04305106","Recruiting","No","18 Years","80 Years","All","2020-03-17","140.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). ","N/A","China"," ; ; ; ","Yihai Cao, Dr;Yuguo Chen, Dr;Jiaojiao Pang, Dr;Jiaojiao Pang, Dr","",";;jiaojiaopang@126.com;jiaojiaopang@126.com",";;18560089129;+86 18560089129","Qilu Hospital of Shandong University, Karolinska Institutet;Qilu Hospital of Shandong University;","<br>        Inclusion Criteria:<br><br>          1. Age: 18-80 years old, male and female;<br><br>          2. Covid-19 confirmed cases;<br><br>          3. Comply with any of the following:<br><br>               -  Dyspnea, RR = 30 times / min;","","COVID-19 Pneumonia","Drug: Bevacizumab","The time from randomization to clinical improvement","","","","Yes","0","          ",""
"NCT04306393","2020-03-30","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","NOSARSCOVID","Massachusetts General Hospital","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04306393","Recruiting","No","18 Years","99 Years","All","2020-03-21","200.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 2","United States"," ; ; ","Lorenzo Berra, MD;Lorenzo Berra, MD;Lorenzo Berra, MD","",";lberra@mgh.harvard.edu;",";+16176437733;","Massachusetts General Hospital;","<br>        Inclusion Criteria:<br><br>          -  >/= 18 years old<br><br>          -  ICU admission<br><br>          -  Intubation and mechanical ventilation<br><br>          -  Positivity of 2019-nCoV rt-PCR<br><br>          -  PaO2/FiO2 ra","","SARS (Severe Acute Respiratory Syndrome);Coronavirus","Drug: Nitric Oxide Gas","Change of arterial oxygenation at 48 hours from enrollment","","","","Yes","0","          ",""
"ChiCTR2000030706","2020-03-16","Cancelled by the investigator                       Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)","Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid                                                                                                                                                                ","","Affiliated Hospital of Zunyi Medical University","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50001","Recruiting","No","1.0","100.0","Both","2020-02-09","Target condition:300;Difficult condition:200","Diagnostic test","Sequential","0.0","China","Guangtao huang","","149 Dalian Road, Zunyi, Guizhou, China","haitao3140@sina.com","+86 18085287828","Affiliated Hospital of Zunyi Medical University","Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2 have either of the following epidemiological histories consistent with the following two clinical manifestations:<br>A comprehensive analysis was conducted based on the following epidemiologic","Exclusion criteria: 1. Suspected patients unable to collect nasopharyngeal swabs;<br>2. Pneumonia caused by other pathogens.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&#32;product&#32;of&#32;SARS-CoV-2.;","Sensitivity, specificity and accuracy;","","","","No","0","          ",""
"ChiCTR2000030690","2020-03-16","Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)","Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection                                                                                                                                                                                ","","The Third Affiliated Hospital of the Second Military Medical University","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50261","Recruiting","No","18.0","80.0","Both","2020-02-10","Two groups:30;","Basic Science","Factorial","N/A","China","Wang Hongyang","","225 Changhai Road, Yangpu District, Shanghai, China","hywangk@vip.sina.com","+86 13801955367","The Third Affiliated Hospital of the Second Military Medical University","Inclusion criteria: COVID-19 confirmed that the clinical symptoms of patients disappeared, after imaging examination, virus nucleic acid test, in line with the discharge criteria of convalescent patients.","Exclusion criteria: 1) < 18 years old or = 80 years old; <br>2) pregnant and lactating women; <br>3) patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system.","Novel Coronavirus Pneumonia (COVID-19)","Two groups:Nil;","Lymphocyte grouping;","","","","No","0","          ",""
"NCT04291053","2020-03-30","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","","Tongji Hospital","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04291053","Not recruiting","No","18 Years","75 Years","All","2020-04-01","550.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3",""," ","Lin Chen","","chenlin_tj@126.com","8613517260864.0","","<br>        Inclusion Criteria:<br><br>          1. Aged between 18 and 75 years, extremes included, male or female<br><br>          2. Patients diagnosed with mild or common type COVID-19, according to the official<br>             guideline ""Pneumo","","COVID-19","Drug: Huaier Granule","Mortality rate","","","","Yes","0","          ",""
"NCT04293692","2020-03-30","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus","","Puren Hospital Affiliated to Wuhan University of Science and Technology","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04293692","Not recruiting","No","18 Years","75 Years","All","2020-02-24","0.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). ","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          1. Male or female, 18 years old = age = 75years old;<br><br>          2. CT image is characteristic of 2019 novel coronavirus pneumonia;<br><br>          3. Laboratory confirmation of 2019-nCoV infec","","COVID-19","Biological: UC-MSCs;Other: Placebo","Size of lesion area by chest imaging;Blood oxygen saturation","","","","Yes","0","          ",""
"NCT04305574","2020-03-30","Social Media Use During COVID-19","Getting it Right: Towards Responsible Social Media Use During a Pandemic","","Jean Liu","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04305574","Recruiting","No","21 Years","N/A","All","2020-03-08","5000.0","Observational","","Phase 2","Singapore"," ; ; ","Jean Liu, PhD;Jean Liu, PhD;Jean Liu, PhD","",";jeanliu@yale-nus.edu.sg;jeanliu@yale-nus.edu.sg",";66013694;","Yale-NUS College;","<br>        Inclusion Criteria:<br><br>          -  At least 21 years<br><br>          -  Has stayed in Singapore for at least 2 years<br><br>        Exclusion Criteria:<br><br>          -  Below 21 years<br><br>          -  Has stayed in Singa","","Coronavirus;Depression;Anxiety;Stress","Behavioral: Use of social media during COVID-19","Assessment of COVID-19 situation;Depression, Anxiety and Stress Scale","","","","Yes","0","          ",""
"NCT04308668","2020-03-30","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","Post-exposure Prophylaxis and Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","COVID-19 PEP","University of Minnesota","2020-03-11","2020-03-11","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04308668","Recruiting","No","18 Years","N/A","All","2020-03-17","3000.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","United States"," ; ","David Boulware, MD, MPH;David Boulware (Please Email), MD, MPH","",";covid19@umn.edu",";612-624-9996","University of Minnesota;","<br>        Inclusion Criteria:<br><br>          -  Provision of informed consent<br><br>          -  Exposure to a COVID19 case within 4 days as either a healthcare worker or household<br>             contact, OR<br><br>          -  Symptomatic C","","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection;Coronavirus;Coronavirus Infections","Drug: Hydroxychloroquine;Other: Placebo","Incidence of COVID19 Disease among those who are asymptomatic at trial entry;Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry","","","","Yes","0","          ",""
"NCT04303507","2020-03-30","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","COPCOV","University of Oxford","2020-03-06","2020-03-06","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04303507","Not recruiting","No","16 Years","N/A","All","2020-04-01","40000.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). ","N/A",""," ","William Schilling, MD","","William@tropmedres.ac","+66 2 203-6333","","<br>        Study Participants<br><br>        These are of two types:<br><br>        A. Adult volunteers (exact age is dependent on countries) working as a healthcare worker or<br>        frontline (i.e. patient contact) in a healthcare facility or ","","COVID19;Coronavirus;Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo","Number of symptomatic COVID-19 infections;Symptoms severity of COVID-19","","","","Yes","0","          ",""
"NCT04304313","2020-03-30","A Pilot Study of Sildenafil in COVID-19","A Pilot Study of Sildenafi in the Treatment of COVID-19","","Tongji Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04304313","Recruiting","No","18 Years","N/A","All","2020-02-09","10.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","China"," ; ","Qing Ning, Professor;Qin Ning, professor","","qning@vip.sina.com;qning@vip.sina.com","+8613971521450;","","<br>        Inclusion Criteria:<br><br>          1. Patients diagnosed as COVID-19:<br><br>               1. mild patient: fever,respiratory and other symptoms, the manifestation of<br>                  pneumonia can be seen on imaging.<br><br>   ","","COVID-19","Drug: Sildenafil citrate tablets","Rate of disease remission;Rate of entering the critical stage;Time of entering the critical stage","","","","Yes","0","          ",""
"NCT04305457","2020-03-30","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","NoCovid","Massachusetts General Hospital","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04305457","Recruiting","No","18 Years","N/A","All","2020-03-21","240.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ; ","Lorenzo Berra;Lorenzo Berra, MD","","lberra@mgh.harvard.edu;lberra@mgh.harvard.edu","+16176437733;","","<br>        Inclusion Criteria:<br><br>          1. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any<br>             specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.<br><br>          2. Hospital admission wit","","Coronavirus Infections;Pneumonia, Viral;Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation","","","","Yes","0","          ",""
"NCT04306705","2020-03-30","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19","TACOS","Tongji Hospital","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04306705","Recruiting","No","18 Years","80 Years","All","2020-02-20","120.0","Observational","","Phase 4","China"," ; ; ","SHAOXIAN HU, M.D;YIKAI YU, M.D;AIHUA DU, M.D","",";yuyikai@163.com;",";+1 (484) 995-5917;+86 2783662886","Tongji Hospital;","<br>        Inclusion Criteria:<br><br>          1. Agrees to the collection of oropharyngeal or anal swabs and venous blood per protocol.<br><br>          2. Male or non-pregnant female adult =18 years of age at time of enrollment.<br><br>        ","","Covid-19;SARS;Cytokine Storm;Cytokine Release Syndrome;Tocilizumab","Drug: Tocilizumab;Other: Standard of care;Procedure: Continuous renal replacement therapy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14","","","","Yes","0","          ",""
"NCT04306497","2020-03-30","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province","CTOROTSADTOC","Jiangsu Famous Medical Technology Co., Ltd.","2020-03-01","2020-03-01","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04306497","Recruiting","No","18 Years","75 Years","All","2020-03-02","340.0","Observational","","Phase 2","China"," ; ","Haibo Cheng, phD;Lei Cui, phD","","363994906@qq.com;houy@famousmed.net","13815857118;13951266803","","<br>        Inclusion Criteria:<br><br>          -  It conforms to the diagnostic criteria of confirmed cases of COVID-19;<br><br>          -  Age from 18-75, regardless gender.<br><br>          -  The patient informed consent and sign the informed","","COVID-19","Drug: TCM prescriptions","The relief / disappearance rate of main symptoms;Chest CT absorption","","","","Yes","0","          ",""
"NCT04310228","2020-03-30","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","","Peking University First Hospital","2020-03-09","2020-03-09","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04310228","Recruiting","No","18 Years","65 Years","All","2020-03-08","150.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ; ","Guiqiang Wang;Guiqiang Wang","",";john131212@sina.com",";13911405123","Peking University First Hospital;","<br>        Inclusion Criteria:<br><br>          1. Clinically diagnosed with Corona Virus Disease 2019<br><br>          2. Increased interleukin-6<br><br>          3. Sign the informed consent<br><br>          4. Subjects who can take medicine o","","COVID-19","Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","Clinical cure rate","","","","Yes","0","          ",""
"NCT04311697","2020-03-30","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","COVID-AIV","NeuroRx, Inc.","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04311697","Not recruiting","No","18 Years","100 Years","All","2020-04-01","120.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2","United States;Israel;United States"," ; ; ","Jonathan C Javitt, MD, MPH;Robert E Besthof, MIM;Yaron Bar-Lavie, MD, FCCP","",";rbesthof@neurorxpharma.com;y_barlavie@rambam.health.gov.il",";+14842546134;04-777-2601","Relief Therapeutics;","<br>        Inclusion Criteria:<br><br>          -  ARDS associated with COVID-19 infection<br><br>          -  Medical necessity for endotracheal intubation and mechanical ventilation<br><br>          -  Physician determination that patient is on ","","Acute Respiratory Distress Syndrome;Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);Corona Virus Infection","Drug: Aviptadil by intravenous infusion + maximal intensive care;Drug: Normal Saline Infusion + Maximal intensive care","Mortality;PaO2:FiO2 ratio","","","","Yes","0","          ",""
"NCT04312100","2020-03-30","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Sequential Oxygen Therapy Strategy for Patients With COVID-19","SOTSPC","Henan Provincial People's Hospital","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04312100","Recruiting","No","18 Years","75 Years","All","2020-02-01","30.0","Observational","","N/A","China"," ; ; ","Xiaoju Zhang, PhD;Ziqi Wang, MD;Li Li, Master","",";13781919609@163.com;sykyxmbgs@163.com",";+86-13781919609;+86-13619842879","Henan Provincial People's Hospital;","<br>        Inclusion Criteria:<br><br>          -  Patients diagnosed with COVID-19<br><br>               -  Aged between 18-75 years;<br><br>                    -  Willing to sign the informed consent voluntarily.<br><br>        Exclusion Crite","","Coronavirus Disease-2019","Other: oxygen treatment","Incidence of respiratory failure","","","","Yes","0","          ",""
"ChiCTR2000030580","2020-03-16","Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial                                                  ","","Shanghai General Hospital","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50693","Recruiting","No","18.0","80.0","Both","2020-02-01","experimental group:30;control group:30;","Interventional study","Parallel","4.0","China","Min Zhang","","NO.85 Wujin Road, Hongkou District, Shanghai, China","maggie_zhangmin@163.com","+86 18121288279","Shanghai General Hospital","Inclusion criteria: (1) aged 18-80 years old;<br>(2) severe (including critical risk factors) and critical patients with confirmed novel coronavirus pneumonia;<br>(3) blood CRP and ESR were more than twice higher than normal or TNFa and Il-6 were higher","Exclusion criteria: (1) pregnant or breast-feeding women;<br>(2) ALT/AST > 5 times ULN, neutrophils < 0.5x10^9/L, platelets less than 50x10^9/L;<br>(3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases;<br>(4) patien","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;","","","","No","0","          ",""
"ChiCTR2000030558","2020-03-16","Cancelled by the investigator             Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital                                                                              ","","Guangzhou Panyu Central Hospital","2020-03-07","2020-03-07","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50678","","No","1.0","80.0","Both","2020-03-07","1:132;2:132;","Epidemilogical research","Sequential","Retrospective study","China","Hanwei Chen","","8 Fuyu Road East, Qiaonan Street, Panyu District ,Guangzhou, Guangdong, China","docterwei@sina.com","+86 18922238906","Guangzhou Panyu central hospital","Inclusion criteria: Epidemiological history:<br>1. History of residence or travel in Hubei province within 14 day before the onset of illness;<br>2. Exposure history to resident or traveler in Hubei province within 14 days before the onset of illness.<","Exclusion criteria: Persons who do not meet the inclusion criteria","Novel Coronavirus Pneumonia (COVID-19)","1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;","CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;","","","","Yes","0","          ",""
"NCT04310865","2020-03-30","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","","Zhong Wang","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04310865","Not recruiting","No","18 Years","N/A","All","2020-03-20","116.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2/Phase 3","China"," ; ; ; ; ","Dong Shang, M.D.;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.;Zhong Wang, M.D.;Jun Liu, M.D.","",";;;;franlj1104@aliyun.com",";;;;8610-64093207","Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine;China Academy of Chinese Medical Sciences;","<br>        Inclusion Criteria:<br><br>          1. Age =18 years at time of signing Informed Consent Form;<br><br>          2. Those who meet the diagnosis of severe new coronavirus pneumonia with laboratory<br>             confirmed infection with","","COVID-19;Severe Pneumonia;Chinese Medicine","Drug: Yinhu Qingwen Granula;Drug: Yin Hu Qing Wen Granula(low does);Other: standard medical treatment","changes in the ratio of PaO2 to FiO2 from baseline","","","","Yes","0","          ",""
"NCT04311177","2020-03-30","Losartan for Patients With COVID-19 Not Requiring Hospitalization","Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","","University of Minnesota","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04311177","Not recruiting","No","18 Years","N/A","All","2020-03-16","516.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2","United States"," ; ; ","Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","",";;ctignane@umn.edu",";;612-625-7911","University of Minnesota;University of Minnesota;","<br>        Inclusion Criteria:<br><br>          -  Presumptive positive laboratory test for SARS-CoV-2 or upper respiratory infection<br>             with recent exposure to laboratory-proven SARS-CoV-2-infected person<br><br>          -  Negative ","","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","Drug: Losartan;Other: Placebo","Hospital Admission","","","","Yes","0","          ",""
"NCT04311398","2020-03-30","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","","Huashan Hospital","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04311398","Not recruiting","No","16 Years","100 Years","All","2020-03-14","100.0","Observational","","N/A","China"," ; ","Wenhong Zhang, Doctor;Wenhong Zhang, PhD,MD","","zhangwenhong@fudan.edu.cn;zhangwenhong@fudan.edu.cn","13801844344;+86 21 52889999","","<br>        Inclusion Criteria:<br><br>          -  Patients went to the fever clinic with respiratory infectious symptoms<br><br>        Exclusion Criteria:<br><br>          -  none<br>      ","","COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Sensitivity, spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","","","","Yes","0","          ",""
"NCT04313946","2020-03-30","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations","AI-COVID-Xr","Professor Adrian Covic","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04313946","Recruiting","No","N/A","N/A","All","2020-03-18","200.0","Observational","","N/A","Romania"," ; ; ","Alexandru Burlacu, Lecturer;Alexandru Burlacu, MD, PhD;Alexandru Burlacu, Md, PhD","",";alexandru.burlacu@umfiasi.ro;alexandru.burlacu@umfiasi.ro",";0040744488580;0040744488580","University of Medicine and Pharmacy Gr T Popa - Iasi;","<br>        Inclusion Criteria:<br><br>          -  flu-like symptoms: myalgia, cough, fever, sputum<br><br>          -  Chest X-Rays<br><br>          -  COVID-19 biological tests<br><br>        Exclusion Criteria:<br><br>          -  patient r","","COVID-19;Pneumonia, Viral;Influenza With Pneumonia;Flu Symptom;Flu Like Illness;Pneumonia, Interstitial;Pneumonia, Ventilator-Associated;Pneumonia Atypical","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","COVID-19 positive X-Rays;COVID-19 negative X-Rays","","","","Yes","0","          ",""
"NCT04312997","2020-03-30","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","","Pulmotect, Inc.","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04312997","Not recruiting","No","18 Years","N/A","All","2020-04-01","100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2","United States"," ; ","Colin Broom, MD;Colin Broom, MD","",";clinicaltrials@pulmotect.com",";713-579-9226","Pulmotect, Inc.;","<br>        Inclusion Criteria:<br><br>          -  1. Subjects must have a documented positive test for the COVID-19 virus within 72<br>             hours of the administration of study drug<br><br>          -  2. Subjects who have no requirement f","","COVID-19","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Severity of COVID-19","","","","Yes","0","          ",""
"NCT04313023","2020-03-30","The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19","","Pulmotect, Inc.","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04313023","Not recruiting","No","18 Years","N/A","All","2020-04-01","200.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2",""," ; ","Colin Broom, MD;Colin Broom, MD","",";clinicaltrials@pulmotect.com",";713-579-9226","Pulmotect, Inc.;","<br>        Inclusion Criteria:<br><br>          -  1. Subjects must have documented exposure to COVID-19 and have a documented negative<br>             test for the virus within 72 hours of the administration of study drug<br><br>          -  2. Su","","COVID-19","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Prevention of COVID-19","","","","Yes","0","          ",""
"NCT04318015","2020-03-30","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","PHYDRA","National Institute of Respiratory Diseases, Mexico","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318015","Not recruiting","No","18 Years","N/A","All","2020-04-01","400.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3",""," ; ; ; ; ; ; ; ; ","Jorge Rojas-Serrano, MD, PhD.;Rogelio Perez-Padilla, MD;Felipe Jurado-Camacho, MD. MSc;Ireri Thirion-Romero, MD, MSc;Sebastian Rodrguez-Llamazares, MD, MPH;Carmen Hernandez Crdenas, MD, MSc;Cristobal Guadarrama-Prez, MD;Alejandra Ramrez-Venegas, M","",";;;;;;;;lfjcamacho@comunidad.unam.mx",";;;;;;;;+52 55871700","National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases ","<br>        Inclusion Criteria:<br><br>          -  18 years old upon study start<br><br>          -  Healthcare personnel exposed to patients with COVID-19 respiratory disease:<br>             physicians, nurses, chemists, pharmacists, janitors, st","","COVID-19;Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Symptomatic COVID-19 infection rate","","","","Yes","0","          ",""
"NCT04314232","2020-03-30","Mechanisms to Morbidity and Mortality for Covid-19","Changes in Organ Specific Biomarkers, Virus Expression and Prognosis for Covid-19","COVID MECH","University Hospital, Akershus","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04314232","Not recruiting","No","18 Years","N/A","All","2020-03-23","200.0","Observational","","Phase 3","","","","","","","","<br>        Inclusion Criteria:<br><br>          -  All patients >18 years of age with a positive test for SARS-CoV2 are eligble for<br>             inclusion.<br><br>          -  Healty age-matched volunteers will be included as a control group<br","","Coronavirus;SARS","","Change in viral expression in association to organspecific biomarkers","","","","Yes","0","          ",""
"NCT04314817","2020-03-30","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","CovidTox","Groupe Hospitalier Pitie-Salpetriere","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04314817","Recruiting","No","N/A","N/A","All","2020-03-17","1000.0","Observational","","Phase 1","France"," ; ; ","Joe-Elie Salem, MD, PhD;Lee S Nguyen, MD, PhDc;Lee S Nguyen, MD, PhDc","",";nguyen.lee@icloud.com;",";0033158414143;","Clinical Investigations Center;","<br>        Inclusion Criteria:<br><br>          -  all patients treated for Covid-19<br><br>        Exclusion Criteria:<br><br>          -  Chronology not compatible between the drug and the toxicity<br>      ","","Coronavirus;Iatrogenic Disease;Acute Kidney Injury;ARDS, Human","Drug: Any drug used to treat Covid-19","Renal failure","","","","Yes","0","          ",""
"NCT04316299","2020-03-30","Acute Kidney Injury in Patients Hospitalized With COVID-19","Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study","","Zhenhua Zen","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04316299","Not recruiting","No","18 Years","N/A","All","2020-02-26","287.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  COVID-19 pneumonia patients diagnosed by WHO criteria<br><br>        Exclusion Criteria:<br><br>          -  Patients who were younger than 18 years,<br><br>          -  Patients who had undergo","","COVID-19;Acute Kidney Injury;Kidney Function","","Rate of Acute Kidney Injury","","","","Yes","0","          ",""
"NCT04316884","2020-03-30","Mechanisms for Organ Dysfunction in Covid-19","Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19","UMODCOVID19","Uppsala University","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04316884","Recruiting","No","18 Years","N/A","All","2020-03-12","100.0","Observational","","Phase 4","Sweden"," ; ; ","Robert Frithiof, MD. PhD;Robert Frithiof, MD. PhD.;Robert Frithiof, MD. PhD.","",";robert.frithiof@surgsci.uu.se;robert.frithiof@surgsci.uu.se",";0736563473;073-6563473","Uppsala University Hospital;","<br>        Inclusion Criteria:<br><br>          -  Admitted to intensive care<br><br>          -  suspected or verified COVID-19<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy or breastfeeding<br><br>          -  Preexisting ","","COVID-19;Organ Dysfunction Syndrome Sepsis;Organ Dysfunction Syndrome, Multiple;Septic Shock;Acute Kidney Injury;Acute Respiratory Distress Syndrome","","Acute Kidney Injury","","","","Yes","0","          ",""
"NCT04317092","2020-03-30","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","TOCIVID-19","National Cancer Institute, Naples","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04317092","Recruiting","Yes","N/A","N/A","All","2020-03-19","330.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Italy"," ; ","Francesco Perrone, MD, PhD;Francesco Perrone, MD, PhD","",";f.perrone@istitutotumori.na.it",";+390815903571","Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale;","<br>        Inclusion Criteria:<br><br>          1. Any gender<br><br>          2. No age limit<br><br>          3. Informed consent for participation in the study<br><br>          4. Virological diagnosis of Sars-CoV2 infection (PCR)<br><br>  ","","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate","","","","Yes","True ","parent    ",""
"ChiCTR2000030329","2020-03-16","Cancelled by the investigator                          Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)                                                                                                    ","","The Second Affiliated Hospital of Xi'an Medical University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49779","Not Recruiting","No","18.0","65.0","Both","2020-03-05","Control group:30;CIK group:30;NK group:30;","Interventional study","Parallel","0.0","China","Gao Jun","","167 Fangdong Street, Baqiao District, Xi'an, Shaanxi, China","13816012151@163.com","+86 13816012151","The Second Affiliated Hospital of Xi'an Medical University","Inclusion criteria: 1. New-type coronavirus infection is diagnosed as mild or common (diagnosed according to the ""Notice on the Issuance of a New Coronavirus-Infected Pneumonia Diagnosis and Treatment Plan (Trial Implementation of the Sixth Edition)"") or ","Exclusion criteria: Doctors and researchers consider that the patient inappropriate to enroll in the study.","Novel Coronavirus Pneumonia (COVID-19)","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;","","","","Yes","0","          ",""
"ChiCTR2000030306","2020-03-16","Cancelled by the investigator                               Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development","Novel coronavirus pneumonia (COVID-19) in asymptomatic patients: a single center, prospective, open clinical study                                                                                                                                             ","","Luohu hospital group medical center of Shenzhen University","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50222","","No","18.0","60.0","Both","2020-03-19","Case series:15;","Observational study","Sequential","0.0","China","Bi Xiaohui","","33 Zhongyuan Road, Buji Town, Longgang District, Shenzhen, Guangdong, China  ","524712958@qq.com","+86 15618795225","Luohu hospital group medical center of Shenzhen University","Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;<br>2. According to the new type of coronavirus ","Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;<br>2. The subject suffers from active psychosis, which the researcher believes may interfere","Novel Coronavirus Pneumonia (COVID-19)","Case series:no;","Time to disease recovery;Time and rate of coronavirus become negative;","","","","Yes","0","          ",""
"NCT04314271","2020-03-30","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","","Xiangya Hospital of Central South University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04314271","Recruiting","No","18 Years","N/A","All","2020-03-20","80.0","Observational [Patient Registry]","","N/A","China"," ; ; ","Zhang Li Na, MD;Zhao Ch Guang, MD;Xiao","",";562122649@qq.com;xyyyllwyh@126.com",";+86136673520046;","Xiangya Hospital;","<br>        Inclusion Criteria:<br><br>          1. age >18 years old<br><br>          2. identify the patients infected with novel coronavirus pneumonia;<br><br>          3. the patient completed CT examination;<br><br>          4. sign the info","","Novel Coronavirus Pneumonia","","characteristics of cardiopulmonary ultrasound","","","","Yes","0","          ",""
"NCT04315870","2020-03-30","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy","I-COVID","Federico II University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04315870","Recruiting","No","18 Years","50 Years","Female","2020-01-01","20.0","Observational [Patient Registry]","","N/A","Italy"," ","Gabriele Saccone, MD","","gabriele.saccone@unina.it","817462202.0","","<br>        Inclusion Criteria:<br><br>          -  pregnant women with laboratory-confirmed 2019-n-CoV<br>      ","","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","","","","Yes","0","          ",""
"NCT04315896","2020-03-30","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","HYDRA","National Institute of Respiratory Diseases, Mexico","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04315896","Not recruiting","No","18 Years","80 Years","All","2020-03-23","500.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3",""," ; ; ; ; ; ; ; ","Carmen Hernandez-Crdenas, MD. MSc.;Luis-Felipe Jurado-Camacho, MD;Ireri Thirion-Romero, MD. MSc;Sebastian Rodriguez-Llamazares, MD.MPH;Rogelio Perez-Padilla, MD. PhD;Cristobal Guadarrama, MD MSc;Joel Vasquez-Prez, MD;Carmen Hernandez-Crdenas, MD. MS","",";;;;;;;cmhcar@hotmail.com",";;;;;;;54871700","National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases ","<br>        Inclusion Criteria:<br><br>          1. Signed informed consent<br><br>          2. negative pregnancy test in women<br><br>          3. COVID-19 confirmed by rtPCR in any respiratory sample.<br><br>          4. Severe COVID-19 diseas","","COVID-19;Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","All-cause hospital mortality","","","","Yes","0","          ",""
"NCT04315987","2020-03-30","NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Azidus Brasil","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04315987","Not recruiting","No","18 Years","N/A","All","2020-04-01","24.0","Interventional","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1",""," ","Florentino de Araujo Cardoso Filho","","florentino.cardoso@hospitalcare.com.br","+55 19 991232882","","<br>        Inclusion Criteria:<br><br>          1. Male or female, aged = 18 years<br><br>          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase<br>             chain reaction (RT-PCR) from any diagnostic sa","","COVID-19 Pneumonia","Biological: NestCell;Biological: NestCell","Disappear time of ground-glass shadow in the lungs","","","","Yes","0","          ",""
"NCT04318418","2020-03-30","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Neuromed IRCCS","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318418","Not recruiting","No","N/A","N/A","All","2020-03-23","5000.0","Observational","","Phase 1","Italy"," ; ; ","Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo","",";dicastel@ngi.it;",";3289035621;","IRCCS Neuromed;","<br>        Inclusion Criteria:<br><br>        Patients hospitalized for COVID-19<br><br>        Exclusion Criteria:<br><br>        none<br>      ","","COVID-19","","Severe COVID-19","","","","Yes","0","          ",""
"NCT04318444","2020-03-30","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","","Columbia University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318444","Not recruiting","No","18 Years","N/A","All","2020-03-01","1600.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2/Phase 3","United States"," ; ","Elizabeth Oelsner, MD, MPH;Elizabeth Oelsner, MD, MPH","",";eco7@cumc.columbia.edu",";212-305-9056","Columbia University Irving Medical Center;","<br>        Inclusion Criteria:<br><br>          -  Household contact of index case: currently residing in the same household as an<br>             individual evaluated at NYP via outpatient, emergency department (ED), or inpatient<br>             se","","COVID-19;Corona Virus Infection","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Number of participants with symptomatic, lab-confirmed COVID-19.","","","","Yes","0","          ",""
"NCT04319315","2020-03-30","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak","","Assiut University","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04319315","Recruiting","No","25 Years","65 Years","All","2020-03-11","400.0","Observational","","N/A","Egypt"," ; ; ","Aliae Mohamed-Hussein;Aliae Mohamed-Hussein;Aliae Hussein, MD","",";aliaehussein@aun.edu.eg;aliaehussein@aun.edu.eg",";01222302352;01222302352","Assiut University;","<br>        Inclusion Criteria:<br><br>          -  Medical Physicians in Middle East area<br><br>        Exclusion Criteria:<br><br>          -  none<br>      ","","COVID-19","Other: survey","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","","","","Yes","0","          ",""
"NCT04320615","2020-03-30","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Hoffmann-La Roche","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320615","Not recruiting","No","18 Years","N/A","All","2020-04-03","330.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ","Phase 3",""," ; ","Clinical Trials;Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm","",";global-roche-genentech-trials@gene.com",";888-662-6728","Hoffmann-La Roche;","<br>        Inclusion Criteria:<br><br>          -  Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive<br>             PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and<br>        ","","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ);Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale","","","","Yes","0","          ",""
"NCT04318366","2020-03-30","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","COVID-BioB","Universit Vita-Salute San Raffaele","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318366","Recruiting","No","18 Years","N/A","All","2020-03-19","1000.0","Observational","","N/A","Italy"," ; ","Giovanni Landoni, Professor;Giovanni Landoni, Professor","","landoni.giovanni@hsr.it;landoni.giovanni@hsr.it","+390226436151;","","<br>        Inclusion Criteria:<br><br>          -  Patients admitted to hospital with biological samples positive for SARS-CoV-2<br><br>          -  Patients admitted to hospital with negative test but clinical and radiological<br>             char","","Coronavirus Infections","Other: Observational Study","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","","","","Yes","0","          ",""
"NCT04319016","2020-03-30","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-preg","Federico II University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04319016","Recruiting","No","N/A","N/A","Female","2020-01-01","20.0","Observational [Patient Registry]","","N/A","Italy"," ","Gabriele Saccone","","gabriele.saccone@libero.it","3394685179.0","","<br>        Inclusion Criteria:<br><br>          -  pregnant women with laboratory-confirmed 2019-n-CoV<br>      ","","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","","","","Yes","0","          ",""
"NCT04319900","2020-03-30","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","","Beijing Chao Yang Hospital","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04319900","Recruiting","No","18 Years","75 Years","All","2020-03-05","150.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). ","Phase 2/Phase 3","China"," ; ","Shumin Wang, Phd.;Shumin Wang, Phd.","","shuminwang7000@163.com;shuminwang7000@163.com","+86 13488760399;+86 13488760399","","<br>        Inclusion Criteria:<br><br>          -  Male and female, 18-75 years old<br><br>          -  Patients previously diagnosed with novel coronavirus pneumonia: the course of illness<br>             is no more than 14 days; if the course of ","","Novel Coronavirus Pnuemonia","Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo","Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms","","","","Yes","0","          ",""
"NCT04320017","2020-03-30","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","JOCOVID","Groupe Hospitalier Pitie-Salpetriere","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320017","Recruiting","No","16 Years","N/A","All","2020-03-20","500.0","Observational","","N/A","France"," ; ","Joe-Elie Salem, MD-PhD;Joe-Elie Salem, MD-PhD","","joe-elie.salem@aphp.fr;joe-elie.salem@aphp.fr","01 42 17 85 31;01 42 17 85 31","","<br>        Inclusion Criteria:<br><br>        - COVID-19 positive patients admitted in a ward identified by positive PCR on nasal swab<br>        samples<br><br>        Exclusion Criteria:<br><br>        - Patients for which electrocardiogram or ","","COVID-19;Myocardial Injury;Myocarditis","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay","","","","Yes","0","          ",""
"ChiCTR2000030221","2020-03-16","Cancelled by the investigator               Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                 ","","Guangzhou Panyu Central Hospital","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50071","Recruiting","No","18.0","60.0","Both","2020-01-31","Case series:960;","Health services reaserch","Sequential","0.0","","Zhu Haibing","","8 East Fuyu Road, South Bridge Street, Panyu District, Guangzhou, Guangdong, China","zhb-ck@163.com","+86 13826041759","Central Hospital of Panyu District, Guangzhou City","Inclusion criteria: All staff, excluding the internship and probationer, who aged from 18y to 60y and volunteered for this survey, were included in this survey.","Exclusion criteria: Employees who go out for further study or leave, people with previous mental disorders, and sufferers who recently undergo a major injury to work or family life, were excluded in this survey.","Sleep; Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","sleep status and related factors of insomnia;","","","","No","0","          ",""
"ChiCTR2000030187","2020-03-16","Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                      ","","Jingzhou First People's Hospital","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50057","Recruiting","No","18.0","80.0","Both","2020-02-25","Experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Wei Xiao","","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","99xw@sina.com","+86 18972161798","Jingzhou First People's Hospital","Inclusion criteria: 1. Sign the written informed consent;<br>2. Aged 18-80 years old;<br>3. Meet the diagnostic criteria for novel coronavirus infection(trial version sixth), confirmed by combining with the epidemiological history, clinical manifestatio","Exclusion criteria: 1. Patients who are participating in clinical trials of other drugs;<br>2. Pregnant or lactating women;<br>3. ALT / AST > 2-fold ULN;<br>4. Expected survival time < 1 week;<br>5. With serious liver disease;<br>6. Patients taking o","Novel coronavirus pneumonia (COVID-19)","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;","","","","Yes","0","          ",""
"NCT04316728","2020-03-30","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","","Centro Studi Internazionali, Italy","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04316728","Not recruiting","No","18 Years","N/A","All","2020-03-01","200.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ","N/A","Italy"," ; ; ","Maurizio Cipolla, MD;Antonio V Gaddi, MD, MSc;Maurizio Cipolla, MD","",";antonio.gaddi@ehealth.study;maurizio.cipolla@ehealth.study",";+393920039246;","Medical director of UCCP CATANZARO, Italy;","<br>        Inclusion Criteria:<br><br>          -  Adults healthcare workers (HCW) OR<br><br>          -  Chronic patients with at least 2 chronic medical conditions<br><br>        Exclusion Criteria:<br><br>          -  People that have been in","","Coronavirus Infections","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Number of patients with constant negative results;Number of patients with positive test with a positive PCR for COVID-19;Overall Number of patients positive for COVID-19;Overall Number of patients negative for COVID-19;Number of patients with contrasting ","","","","Yes","0","          ",""
"NCT04319445","2020-03-30","Mindfulness During COVID-19","Mindfulness During COVID-19 - Remote Mindfulness Sessions","","Wake Forest University Health Sciences","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04319445","Not recruiting","No","N/A","N/A","All","2020-03-01","200.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ","N/A",""," ; ","Rebecca E Wells, MD, MPH;Rebecca E Wells, MD, MPH","",";rewells@wakehealth.edu",";336-716-2357","Wake Forest University Health Sciences;","<br>        Inclusion Criteria:<br><br>          -  Any person interested in participating in the mindfulness session will be eligible to<br>             complete the pre/post surveys and participate in the mindfulness session.<br><br>        Exclus","","Migraine Disorders;Stress;Anxiety","Behavioral: Mindfulness session(s)","Helpfulness of the session;Platform effectiveness","","","","Yes","0","          ",""
"NCT04320238","2020-03-30","Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff","An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","","Shanghai Jiao Tong University School of Medicine","2020-03-21","2020-03-21","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320238","Recruiting","No","18 Years","65 Years","All","2020-01-21","2944.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 3","China"," ; ","Zhongji Meng;Zhongji Meng","","zhongji.meng@163.com;zhongji.meng@163.com","18971905757;+86-18971905757","","<br>        Inclusion Criteria:<br><br>          -  Formally serving medical staff in Taihe Hospital;<br><br>        Exclusion Criteria:<br><br>          -  pregnant women; severe chronic diseases who are unable to participate in daily routine<br>","","2019 Novel Coronavirus Infection","Drug: recombinant human interferon Alpha-1b;Drug: thymosin alpha 1","new-onset COVID-19","","","","Yes","0","          ",""
"NCT04320472","2020-03-30","Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection","Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection","NeuroCOVID19","Ictal Group","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320472","Recruiting","No","18 Years","N/A","All","2020-03-23","250.0","Observational [Patient Registry]","","N/A","France"," ; ; ","Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD","",";stlegriel@gmail.com;stephane.legriel@ictalgroup.org",";33139638839;33139638839","Ictal Group;","<br>        Inclusion Criteria:<br><br>          -  Critical care admission<br><br>          -  Admission for/with acute encephalopathy defined as a rapidly developing (over less<br>             than 4 weeks, but usually within hours to a few days) ","","COVID-19;Encephalopathy;Critically Ill","Other: Follow up","prevalence","","","","Yes","0","          ",""
"NCT04321265","2020-03-30","Outcomes and Prognostic Factors in COVID-19","Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients","COVIP","Heinrich-Heine University, Duesseldorf","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321265","Recruiting","No","70 Years","N/A","All","2020-03-19","4000.0","Observational","","Phase 1","Germany"," ; ","Christian Jung, MD;Christian Jung, MD, PhD","","contact@vipstudy.org;contact@vipstudy.org","+2118118800;","","<br>        Inclusion Criteria:<br><br>          1. Age > 70 years<br><br>          2. ICU-Admission<br><br>          3. Infection or suspected infection with SARS-CoV-2<br><br>        Exclusion Criteria:<br><br>        1. Age <70 years<br>   ","","COVID-19;Elderly Patients;Critical Illness;Survival;Old Age","","Survival","","","","Yes","0","          ",""
"NCT04321278","2020-03-30","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Alliance Covid-19 Brasil II)","Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Alliance COVID-19 Brasil II - Severely-ill Patients","","Hospital Israelita Albert Einstein","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321278","Not recruiting","No","18 Years","N/A","All","2020-03-23","440.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","Brazil"," ; ","Otvio Berwanger, PhD;ARO-HIAE Academic Research Organization HIAE","",";aro.clinicaltrials@einstein.br",";+55 (11) 2151-1233","Hospital Israelita Albert Einstein;","<br>        Inclusion Criteria:<br><br>          1. Males and females aged > 18 years;<br><br>          2. Probable or confirmed infection by SARS-CoV2 presenting with one of the following:<br><br>               -  Need for oxygen supplementation >","","Coronavirus Infections;Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine","Evaluation of the clinical status","","","","Yes","0","          ",""
"NCT04321928","2020-03-30","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","PROACTIVE-19","University of Pecs","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321928","Not recruiting","No","60 Years","N/A","All","2020-04-01","7576.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor). ","N/A",""," ; ","Pter Hegyi, MD, PhD, DSc;Pter Hegyi, MD, PhD, DSc","",";hegyi2009@gmail.com",";+36703751031","Insitute for Translational Medicine, University of Pcs, HU;","<br>        The inclusion criteria are:<br><br>          1. age over 60 years;<br><br>          2. informed consent to participate.<br><br>        The exclusion criteria are:<br><br>          1. confirmed COVID-19 infection (active or recovered);","","SARS-CoV-2;Coronavirus;COVID-19;2019-nCoV;2019nCoV","Behavioral: Personalized health education;Behavioral: General health education","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases","","","","Yes","0","          ",""
"NCT04322123","2020-03-30","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus","An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients","Coalition-I","Hospital do Coracao","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322123","Not recruiting","No","18 Years","N/A","All","2020-04-06","630.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","Brazil"," ; ","Fernando Zampieri, PhD;Fernando Zampieri, PhD","",";fzampieri@hcor.com.br",";+55 11 97093-1539","Hospital do Corao;","<br>        Inclusion Criteria:<br><br>          -  Patients with suspected or confirmed COVID-19 admitted to inpatient units and<br>             intensive care units<br><br>        Exclusion Criteria:<br><br>          -  Need for oxygen supplemen","","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product;Drug: Hydroxychloroquine + azithromycin","Evaluation of the clinical status","","","","Yes","0","          ",""
"ChiCTR2000029895","2020-03-16","Cancelled by investigator                Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                   ","","Guangzhou Eighth People's Hospital","2020-02-16","2020-02-16","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49569","Recruiting","No","18.0","","Both","2020-02-16","Case series:160;","Interventional study","Single arm","43862.0","China","Weiping Cai","","627 Dongfeng Road East, Guangzhou, Guangdong, China","gz8hcwp@126.com","+86 020-83710825","Guangzhou Eighth People's Hospital","Inclusion criteria: (1)Aged >=18 years old, gender unlimited, inpatient;<br>(2) Novel coronavirus nucleic acid positive in pharyngeal swab specimen by real-time fluorescent RT-PCR;<br>(3) Clinical classification is ordinary or severe patients;<br>(4) I","Exclusion criteria: (1) Known or suspected to be allergic to the components of GD31;<br>(2) Mild or critical patients in clinical classification;<br>(3) Severe liver diseases (such as child Pugh score >=C, TBIL >=2 ULN, AST >=5 ULN), or HBsAg positive<","Novel Coronavirus Pneumonia (COVID-19)","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;","","","","Yes","0","          ",""
"ChiCTR2000029837","2020-03-16","Cancelled by the investigator          A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia                                        ","","Jingzhou Central Hospital","2020-02-15","2020-02-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49495","Not Recruiting","No","18.0","65.0","Both","2020-02-17","Phosphoric chloroquine:80;Placebo:40;","Interventional study","Parallel","4.0","China","Jinghua Mao","","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","hbjzyyywlc@163.com","+86 071 68497225","Jingzhou Central Hospital","Inclusion criteria: Subjects who meet the all of the following criterion to be elegiable for this study:<br>1. Meet the requirements of the ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)"";<br>2. Aged 18 ","Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;<br>2. With pneumonia infected by other virus;<br>3. With one of following abnormal","Novel Coronavirus Pneumonia (COVID-19)","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy re","Time of conversion to be negative of novel coronavirus  nucleic acid;","","","","Yes","0","          ",""
"NCT04321616","2020-03-30","The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2","The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","","Oslo University Hospital","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321616","Not recruiting","No","18 Years","N/A","All","2020-03-26","700.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3",""," ; ; ; ; ; ; ; ","Paul Aukrust, MD, Professor;Andreas Barratt-Due, MD, PhD;Trine Ksine, MD;Katerina Nezvalova-Henriksen, Pharm D, PhD;Anne Margarita Dyrhol Riise, MD, Professor;Marius Trseid, MD, PhD;Inge Christoffer Olsen, PhD;Paul Aukrust, MD, Professor","",";;;;;;;paukrust@ous-hf.no",";;;;;;;0047 46778374","Oslo University Hospital;Oslo University Hospital;Oslo University Hospital;Oslo Hospital Pharmacies;Oslo University Hospital;Oslo University Hospital;NorCRIN;","<br>        Inclusion Criteria:<br><br>          1. Adult patients, 18 years and above<br><br>          2. Confirmed SARS-2-CoV-2 infection by PCR<br><br>          3. Admitted to the hospital ward or the ICU<br><br>          4. Subjects (or legal","","SARS-CoV Infection;COVID 19;Acute Respiratory Distress Syndrome ARDS","Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC","In-hospital mortality","","","","Yes","0","          ",""
"NCT04321993","2020-03-30","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","","Lisa Barrett","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321993","Not recruiting","No","18 Years","N/A","All","2020-03-01","1000.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2",""," ","Barbara Goodall","","barbara.goodall@nshealth.ca","(902) 292-0132","","<br>        Inclusion Criteria:<br><br>          -  18 years or older<br><br>          -  Moderate to severe COVID-19 associated disease as defined by the WHO<br><br>          -  Hospitalized patient<br><br>          -  Willing and able to provid","","COVID-19","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate;Drug: Baricitinib (janus kinase inhibitor);Drug: Sarilumab (anti-IL-6 receptor)","Clinical status of subject at day 15 (on a 7 point ordinal scale).","","","","Yes","0","          ",""
"NCT04323592","2020-03-30","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","MP-C19","University of Trieste","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323592","Recruiting","No","18 Years","80 Years","All","2020-03-23","104.0","Interventional","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","Italy"," ; ; ","Francesco Salton, MD;Francesco Salton, MD;marco confalonieri, MD","",";francesco.salton@gmail.com;mconfalonieri@units.it",";3486986287;+393356895168","University of Trieste;","<br>        Inclusion Criteria:<br><br>          1. SARS-CoV-2 positive<br><br>          2. Age >17 years and < 80 years<br><br>          3. P/F < 250 mmHg<br><br>          4. Bilateral pneumonia (infiltrates/interstitial)<br><br>          5. C","","Severe Acute Respiratory Syndrome (SARS) Pneumonia;Coronavirus Infections;ARDS, Human","Drug: Methylprednisolone;Other: standard care","Composite primary end-point;death;Admission to ICU;Endotracheal intubation (invasive mechanical ventilation)","","","","Yes","0","          ",""
"NCT04323800","2020-03-30","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","CSSC-001","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323800","Not recruiting","No","18 Years","N/A","All","2020-04-01","150.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). ","Phase 2",""," ; ","Darin Ostrander, PhD;Darin Ostrander, PhD","",";dostran1@jhmi.edu",";410-614-6702","Johns Hopkins University;","<br>        Inclusion Criteria:<br><br>          -  Subjects must be 18 years of age or older<br><br>          -  Close contact* exposure to person with COVID-19 within 96 hours of enrollment (and 120<br>             hours of receipt of plasma)<br>","","Coronavirus;Convalescence","Biological: Anti- SARS-CoV-2 Plasma;Biological: SARS-CoV-2 non-immune Plasma","Cumulative incidence of composite outcome of disease severity","","","","Yes","0","          ",""
"ChiCTR2000029826","2020-03-16","Cancelled by the investigator            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumoni","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)                             ","","Jingzhou Central Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49481","Not Recruiting","No","18.0","75.0","Both","2020-02-17","Phosphoric chloroquine:30;Placebo:15;","Interventional study","Parallel","4.0","China","Jinghua Mao","","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","hbjzyyywlc@163.com","+86 071 68497225","Jingzhou Central Hospital","Inclusion criteria: 1. Patients who meet the requirements of the New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);<br>2. Aged 18-75 years male or female;<br>3. Serious patient meet one of the following:<br","Exclusion criteria: If subject meet one of the following exclusion critera, he/she cannot be enrolled in this study:<br>1. Be dysphagia and cannot receive drud by oral administration;<br>2. Complicated with pneumonia infected by other virus;<br>3. Alle","Novel Coronavirus Pneumonia (COVID-19)","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)"";Placebo:2 tablets placebo BID;","Mortality rate;","","","","Yes","0","          ",""
"ChiCTR2000029820","2020-03-16","Cancelled by investigator                                      A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                               ","","Wuhan Asia General Hospital","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49492","","No","1.0","90.0","Both","2020-02-01","Case series:410;","Observational study","Sequential","N/A","China","Huang Keqiang","","300 Taizihu north Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei, China","hkq123123@163.com","+86 15287110369","Wuhan Asia General Hospital","Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital","Exclusion criteria: 2020.01.01 Patients who have tested negative for new coronavirus in our hospital","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","DEATH;","","","","No","0","          ",""
"NCT04322344","2020-03-30","Escin in Patients With Covid-19 Infection","Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","add-on-COV2","University of Catanzaro","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322344","Recruiting","No","18 Years","75 Years","All","2020-03-23","120.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider). ","Phase 2/Phase 3","Italy"," ; ","LUCA GALLELLI;LUCA GALLELLI","","gallelli@unicz.it;gallelli@unicz.it","3339245656;3339245656","","<br>        Inclusion Criteria:<br><br>          -  Aged between 18 and 75 years, extremes included, male or female<br><br>          -  Positivity to covid-19 screening test in molecular biology<br><br>          -  In escin group: Low response to s","","Coronavirus Infections","Drug: Escin;Drug: standard therapy","Mortality rate;Clinical status evaluated in agreement with guidelines","","","","Yes","0","          ",""
"NCT04322565","2020-03-30","Colchicine Efficacy in COVID-19 Pneumonia","COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA","","Lucio Manenti","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322565","Not recruiting","No","18 Years","85 Years","All","2020-04-01","100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2",""," ","Lucio Manenti, MD","","lmanenti@ao.pr.it","393400732913.0","","<br>        Inclusion Criteria:<br><br>          -  According to the risk stratification criteria of the Emilia-Romagna Region, Italy<br>             (accessed on March 24th, 2020 http://www...), eligible patients will belong to the<br>             S","","Coronavirus Infections;Pneumonia, Viral","Drug: Colchicine","Clinical improvement;Hospital discharge","","","","Yes","0","          ",""
"NCT04322773","2020-03-30","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","TOCIVID","Marius Henriksen","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322773","Not recruiting","No","18 Years","N/A","All","2020-03-25","200.0","Interventional","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Denmark"," ; ; ","Lars Erik Kristensen, PhD;Lars Erik Kristensen, PhD;Lars Erik Kristensen, PhD","",";lars.erik.kristensen@regionh.dk;lars.erik.kristensen@regionh.dk",";0045 38164157;0045 38164157","The Parker Institute;","<br>        Inclusion Criteria:<br><br>          -  SARS-CoV-2 infection confirmed by real time-PCR and<br><br>          -  Positive imaging: consolidation, ground glass opacities, or bilateral pulmonary<br>             infiltration either by CT-sca","","Corona Virus Disease","Drug: RoActemra iv;Drug: RoActemra sc;Drug: Kevzara sc;Other: Standard medical care","Time to independence from supplementary oxygen therapy","","","","Yes","0","          ",""
"NCT04322786","2020-03-30","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.","","University College, London","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322786","Not recruiting","No","18 Years","N/A","All","1998-01-01","1302508.0","Observational","","Phase 2","","","","","","","","<br>        Inclusion Criteria:<br><br>          -  We identify individuals aged 18 years or older and registered in the current primary<br>             care practice for at least one year.<br><br>        Exclusion Criteria:<br><br>          -  We","","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Drug: ACE inhibitor","Incidence of influenza","","","","No","0","          ",""
"NCT04320862","2020-03-30","Pandemic Response Network","Pandemic Response Network: Duke Community Health Watch","","Duke University","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320862","Not recruiting","No","N/A","N/A","All","2020-03-31","20000.0","Observational","","N/A","United States"," ; ","Becky Smith, MD;Mark Sendak, MD, MPP","",";mark.sendak@duke.edu",";919-684-3234","Duke University;","<br>        Inclusion Criteria:<br><br>          -  flu-like symptoms<br><br>          -  a viral test order for COVID-19<br><br>          -  confirmed COVID-19<br><br>          -  concern for exposure to COVID-19<br><br>        Exclusion Crite","","COVID-19;SARS-CoV-2;Coronavirus;Influenza -Like Illness;Lower Resp Tract Infection;Upper Resp Tract Infection","","Number of participants who experience inpatient admission","","","","Yes","0","          ",""
"NCT04321096","2020-03-30","The Impact of Camostat Mesilate on COVID-19 Infection","The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","CamoCO-19","University of Aarhus","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321096","Not recruiting","No","18 Years","110 Years","All","2020-03-31","180.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 1/Phase 2","Denmark"," ; ","Lars stergaard, Professor;Ole S Sgaard, MD PhD","",";olesoega@rm.dk",";+45 78452842","Head of Department;","<br>        Inclusion Criteria:<br><br>          -  Documented COVID-19 infection as evidenced by positive PCR (or comparable clinical<br>             assay) for SARS-CoV-2<br><br>          -  Less than 48 hours since time of hospital admission OR i","","Corona Virus Infection","Drug: Camostat Mesilate;Drug: Placebo oral tablet","Days to clinical improvement from study enrolment","","","","Yes","0","          ",""
"NCT04321421","2020-03-30","Hyperimmune Plasma for Critical Patients With COVID-19","Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","COV19-PLASMA","Foundation IRCCS San Matteo Hospital","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321421","Not recruiting","No","18 Years","N/A","All","2020-03-17","49.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","Italy"," ","Cesare Perotti, MD","","","","Foundation IRCCS San Matteo Hospital","<br>        Inclusion Criteria:<br><br>          -  age >=18 yrs<br><br>          -  positive for reverse transcription polymerase chain reaction (RT-PCR) severe acute<br>             respiratory syndrome (SARS)-CoV-2<br><br>          -  Acute res","","COVID-19","Other: hyperimmune plasma","death","","","","Yes","0","          ",""
"NCT04322188","2020-03-30","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications","SISCO","A.O. Ospedale Papa Giovanni XXIII","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322188","Recruiting","No","18 Years","N/A","All","2020-03-19","50.0","Observational","","Phase 1","Italy"," ; ; ","Giuseppe GRITTI, MD;GIUSEPPE GRITTI, MD;Alessandro Rambaldi, MD","",";g.gritti@asst-pg23.it;arambaldi@asst-pg23.it",";+39.0352673684;+39 035 2673683","ASST PAPA GIOVANNI XXIII;","<br>        Inclusion Criteria:<br><br>          1. Clinical and radiological diagnosis of pulmonary infection by COVID-19<br><br>          2. Positive microbiological evidence of SARS-CoV-2 infection<br><br>          3. Diagnosis of acute respirat","","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection","","Cohort A: reduction of the need of invasive ventilation or 30-day mortality;Cohort B: reduction of mortality","","","","Yes","0","          ",""
"ISRCTN86534580","2020-03-30","A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above","Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)                                                                                                                                                                        ","","University of Oxford","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ISRCTN","http://isrctn.com/ISRCTN86534580","Recruiting","No","","","Both","2020-03-25","3000.0","Interventional","Pragmatic open prospective individually randomised platform randomised controlled clinical trial in community care (Treatment)","Phase III","United Kingdom","Emma;Julie","Ogburn;Allen","
                    Nuffield Department of Primary Care Health Sciences, University of Oxford
                    Radcliffe Observatory Quarter, Woodstock Road
                ;
                    Nuffield Department of Primary Care Health Sciences, Uni","emma.ogburn@phc.ox.ac.uk;julie.allen@phc.ox.ac.uk","-;+44 (0)1865 617868",";","Inclusion criteria: <br>                1. Participant is willing and able to give informed consent for participation in the study<br>                2. Participant is willing to comply with all trial procedures<br>                3. Onset of symptoms of ","Exclusion criteria: <br>                1. Pregnancy<br>                2. Breastfeeding<br>                3. Known severe hepatic impairment<br>                4. Known severe renal impairment<br>                5. Known porphyrias<br>                6.","COVID-19 (SARS-CoV-2 infection) <br>Infections and Infestations <br>Coronavirus infection, unspecified site","<br>                The trial will initially be two-arm, comparing usual care to usual care with hydroxychloroquine treatment.<br><br>                The trial will be implemented in the first instance in practices that are already part of the RCGP RSC Ne","The need for hospital admission or death, for patients aged =50 years with comorbidity, and aged =65 with or without comorbidity and suspected COVID-19 infection during time of prevalent COVID-19 infections, measured by hospital admission or mortality rel","","2021-03-24","","Yes","0","          ",""
"ISRCTN14966673","2020-03-30","Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?","Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)                                           ","","University Hospital Southampton NHS Foundation Trust","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ISRCTN","http://isrctn.com/ISRCTN14966673","Recruiting","No","","","Both","2020-03-20","500.0","Interventional","Prospective interventional non-randomised pre and post implementation study (Diagnostic)","Not Applicable","United Kingdom","","","","","","","Inclusion criteria: <br>                1. Is a patient in ED, AMU, HDU, GICU, medical wards, or another location within Southampton General Hospital, University Hospital Southampton NHS Foundation Trust (UHS)<br>                2. Aged =18 years old<br> ","Exclusion criteria: <br>                1. Not fulfilling all the inclusion criteria<br>                2. Declines nasal/pharyngeal swabbing<br>                3. Consent declined or consultee consent declined<br>                4. Already recruited to t","COVID-19 (SARS-CoV-2 infection) <br>Infections and Infestations <br>Coronavirus infection, unspecified site","Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient fo","Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation","","2021-04-01","","Yes","0","          ",""
"NCT04264533","2020-03-23","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","","ZhiYong Peng","2020-02-04","2020-02-04","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04264533","Recruiting","No","18 Years","N/A","All","2020-02-14","140.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). ","Phase 2","China"," ; ; ","Zhiyong Peng, professor;Zhiyong Peng, professor;Zhiyong Peng, professor","",";pengzy5@hotmail.com;",";+8618672396028;","Wuhan University;","<br>        Inclusion Criteria:<br><br>          1. = 18 years old;<br><br>          2. Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and<br>             Clinical management of 2019-nCoV infected pneumonia);<br><","","Vitamin C;Pneumonia, Viral;Pneumonia, Ventilator-Associated","Drug: VC;Drug: Sterile Water for Injection","Ventilation-free days","","","","Yes","0","          ",""
"NCT04306055","2020-03-23","Blood Donor Recruitment During Epidemic of COVID-19","Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China","","Guangzhou Blood Center","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04306055","Not recruiting","No","18 Years","60 Years","All","2020-03-12","1500.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). ","N/A","","","","","","","","<br>        Inclusion Criteria:<br><br>          -  Blood donors whose last donation were between 1 Jan to 31 March, 2019.<br><br>        Exclusion Criteria:<br><br>          -  Blood donors whose blood test results were positive.<br>      ","","Blood Donation","Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information","Differences of attitude about blood donation towards different questionnaires","","","","Yes","0","          ",""
"NCT04308187","2020-03-23","Influence of the COvid-19 Epidemic on STRESS","The COVISTRESS Study: Influence of the COvid-19 Epidemic on STRESS","COVISTRESS","University Hospital, Clermont-Ferrand","2020-03-12","2020-03-12","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04308187","Not recruiting","No","N/A","N/A","All","2020-03-11","50000.0","Observational [Patient Registry]","","Phase 2","France"," ; ; ","Frderic DUTHEIL;Lise Laclautre;Lise Laclautre","",";promo_interne_drci@chu-clermontferrand.fr;",";0473754963;0473754963","University Hospital, Clermont-Ferrand;","<br>        Inclusion Criteria:<br><br>          -  Anyone volunteer to participate<br><br>        Exclusion Criteria:<br><br>          -  Anyone non-voluntary to participate<br>      ","","Stress, Psychological","","Stress","","","","Yes","0","          ",""
"ChiCTR2000031115","2020-03-23","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                 ","","Zhengzhou People's Hospital","2020-03-22","2020-03-22","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51032","Recruiting","No","18.0","80.0","Both","2020-05-01","Case series:30;","Observational study","Sequential","0.0","China","Jiao Xianfa","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","278353780@qq.com","+86 13674950311","Zhengzhou People's Hospital","Inclusion criteria: COVID-19 patient","Exclusion criteria:  Under 18 years of age, suffering from autoimmune diseases","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","T lymphocyte subsets;","","","","Yes","0","          ",""
"ChiCTR2000031361","2020-03-30","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)                                                                                     ","","Hubei Maternal and Child Health Care Hospital","2020-03-28","2020-03-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51385","Not Recruiting","No","18.0","50.0","Female","2020-03-31","Cesarean section:2000;","Observational study","Sequential","Retrospective study","China","Shen Chan","","745 Wuluo Road, Hongshan District, Wuhan, Hubei, China","sunnyabs1215@163.com","+86 18986161976","Maternal and Child Health Hospital of Hubei Province","Inclusion criteria: Including maternal cases who performed emergency cesarean section in our hospital from January 24, 2020 to March 10, 2020","Exclusion criteria: Incomplete case data. ","Cesarean delivery","Cesarean section:Case Series;","fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;","","","","Yes","0","          ",""
"ChiCTR2000031336","2020-03-30","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                       ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-28","2020-03-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51517","Not Recruiting","No","18.0","90.0","Both","2020-04-12","Target condition:1000;Difficult condition:0","Diagnostic test","Sequential","N/A","China","Fan Yang","","1277 Jiefang Avenue, Wuhan, Hubei, China","fyang@vip.163.com","+86 027 85726309","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1) Positive;<br>2) There is a CT examination in our hospital.","Exclusion criteria: 1) Those with poor CT image quality;<br>2) Patients who are unwilling to participate in the study.","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:new&#32;artificial&#32;intelligence-based&#32;prognosis&#32;assessment&#32;system;","sensitivity;accuracy;specificity;","","","","Yes","0","          ",""
"ChiCTR2000030992","2020-03-23","A medical records based study for the diagnosis and prognosis prediction AI model of novel coronavirus pneumonia (COVID-19)","The Diagnosis and prognosis prediction of novel coronavirus pneumonia (COVID-19) based on AI and Radiomics                                                                                                                                                     ","","Changzheng Hospital, Naval Military Medical University, Shanghai","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51338","Recruiting","No","","","Both","2020-03-10","Target condition:1000;Difficult condition:0","Diagnostic test","Sequential","Retrospective study","","Fan Li","","415 Fengyang Road, Huangpu District, Shanghai, China ","fanli0930@163.com","+86 13564684699","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University","Inclusion criteria: (1) To include confirmed, suspected and clinically diagnosed cases according to the fifth edition of the diagnosis and treatment guidelines for COVID-19 issued by the national health and construction commission;<br>(2) Among the patie","Exclusion criteria: 1) Patients with severe respiratory movement artifacts <br>2) Children, pregnant women and lactating women;","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcomes;Index test:the&#32;diagnosis&#32;and&#32;prognosis&#32;prediction&#32;AI&#32;model;","SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000030989","2020-03-23","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial                                                                                             ","","Beijing Normal University","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51331","Not Recruiting","No","11.0","18.0","Both","2020-03-20","SFBT group:38;Waiting Group:38;","Interventional study","Parallel","N/A","China","Shitao Chen","","19 Xin-Jie-Kou-Wai Street, Haidian District, Beijing, China","kittychen36@gmail.com","+86 15967196694","Mental Health Service Center, Beijing Normal University","Inclusion criteria: 1. Aged 11-18 years middle school students;<br>2. GAD-7 score above 10;<br>3. willing to participate this study and receive their legal guardian's informed consent;<br>4. Have stable internet and quiet space to receive internet base","Exclusion criteria: 1) Have other severe psychological diagnosis;<br>2) Have suicidal ideation and plan during the past 2 week;<br>3) Not willing to let their legal guardian know their participation;<br>4) Currently taking psychiatric medication;<br>5","Novel Coronavirus Pneumonia (COVID-19); Anxiety Disorder","SFBT group:Internet based SFBT;Waiting Group:Wait ;","GAD-7;STAI-Y (C);","","","","Yes","0","          ",""
"NCT04323228","2020-03-30","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","ONSCOVID19","King Saud University","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323228","Not recruiting","No","18 Years","65 Years","All","2020-04-01","30.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider). ","Phase 4",""," ","Mahmoud M.A. Abulmeaty, M.D., FACN","","mabulmeaty@ksu.edu.sa","966548155983.0","","<br>        Inclusion Criteria:<br><br>          -  Confirmed SARS-CoV-2 infection<br><br>          -  COVID-19 patient in stable condition (i.e., not requiring ICU admission).<br><br>        Exclusion Criteria:<br><br>          -  Tube feeding o","","COVID-19","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants;Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial;Change from baseline Serum ferritin level at end of the trial;Change from baseline serum Interleukin-6 concentration at end of the trial;Change from baseline serum ","","","","Yes","0","          ",""
"NCT04323631","2020-03-30","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","","Rambam Health Care Campus","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323631","Not recruiting","No","18 Years","N/A","All","2020-03-01","1116.0","Interventional","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Early Phase 1",""," ; ","Paul;Paul","",";M_paul@rambam.health.gov.il",";+972-50-2062140","Rambam MC;","<br>        Inclusion Criteria:<br><br>          -  Adult patients (>18 years)<br><br>          -  Confirmed COVID-19 infection by real-time PCR from a respiratory or other body sample<br>             within 48 hours of testing.<br><br>          -","","COVID-19","Drug: Hydroxychloroquine;Other: The control group will not receive hydroxychloroquine","Number patients developing severe infection or death","","","","Yes","0","          ",""
"NCT04323644","2020-03-30","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","CovidSurg","University of Birmingham","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323644","Not recruiting","No","N/A","N/A","All","2020-03-31","1000.0","Observational","","Early Phase 1",""," ","Aneel Bhangu","","A.A.Bhangu@bham.ac.uk","+44 1216272949","","<br>        Inclusion Criteria:<br><br>          -  Patients undergoing ANY type of surgery in an operating theatre, this includes<br>             obstetrics<br><br>        AND<br><br>        - The patient had COVID-19 infection either at the time","","COVID-19;Coronavirus;Surgery","Procedure: Surgery","30-day mortality","","","","Yes","0","          ",""
"NCT04323878","2020-03-30","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Mario Negri Institute for Pharmacological Research","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323878","Not recruiting","No","18 Years","N/A","All","2020-04-06","3000.0","Observational [Patient Registry]","","Phase 4","","","","","","","","<br>        Inclusion Criteria:<br><br>        All the ED patients positive to or suspected of COVID-19 infection with at least one of the<br>        following symptoms:<br><br>          -  fever<br><br>          -  cough/dyspnea<br><br>        ","","Early CPAP Ventilation in COVID-19 Patients","","Death or need of intubation","","","","Yes","0","          ",""
"NCT04322396","2020-03-30","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","ProPAC-COVID","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322396","Not recruiting","No","N/A","N/A","All","2020-04-01","226.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 4",""," ","Jens-Ulrik Sthr Jensen, MD, PhD","","jens.ulrik.jensen@regionh.dk","4528938168.0","","<br>        Inclusion Criteria:<br><br>          -  Patient admitted to a Danish emergency department, lung medical department or medical<br>             department<br><br>          -  Age >18 years<br><br>          -  Hospitalized <48 hours<br>","","Virus Diseases;Infection Viral","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo oral tablet;Drug: Placebo oral tablet","Number of days alive and discharged from hospital within 14 days","","","","Yes","0","          ",""
"NCT04322487","2020-03-30","Simple, Safe, Same: Lung Ultrasound for COVID-19","Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method","LUSCOVID19","Catholic University of the Sacred Heart","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322487","Not recruiting","No","N/A","N/A","All","2020-04-01","100.0","Observational","","N/A","Italy"," ; ; ; ; ","Riccardo Inchingolo, MD, PhD;Andrea Smargiassi, MD, PhD;Libertario Demi, PhD;Gino Soldati, MD;Libertario Demi, PhD","",";;;;libertario.demi@unitn.it",";;;;00390461283942","Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Dept. of Information Engineering and Computer Science, University of Trento, Italy;Diagnostic and Interventional Ultrasound Uni","<br>        Inclusion Criteria:<br><br>          -  suspected COVID-19 patients,<br><br>          -  known COVID-19 patients.<br><br>        Exclusion Criteria:<br><br>          -  confirmed disease different from COVID-19.<br>      ","","Coronavirus;Epidemic Disease;Pneumonia, Viral","Diagnostic Test: Lung ultrasound","Lung ultrasound grading system for COVID-19 pneumonia","","","","Yes","0","          ",""
"NCT04322513","2020-03-30","Biomarkers for Identification of SARS-COV-2 Infection","Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection","B-DT-COV2","University of Catanzaro","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322513","Recruiting","No","14 Years","75 Years","All","2020-03-24","110.0","Observational","","N/A","Italy"," ; ","LUCA GALLELLI;LUCA GALLELLI","","gallelli@unicz.it;gallelli@unicz.it","3339245656;3339245656","","<br>        Inclusion Criteria:<br><br>          -  Aged between 18 and 75 years, extremes included, male or female In conscious patients,<br>             ability to understand and the willingness to sign a written informed consent document;<br>     ","","Coronavirus","Diagnostic Test: Biomarkers expression","Biomarkers expression;Liver Biomarkers expression","","","","Yes","0","          ",""
"NCT04323514","2020-03-30","Use of Ascorbic Acid in Patients With COVID 19","Use of Ascorbic Acid in Patients With COVID 19","","University of Palermo","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323514","Recruiting","No","N/A","N/A","All","2020-03-13","500.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","Italy"," ; ","Salvatore Corrao, MD;Salvatore Corrao, MD","","s.corrao@tiscali.it;s.corrao@tiscali.it","+390916662717;+390916662717","","<br>        Inclusion Criteria:<br><br>          -  In case of doubt of interstitial pneumonia with indications for intubation<br><br>          -  Positive swab test of SARS-CoV-2<br><br>          -  Interstitial pneumonia<br><br>          -  Sig","","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality","","","","Yes","0","          ",""
"ChiCTR2000031324","2020-03-30","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19)","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of COVID-19                                                                                                                       ","","Nanjing University Medical College Affiliated Drum Tower Hospital","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51668","Not Recruiting","No","","","Both","2020-04-10","Case series:300;","Observational study","Sequential","N/A","","Wei Min","","321 Zhongshan Road, Gulou District, Nanjing, Jiangsu, China","824647903@qq.com","+86 15850531741","Nanjing University Medical College Affiliated Drum Tower Hospital","Inclusion criteria: (1) the medical staff on the frontline of the clinical fight against COVID - 19 epidemic should wear protective equipment such as N95 / KN95 respirator, goggles or mask, protective clothing or isolation clothing when they go to hubei p","Exclusion criteria: No","Novel Coronavirus Pneumonia (COVID-19); medical adhesive-related skin injury","Case series:none;","Incidence of medical adhensive-related injury;","","","","Yes","0","          ",""
"ChiCTR2000031272","2020-03-30","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak                                                                                               ","","China European International Business School (CEIBS)","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51455","Not Recruiting","No","22.0","47.0","Both","2020-02-18","mindfulness intervention group:60;control group:50;","Interventional study","Quasi-randomized controlled","N/A","China","Zheng Xue","","699 Hongfeng Road, Pudong New District, Shanghai, China","zhengxue.academic@gmail.com","+86 17717830223","China European International Business School (CEIBS)","Inclusion criteria: Eligible participants are residents who were located in Wuhan during the lockdown starting from 23 January 2020 due to the Coronavirus breakout. The study was conducted for 12 days between 20 Feb to 2 March","Exclusion criteria: Participants who were not located in Wuhan when we conducted the study and those who did not practice mindfulness or mind-wandering exercise over the next 10 days.","Sleep, stress and anxiety","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","Anxiety level;Sleep;","","","","No","0","          ",""
"NCT04324073","2020-03-30","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","CORIMUNO-SARI","Assistance Publique - Hpitaux de Paris","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324073","Not recruiting","No","18 Years","N/A","All","2020-03-26","180.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","France"," ; ","Olivier HERMINE, MD-PhD;olivier HERMINE, MD PHD","","ohermine@gmail.com;ohermine@gmail.com","603707920;603707920","","<br>        Inclusion Criteria:<br><br>          1. Patients included in the CORIMUNO-19 cohort<br><br>          2. Patients belonging to one of the 2 following groups:<br><br>               -  Group 1: patients not requiring ICU at admission with ","","Corona Virus Infection","Drug: Sarilumab","Survival without needs of ventilator utilization at day 14.;WHO progression scale <=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14;WHO progression scale <=7 at day 4","","","","Yes","0","          ",""
"NCT04324528","2020-03-30","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV_ECMO","Dr. Alexander Supady","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324528","Not recruiting","No","18 Years","100 Years","All","2020-04-01","30.0","Interventional","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A",""," ; ","Alexander Supady, Dr., MPH;Alexander Supady, Dr., MPH","",";alexander.supady@universitaets-herzzentrum.de",";+49761270","University Clinic Freiburg;","<br>        Inclusion Criteria:<br><br>          -  SARS-CoV-2-infection with COVID-pneumonia<br><br>          -  vv-ECMO therapy<br><br>        Exclusion Criteria:<br><br>          -  pregnancy, breastfeeding<br>      ","","Coronavirus;COVID-19;SARS-CoV Infection;Respiratory Failure;Cytokine Storm","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber);Device: vv-ECMO only (no cytokine adsorption)","interleukin-6 (IL-6) level after 72 hours","","","","Yes","0","          ",""
"NCT04325412","2020-03-30","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","CAPACITY-COVID","UMC Utrecht","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04325412","Recruiting","No","18 Years","N/A","All","2020-03-23","1000.0","Observational [Patient Registry]","","N/A","Netherlands"," ; ","Folkert W. Asselbergs, MD, PhD;Marijke Linschoten, MD","","f.w.asselbergs@umcutrecht.nl;m.p.m.linschoten@umcutrecht.nl","+31 (0) 88 755 5555;+31 (0)88 755 5555","","<br>        Inclusion Criteria:<br><br>          -  Highly suspected/confirmed infection with SARS-CoV-2<br><br>        Exclusion Criteria:<br><br>        - Patients that opt-out<br>      ","","COVID-19; Cardiovascular Diseases","","The incidence of cardiovascular complications in patients with COVID-19","","","","Yes","0","          ",""
"NCT04325633","2020-03-30","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","Assistance Publique - Hpitaux de Paris","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04325633","Not recruiting","No","18 Years","N/A","All","2020-03-27","584.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3",""," ; ","Frdric ADNET, MD, PhD;Frdric ADNET, MD, PhD","",";frederic.adnet@aphp.fr",";+33 1-48-96-44-08","Assistance Publique - Hpitaux de Paris;","<br>        Inclusion Criteria:<br><br>          -  COVID-19 infected patient<br><br>          -  Age 18 years or older<br><br>          -  Presence of pneumonia<br><br>          -  PaO2/FiO2 < 300 mm Hg or SpO2 < 93% in air ambient or need to su","","COVID-19","Drug: 1: Naproxen;Drug: 2: Standard of care","Mortality all causes at day30","","","","Yes","0","          ",""
"ChiCTR2000031252","2020-03-30","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection                                                                                                                                                                  ","","Chongqing Medical University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51559","Not Recruiting","No","","","Both","2020-02-10","Case series:60;","Observational study","Cohort study","N/A","China","Qiuling Shi","","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","qshi@cqmu.edu.cn","+86 023-68485008","Department of Public Health and Management, Chongqing Medical University","Inclusion criteria: (1) Have a clear history of contact with confirmed cases;<br>(2) Two consecutive positive nucleic acid tests;<br>(3) No clinically relevant symptoms;<br>(4) Patient voluntary.","Exclusion criteria: (1) Patients have clinical symptoms or CT positive changes;<br>(2) Patients have no willingness to participate in the study;<br>(3) Patients with unconsciousness.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;","","","","No","0","          ",""
"ChiCTR2000031246","2020-03-30","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                             ","","School of Public Health and Management, Chongqing Medical University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51535","Not Recruiting","No","","","Both","2020-02-01","Case series:68;","Observational study","Sequential","N/A","China","Xiaojun Tang","","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","tangxiaoj0726@qq.com","+86 13668023656","School of Public Health and Management, Chongqing Medical University","Inclusion criteria: 1. History of contact with confirmed cases;<br>2. During the 14-day clinical observation period after contact with the confirmed case;<br>3. Nucleic acid test positive twice in a row;<br>4. Without any clinically relevant symptoms;","Exclusion criteria: 1. Have clinical symptoms or CT positive changes;<br>2. Patients no willingness to participate in the study;<br>3. Patients with consciousness disorders.","Novel Coronavirus Pneumonia (COVID-19)","Case series:NO;","IgG antibody;IgM antibody;Throat swab virus nucleic acid test;","","","","No","0","          ",""
"ChiCTR2000030941","2020-03-23","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggang.                                                                                                                 ","","Hu'nan Provincial People's Hospital, Hu'nan Normal University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51000","Recruiting","No","","","Both","2020-01-28","Case series:200;","Observational study","Sequential","N/A","China","YY Chen","","61 West Jiefang Road, Changsha, Hu'nan, China","chenyinyin1212@hunnu.edu.cn","+86 13637403483","Hu'nan Provincial People's Hospital, Hu'nan Normal University","Inclusion criteria: Severe patients diagnosed with novel coronavirus pneumonia (COVID-19) in Huanggang City, and admitted to the Dabie mountain regional treatment center in huanggang from Jan.28th,2020 to Mar.12th,2020.","Exclusion criteria: Patients who died within 24h after admission.","novel coronavirus pneumonia (COVID-19)","Case series:Nil;","clincical characteristics;","","","","No","0","          ",""
"ChiCTR2000030939","2020-03-23","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia                                                                                                                     ","","PLA General Hospital","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51059","Recruiting","No","14.0","","Both","2020-03-16","Case series:10;","Interventional study","Non randomized control","0.0","China","Gang Sun","","28 Fuxing Road, Haidian District, Beijing, China","sunok301@126.com","+86 13501078679","PLA General Hospital","Inclusion criteria: (1) all patients with clearly diagnosed NCP who voluntarily receive treatment and do not participate in other clinical trials;<br>(2) aged >=18 years, approved by the ethics committee, fully understand and sign the informed consent.","Exclusion criteria: (1) those who do not meet the above inclusion criteria;<br>(2) pregnant and lactating women;<br>(3) severe basic diseases of the liver (Child Pugh score >=C, AST > 5 times the upper limit);<br>(4) serious renal damage basic diseases","Novel Coronavirus Pneumonia (COVID-19)","Case series:oral CSA0001;","nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C","","","","No","0","          ",""
"NCT04323787","2020-03-30","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)","VIRUS","Mayo Clinic","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323787","Recruiting","No","N/A","N/A","All","2020-04-01","50000.0","Observational","","N/A","United States"," ","Rahul Kashya, MBBS","","","","Mayo Clinic","<br>        Inclusion Criteria:<br><br>          -  COVID-19 PCR positive (within 7 days)<br><br>          -  COVID-19 PCR pending<br><br>          -  COVID-19 high clinical suspicion<br><br>        Exclusion Criteria:<br><br>          -  Patie","","Coronavirus","Other: observational","ICU and hospital mortality of COVID-19 patients","","","","Yes","0","          ",""
"NCT04323839","2020-03-30","PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","PRIORITY (Pregnancy Coronavirus Outcomes Registry)","PRIORITY","University of California, San Francisco","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323839","Recruiting","No","18 Years","N/A","Female","2020-03-20","1000.0","Observational [Patient Registry]","","N/A","United States"," ; ; ","Vanessa Vacoby, MD, MAS;Ruth Gebrezghi;Study Coordinator","",";PRIORITYCOVID19@ucsf.edu;PRIORITYCOVID19@ucsf.edu",";(415) 754-3749;415-754-3749","University of California, San Francisco;","<br>        Inclusion Criteria:<br><br>          1. Pregnant women or women who have been pregnant within the last 6 weeks<br><br>          2. Able to give informed consent<br><br>          3. Diagnosed with COVID-19; or being evaluated for COVID-1","","Pregnancy;Coronavirus;COVID-19","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19;Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19","","","","Yes","0","          ",""
"NCT04324021","2020-03-30","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1","","Swedish Orphan Biovitrum","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324021","Not recruiting","No","30 Years","79 Years","All","2020-03-01","54.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","Italy"," ; ","Emanuele Nicastri, MD;Cristina de Min, MD / CMO","",";sobi.immuno@sobi.com",";+46 8 697 20 00","Direttore Dipartimento di Malattie Infettive;","<br>        Inclusion Criteria:<br><br>          1. Signed informed consent provided by the patient, or by the patient's legally<br>             authorized representative(s), as applicable.<br><br>          2. Documented presence of SARS-CoV-2 infec","","SARS-CoV-2","Biological: Emapalumab;Biological: Anakinra","Treatment success","","","","Yes","0","          ",""
"NCT04324047","2020-03-30","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","CORIMUNO-19","Assistance Publique - Hpitaux de Paris","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324047","Not recruiting","Yes","18 Years","N/A","All","2020-03-26","1000.0","Observational","","N/A",""," ","Olivier HERMINE, MD-PhD","","ohermine@gmail.com","603707920.0","","<br>        Inclusion Criteria:<br><br>          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or<br>             public health assay in any specimen < 72 hours and/or CT Scan prior to randomization<br>       ","","Corona Virus Infection","","Survival;WHO progression scale COVID 19","","","","Yes","True ","parent    ",""
"ChiCTR2000031244","2020-03-30","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a cohort study                                                                                                                                                ","","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51486","Not Recruiting","No","18.0","99.0","Both","2020-03-25","Case series:200;","Observational study","Sequential","N/A","China","Wei Wang","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","wwang@vip.126.com","+86 13871143176","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: Patients with Covid-19 discharged from the hospital meet the following criteria:<br>(1) clinical and inpatient data are completely available;<br>Must include: blood routine on admission and discharge; chest CT; antibody test results ","Exclusion criteria: Pregnant women; less than 18 years old; serious diseases (cardiovascular diseases, respiratory diseases, digestive diseases, etc); patients with tumor; patients who can not cooperate","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","RT-PCR test for Covid-19;CT image;Covid-19 antibody test;","","","","Yes","0","          ",""
"ChiCTR2000031203","2020-03-30","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)                                                                                                        ","","Zhengzhou People's Hospital","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51030","Recruiting","No","18.0","75.0","Both","2020-03-16","1:14;2:14;","Interventional study","Parallel","0.0","China","Fu Liran","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","fuliran@126.com","+86 15837117112","Zhengzhou People's Hospital","Inclusion criteria: 1. Those who meet the above-mentioned diagnostic criteria and have reached the standards of separation and discharge after clinical treatment;<br>2. The patient was conscious, without aphasia, mental retardation, literacy, volunteered","Exclusion criteria: 1. Cases of clinical treatment of pneumonia;<br>2. Those who cannot understand the content of the scale and cannot evaluate the curative effect;<br>3. Suicide-prone by the doctor;<br>4. pregnant women, those with severe cardiovascul","Novel Coronavirus Pneumonia (COVID-19)","1:Blank;2:Moxibustion treatment;","TCM Syndrome Scale;","","","","No","0","          ",""
"ISRCTN83971151","2020-03-30","Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients","
                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care
                                                                                            ","","World Health Organization","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ISRCTN","http://isrctn.com/ISRCTN83971151","Recruiting","No","","","Both","2020-03-26","10000.0","Interventional","Open-label randomized multicountry clinical trial  (Treatment)","Phase III","Argentina;Brazil;Canada;Germany;Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand","","","","","","","Inclusion criteria: <br>                1. Adults (aged =18 years) hospitalized with definite COVID-19<br>                2. Not already receiving any of the study drugs<br>                3. Without known allergy or contraindications to any of them (in t","Exclusion criteria: <br>                1. Any of the available study drugs are contra-indicated (e.g. because of patient characteristics, chronic liver or heart disease, or some concurrent medication)<br>                2. Pregnant<br>                3. ","COVID-19 (SARS-CoV-2 infection) <br>Infections and Infestations <br>COVID-19 (SARS-CoV-2 infection)","<br>                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups","All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study","","2021-03-25","","Yes","0","          ",""
"ChiCTR2000031376","2020-03-30","A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","Safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy                                                                                                                                       ","","Peking University Third Hospital","2020-03-29","2020-03-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51724","Recruiting","No","18.0","?","Both","2020-03-28","Mild:400;severe:200;","Observational study","Factorial","N/A","China","Dongyang Liu","","49 North Huayuan Road, Haidian District, Beijing, China","liudongyang@vip.sina.com","+86 18610966092","Peking University Third Hospital","Inclusion criteria: 1. Aged 18 to 75 years;<br>2. Patients with confirmed cases meeting the following criteria:<br>(1) Epidemiology history;<br>(2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items; no","Exclusion criteria: 1.Patients with server diseases of the blood system;<br> Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upp","Novel Coronavirus Pneumonia (COVID-19)","Mild:No;severe:No;","Safety;Effectiveness;","","","","No","0","          ",""
"ChiCTR2000030922","2020-03-23","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection                                                                                                                     ","","Foshan First People's Hospital","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51141","Recruiting","No","18.0","65.0","Both","2020-02-26","A:15;B:15;","Interventional study","Parallel","N/A","China","Bin Zhang/Yinong Ye","","81 Lingnan Avenue North, Foshan, Guangdong, China","FSYYN001@126.com","+86 18038860666","Department of Infectious Diseases, Foshan First People's Hospital","Inclusion criteria: (1) Aged 18 to 65 years old;<br>(2) Patients with mild or normal type who have been diagnosed with new type of coronavirus infection [in accordance with the diagnostic criteria of the Notice on Printing and Distributing New Coronaviru","Exclusion criteria: (1) Female patients who are pregnant or planning to become pregnant within 7 months;<br>(2) ALT is higher than 10 times the upper limit of normal value, or total bilirubin is highter than 2 times the upper limit of normal value, or th","Novel Coronavirus Pneumonia (COVID-19)","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;","","","","No","0","          ",""
"ChiCTR2000030906","2020-03-23","A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)","A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years                                                                                  ","","Jiangsu Provincial Center for Disease Control and Prevention","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51154","Recruiting","No","18.0","60.0","Both","2020-03-10","1:36;2:36;3:36;","Prevention","Non randomized control","1.0","China","Zhu Fengcai","","172 Jiangsu Road, Gulou District, Nanjing District, Jiangsu, China","iszfc@sina.com","+86 025 83759418","Jiangsu Provincial Center for Disease Control and Prevention","Inclusion criteria: 1. Aged between 18 and 60 years;<br>2. Able to understand the content of informed consent and willing to sign the informed consent;<br>3. Able and willing to complete all the secluded study process during the whole follow-up period o","Exclusion criteria: 1. Family history of seizure, epilepsy, brain or mental disease;<br>2. Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past;<br>3. Woman who is preg","Novel Coronavirus Pneumonia (COVID-19)","1:Low dose (5E10vp);2:Middle dose (1E11vp);3:High dose (1E11vp);","adverse reactions 7 days post injection;","","","","No","0","          ",""
"NCT04324463","2020-03-30","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","ACT COVID19","Population Health Research Institute","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324463","Not recruiting","No","18 Years","N/A","All","2020-04-01","1500.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","Canada"," ; ; ; ","Richard Whitlock, MD PhD;Emilie Belley-Cote, MD PhD;ACT COVID-19 Study Coordinator;ACT COVID-19 Study Coordinator","",";;ACT.ProjectTeam@PHRI.ca;ACT.ProjectTeam@PHRI.ca",";;905-297-3479;","Population Health Research Institute;Population Health Research Institute;","<br>        Inclusion Criteria:<br><br>          -  Age = 18 years of age<br><br>          -  Informed consent<br><br>          -  COVID-19 confirmed by established testing<br><br>        Exclusion Criteria:<br><br>          -  Known glucose-6-","","Coronavirus;Severe Acute Respiratory Syndrome","Drug: Azithromycin;Drug: Chloroquine","Outpatients: Hospital Admission or Death;Inpatients: Invasive mechanical ventilation or mortality","","","","Yes","0","          ",""
"NCT04324489","2020-03-30","DAS181 for COVID-19: Compassionate Use","DAS181 for Severe COVID-19: Compassionate Use","","Renmin Hospital of Wuhan University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324489","Recruiting","No","18 Years","70 Years","All","2020-03-06","4.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ; ; ","Zuojiong Gong, MD;Zuojiong Gong, MD;Zuojiong Guong, MD","",";zjgong@163.com;",";027-88999120;","Renmin Hospital of Wuhan University;","<br>        Key Inclusion Criteria:<br><br>          1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens<br><br>          2. Hypoxemic<br><br>          3. Severe COVID-19<br><br>          4. If female, subject must not","","COVID-19","Drug: DAS181","Improved clinical status;Return to room air","","","","Yes","0","          ",""
"NCT04324996","2020-03-30","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","","Chongqing Public Health Medical Center","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324996","Recruiting","No","18 Years","N/A","All","2020-03-21","90.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 1/Phase 2","China"," ; ; ","Min Liu, A.B;Min Liu, A.B;Min Liu, A.B","",";gwzxliumin@foxmail.com;gwzxliumin@foxmail.com",";13668072999;13668072999","Chongqing Public Health Center;","<br>        Inclusion Criteria:<br><br>          1. Sign written informed consent;<br><br>          2. Age =18 years;<br><br>          3. Conforms to the NCP Critical and Critical Diagnostic Standards, namely ""Pneumonitis<br>             Diagnosis","","COVID-19","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Clinical response;Side effects in the treatment group","","","","Yes","0","          ",""
"NCT04325646","2020-03-30","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","CORSER","Institut Pasteur","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04325646","Recruiting","No","5 Years","N/A","All","2020-03-13","1000.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ","N/A","France"," ","Bruno HOEN, Pr","","bruno.hoen@pasteur.fr","+33 1 40 61 37 60","","<br>        Inclusion Criteria:<br><br>          -  Affiliated with or benefiting from a Social Security system<br><br>          -  State of health compatible with a blood sample as defined in the protocol<br><br>        For CORSER-1 subjects:<br>","","SARS (Severe Acute Respiratory Syndrome);COVID-19","Other: Human Biological samples","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.","","","","Yes","0","          ",""
"ChiCTR2000031199","2020-03-30","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                      ","","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51478","Recruiting","No","18.0","80.0","Both","2020-03-24","Case series:150;","Observational study","Sequential","Retrospective study","China","Fan Rong","","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China ","fanrong3463@163.com","+86 13808454319","","Inclusion criteria: According to the clinical diagnostic criteria of the seventh or latest edition  ""diagnosis and treatment of pneumonia with novel coronavirus infection"", severe COVID-19 pneumonia was clinically diagnosed.","Exclusion criteria: (1) Patients who are participating in clinical trials of other drugs;<br>(2) Pregnant or lactating women;<br>(3) Patients with rheumatism-related diseases;<br>(4) Long-term oral anti-rejection drugs or immunomodulatory drugs;<br>(5","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Cure rate;improvement rate;","","","","Yes","0","          ",""
"ChiCTR2000031176","2020-03-30","Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic","Study on home pharmaceutical care for chronic patients over the new coronavirus pneumonia epidemic                                                                                                                                                             ","","People's hospital of Zhengzhou","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51443","Recruiting","No","45.0","80.0","Both","2020-02-20","Homeopathic patient:100;","Observational study","Sequential","N/A","China","Zhang Yi","","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","nicole8611@163.com","+86 13837167212","People's hospital of Zhengzhou","Inclusion criteria: Homeopathic patient","Exclusion criteria: Patients in hospital, complicated with other acute and severe diseases, etc","Chronic diseases such as hypertension, diabetes, malignant tumor, immunosuppressive state, etc","Homeopathic patient:The popular science education;","Patient satisfaction;","","","","No","0","          ",""
"ChiCTR2000030519","2020-03-23","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia COVID-19                                                                                                                                                     ","","Guangzhou Eighth People's Hospital","2020-03-05","2020-03-05","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50604","Not Recruiting","No","18.0","85.0","Both","2020-03-06","Case series:40;","Observational study","Sequential","0.0","China","Chuo Li","","8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","gz8hlc@126.com","+86 15989096626","Guangzhou Eighth People's Hospital","Inclusion criteria: 1. Pharyngeal swabs and / or anal swab specimens are positive for new coronavirus nucleic acids, or viral gene sequencing is highly homologous to known new coronaviruses;<br>2. Males and females aged 18 to 85 years;<br>3. Participant","Exclusion criteria: 1. Patients who have contraindications to specimen collection, such as: coagulopathy, rectal tumors, anal canal disease, severe cardiopulmonary dysfunction, etc .;<br>2. Patients with mental illness cannot cooperate with sampling;<br","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","RNA of  Coronavirus;","","","","Yes","0","          ",""
"ChiCTR2000030254","2020-03-23","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study                                                                                               ","","Zhongnan Hospital of Wuhan University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50137","Not Recruiting","No","18.0","100.0","Both","2020-02-20","Experimental group:120;Control group:120;","Interventional study","Parallel","0.0","China","Xinghuan Wang","","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","wangxinghuan@whu.edu.cn","+86 027 67813096","Zhongnan Hospital of Wuhan University","Inclusion criteria: (1) Aged 18 years or older; <br>(2) Voluntarily signed informed consent;<br>(3) Hospitalized patients diagnosed as COVID-19.","Exclusion criteria: (1) Allergic to fabiravir or abidol;<br>(2) ALT/AST increased 5 times higher than the upper limit of normal, or with child Pugh C;<br>(3) Severe patients with expected survival time < 48 hours;<br>(4) Pregnancy;<br>(5) HIV positive","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Farpiravir tablets;Control group:Abidole tablets;","Clinical recovery rate of day 7;","","","","No","0","          ",""
"ChiCTR2000031356","2020-03-30","Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19)","Altered brain structure and function in patients with COVID-19 after rehabilitation                                                                                                                                                                            ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-28","2020-03-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51499","Not Recruiting","No","18.0","80.0","Both","2020-04-12","mild recovery:200;severe recovery:200;control:200;","Observational study","Factorial","N/A","China","Wenliang Fan","","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","fwl@hust.edu.cn","+86 027 85726727","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1) About one month after the recovery of COVID-19;<br>2) No other neurological diseases.","Exclusion criteria: 1) POSITIVE;<br>2) Those who cannot cooperate to complete the magnetic resonance examination.","Novel Coronavirus Pneumonia (COVID-19)","mild recovery:none;severe recovery:none;control:none;","brain volume;white matter;brain function;","","","","Yes","0","          ",""
"ChiCTR2000031330","2020-03-30","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation                                                                                                 ","","Shandong Eye Institute","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51504","Recruiting","No","8.0","25.0","Both","2020-03-18","Case series:160;","Observational study","Sequential","N/A","China","Xianli Du","","5 Yan-Er-Dao Road, Qingdao, Shandong, China","lilibestever@126.com","+86 15192552255","Shandong Eye Institute","Inclusion criteria: 1. Myopia teenagers who were first fitted with or re-examined orthokeratology lens in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages;<br>2.The cornea is ","Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.","Myopia","Case series:orthokeratology lens;","Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","","","","No","0","          ",""
"NCT04325672","2020-03-30","Convalescent Plasma to Limit Coronavirus Associated Complications","Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","","Mayo Clinic","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04325672","Not recruiting","No","18 Years","N/A","All","2020-04-01","20.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). ","Phase 2","United States"," ; ","Michael Joyner, MD;Shelly Roberts, RN","",";roberts.shelly@mayo.edu",";507-255-2807","Mayo Clinic;","<br>        Inclusion Criteria:<br><br>          -  Patients must be 18 years of age or older<br><br>          -  Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19<br>             SARS-CoV-2 RT-PCR testing. Patient is wil","","Coronavirus","Biological: Convalescent Plasma","RNA in SARS-CoV-2;ICU Admissions;Hospital Mortality;Hospital Length of Stay (LOS)","","","","Yes","0","          ",""
"ACTRN12620000421932","2020-03-30","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)                                                                                                                                                            ","","The Prince Charles Hospital","2020-03-30","2020-03-30","2020-01-04 15:51:14 ","ANZCTR","https://anzctr.org.au/ACTRN12620000421932.aspx","Recruiting","No","No limit","No limit","Both males and females","2020-03-05","400.0","Observational","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Both;","Not Applicable","Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of;Japan;Italy;Singapore;Viet Nam;Thailand;United Kingdom;United States of America","","","","","","","Inclusion criteria: 1.	Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and/or next-generation sequencing<br>2.	Admission to an intensive care unit<br>","Exclusion criteria: 1.	Patients treated with mechanical ventilation for other concomitant causes.<br>2.	Patients treated with ECMO for other concomitant causes<br>","2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19);Respiratory Infection; <br>2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19) <br>Respiratory Infection;Infection - Studies of infection and infectious agents;Respiratory - Other respi","In patients in patients with 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in eff","Mortality<br>[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]","","","","No","0","          ",""
"ChiCTR2000030962","2020-03-30","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study                                                                     ","","Hospital of Chengdu University of Traditional Chinese Medicine","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51254","Not Recruiting","No","","","Both","2020-03-01","Case series:60;","Observational study","Single arm","N/A","China","Peiyang Gao","","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China","gaopy930@126.com","+86 18980025566","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: 1. Patients with severe and critical COVID-19 diagnosed in accordance with the Novel Coronavirus infected Pneumonia Diagnosis and Treatment Plan (Trial Version 6);<br>2. Aged >=18 years, both men and women;<br>3. Agree to participate","Exclusion criteria: 1. Those who cannot receive Chinese medicine treatment;<br>2. Patients with allergies to certain traditional Chinese medicine decoctions or traditional Chinese medicine injections;<br>3. Cases where complete diagnosis and treatment i","Novel Coronavirus Pneumonia (COVID-19)","Case series:standard treatment + syndrome differentiation and treatment of TCM;","fatality rate;the ratio of patients transforming from severe/critical to light;Non-invasive/invasive mechanical ventilation time;","","","","No","0","          ",""
"ChiCTR2000030938","2020-03-30","Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19)","Clinical investigation and reseach on TCM syndrome of COVID-19                                                                                                                                                                                                 ","","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51239","Recruiting","No","18.0","??","Both","2020-02-28","confirmed group:100;control group:60;","Observational study","Factorial","0.0","China","Sun Hongyuan","","88 Changling Road, Xiqing District, Tianjin, China","sunhongyuan12@163.com","+86 18222521385","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Inclusion criteria: The patients in the confirmed group met the diagnostic criteria of COVI-19.The control group excluded the suspected patients diagnosed with COVID-19; Aged>=18 years.","Exclusion criteria: 1. Those who do not meet the inclusion criteria;<br>2. Without the informed consent of the patient;<br>3. Unable to cooperate with the information collection due to illness or other reasons.","Novel Coronavirus Pneumonia (COVID-19)","confirmed group:none;control group:none;","traditional Chinese medicine symptom;","","","","No","0","          ",""
"ChiCTR2000031329","2020-03-30","Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases","Influence of COVID-19 on disease activity, medical and mental condition of patients with rheumatic diseases                                                                                                                                                    ","","Guangdong Second Provincial General Hospital","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51667","Recruiting","No","18.0","100.0","Both","2020-03-11","Case series:120;","Observational study","Sequential","N/A","","Tianwang Li","","466 Xingang Middle Road, Guangzhou, Guangdong, China","litian-wang@163.com","+86 13710874687","Guangdong Second Provincial General Hospital","Inclusion criteria: Patients should fulfill the diagnosis criteria of rheumatoid arthritis in 2009, systemic lupus erythematosus in 2009, axial spondyloarthritis in 2009 or gout in 2015.","Exclusion criteria: 1. Pregnant or breast-fed women;<br>2. age < 18 years;<br>3. Participating in any clinical trail in 12 weeks before signing informed consent form;<br>4. refuse to sign the informed consent form;<br>5. individuals who suffer from se","Rheumatic diseases; Novel Coronavirus Pneumonia (COVID-19)","Case series:None.;","medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;","","","","No","0","          ",""
"ChiCTR2000031328","2020-03-30","The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)                                                                                                                                   ","","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51425","Recruiting","No","18.0","","Both","2020-03-13","Group M:30;Group C:30;","Interventional study","Parallel","N/A","China","Yuan-hao Wu","","314 West Anshan Road, Nankai District, Tianjin, China","doctor.wuyh@gmail.com","+86 022 27986625","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Inclusion criteria: 1. Mild or moderate cases who meet the ""Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia"" issued by the National Health And Health Council are trialled in the fifth and sixth editions of clinical diagnosis and diagnosti","Exclusion criteria: 1. Combining patients with severe primary respiratory diseases, or with other pathogenic microbial pneumonia that needs to be identified in relation to COVID-19;<br>2. Combining systems such as heart, brain, lung, liver and kidney syl","Novel Coronavirus Pneumonia (COVID-19)","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in a","Self-assessment of sleep quality;Efficient of sleep improvement;","","","","No","0","          ",""
"ChiCTR2000030817","2020-03-30","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound                                                                                                                         ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50631","Recruiting","No","","","Both","2020-02-28","Light group:200;Common group:200;Severe group:200;Critical group:200;","Observational study","Factorial","0.0","China","Mingxing Xie","","1277 Jiefang Avenue, Wuhan, Hubei, China ","xiemx@hust.edu.cn","+86 13607108938","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)  ","Exclusion criteria: no exclusion critereia","Novel Coronavirus Pneumonia (COVID-19)","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","","","","No","0","          ",""
"ChiCTR2000029982","2020-03-30","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism                                                         ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49724","Recruiting","No","","","Both","2020-03-26","COVID-19 group:100;Healthy people:50;","Observational study","Factorial","0.0","China","Jin Yang","","1277 Jiefang Avenue, Wuhan, Hubei, China","whuhjy@sina.com","+86 13554361146","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"";<br>2. Those without broad-spectrum antibacterial,","Exclusion criteria: 1. A coma, MODS or death occurred on admission;<br>2. The estimated survival time is <7 days;<br>3. The patient's medical history is not detailed and relatives cannot be contacted.","novel coronavirus pneumonia (COVID-19)","COVID-19 group:NA;Healthy people:NA;","Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation i","","","","Yes","0","          ",""
"ACTRN12620000417987","2020-03-30","Chloroquine Chemorophylaxis Countermeasure against COVID-19","Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure                                                ","","Australian Defence Force Malaria and Infectious Disease Institute","2020-03-30","2020-03-30","2020-01-04 15:51:14 ","ANZCTR","https://anzctr.org.au/ACTRN12620000417987.aspx","Not Recruiting","No","18 Years","64 Years","Both males and females","2020-03-30","680.0","Interventional","Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy;","Phase 4","Australia","","","","","","","Inclusion criteria: Participants eligible for inclusion in this study must fulfill all of the following criteria:<br>1.	Completion of the written informed consent process (signed) with video recording of the verbal consent process;<br>2.	Male or female ","Exclusion criteria: Participants fulfilling any of the following criteria are not eligible for inclusion in this study:<br>1. History of allergy or intolerance to chloroquine, vitamin C or any excipients.<br>2. Contraindication to taking chloroquine as ","COVID-19 Infection; <br>COVID-19 Infection;Infection - Other infectious diseases","Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.","Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared bet","","","","Yes","0","          ",""
"ChiCTR2000031337","2020-03-30","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic                                                                                          ","","Shandong Eye Institute","2020-03-28","2020-03-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51170","Recruiting","No","8.0","25.0","Both","2020-03-18","Case series:400;","Observational study","Sequential","N/A","China","Xianli Du","","5 Yan-Er-Dao Road, Shi'nan District, Qingdao, Shandong, China","lilibestever@126.com","+86 15192552255","Shandong Eye Institute","Inclusion criteria: 1. Myopia teenagers who have optometry in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages,including those newly diagnosed patients who have been fitted wit","Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.","Myopia; Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","","","","No","0","          ",""
"ChiCTR2000031327","2020-03-30","Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records","Clinical characteristics and death risk factors in COVID-19 patients                                                                                                                                                                                           ","","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51669","Not Recruiting","No","18.0","100.0","Both","2020-04-01","Case series:120;","Observational study","Sequential","Retrospective study","China","Hong Qiu","","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","tjqiuhong@163.com","+86 13986296106","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Diagnosed as COVID-19 confirmed patient with a throat swab test;<br>2. Aged >=18 years;<br>3. Diagnosed as critical ill patients according to the New Coronavirus Pneumonia Diagnosis and Treatment Plan (the seventh edition);<br>4.","Exclusion criteria: 1. Suspected patients;<br>2. Pregnancy and lactation.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Time of death;The hospitalization time;","","","","Yes","0","          ",""
"ChiCTR2000031301","2020-03-30","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury                                                                                                                      ","","China-Japan Union Hospital of Jilin Unversity","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51603","Not Recruiting","No","18.0","100.0","Both","2020-02-01","Case series:100;","Observational study","Sequential","Retrospective study","China","Daoyuan Si","","126 Xiantai Street, Erdao District, Changchun, Jilin, China ","sidaoyuan1984@sina.com","+86 13578949866","China-Japan Union hospital of Jilin University","Inclusion criteria: Confirmed Covid-19 pneumonia patients (Covid-19 pneumonia treatment plan (Seventh Edition) who were admitted from February 2020 to March, and combined with cTnI elevation.","Exclusion criteria: Patients not suitable for study judged by researchers","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","ECG;","","","","No","0","          ",""
"ChiCTR2000031271","2020-03-30","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)                                                                                                                                            ","","The Third Affiliated Hospital of Sun Yat-sen University","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51194","Not Recruiting","No","18.0","65.0","Both","2020-04-01","Control group:40;Experimental group:40;","Interventional study","Parallel","0.0","China","Zhuang-Gui Chen","","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","chenzhuanggui@126.com","+86 13600009221","Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-sen University","Inclusion criteria: Novel coronavirus pneumonia diagnosis and treatment plan (trial version seventh) was revised to meet the diagnostic criteria of the 18-65 year old patients","Exclusion criteria: (1) Basic diseases: Patients with severe diabetes, cardiopulmonary insufficiency, chronic kidney disease, chronic liver failure, cirrhosis, etc. before onset; tumor patients; patients with azotemia;<br>(2) Not willing to participate i","Novel Coronavirus Pneumonia (COVID-19)","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","Hospital stay or death ratio of experimental group / death ratio of control group;","","","","Yes","0","          ",""
"ChiCTR2000031245","2020-03-30","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients                                                                                                                                                      ","","Renmin Hospital of Wuhan University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51518","Recruiting","No","25.0","77.0","Both","2020-01-25","Case series:2000;","Observational study","Sequential","Retrospective study","China","Zhongyuan Xia","","99 Zhangzhidong Road, Wuhan, Hubei, China","wanzimili@sina.com","+86 17762551726","Renmin Hospital of Wuhan University","Inclusion criteria: We did a retrospective review of medical records from surgical patients with COVID-19 pneumonia admitted to Renmin Hospital of Wuhan University from January 13 to March 12, 2020.","Exclusion criteria: not in this period","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Rate of COVID-19, distribution, time of onset and outcome;","","","","No","0","          ",""
"ChiCTR2000030224","2020-03-23","Cancelled by the investigator                Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                             ","","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49968","Not Recruiting","No","18.0","100.0","Both","2020-02-26","1 the critical group :8;2 the severe group:8;3 the control group of the critical group:8;4 the control group of the severe group:8;","Interventional study","Parallel","N/A","China","Chengyun Liu","","1277 Jiefang Avenue, Wuhan, Hubei, China","chengyunliu@hust.edu.cn","+86 18007117616","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Female patients aged >=18 years who were of childbearing years were excluded from pregnancy and agreed to use non-drug contraceptive measures during the study period;<br>2. SARS-CoV-2 nucleic acid test positive;<br>3. Lung CT exam","Exclusion criteria: 1. Allergy to drugs and excipients used in this study;<br>2. Pregnant and lactating women and women of child-bearing years did not agree to use contraception during the experiment;<br>3.Have malignant tumor or hypercoagulant state;<","Novel Coronavirus Pneumonia (COVID-19)","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;","","","","Yes","0","          ",""
"ChiCTR2000030168","2020-03-23","Cancelled by the investigator                   A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)","A prospective real world study on Compound Houttuyniae Mixture used in people of the observation period in close contact with novel coronavirus pneumonia (COVID-19)                                                                                           ","","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","2020-02-24","2020-02-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49433","Not Recruiting","No","18.0","??","Both","2020-02-29","Experimental group:1000;Control group:1000;","Observational study","Non randomized control","N/A","China","Dawei Wang","","100 Shizhi Street, Hongshan Road, Nanjing, Jiangsu, China","cleverwdw@126.com","+86 025-52362054","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Inclusion criteria: 1) Those who have close contact with patients with novel coronavirus pneumonia;<br>2) Be over 18 years old (including 18 years old);<br>3) Voluntarily sign written informed consent.","Exclusion criteria: 1) According to the researcher's judgment, the diseases that have been or have suffered may affect the patients to participate in the trial;<br>2) Those who are allergic to the known ingredients of this medicine;<br>3) Pregnant or la","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Increased Compound Houttuynia Mixture in real world situations;Control group:None(People who do not receive Compound Houttuynia Mixture in real world situations);","Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;","","","","Yes","0","          ",""
"ChiCTR2000031247","2020-03-30","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)                                                                                                                                               ","","West China Hospital, Sichuan University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51540","Recruiting","No","","","Both","2020-03-01","Case series:500;","Observational study","Sequential","N/A","","Xiandong Meng","","28 Dianxin Road South, Wuhou District, Chengdu, Sichuan, China","wchmhcmxd@163.com","+86 18980605046","West China Hospital, Sichuan University","Inclusion criteria: Medical staff involved in COVID-19 prevention and control.","Exclusion criteria: Medical staff without informed consent.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","mental state;","","","","No","0","          ",""
"ChiCTR2000031214","2020-03-30","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis                                                                                                                              ","","Wuhan Third Hospital","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51509","Not Recruiting","No","18.0","80.0","Both","2020-03-31","Case series:60;","Observational study","Sequential","0.0","China","GAO Tian-lin","","349 Hangzhou Road, Yangpu District, Shanghai, China","2235658154@qq.com","+86 18930132792","The First Rehabilitation Hospital of Shanghai  ","Inclusion criteria: (1) a patient who meets the diagnostic criteria of novel coronavirus pneumonia and is confirmed by lung CT or nucleic acid examination;<br>(2) stable condition, normal cognitive function, able to understand tests and requirements;<br","Exclusion criteria: (1) patients with severe basic diseases and intolerance such as cardiopulmonary function;<br>(2) patients combined with diseases affecting the assessment; with communication and cognitive impairment, unclear consciousness and unable t","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;","","","","Yes","0","          ",""
"ChiCTR2000031227","2020-03-30","Clinical features and prognosis of invasive echanicalventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","Clinical features and prognosis of  invasive mechanicalventilation patients  with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study                                                                ","","Renmin Hospital of Wuhan University","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51473","Not Recruiting","No","0.0","100.0","Both","2020-03-26","Case series:40;","Observational study","Case-Control study","Retrospective study","","Qingta Meng","","238 Jiefang Road / 99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","mengqt2013@hotmail.com","+86 13995569560","Department of anesthesiology, Renmin Hospital of Wuhan University","Inclusion criteria: 1. The diagnosis of COVID-19 was confirmed;<br>2. Patients with invasive mechanical ventilation.","Exclusion criteria: 1. Patients with cardiac arrest before endotracheal intubation;<br>2. Patients with severe medical record information registration defects;<br>3. Patients whose condition is not stable and whose prognosis cannot be determined.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Clinical features and prognosis;","","","","Yes","0","          ",""
"ChiCTR2000030940","2020-03-30","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)                                                                                                                             ","","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51061","Not Recruiting","No","18.0","80.0","Both","2020-02-01","Experimental group:38;control group:38;","Interventional study","Non randomized control","N/A","China","Wei Lu","","725 Wanping Road South, Xuhui District, Shanghai, China","icuwei@163.com","+86 18917763194","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;<br>2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;<br>3. Aged 18 to 80 years;<br>4. Signed informed cons","Exclusion criteria: 1) novel coronavirus pneumonia is not in conformity with the standard diagnostic criteria.            <br>2) The age is less than 18 years old or more than 80 years old;            <br>3) Patients with allergy to traditional Chinese ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Basic treatment of Western medicine + ""Baidu Duan Fang"" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + ""Baidu Duan Fang"" + routine nursing treatment;","Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;","","","","No","0","          ",""
"IRCT20200128046294N2","2020-03-24","Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19)","A prospective randomized controlled trial comparing Sovodak (Sofosbuvir+Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment                                                             ","","Digestive Disease Research Institute","2020-03-14","2020-03-14","2020-01-04 15:51:14 ","IRCT","http://en.irct.ir/trial/46463","Not Recruiting","No","18 years","no limit","Both","2020-03-26","70.0","interventional","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using compu","3.0","Iran (Islamic Republic of)","Dr Hossein Poustchi","","Shariati Hospital, Kargar Street, Tehran","h.poustchi@gmail.com","+98 21 8241 5000","Tehran University of Medical Sciences","Inclusion criteria: Both genders<br>Age =18 years at time of signing Informed Consent Form<br>Willing and able to provide written informed consent prior to performing study to any assigned treatment arm<br>Must agree not to enroll in another study of an i","Exclusion criteria: Known allergic reaction to Sofosbuvir or Daclatasvir<br>Pregnant or breastfeeding, or positive pregnancy test<br>Receipt of any experimental treatment for COVID-19 prior to the time of the screening evaluation<br>Heart rate < 60/min<br","COVID-19. <br>COVID-19;U07.1","Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of ","Clinical recovery (composite) within 14 days from initiation of study treatment until normalization of fever (=37.2 C oral), respiratory rate (=24/minute on room air), and oxygen saturation (=94% on room air),  sustained for at least 24 hours. Timepoint","","","","Yes","0","          ",""
"NCT03331445","2020-03-30","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","NONTM","University of British Columbia","2017-10-25","2017-10-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT03331445","Not recruiting","No","14 Years","N/A","All","2017-10-24","20.0","Interventional","Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Canada"," ","Jeremy D Road, MD","","","","Professor","<br>        Inclusion Criteria:<br><br>          -  Written informed consent.<br><br>          -  Has been previously diagnosed with NTM, Burkholderia spp and Aspergillus spp. or<br>             Corona-like viral infection:<br><br>               1","","Respiratory Tract Infections","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects","","","","Yes","0","          ",""
"ChiCTR2000031198","2020-03-30","A medical records based study for clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                            ","","Nothern Jiangsu People's Hospital","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51488","Recruiting","No","18.0","90.0","Both","2020-04-01","Case series:150;","Observational study","Sequential","Retrospective study","China","Jun Shao","","98 Nantong Road West, Guangling District, Yangzhou, Jiangsu, China","sjun1982@163.com","+86 18051061365","Nothern Jiangsu People's Hospital","Inclusion criteria: This retrospective cohort study included a cohorts of adult inpatients (>=18 years old) from Department of Respiratory and Critical Care, The First People's Hospital of Jiangxia District, Wuhan(China) between January 29, 2020 to Februa","Exclusion criteria: Age < 18 years old, clinical data missing.","Novel Coronavirus Pneumonia (COVID-19)","Case series:none;","mortality;","","","","Yes","0","          ",""
"ChiCTR2000031196","2020-03-30","Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets                                                                                                                                            ","","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51112","Recruiting","No","16.0","85.0","Both","2020-01-10","treatment group:60;control group:30;","Interventional study","Non randomized control","Retrospective study","China","Zhe Xu","","100 West 4th Ring Middle Road, Fengtai District, Beijing, China","xuzhe302@139.com","+86 15001111836","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","Inclusion criteria: 1. patients aged 16-85 male or female; <br>2. they were willing to sign the informed consent;<br>3. The novel coronavirus nucleic acid was detected by real-time fluorescence RT-PCR in sputum, throat swabs, and lower respiratory tract","Exclusion criteria: 1. Pregnant or lactating women;<br>2. patients with malignant tumor, other serious systemic diseases and psychosis; <br>3. patients with severe liver dysfunction; <br>4. recent or participating in other clinical trials; <br>5. evid","Novel Coronavirus Pneumonia (COVID-19)","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","time till the SARS-CoV-2 clearance;","","","","No","0","          ",""
"ChiCTR2000030937","2020-03-30","A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial                                                                                                                  ","","The First Affiliated Hospital of Guangzhou Medical University","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51240","Recruiting","No","18.0","","Both","2020-03-19","Experimental group:72;Control group:72;","Interventional study","Parallel","4.0","China","Li Shi-yue","","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","lishiyue@188.com","+86 13902233925","the First Affiliated Hospital of Guangzhou Medical University","Inclusion criteria: (1) Aged >=18 years;<br>(2) 2019-nCoV pneumonia is diagnosed according to the standard of diagnosis and treatment;<br>(3) Patient's condition has reached the standard of desolation / discharge specified according to the diagnosis and","Exclusion criteria: (1) Known or suspected allergy to the components of the study drug;<br>(2) Acute infection of other viruses and bacteria has not been cured;<br>(3) The function of liver and kidney was abnormal (ALT/AST>=2 times of the upper limit of","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;","","","","Yes","0","          ",""
"ChiCTR2000030704","2020-03-30","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                     ","","The First People's Hospital of Jiangxia District, Wuhan","2020-03-10","2020-03-10","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50778","","No","7.0","90.0","Both","2020-02-10","Experimental group:25;Control group:25;","Interventional study","Cross-over","4.0","China","Hu Xingxing","","100 Shizi Street, Hongshan Road, Qixia District, Nanjing, Jiangsu, China","huxingxing82@163.com","+86 17327006987","Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine","Inclusion criteria: 1. Novel coronavirus pneumonia is diagnosed met the fifth edition of the national health and Health Committee;<br>2. Respiratory rate in calm state >=30 times / min; OR Finger pulse oxygen saturation under rest and non oxygen absorpti","Exclusion criteria: 1. Aged < 7-year-old;<br>2. previous arrhythmia;<br>3. previous chronic respiratory failure caused by other diseases, such as heart failure, thoracic deformity, structural lung disease, etc.;<br>4. hemodynamic instability;<br>5. se","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","PO2/FiO2;ROX INDEX;","","","","No","0","          ",""
"NCT03680274","2020-03-30","Lessening Organ Dysfunction With VITamin C","Lessening Organ Dysfunction With VITamin C (LOVIT)","LOVIT","Universit de Sherbrooke","2018-09-19","2018-09-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT03680274","Recruiting","No","18 Years","N/A","All","2018-11-08","800.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","Canada"," ; ; ; ","Franois Lamontagne, MD FRCPC MSc;Neill Adhikari, MDCM FRCPC MSc;Marie-Helene Masse;Marie-Helene Masse","",";;marie-helene.masse3@usherbrooke.ca;marie-helene.masse3@usherbrooke.ca",";;819-346-1110;819-346-1110","Universit de Sherbrooke and CIUSSS de l'Estrie - CHUS;Sunnybrook Health Sciences Centre, University of Toronto;","<br>        Inclusion Criteria:<br><br>          1. Admitted to the intensive care unit with proven or suspected infection as the main<br>             diagnosis;<br><br>          2. Currently treated with a continuous IV infusion of vasopressors (no","","Sepsis;Vitamin C;Intensive Care Unit;COVID-19;Pandemic;Coronavirus","Drug: Vitamin C;Other: Control","Number of deceased participants or with persistent organ dysfunction","","","","Yes","0","          ",""
"NCT04226157","2020-03-30","Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *Due to COVID-19 Outbreak in United States the Investigators Have Paused All In-person Enrollment and Will Re-evaluate on May 1st*","Home Blood Pressure Self-Management in Hypertensive Stroke Survivors: a Pilot Study","HBPS","MedStar Georgetown University Hospital","2020-01-09","2020-01-09","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04226157","Recruiting","No","18 Years","N/A","All","2019-02-21","32.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","N/A","United States"," ; ","Mary Carter Denny, MD;Mary Carter Denny","","MaryCarter.Denny@medstar.net;MaryCarter.Denny@medstar.net","202-444-8532;202-444-8532","","<br>        Inclusion Criteria:<br><br>          -  Acute ischemic stroke in the past 180 days of screening<br><br>          -  Age >/= 18 years old<br><br>          -  Automated Office Blood Pressure =135 systolic or =85 diastolic at time of scree","","Ischemic Stroke;Hypertension","Device: Home Blood Pressure Monitoring Device (Qardio Arm);Other: Primary Care Provider Blood Pressure Management","Feasibility of blood pressure self management in stroke survivors","","","","No","0","          ",""
"NCT04263402","2020-03-30","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","","Tongji Hospital","2020-02-02","2020-02-02","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04263402","Recruiting","No","18 Years","N/A","All","2020-02-01","100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 4","China"," ; ","Qing Ning, Professor;Qin Ning, professor","","qning@vip.sina.com;qning@vip.sina.com","+8613971521450;","","<br>        Inclusion Criteria:<br><br>        1.Meet the definition of severe pneumonia(Comply with any of the followings):<br><br>          1. Shortness of breath,RR=30 bpm;<br><br>          2. In a resting state:SPO2=93%;<br><br>          3. P","","2019-nCoV Severe Pneumonia","Drug: Methylprednisolone;Drug: Methylprednisolone","Rate of disease remission;Rate and time of entering the critical stage","","","","Yes","0","          ",""
"ChiCTR2000030988","2020-03-30","A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial                                                          ","","Guangdong Provincial Hospital of Chinese Medicine","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51317","Not Recruiting","No","18.0","85.0","Both","2020-03-23","Experimental group:102;control group:102;","Interventional study","Parallel","N/A","China","Zhongde Zhang","","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","doctorzzd99@163.com","+86 13903076359","Guangdong Provincial Hospital of Chinese Medicine","Inclusion criteria: (1) Meet the diagnostic criteria for patients with COVID-19 of the Proposal of Diagnosis and Treatment of COVID-19;<br>(2) Aged 18-85 years;<br>(3) To agree to participate in the study and sign the informed consent","Exclusion criteria: (1) Critical patients;<br>(2) TCM diagnosis of yang deficiency syndrome, manifested as limb warm, thin stools, chills, etc.;<br>(3) Patients who cannot guarantee compliance during treatment, and patients who are difficult to administ","Novel Coronavirus Pneumonia (COVID-19)","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","Inflammation absorption on Chest CT;","","","","Yes","0","          ",""
"ChiCTR2000030330","2020-03-30","Cancelled by the investigator                               Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)","the effects of 6-minute walk training on walking distance, oxygen saturation, heart rate and global rating of change of normal or critial novel coronavirus pneumonia (COVID-19)                                                                               ","","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","2020-02-28","2020-02-28","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50274","","No","18.0","","Both","2020-02-28","Case series:10;","Observational study","Sequential","N/A","China","Ming Wu","","17 Lujiang Road, Luyang District, Hefei, Anhui, China","ahslyywm@163.com","+86 18655106697","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Inclusion criteria: 1. Normal and severe cases diagnosed in accordance with the diagnosis for pneumonia of novel coronavirus infection;<br>2. Viral nucleic acid test is negative or positive after treatment;<br>3. Aged >= 18 years;<br>4. Patients with c","Exclusion criteria: 1. Pneumonia caused by other reasons;<br>2. Have contraindications that can not participate in sports activities;<br>3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively;<br>4. Patients wit","Novel Coronavirus Pneumonia (COVID-19)","Case series:6-minute walk training;","walking distance;oxygen saturation;heart rate;","","","","Yes","0","          ",""
"ChiCTR2000030288","2020-03-30","Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                  ","","China Academy of Chinese Medical Sciences","2020-02-27","2020-02-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50202","Recruiting","No","18.0","75.0","Both","2020-02-27","experimental group:102;control group:102;","Interventional study","Parallel","N/A","China","Huang Luqi; Ruan Lianguo","","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","huangluqi01@126.com","+86 010-64089801","China Academy of Chinese Medical Sciences","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the ""Diagnosis and Treatment Program for COVID-19""(trial version 6th);<br>(2) Aged >= 18 years;<br>(3) Agree to participate in the trial, and the patient, the legal","Exclusion criteria: (1) Critical patients;<br>(2) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route;<br>(3) Patients with severe primary respiratory ","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:TCM formula and general treatment based on ""Diagnosis and Treatment Program for COVID-19"" (trial version 6th);control group:general treatment based on ""Diagnosis and Treatment Program for COVID-19"" (trial version 6th);","The time to 2019-nCoV RNA negativity in patients;","","","","Yes","0","          ",""
"ChiCTR2000030256","2020-03-30","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China                                                                                                                                                ","","Daping Hospital,Army Medical University","2020-02-26","2020-02-26","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50078","Not Recruiting","No","","","Both","2020-02-01","Case series:1000;","Epidemilogical research","Sequential","Retrospective study","China","Cao Guoqiang","","10 Changjiang Branch Road, Yuzhong District, Chongqing, China","cgq1963@163.com","+86 023 68757780","Daping Hospital, Army Medical University","Inclusion criteria: Patients admitted to the hospital","Exclusion criteria: NO","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Epidemiological and clinical characteristics;","","","","No","0","          ",""
"ChiCTR2000030028","2020-03-30","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)                                                                                                                              ","","West China Hospital","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49840","Not Recruiting","No","18.0","","Both","2020-02-24","Experimental group:20;Control group:20;","Interventional study","Parallel","0.0","China","Yan Kang","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","kangyan_hx@163.com","+86 18980601556","West China Hospital, Sichuan University","Inclusion criteria: (1) RT-PCR detection of the respiratory or blood samples shows positive nucleic acid of the novel coronavirus;<br>(2) Gene sequence of the virus in respiratory or blood samples are highly homologous to the known coronaviruses;<br>(3)","Exclusion criteria: (1) Subjects who have any active autoimmune disease or history of autoimmune disease;<br>(2) Subjects who received immunosuppressive therapy by using immunosuppressant, or systemic or absorbable topic hormone therapy (temprednisone or","novel coronavirus disease (COVID-19)","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lym","","","","Yes","0","          ",""
"NL8473","2020-03-30","Immunity against SARS-CoV-2 in Dutch population","Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2                                                                                                                                                        ","","National Institute for Public Health and the Environment (RIVM)","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","Netherlands Trial Register","https://trialregister.nl/trial/8473","Not Recruiting","No","","","","2020-03-23","4000.0","Observational","
                        Randomized: No, 
                        Masking: None, 
                        Control: Not applicable, 
                        Group: undefined, 
                        Type: Single arm
","","The Netherlands","Alienke","Wijmenga-Monsuur","","alienke.wijmenga@rivm.nl","NA","","Inclusion criteria: Subject previously participated in the PIENTER 3 study (2016/17) and had indicated that they could be approached for a follow-up study.","Exclusion criteria: There are no exclusion criteria.","COVID-19, SARS-CoV-2","Not applicable","To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of<br>the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum","","","","Yes","0","          ",""
"NCT04273763","2020-03-30","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","","Second Affiliated Hospital of Wenzhou Medical University","2020-02-14","2020-02-14","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04273763","Recruiting","No","18 Years","80 Years","All","2020-02-16","60.0","Interventional","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ","XIAN SHEN, phd","","","","The 2nd Affiliated Hospital of Wenzhou Medical University","<br>        Inclusion Criteria:<br><br>          -  Aged between 18 and 80 years (Including 18and 80years, male or female).<br><br>          -  One of them:<br><br>               1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel ","","Novel Coronavirus Pneumonia;2019-nCoV","Drug: Bromhexine Hydrochloride Tablets;Drug: Arbidol Hydrochloride Granules;Drug: Recombinant Human Interferon a2b Spray","Time to clinical recovery after treatment;Rate of aggravation","","","","Yes","0","          ",""
"NCT04280705","2020-03-30","Adaptive COVID-19 Treatment Trial (ACTT)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","","National Institute of Allergy and Infectious Diseases (NIAID)","2020-02-20","2020-02-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04280705","Recruiting","Yes","18 Years","99 Years","All","2020-02-21","440.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ","Phase 3","United States;Japan;Korea, Republic of;Singapore;Japan;Korea, Republic of;Singapore;United States"," ","20-0006 Central Contact","","DMIDClinicalTrials@niaid.nih.gov","13017617948.0","","<br>        Inclusion Criteria:<br><br>          1. Admitted to a hospital with symptoms suggestive of COVID-19 infection.<br><br>          2. Subject (or legally authorized representative) provides written informed consent prior<br>             to ","","Corona Virus Infection","Other: Placebo;Drug: Remdesivir","Percentage of subjects reporting each severity rating on an 8-point ordinal scale","","","","Yes","True ","parent    ",""
"NCT04283396","2020-03-30","Study for Novel Coronavirus Pneumonia (NCP)","Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP)","","Wuhan Union Hospital, China","2020-02-13","2020-02-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04283396","Recruiting","No","18 Years","90 Years","All","2020-02-21","2000.0","Observational","","N/A","China"," ; ","Yang Jin;Yang Jin","","whunjy@126.com;whuhjy@126.com","13554361146;13554361146","","<br>        Inclusion Criteria:<br><br>          -  Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to<br>             ""Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial<br>          ","","Novel Coronavirus Pneumonia","Combination Product: systemic treatment","recovery","","","","Yes","0","          ",""
"NCT04287686","2020-03-30","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19","","The First Affiliated Hospital of Guangzhou Medical University","2020-02-21","2020-02-21","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04287686","Not recruiting","No","18 Years","80 Years","All","2020-02-01","0.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","N/A","China"," ","Yimin Li, PhD, MD","","","","The First Affiliated Hospital of Guangzhou Medical University","<br>        Inclusion Criteria:<br><br>          1. Laboratory diagnosis:<br><br>               -  Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR,<br><br>               -  The viral gene sequencing of the respiratory spe","","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Time course of body temperature (fever);Viral load over time","","","","Yes","0","          ",""
"ChiCTR2000030198","2020-03-30","Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)                                                         ","","West China Hospital of Sichuan University","2020-02-25","2020-02-25","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=50066","Not Recruiting","No","","","Both","2020-02-24","experimental group:30;control group:30;","Interventional study","Parallel","0.0","China","Chengqi He","","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","hxkfhcq@126.com","+86 18980601618","West China Hospital, Sichuan University","Inclusion criteria: 1. Patients discharged from severe or critical new coronavirus pneumonia;<br>2. Adults over 18 years of age who signed the informed consent;<br>3. Study participants are willing to accept random assignment to any designated treatment","Exclusion criteria: 1. Pneumonia caused by other reasons;<br>2. Have contraindications that can not participate in sports activities;<br>3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively.","Novel Coronavirus Pneumonia (COVID-19)","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","pulmonary function;","","","","No","0","          ",""
"NL8460","2020-03-30","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study                                                                                                                                                                      ","","none","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","Netherlands Trial Register","https://trialregister.nl/trial/8460","Recruiting","No","","","","2020-03-16","50.0","Observational","
                        Randomized: No, 
                        Masking: None, 
                        Control: Not applicable, 
                        Group: undefined, 
                        Type: Single arm
","","The Netherlands","JAH","VAN Oers","","jah.vanoers@etz.nl","132213808.0","","Inclusion criteria: SARS-CoV 2 PCR positive patients at the intensive care","Exclusion criteria: SARS-CoV 2 PCR negative OR no SARS-CoV 2 PCR","Lower respiratory tract infections","During routine daily laboratory rounds blood will be stored at -80 C until biomarkers will be assayed later.","28-day mortality","","","","Yes","0","          ",""
"EUCTR2020-001243-15-BE","2020-03-30","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19                                                                                                  ","","UZLeuven","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-26","200.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Best clinical prac","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","Belgium","Laurens Liesenborghs","","Herestraat 49","laurens.liesenborghs@uzleuven.be","","UZ Leuven","Inclusion criteria: <br>1.	Subject (=18 years old) or legally authorized representative provides informed consent prior to initiation of any study procedures. When signed informed consent is not possible (e.g. due to restrictions to prevent viral transmis","Exclusion criteria: <br>1. ALT/AST > 5 times the upper limit of normal. <br>2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)  <br>3. Pregnancy or breast feeding. <br>4. Allergy to any study medication<br>5. Any medical c","COVID-19 <br>MedDRA version: 20.0
Level: LLT
Classification code 10038700
Term: Respiratory infection
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Product Name: itraconazole<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ITRACONAZOLE<br>CAS Number: 84625-61-6<br><br>Product Name: itraconazole<br>Pharmaceutical Form: Oral solution<br>INN or Proposed INN: ITRACONAZOLE<br>CAS Number:","Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.;Secondary Objective: To evaluate clinical","","","","No","0","          ",""
"NCT04302766","2020-03-30","Expanded Access Remdesivir (RDV; GS-5734)","Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734)","","U.S. Army Medical Research and Development Command","2020-03-02","2020-03-02","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04302766","Not recruiting","No","N/A","N/A","All","2020-03-01","","Expanded Access","","N/A",""," ","Sandi K Parriott","","sandi.k.parriott.mil@mail.mil","301-619-6824","","<br>        Inclusion Criteria:<br><br>          -  DoD-affiliated personnel as defined in DoDI 6200.02, which includes<br>             emergency-essential civilian employees and/or contractor personnel accompanying the<br>             Armed Forces w","","Coronavirus Disease 2019","Drug: Remdesivir","","","","","Yes","0","          ",""
"NCT04308317","2020-03-30","Tetrandrine Tablets Used in the Treatment of COVID-19","Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","TT-NPC","Henan Provincial People's Hospital","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04308317","Recruiting","No","18 Years","75 Years","All","2020-03-05","60.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  Patients with mild and severe cases who have been diagnosed with new coronavirus<br>             pneumonia according to the ""Pneumonitis Diagnosis and Treatment -<br><br>          -  Plan for New C","","Corona Virus Disease 2019,COVID-19","Drug: Tetrandrine","Survival rate","","","","Yes","0","          ",""
"NCT04312009","2020-03-30","Losartan for Patients With COVID-19 Requiring Hospitalization","Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","","University of Minnesota","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04312009","Not recruiting","No","18 Years","N/A","All","2020-03-16","200.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2","United States"," ; ; ","Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","",";;ctignane@umn.edu",";;612-625-7911","University of Minnesota;University of Minnesota;","<br>        Inclusion Criteria:<br><br>          -  Presumptive positive laboratory test for SARS-CoV-2 or upper respiratory infection<br>             with recent exposure to laboratory-proven SARS-CoV-2-infected person<br><br>          -  Negative ","","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","Drug: Losartan;Other: Placebo","Sequential Organ Failure Assessment (SOFA) Respiratory Score","","","","Yes","0","          ",""
"NCT04312243","2020-03-30","NO Prevention of COVID-19 for Healthcare Providers","Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","NOpreventCOVID","Massachusetts General Hospital","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04312243","Not recruiting","No","18 Years","99 Years","All","2020-03-20","460.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 2",""," ","Lorenzo Berra, MD","","lberra@mgh.harvard.edu","16176437733.0","","<br>        Inclusion Criteria:<br><br>          1. Age =18 years<br><br>          2. Negative SARS CoV-2 rt-PCR test at screening<br><br>          3. Scheduled to work with SARS-CoV-2 infected patients<br><br>        Exclusion Criteria:<br><br","","Coronavirus Infections;Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis","","","","Yes","0","          ",""
"EUCTR2020-001010-38-NO","2020-03-30","NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: A TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19                                        ","","Akershus University Hospital","2020-03-16","2020-03-16","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-23","200.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Standard of care
N","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
","Norway","Department of Infectious Diseases","","Sykehusveien 25","jan.erik.berdal@medisin.uio.no","4767960000.0","Akershus University Hospital","Inclusion criteria: <br>	Hospitalised<br>	Adults 18 year or older<br>	Moderately severe disease (NEWS score = 6)<br>	SARS-CoV-2 positive nasopharyngeal swab <br>	Signed informed consent must be obtained and documented according to ICH G","Exclusion criteria: <br>	Requiring ICU admission at screening<br>	History of psoriasis<br>	Tinnitus, reduced hearing<br>	Visual impairment <br>","SARS-COV-2 infection <br>MedDRA version: 21.1
Level: LLT
Classification code 10037373
Term: Pulmonary disorder
System Organ Class: 100000004855
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Plaquenil<br>Product Name: Plaquenil<br>Pharmaceutical Form: Film-coated tablet<br><br>","Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.;Secondary Objective: 	Assess the impact of early treatment with chloroquine in patients w","","","","Yes","0","          ",""
"EUCTR2020-001254-22-BE","2020-03-30","Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC            ","","University Hospital Ghent","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-24","80.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: standard of care
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
","Belgium","HIRUZ CTU","","C. Heymanslaan 10","hiruz.ctu@uzgent.be","3293320500.0","University Hospital Ghent","Inclusion criteria: <br>-Recent (=2weeks prior to randomization) PCR-Confirmed (GLIMS) COVID19 infection<br>-Presence of acute hypoxic respiratory failure defined as (either or both)<br>saturation below 93% on minimal 2 l/min O2<br>PaO2/FiO2 below 300","Exclusion criteria: <br>- Patients with known history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the product. <br> <br","Acute hypoxic respiratory failure of COVID-19 patients <br>MedDRA version: 21.1
Level: LLT
Classification code 10074615
Term: Hypoxic respiratory failure
System Organ Class: 100000004855
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Leukine<br>Product Name: Leukine<br>Pharmaceutical Form: Powder for nebuliser solution<br>INN or Proposed INN: SARGRAMOSTIM<br>CAS Number: 123774-72-1<br>Concentration unit: g microgram(s)<br>Concentration type: equal<br>Concentration nu","Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .;Secondary Obje","","","","Yes","0","          ",""
"EUCTR2020-000919-69-NL","2020-03-30","Reducing health care workers absenteeism in Coronavirus 2019 pandemic nu enhancement of the immune system through vaccination with Bacillus Calmette-Gurin","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA                                                     ","","University Medical Center","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-17","1000.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
","Netherlands","Marc J. M. Bonten","","Heidelberglaan 100","M.J.M.Bonten@umcutrecht.nl","00318875 503 50 ","University Medical Center Utrecht","Inclusion criteria: <br>In order to be eligible to participate in this study, a subject must meet the following criteria:<br>	Adult (=18 years) <br>	Male or female<br>	Hospital personnel (expected to) taking care for patients with SARS-CoV-2 infe","Exclusion criteria: <br>A potential subject who meets any of the following criteria will be excluded from participation in this study:<br>	Known allergy to (components of) the BCG vaccine or serious adverse events to prior BCG administration  <br>	K","SARS-CoV-2  infection <br>MedDRA version: 20.0
Level: HLT
Classification code 10047490
Term: Virus identification and serology
System Organ Class: 100000004848
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.<br>Pharmaceutical Form: Concentrate and solvent for solution for injection<br>Pharmaceutical form of the placebo: Concentrate and solvent for solut","Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase o","","","","Yes","0","          ",""
"EUCTR2020-001224-33-DE","2020-03-30","Systematic study of the medicine hydroxychloroquine against placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19                                                                                                          ","","Universittsklinikum Tbingen","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-25","220.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","Germany","Project management,Diane Egger-Adam","","Wilhelmstr. 27","diane.egger-adam@uni-tuebingen.de","4970712982191.0","Universittsklinikum Tbingen","Inclusion criteria: <br>	Written informed consent<br>	Age above 18 years<br>	Women of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less th","Exclusion criteria: <br>	Respiratory rate >24/min<br>	Pregnancy or lactation<br>	Weight <50 kg<br>	Hemodynamic/rhythm instability<br>	Acute myocardial infarction Type 1<br>	Use of concomitant medications that prolong the QT/QTc interval.","Acute coronavirus disease 2019 <br>MedDRA version: 20.1
Level: PT
Classification code 10053983
Term: Corona virus infection
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Quensyl<br>Pharmaceutical Form: Capsule<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>","Main Objective: Primary objective: Effect of HCQ on in vivo viral clearance. ;Secondary Objective: Exploratory objectives are to assess the effect of infection and HCQ treatment on clinical outcome, cardiac function, mucosal, humoral and cellular immune r","","","","Yes","0","          ",""
"NCT04312464","2020-03-30","Myocardial Damage in COVID-19","Retrospective Study of Myocardial Damage in COVID-19","","Wuhan Union Hospital, China","2020-03-04","2020-03-04","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04312464","Recruiting","No","18 Years","N/A","All","2020-01-01","500.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  (1) Age =18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3)<br>             Lung involvement confirmed with chest imaging.<br><br>        Exclusion Criteria:<br><br>      ","","COVID-19;Cardiovascular Diseases","Other: non","The myocardial injury incidence;The risk factors analysis for the death","","","","Yes","0","          ",""
"NCT04313127","2020-03-30","A Phase I Clinical Trial in 18-60 Adults","A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","APICTH","CanSino Biologics Inc.","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04313127","Recruiting","No","18 Years","60 Years","All","2020-03-16","108.0","Interventional","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label). ","Phase 1","China"," ; ; ; ; ","Zhu Fengcai;Guan Xuhua;Wang Wei;Wang Wenjuan;Wang Zhao","",";;;wangwj@jscdc.cn;markwangzhao@qq.com",";;;025-83759911;13476011311","Jiangsu Province Centers for Disease Control and Prevention;Hubei Provincial Center for Disease Control and Prevention;Tongji Hospital;","<br>        Inclusion Criteria:<br><br>          -  Aged between 18 and 60 years.<br><br>          -  Able to understand the content of informed consent and willing to sign the informed<br>             consent<br><br>          -  Able and willing ","","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Safety indexes of adverse reactions","","","","Yes","0","          ",""
"NCT04313322","2020-03-30","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","","Stem Cells Arabia","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04313322","Recruiting","No","18 Years","N/A","All","2020-03-16","5.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1","Jordan"," ; ","Adeeb M AlZoubi, Ph.D.;Adeeb M Alzoubi, Ph.D.","","adeebalzoubi@stemcellsarabia.net;adeebalzoubi@stemcellsarabia.net","+962795337575;+962795337575","","<br>        Inclusion Criteria:<br><br>        COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.<br><br>        Exclusion Criteria:<br><br>          -  Participants in other clinical trials<br><br>          - ","","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome;CT Scan;RT-PCR results","","","","Yes","0","          ",""
"NCT04315298","2020-03-30","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","","Regeneron Pharmaceuticals","2020-03-15","2020-03-15","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04315298","Recruiting","No","18 Years","N/A","All","2020-03-16","400.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 2/Phase 3","United States"," ; ","Clinical Trial Management;Clinical Trials Administrator","",";clinicaltrials@regeneron.com",";844-734-6643","Regeneron Pharmaceuticals;","<br>        Key Inclusion Criteria:<br><br>          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction<br>             (PCR) or other commercial or public health assay<br><br>          -  Hospitalized with illne","","COVID-19","Drug: Sarilumab;Drug: Placebo","Time to resolution of fever for at least 48 hours without antipyretics for 48 hours;Percentage of patients reporting each severity rating on a 6-point ordinal scale","","","","Yes","0","          ",""
"EUCTR2020-000982-18-NO","2020-03-30","A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19)","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - N-ReCOVID 19                                                                                                                   ","","Oslo University Hospital","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-26","443.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: yes
Other specify the comparator: Standard of care
N","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): yes
","Norway","Sect. Clin. Imm. & Infect. Diseases","","Sognsvannsveien 20","andreas.barrattdue@gmail.com","4723071916.0","Oslo university hospital","Inclusion criteria: <br>1.	Adult patients, 18 years and above<br>2.	Confirmed SARS-2-CoV-2 infection by PCR<br>3.	Admitted to the hospital ward or the ICU<br>4.	Subjects (or legally authorized representative) provides written informed consent prior to ","Exclusion criteria: <br>1.	Severe co-morbidity with life expectancy <3 months according to investigators assessment<br>2.	ASAT/ALAT > 5 times the upper limit of normal<br>3.	Acute co-morbidity within 7 days before inclusion such as myocardial infarction","SARS-COV-2 infection <br>MedDRA version: 21.1
Level: LLT
Classification code 10037373
Term: Pulmonary disorder
System Organ Class: 100000004855
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Plaquenil<br>Product Name: Plaquenil<br>Pharmaceutical Form: Film-coated tablet<br><br>","Main Objective: 1.	To investigate the effect of Remdesivir and Hydroxychloroquine in COVID 19 infection in relation to the defined primary and secondary endpoints.<br>2.	To compare the effect of early versus late intervention with Remdesivir and Hydroxych","","","","Yes","0","          ",""
"EUCTR2020-001023-14-GB","2020-03-30","a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients with COVID-19","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG0","","Synairgen Research Limited","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14","Authorised","No","","","<br>Female: yes<br>Male: yes<br>","2020-03-17","400.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","United Kingdom","Jody Brookes","","Mailpoint 810, Level F, Southampton General Hospital, Tremona Road","jody.brookes@synairgen.com","2380512800.0","Synairgen Research Ltd","Inclusion criteria: <br>1. Positive virus test for SARS-CoV-2<br><br>2. Male or female, =18 years of age at the time of consent <br><br>3. Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-r","Exclusion criteria: <br>1. > 24 hours after confirmation of SARS-CoV-2 infection <br><br>2. Any condition, including findings in the patients medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constit","COVID-19 <br>MedDRA version: 20.0
Level: LLT
Classification code 10051905
Term: Coronavirus infection
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Product Name: Interferon beat-1a (IFN-1a)<br>Product Code: SNG001<br>Pharmaceutical Form: Inhalation solution<br>INN or Proposed INN: Interferon beta-1a<br>Current Sponsor code: SNG001<br>Concentration unit: million IU million international units<br","Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.;Secondary Objective: To understand more about the biology of how SNG001 affects pa","","","","Yes","0","          ",""
"NCT04315948","2020-03-30","Trial of Treatments for COVID-19 in Hospitalized Adults","Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","DisCoVeRy","Institut National de la Sant Et de la Recherche Mdicale, France","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04315948","Recruiting","No","18 Years","N/A","All","2020-03-22","3100.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","France"," ; ","Florence Ader, MD;Florence Ader, MD","",";florence.ader@chu-lyon.fr",";+33 (0)4 72 07 15 60","Hospices Civils de Lyon;","<br>        Inclusion Criteria:<br><br>          -  Adult =18 years of age at time of enrolment.<br><br>          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other<br>             commercial or public health assay in an","","Corona Virus Infection","Drug: Remdesivir;Drug: Lopinavir/ritonavir;Drug: Interferon Beta-1A;Drug: Hydroxychloroquine;Other: Standard of care","Percentage of subjects reporting each severity rating on a 7-point ordinal scale","","","","Yes","0","          ",""
"NCT04316377","2020-03-30","Norwegian Coronavirus Disease 2019 Study","Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","NO COVID-19","University Hospital, Akershus","2020-03-13","2020-03-13","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04316377","Not recruiting","No","18 Years","N/A","All","2020-03-23","202.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4",""," ; ","Olav Dalgard, MD PhD;Olav Dalgard, MD PhD","",";odalgard@uio.no",";+47 92616800","Akerhus University Hospital;","<br>        Inclusion Criteria:<br><br>          -  Hospitalised<br><br>          -  Adults 18 year or older<br><br>          -  Moderately severe disease (NEWS score = 6)<br><br>          -  SARS-CoV-2 positive nasopharyngeal swab<br><br>     ","","Corona Virus Infection","Drug: Hydroxychloroquine Sulfate","Rate of decline in SARS-CoV-2 viral load","","","","Yes","0","          ",""
"NCT04317040","2020-03-30","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","SAC-COVID","OncoImmune, Inc.","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04317040","Not recruiting","No","18 Years","N/A","All","2020-05-01","230.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","United States"," ; ","Shyamasundaran Kottilil;Pan Zheng, MD, PhD","",";pzheng@oncoimmune.com",";(202) 7516823","Institute of Human Virology, University of Maryland Baltimore;","<br>        Inclusion Criteria:<br><br>          1. Should be at least 18 years of age,<br><br>          2. Male or female,<br><br>          3. Diagnosed with COVID-19 and confirmed SARS-coV-2 viral infection.<br><br>          4. Able to sign the","","Severe Coronavirus Disease (COVID-19)","Drug: CD24Fc;Drug: Placebo","Improvement of COVID-19 disease status","","","","Yes","0","          ",""
"NCT04318301","2020-03-30","Hypertension in Patients Hospitalized With COVID-19","Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study","HT-COVID19","Zhenhua Zen","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318301","Not recruiting","No","18 Years","100 Years","All","2020-03-21","275.0","Observational","","N/A","China","","","","","","","<br>        Inclusion Criteria:<br><br>          -  COVID-19 pneumonia patients diagnosed by WHO criteria<br><br>        Exclusion Criteria:<br><br>          -  Patients who were younger than 18 years.<br><br>          -  Patients whose entire st","","COVID-19;Hypertension","","Rate of Death","","","","Yes","0","          ",""
"NCT04318314","2020-03-30","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","University College, London","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04318314","Recruiting","No","18 Years","N/A","All","2020-03-18","400.0","Observational [Patient Registry]","","N/A","United Kingdom"," ; ; ; ; ; ; ; ; ","James C Moon;Gabriella Captur;Charlotte Manisty;Ben O'Brien;Hugh Montgomery;Steffen Petersen;Thomas Treibel;James C Moon, MD MBBS MRCP;James Moon","",";;;;;;;bartshealth.covid-hcw@nhs.net;",";;;;;;;07570911438;","BHC & UCL;RFH & UCL;BHC & UCL;BHC & QMUL;UCL;BHC & QMUL;Barts Heart Center;","<br>        Inclusion Criteria:<br><br>          -  healthy asymptomatic healthcare workers attending hospital (place of work)<br><br>        Exclusion Criteria:<br><br>          -  SARS-CoV-2 positive or symptomatic healthcare workers<br>      ","","Health Care Worker Patient Transmission;Coronavirus;Coronavirus Infections;Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Seroconversion to SARS-CoV-2 positivity","","","","Yes","0","          ",""
"NCT04319211","2020-03-30","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease","COVID-19","Istanbul University-Cerrahpasa","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04319211","Not recruiting","No","18 Years","55 Years","All","2020-03-25","200.0","Observational","","Phase 3","Turkey"," ; ; ","Ipek Yeldan, Prof.;Eren Avcil, M.Sc,Pt;Eren Avcil, M.Sc,Pt","",";erenavcil@gmail.com;erenavcil@gmail.com",";+9005320683378;+9005320683378","Istanbul University-Cerrahpasa;","<br>        Inclusion Criteria:<br><br>          -  Being between the ages of 18-55<br><br>          -  To continue their active education or business life before the social isolation<br>             period.<br><br>          -  Spending time at ho","","Healthy People","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","International Physical Activity Questionnaire (IPAQ);Health-Related Quality of Life SF-12 Scale;Beck Depression Scale","","","","Yes","0","          ",""
"NCT04320056","2020-03-30","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia","Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-","","Laval University","2020-03-19","2020-03-19","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320056","Not recruiting","No","18 Years","N/A","All","2020-04-06","216.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). ","N/A",""," ","Franois Lellouche","","francois.lellouche@criucpq.ulaval.ca","418-656-8711","","<br>        Inclusion Criteria:<br><br>          -  Age> 18 years old<br><br>          -  patients with acute respiratory failure related to suspected community acquired<br>             pneumonia (viral and non viral) requiring oxygen therapy < 6 L/","","Coronavirus;Pneumonia;Oxygen Toxicity","Other: Standard administration of oxygen flow;Device: Automated oxygen administration - FreeO2","The number of interventions;Duration of interventions","","","","Yes","0","          ",""
"NCT04320277","2020-03-30","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","BARI-COVID","Hospital of Prato","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320277","Recruiting","No","18 Years","85 Years","All","2020-03-16","60.0","Interventional","Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","Italy"," ; ; ","Fabrizio Cantini, MD;Fabrizio Cantini, MD;Fabrizio Cantini","",";fbrzcantini@gmail.com;fbrzcantini@gmail.com",";+393408075607;+39 3408075607","Hospital of Prato, Italy;","<br>        Inclusion Criteria:<br><br>          -  All consecutive patients with mild to moderate COVID-19 infection<br><br>          -  Age >18 years,<br><br>          -  Clinical diagnosis of COVID19 infection<br><br>          -  Patients shou","","Pharmacological Action","Drug: Baricitinib","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.","","","","Yes","0","          ",""
"NCT04320511","2020-03-30","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","","William Beaumont Hospitals","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320511","Recruiting","No","18 Years","N/A","All","2020-03-23","25.0","Observational","","Phase 4","United States"," ; ","Girish B Nair, MD;Joanne Gondert, RN, BSN","",";joanne.gondert@beaumont.org",";248-898-0343","William Beaumont Hospitals;","<br>        Inclusion criteria:<br><br>          1. Adults >18 years of age<br><br>          2. Informed consent<br><br>          3. A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease defined as oxygen ><br>             90% on room ","","SARS-COV2;Severe Acute Respiratory Syndrome;COVID-19","Device: CT-V","Predictive association between CT-V, PBM score and disease progression","","","","Yes","0","          ",""
"NCT04320732","2020-03-30","Risk Factors for Community- and Workplace Transmission of COVID-19","Risk Factors for Community- and Workplace Transmission of COVID-19","","Oslo University Hospital","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320732","Not recruiting","No","18 Years","N/A","All","2020-03-28","50000.0","Observational","","N/A",""," ","Arne Sraas, MD, PhD","","Arne.Vasli.Lund.Soraas@rr-research.no","4790652904.0","","<br>        Inclusion Criteria:<br><br>          -  Norwegian adult<br><br>        Exclusion Criteria:<br><br>          -  Unable to consent<br>      ","","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Rate of COVID-19 infection","","","","Yes","0","          ",""
"NCT04320953","2020-03-30","Non-contact Endoscopy at Covid-19 Outbreak","Non-contact Endoscopy at Covid-19 Outbreak","","Changhai Hospital","2020-03-21","2020-03-21","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04320953","Not recruiting","No","18 Years","80 Years","All","2020-03-16","1.0","Interventional","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ","N/A","China"," ","Zhuan Liao, MD","","","","Changhai Hospital","<br>        Inclusion Criteria:<br><br>          -  Signed the informed consents before joining this study<br><br>        Exclusion Criteria:<br><br>          -  Dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal<br","","Gastrointestinal Disease;Infectious Disease","Device: Non-contact MCE system","Technical success","","","","Yes","0","          ",""
"NCT04321174","2020-03-30","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","CORIPREV-LR","Darrell Tan","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321174","Not recruiting","No","18 Months","N/A","All","2020-03-30","1220.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). ","Phase 3","Canada"," ; ; ","Darrell Tan, MD FRCPC PhD;Attia Qamar, BEng;Adrienne Chan, MD MPH FRCPC","",";Attia.Qamar@unityhealth.to;adrienne.chan@sunnybrook.ca",";416-864-6060;","St. Michael's Hospital, Toronto;","<br>        Inclusion Criteria:<br><br>          1. High risk close contact with a confirmed COVID-19 case during their symptomatic<br>             period, including one day before symptom onset, within the past 1-7 days. High risk<br>             cl","","Coronavirus Infections;Post-exposure Prophylaxis","Drug: Lopinavir/ritonavir","Microbiologic evidence of infection","","","","Yes","0","          ",""
"NCT04321811","2020-03-30","Behavior, Environment And Treatments for Covid-19","A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19)","BEAT19","xCures","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04321811","Recruiting","No","18 Years","N/A","All","2020-03-21","100000.0","Observational [Patient Registry]","","N/A","United States"," ; ; ","Mark Shapiro;xCures;xCures","",";info@xcures.com;info@xcures.com",";6505303636;650-530-3636","xCures;","<br>        Inclusion Criteria:<br><br>          -  People who are feeling sick and have tested positive for COVID-19<br><br>          -  People who are feeling sick but have not tested positive for COVID-19<br><br>          -  People who are not f","","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Define Natural Symptom Course","","","","Yes","0","          ",""
"NCT04322682","2020-03-30","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19","Montreal Heart Institute","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04322682","Recruiting","No","40 Years","N/A","All","2020-03-23","6000.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 3","Canada"," ; ; ; ","Jean-Claude Tardif, MD;Zohar Bassevitch, B.SC.;Jean-Claude Tardif, MD;Chantal Lacoste","",";;jean-claude.tardif@icm-mhi.org;chantal.lacoste@icm-mhi.org",";;514-376-3330;514 376-3330","Montreal Heart Institute;Montreal Health Innovations Coordinating Center;","<br>        Inclusion Criteria:<br><br>          1. Males and females, at least 40 years of age, capable and willing to provide informed<br>             consent;<br><br>          2. Patient must have received a diagnosis of COVID-19 infection within","","Corona Virus Infection","Drug: Colchicine;Drug: Placebo oral tablet","Number of participants who die or require hospitalization due to COVID-19 infection","","","","Yes","0","          ",""
"NCT04323332","2020-03-30","Traditional Chinese Medicine for Severe COVID-19","A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","","Xiyuan Hospital of China Academy of Chinese Medical Sciences","2020-03-08","2020-03-08","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323332","Not recruiting","No","N/A","85 Years","All","2020-03-01","50.0","Interventional","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","China"," ; ; ","Hao Li, Professor;Hao Li, Professor;Hao Li, Prof.","",";xyhplihao1965@126.com;xyhplihao1965@126.com",";+0086-133113382093;01062835088","Xiyuan Hospital of China Academy of Chinese Medical Sciences;","<br>        Key Inclusion Criteria:<br><br>          1. Patients were diagnosed as severe COVID-19 according to the Coronavirus disease<br>             (COVID-19) Treatment Guidance (Six edition)<br><br>          2. Patients received a combined trea","","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay (days)","","","","Yes","0","          ",""
"NCT04323345","2020-03-30","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","","Misr University for Science and Technology","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04323345","Not recruiting","No","5 Years","75 Years","All","2020-03-25","1000.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator). ","Phase 3","Egypt"," ; ","Mahmoud Tantawy, MD;Mahmoud Tantawy, MD","",";drmtantaway@yahoo.com",";+201221865587","Misr University for Science and Technology","<br>        Inclusion Criteria:<br><br>          -  Meeting the criteria for diagnosis of COVID-19, either clinically or as confirmed by<br>             positive swap.<br><br>        Exclusion Criteria:<br><br>          -  Children below 5 years o","","COVID-19","Dietary Supplement: Natural Honey;Other: Standard Care","Rate of recovery from positive to negative swaps;Fever to normal temperature in days;Resolution of lung inflammation in CT or X ray","","","","Yes","0","          ",""
"NCT04324190","2020-03-30","DIgital Online SuPport for COVID-19 StrEss","Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","DISPOSE","Gunther Meinlschmidt","2020-03-26","2020-03-26","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324190","Not recruiting","No","18 Years","N/A","All","2020-03-01","600.0","Interventional","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Care Provider). ","N/A","Germany"," ; ","Gunther Meinlschmidt, Prof. Dr.;Kati Bermbach","","gunther.meinlschmidt@ipu-berlin.de;contact@selfapy.com","+49 30 300117;+49 (0) 30 - 3982031","","<br>        Inclusion criteria:<br><br>          -  Sufficient German language skills to participate in the assessments.<br><br>          -  Providing informed consent for participation<br>      ","","COVID-19;Psychosocial Stress;Mental Health","Behavioral: Guided online support program;Behavioral: WHO recommendations (waiting condition)","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score","","","","Yes","0","          ",""
"NCT04324606","2020-03-30","A Study of a Candidate COVID-19 Vaccine (COV001)","A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","","University of Oxford","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324606","Not recruiting","No","18 Years","55 Years","All","2020-03-01","510.0","Interventional","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Participant). ","Phase 1/Phase 2","United Kingdom"," ; ","Andrew Pollard, Prof;Volunteer Recruitment Co-ordinator","",";vaccinetrials@ndm.ox.ac.uk",";01865 611424","University of Oxford;","<br>        Inclusion Criteria:<br><br>          -  Healthy adults aged 18-55 years.<br><br>          -  Able and willing (in the Investigator's opinion) to comply with all study<br>             requirements.<br><br>          -  Willing to allow t","","Coronavirus","Biological: ChAdOx1 nCoV-19;Other: Saline Placebo","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases;Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)","","","","Yes","0","          ",""
"NCT04324866","2020-03-30","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","","Universita di Verona","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04324866","Not recruiting","No","18 Years","75 Years","All","2020-04-01","300.0","Observational","","Phase 1/Phase 2",""," ","Paolo Gisondi","","paolo.gisondi@univr.it","+39 0458122547","","<br>        Group 1<br><br>        Inclusion Criteria:<br><br>          -  Aged 18 to 75 years old<br><br>          -  Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis<br>             confirmed by the Investigat","","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab","Point prevalence of COVID-19 infection","","","","Yes","0","          ",""
"NCT04325061","2020-03-30","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Dr. Negrin University Hospital","2020-03-25","2020-03-25","2020-01-04 15:51:14 ","ClinicalTrials.gov","https://clinicaltrials.gov/show/NCT04325061","Not recruiting","No","18 Years","N/A","All","2020-04-01","200.0","Interventional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","Spain"," ; ","Jess Villar, MD;Jess Villar, MD","",";jesus.villar54@gmail.com",";+34606860027","Hospital Universitario Dr. Negrin;","<br>        Inclusion Criteria:<br><br>          -  age 18 years or older;<br><br>          -  positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19<br>             in a respiratory tract sample;<br><br>          -  ","","Acute Respiratory Distress Syndrome Caused by COVID-19 Infection","Drug: Dexamethasone","60-day mortality","","","","Yes","0","          ",""
"ISRCTN51287266","2020-03-30","Aspergillosis in patients with severe influenza or coronavirus","Incidence and pathogenesis of invasive aspergillosis in intensive care patients with severe influenza or COVID-19 (AspiFlu)                                                                                                                                    ","","St George's University Hospitals NHS Foundation Trust","2019-12-06","2019-12-06","2020-01-04 15:51:14 ","ISRCTN","http://isrctn.com/ISRCTN51287266","Recruiting","No","","","Both","2019-12-13","70.0","Observational","Observational; Design type: Cohort study (Other)","Not Applicable","United Kingdom","","","","","","","Inclusion criteria: <br>                Current inclusion criteria as of 26/03/2020:<br>                1. Adults > 18 years<br>                2. Admitted to ICU for respiratory support requiring intubation and ventilation for >24 hours<br>              ","Exclusion criteria: <br>                1. Respiratory failure not the primary reason for ICU admission<br>                2. History of proven/ probable invasive pulmonary aspergillosis<br>            ","Aspergillosis <br>Infections and Infestations <br>Aspergillosis","<br>                After consent and enrolment patients in the influenza cohort will undergo a single-draw set of baseline blood tests. This will include peripheral blood mononuclear cells and Paxgene DNA. Approximately 30-40 ml of blood will be taken. B","<br>                1. Incidence and risk factors for invasive aspergillosis (IA) in the study cohort (as per modified AspICU criteria):<br>                1.1. Diagnostic classification of Influenza-associated aspergillosis (IAA) during ICU admission as ","","2021-08-05","","Yes","0","          ",""
"ChiCTR2000031366","2020-03-30","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis                                                                                                                        ","","Chinese PLA General Hospital","2020-03-29","2020-03-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51692","Not Recruiting","No","","","Both","2020-04-01","Case series:5000;","Observational study","Sequential","Retrospective study","China","Kun Xiao","","28 Fuxing Road, Beijing, China","455957898@qq.com","+86 13716608331","","Inclusion criteria: (1) Outpatient and emergency patients of PLA General Hospital;<br>(2) The body temperature higher than 37.3 degree C.","Exclusion criteria: (1) younger than 12 years old;<br>(2) refuse to sign informed consent.","fever; Novel Coronavirus Pneumonia (COVID-19)","Case series:no;","temperature;novel coronavirus;Influenza virus;","","","","Yes","0","          ",""
"ChiCTR2000031365","2020-03-30","To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients","Serum and urine proteins and metabolomic markers in patients with COVID-19                                                                                                                                                                                     ","","WESTLAKE UNIVERSITY","2020-03-29","2020-03-29","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51694","Recruiting","No","1.0","80.0","Both","2020-01-17","Target condition:0;Difficult condition:0","Diagnostic test","Sequential","0.0","China","Haixiao Chen","","150 Ximen Street, Linhai, Zhejiang, China","chenhx@enzemed.com","+86 13706760666","Taizhou Hospital of Zhejiang Province","Inclusion criteria: We anticipate collecting 200 COVID-19 serum samples (40 severe patients, 130 non-severe patients and 30 influza patients) in 2-4 hospitals. At present, there are two cooperate unit, Taizhou Hospital of Zhejiang Province and the First H","Exclusion criteria: Death was excluded. Cases with BMI mismatch were excluded","Novel Coronavirus Pneumonia (COVID-19)","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&#32;metabolomics&#32;and&#32;other&#32;markers,&#32;mass&#32;spectrometer;","proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;","","","","No","0","          ",""
"ChiCTR2000031319","2020-03-30","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial                                                                                 ","","Renmin Hospital of Wuhan University","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51647","Not Recruiting","No","18.0","65.0","Both","2020-04-01","hDPSCs group:10;Control group:10;","Interventional study","Parallel","N/A","China","Prof. Qingsong Ye; Dr. Chenliang Zhou","","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","20215851@qq.com","+86 027 88041919-83920","Center for Regenerative Medicine, Renmin Hospital of Wuhan University","Inclusion criteria: (1) Aged 18-65 years;<br>(2) Voluntarily participate in this clinical trial and sign off ""informed consent form"";<br>(3) Diagnosed with severe pneumonia of COVID: respiratory distress, RR >30 times / min; resting oxygen saturation of","Exclusion criteria: (1) Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;<br>(2) Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit);<br>(3) Patients with known seve","Novel Coronavirus Pneumonia (COVID-19)","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","TTCI;","","","","Yes","0","          ",""
"ChiCTR2000031296","2020-03-30","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death                                                                                                                               ","","Yichang Central people's Hospital","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51584","Not Recruiting","No","18.0","98.0","Both","2020-01-14","Survival and D:200;","Observational study","Sequential","Retrospective study","China","Zhang Rong","","183 Yiling Road, Yichang, Hubei, China","13972046539@163.com","+86 13972046539","Yichang Central People's Hospital","Inclusion criteria: All adult COVID-19 patients cofirmed PCR or CT scan.","Exclusion criteria: other viral pneumonia and COVID-19 in children.","Novel Coronavirus Pneumonia (COVID-19)","Survival and D:none;","clinical features of COVID-19 patients and risk factors of death;","","","","No","0","          ",""
"ChiCTR2000031293","2020-03-30","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk                                                                                                                                                                 ","","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","2020-03-27","2020-03-27","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51629","Recruiting","No","0.0","18.0","Both","2020-03-16","Case series:240;","Observational study","Sequential","N/A","China","Yan Hao, Xiaoping Luo","","1095 Jiefang Avenue, Wuhan, Hubei, China","haoyaner@163.com","+86 13971679960, 13387522645","","Inclusion criteria: Children at medium/low risk aged 0-18 years who were admitted to the department of pediatrics during the study period","Exclusion criteria: 1. Patients at h high risk of SARS-CoV-2 infection;<br>2. The guardian does not agree to sign the informed consent or the guardian does not agree to collect information.","Novel Coronavirus Pneumonia (COVID-19)","Case series:Nil;","Epidemiological characteristics;clinical features;Treatment outcome;","","","","No","0","          ",""
"ChiCTR2000031204","2020-03-30","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia                                                                                                      ","","Beijing you'an Hospital, Capital Medical University","2020-03-24","2020-03-24","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49420","Recruiting","No","","","Both","2020-01-30","Experimental treatment group:150;control group:150;","Interventional study","Parallel","2.0","China","Jin Ronghua","","8 Xi-Tou-Tiao Lane West, You'anmen Street, Fengtai District, Beijing, China","jin_eagle@sina.com","+86 13901374552","Beijing You'an Hospital, Capital Medical University","Inclusion criteria: 1. male and female aged 18-70 years;<br>2. positive result of test for 2019 novel coronavirus nucleic acid;<br>3. Clinical diagnosed with pneumonia;<br>4. onset within 7 days (severe cases can be delayed to 14 days);<br>5. the info","Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or in taking oral medication;<br>2. pregnant and nursing women;<br>3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral dr","Novel Coronavirus Pneumonia (COVID-19)","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);"," Clearance time of virus RNA;","","","","No","0","          ",""
"ChiCTR2000031187","2020-03-30","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                         ","","Wuhan Third Hospital & Tongren Hospital of Wuhan University","2020-03-23","2020-03-23","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51442","Not Recruiting","No","7.0","101.0","Both","2020-03-23","Case series:1292;","Epidemilogical research","Case-Control study","Retrospective study","China","Pengcheng Luo","","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","pluo@whu.edu.cn","+86 13507191363","Wuhan Third Hospital & Tongren Hospital of Wuhan University ","Inclusion criteria: (1) Inpatients in our hospital;<br>(2) Age and gender are not limited;<br>(3) The PT-PCR test is positive or suspected;<br>(4) There is a complete medical record in our hospital medical record system.","Exclusion criteria: (1) Patients who are negative for multiple PT-PCR tests and cannot be diagnosed;<br>(2) Patients with incomplete medical records;<br>(3) There are patients who other researchers believe are not suitable for inclusion in this study.","Novel Coronavirus Pneumonia (COVID-19)","Case series:?;","PT-PCR test;","","","","Yes","0","          ",""
"ChiCTR2000030936","2020-03-30","A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)","Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation                                                                                       ","","Hospital of Chengdu University of Traditional Chinese Medicine.","2020-03-18","2020-03-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51100","Recruiting","No","18.0","75.0","Both","2020-03-10","CM group:2130;WM group:710;","Treatment study","Quasi-randomized controlled","N/A","China","Peiyang Gao","","39 Shi-er-qiao Road, Chengdu, Sichua, China","gaopy930@126.com","+86 18980025566","Hospital of Chengdu University of Traditional Chinese Medicine","Inclusion criteria: 1. During the outbreak of new coronavirus pneumonia, patients with fever caused by respiratory infection (body temperature > 37 degree C), whether or not they are suspected or confirmed cases of new coronary pneumonia;<br>2. Comply wi","Exclusion criteria: 1. Known allergies to the components of this study;<br>2. Non-fever non-new coronary pneumonia diagnosed or suspected;<br>3. Fever caused by other non-infectious causes;<br>4. Patients with tuberculosis, bronchial asthma, chronic ob","Novel Coronavirus Pneumonia (COVID-19)","CM group:Xinguan No. 2 / Xinguan No. 3 alone or + regular treatment;WM group:Regular Ttreatment;","Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;","","","","No","0","          ",""
"ChiCTR2000030923","2020-03-30","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)                                                                                                                             ","","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","2020-03-17","2020-03-17","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=51139","Recruiting","No","0.0","??","Both","2020-02-15","Suspected case treatment group:150;Suspected case control group:150;Confirmed case  treatment group:50;Confirmed case control group:50;","Interventional study","Parallel","0.0","China","Lei Genping","","Plus 2 Weiyang Road West, Xianyang, Shaanxi, China","leigenping2006@163.com","+86 13609219205","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","Inclusion criteria: 1. Novel coronavirus history before entering the group:<br>(1) there were travel history or residential history in Wuhan area or other areas with local cases within 14 days before onset;<br>(2) During the 14 days before onset, there ","Exclusion criteria: 1. Having one of the following infections (influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, SARS coronavirus and other known viral pneumonia);<br>2. Mycoplasma pneumo","Novel Coronavirus Pneumonia (COVID-19)","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medici","Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;","","","","No","0","          ",""
"ChiCTR2000029976","2020-03-30","The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine                                                                                                                               ","","Shanghai University of Traditional Chinese Medicine","2020-02-18","2020-02-18","2020-01-04 15:51:14 ","ChiCTR","http://www.chictr.org.cn/showproj.aspx?proj=49631","Recruiting","No","25.0","65.0","Both","2020-02-18","experimental group:40;control group:40;","Interventional study","Parallel","0.0","China","Shan Chunlei","","1200 Cailun Road, Pudong New District, Shanghai, China ","shanclhappy@163.com","+86 18616974986","Shanghai University of Traditional Chinese Medicine","Inclusion criteria: A novel coronavirus pneumonia is 25-65 years old. It has no gender limitation. It has clinical symptoms such as cough, chest tightness and fatigue. Physical energy can withstand indoor standing for 20 minutes or 2 times a day.","Exclusion criteria: He has been suffering from respiratory system disease, unstable condition, risk of falling, severe other organ disease or mental disease, cognitive or language communication disorders.","Novel Coronavirus Pneumonia  (COVID-19)","experimental group:Fitness Qigong Yangfei prescription;control group:general advice and related psychological comfort.;","Oxygen Inhalation Frequency;Oxygen Intake Time;cough;Degree of expiratory dyspnoea;","","","","Yes","0","          ",""
"EUCTR2020-001162-12-FR","2020-03-30","Sarilumab COVID-19","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19                                                                                                   ","","Sanofi-aventis Recherche et Dveloppement","2020-03-20","2020-03-20","2020-01-04 15:51:14 ","EU Clinical Trials Register","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12","Authorised","Yes","","","<br>Female: yes<br>Male: yes<br>","2020-03-26","460.0","Interventional clinical trial of medicinal product","Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
","France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy","Direction des Oprations Cliniques","","1 avenue Pierre Brossolette","Public-Registry-MA-France@sanofi.com","","Sanofi-aventis France","Inclusion criteria: <br>Participants must have severe disease, multi-system organ dysfunction or critical disease<br>Laboratory-confirmed SARS-CoV-2 infection<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adult","Exclusion criteria: <br>Unlikely to survive for >48 hours from screening<br>Presence of neutropenia less than 2000/mm3, AST or ALT greater than 5 X ULN, platelets less than 50,000/mm3<br>Prior immunosuppressive therapies<br>Use of chronic oral cortico","Corona virus infection <br>MedDRA version: 20.1
Level: PT
Classification code 10053983
Term: Corona virus infection
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]","<br>Trade Name: Kevzara<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: SARILUMAB<br>Current Sponsor code: SAR153191<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number","Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19<br>Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patient","","","","Yes","True ","parent    ",""
